



(51) International Patent Classification:

A61P 3/00 (2006.01) C07D 487/04 (2006.01)

A61P 25/00 (2006.01) C07D 519/00 (2006.01)

A61P 35/00 (2006.01) A61K 31/519 (2006.01)

(21) International Application Number:

PCT/US2022/046416

(22) International Filing Date:

12 October 2022 (12.10.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/254,733 12 October 2021 (12.10.2021) US

63/347,757 01 June 2022 (01.06.2022) US

(71) Applicant: BIOSPLICE THERAPEUTICS, INC.

[US/US]; 9360 Towne Centre Drive, San Diego, California 92121 (US).

(72) Inventors: MITTAPALLI, Gopi Kumar; 10416 Whit-

comb Way, #99, San Diego, California 92127 (US). KUMAR KC, Sunil; 10504 Clasico Court, San Diego, California 92127 (US). MAK, Chi Ching; 11942 Caneridge Road, San Diego, California 92128 (US). HOFILINA, Brian Joseph; 3564 Brookshire St., San Diego, California 92111 (US). TURNER, Lewis Daniel; 7025 Charmant Drive, Unit 309, San Diego, California 92122 (US). EASTMAN, Brian Walter; 10518 Caminito Pollo, San Diego, California 92126 (US). VAKITI, Ramkrishna Reddy; 7699 Palmilla Dr, Apt 3316, San Diego, California 92122 (US). MARAKOVITS, Joseph Timothy; 2403 Summerhill Drive, Encinitas, California 92024 (US).

(74) Agent: CULHANE, Crystal L. et al.; P.O. Box 1022, Min-

neapolis, Minnesota 55440-1022 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))

(54) Title: PYRROLO[2,1-F][1,2,4]TRIAZINES DERIVATIVES AS INHIBITORS OF DYRK1A



I

(57) Abstract: Pyrrolo[2,1-f][1,2,4]triazine compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of pyrrolo[2,1-f][1,2,4]triazine compounds or analogs thereof, in the treatment of disorders characterized by overexpression of DYRK1A (e.g., cancer, Down syndrome, Alzheimer's disease, diabetes, viral infections, and osteoarthritis).



PYRROLO[2,1-F][1,2,4]TRIAZINES DERIVATIVES AS INHIBITORS OF DYRK1A

RELATED APPLICATIONS

[001] This application claims the benefit of U.S. Provisional Application Nos. 63/254,733, filed October 12, 2021, and 63/347,757, filed June 1, 2022, which are incorporated herein by reference in its entirety.

BACKGROUND

Technical Field

[002] This disclosure relates to inhibitors of dual-specificity tyrosine phosphorylation-regulated 1A kinase, and compositions comprising the same. More particularly, it concerns the use of a pyrrolo[2,1-f][1,2,4]triazine compound or salts or analogs thereof, in the treatment of disorders characterized by the abnormal expression and/or activity of DYRK1A (e.g., cancer, Down syndrome, Alzheimer's disease, diabetes, viral infections, and osteoarthritis).

Background

[003] Dual-specificity tyrosine phosphorylation-regulated kinases (DYRK1A, 1B, 2-4) comprise a family of protein kinases within the CMGC group of the eukaryotic kinome. These protein kinases are involved in multiple cellular functions, including intracellular signaling, mRNA splicing, chromatin transcription, DNA damage repair, cell survival, cell cycle control, differentiation, homocysteine/methionine/folate regulation, body temperature regulation, endocytosis, neuronal development, synaptic plasticity, etc. Abnormal expression and/or activity of some of these kinases, DYRK1A in particular, is seen in many human nervous system diseases, such as cognitive deficits associated with Down syndrome, Alzheimer's disease, and related diseases, tauopathies, dementia, Pick's disease, Parkinson's disease, and other neurodegenerative diseases, Phelan-McDermid syndrome, autism, and CDKL5 deficiency disorder. DYRKs are also involved in diabetes, abnormal folate/methionine metabolism, osteoarthritis, several solid cancers (glioblastoma, breast, and pancreatic cancers) and leukemias (acute lymphoblastic leukemia, acute megakaryoblastic leukemia), viral infections (influenza, HIV-1, HCMV, HCV, CMV, HPV), as well as infections caused by unicellular parasites (*Leishmania*, *Trypanosoma*, *Plasmodium*) (*International Journal of Molecular Sciences* (2021), 22(11), 6047). DYRK1A has also been identified as a critical stabilizer of EGFR (*Cell Death & Disease* (2019), 10, 282) which is a crucial

factor contributing to the keratinization, cell hyperproliferation, abnormal differentiation and inflammatory infiltration during the progress of psoriasis.


SUMMARY

[004] The present disclosure provides methods and reagents, involving contacting a cell with an agent, such as a pyrrolo[2,1-f][1,2,4]triazine compound, in a sufficient amount to antagonize DYRK1A activity, e.g., reduced the proliferation of head and neck squamous cell carcinoma, luminal/HER2 breast cancer (*Cell* (2016), 164(1-2), 293–309) or pancreatic adenocarcinoma, as well as impaired the self-renewal capacity of glioblastoma and compromised ovarian cancer spheroid cell viability (*Molecular Cancer Research* (2017), 15(4), 371–381).

[005] The present disclosure also provides methods and reagents, involving contacting a cell with an agent, such as a pyrrolo[2,1-f][1,2,4]triazine compound, in a sufficient amount to antagonize DYRK1A activity, e.g., i) to normalize prenatal and early postnatal brain development; ii) to improve cognitive function in youth and adulthood; and/or iii) to attenuate Alzheimer's-type neurodegeneration.

[006] Some embodiments disclosed herein include DYRK1A inhibitors containing a pyrrolo[2,1-f][1,2,4]triazine core. Other embodiments disclosed herein include pharmaceutical compositions and methods of treatment using these compounds.

[007] One embodiment disclosed herein includes a compound having the structure of Formula I:



I

or a pharmaceutically acceptable salt thereof,

wherein,

R¹ is heteroaryl optionally substituted with 1-10 R³;

R² is selected from the group consisting of unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, unsubstituted $-(C_{1-9} \text{ haloalkyl})$, $-(C_{1-3} \text{ alkylene})_p \text{OR}^4$, $-(C_{1-5} \text{ alkylene})_p$ heterocyclyl optionally substituted with 1-10 R⁵, $-\text{heteroaryl}$ optionally substituted with 1-10 R⁶, and $-(C_{1-5} \text{ alkylene})_p$ carbocyclyl optionally substituted with 1-12 R⁷, wherein each $-(C_{1-5}$

alkylene) is, independently, optionally substituted with 1-5 halide and/or 1-3 unsubstituted $-(C_{1-3} \text{ alkyl})$;

each R^3 is independently selected from the group consisting of halide, unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, unsubstituted $-(C_{1-9} \text{ haloalkyl})$, $-(C_{1-5} \text{ alkylene})_pOR^8$, $-\text{heterocyclyl}$ optionally substituted with 1-10 R^9 , $-\text{carbocyclyl}$ optionally substituted with 1-12 R^{10} , $-C(=O)N(R^{11})_2$, and $-C(=O)R^{12}$, wherein the $-(C_{1-5} \text{ alkylene})$ is optionally substituted with 1-5 halide and/or 1-3 unsubstituted $-(C_{1-3} \text{ alkyl})$;

each R^4 is independently selected from the group consisting of unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, and unsubstituted $-(C_{1-9} \text{ haloalkyl})$;

each R^5 is independently selected from the group consisting of halide, unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, unsubstituted $-(C_{1-9} \text{ haloalkyl})$, and $-\text{OMe}$;

each R^6 is independently selected from the group consisting of halide, unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, unsubstituted $-(C_{1-9} \text{ haloalkyl})$, and $-\text{OMe}$;

each R^7 is independently selected from the group consisting of halide, unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, unsubstituted $-(C_{1-9} \text{ haloalkyl})$, $-N(R^{13})_2$, $-(C_{1-5} \text{ alkylene})_pOR^{14}$, and $-\text{heterocyclyl}$ optionally substituted with 1-10 R^{15} , wherein the $-(C_{1-5} \text{ alkylene})$ is optionally substituted with 1-5 halide and/or 1-3 unsubstituted $-(C_{1-3} \text{ alkyl})$;

each R^8 is independently selected from the group consisting of H, unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, and unsubstituted $-(C_{1-9} \text{ haloalkyl})$;

each R^9 is independently selected from the group consisting of halide, unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, and unsubstituted $-(C_{1-9} \text{ haloalkyl})$;

each R^{10} is independently selected from the group consisting of halide, unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, and unsubstituted $-(C_{1-9} \text{ haloalkyl})$;

each R^{11} is independently selected from the group consisting of H, unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, unsubstituted $-(C_{1-9} \text{ haloalkyl})$, $-(C_{1-5} \text{ alkylene})_p\text{carbocyclyl}$ optionally substituted with 1-12 R^{16} , $-\text{heterocyclyl}$ optionally substituted with 1-10 R^{17} , and $-\text{heteroaryl}$ optionally substituted with 1-10 R^{18} , wherein the $-(C_{1-5} \text{ alkylene})$ is optionally substituted with 1-5 halide and/or 1-3 unsubstituted $-(C_{1-3} \text{ alkyl})$;

each R^{12} is $-\text{heterocyclyl}$ optionally substituted with 1-10 R^{17} ;

each R^{13} is independently selected from the group consisting of H, unsubstituted $-(C_{1-9}$ alkyl), unsubstituted $-(C_{2-9}$ alkenyl), unsubstituted $-(C_{2-9}$ alkynyl), and unsubstituted $-(C_{1-9}$ haloalkyl);

each R^{14} is independently selected from the group consisting of H, unsubstituted $-(C_{1-9}$ alkyl), unsubstituted $-(C_{2-9}$ alkenyl), unsubstituted $-(C_{2-9}$ alkynyl), and unsubstituted $-(C_{1-9}$ haloalkyl);

each R^{15} is independently selected from the group consisting of halide, unsubstituted $-(C_{1-9}$ alkyl), unsubstituted $-(C_{2-9}$ alkenyl), unsubstituted $-(C_{2-9}$ alkynyl), and unsubstituted $-(C_{1-9}$ haloalkyl);

each R^{16} is independently selected from the group consisting of halide, $-OMe$, unsubstituted $-(C_{1-9}$ alkyl), unsubstituted $-(C_{2-9}$ alkenyl), unsubstituted $-(C_{2-9}$ alkynyl), and unsubstituted $-(C_{1-9}$ haloalkyl);


each R^{17} is independently selected from the group consisting of halide, unsubstituted $-(C_{1-9}$ alkyl), unsubstituted $-(C_{2-9}$ alkenyl), unsubstituted $-(C_{2-9}$ alkynyl), and unsubstituted $-(C_{1-9}$ haloalkyl);

each R^{18} is independently selected from the group consisting of halide, unsubstituted $-(C_{1-9}$ alkyl), unsubstituted $-(C_{2-9}$ alkenyl), unsubstituted $-(C_{2-9}$ alkynyl), and unsubstituted $-(C_{1-9}$ haloalkyl);

each p is independently 0 or 1; and

wherein each H atom is optionally, independently replaced by 2H (D) (deuterium).

[008] In another embodiment disclosed herein includes a compound having the structure of Formula I:



I

or a pharmaceutically acceptable salt thereof,

wherein,

R^1 is heteroaryl optionally substituted with 1-10 R^3 ;

R^2 is selected from the group consisting of unsubstituted $-(C_{1-9}$ alkyl), unsubstituted $-(C_{2-9}$ alkenyl), unsubstituted $-(C_{2-9}$ alkynyl), unsubstituted $-(C_{1-9}$ haloalkyl), $-(C_{1-5}$ alkylene)_pOR⁴, $-(C_{1-5}$ alkylene)_pheterocyclyl optionally substituted with 1-10 R^5 , $-(C_{1-5}$ alkylene)_pheterocyclyl optionally substituted with 1-10 R^6 , and $-(C_{1-5}$ alkylene)_pcarbocyclyl optionally substituted with 1-12 R^7 , wherein each $-(C_{1-5}$

alkylene) is, independently, optionally substituted with 1-5 halide and/or 1-3 unsubstituted $-(C_{1-3} \text{ alkyl})$;

each R^3 is independently selected from the group consisting of halide, unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, unsubstituted $-(C_{1-9} \text{ haloalkyl})$, $-(C_{1-5} \text{ alkylene})_pOR^8$, $-(C_{1-5} \text{ alkylene})CN$, $-(C_{1-5} \text{ alkylene})_p\text{heterocyclyl}$ optionally substituted with 1-10 R^9 , $-\text{carbocyclyl}$ optionally substituted with 1-12 R^{10} , $-(C_{1-5} \text{ alkylene})_p\text{heteroaryl}$ optionally substituted with 1-10 R^{19} , $-(C_{1-5} \text{ alkylene})_pC(=O)N(R^{11})_2$, and $-C(=O)R^{12}$, wherein each $-(C_{1-5} \text{ alkylene})$ is, independently, optionally substituted with 1-5 halide and/or 1-3 unsubstituted $-(C_{1-3} \text{ alkyl})$;

each R^4 is independently selected from the group consisting of H, unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, and unsubstituted $-(C_{1-9} \text{ haloalkyl})$;

each R^5 is independently selected from the group consisting of halide, unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, unsubstituted $-(C_{1-9} \text{ haloalkyl})$, $-\text{heterocyclyl}$ optionally substituted with 1-10 R^{15} , $-(C_{1-5} \text{ alkylene})_pOR^{20}$, $-\text{SO}_2R^{22}$, and $-C(=O)R^{23}$, wherein the $-(C_{1-5} \text{ alkylene})$ is optionally substituted with 1-5 halide and/or 1-3 unsubstituted $-(C_{1-3} \text{ alkyl})$;

alternatively, two R^5 attached to the same carbon atom are taken together to form a carbonyl group;

each R^6 is independently selected from the group consisting of halide, unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, unsubstituted $-(C_{1-9} \text{ haloalkyl})$, and $-\text{OMe}$;

each R^7 is independently selected from the group consisting of halide, unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, unsubstituted $-(C_{1-9} \text{ haloalkyl})$, $-\text{N}(R^{13})_2$, $-(C_{1-5} \text{ alkylene})_pOR^{14}$, $-(C_{1-5} \text{ alkylene})_p\text{heterocyclyl}$ optionally substituted with 1-10 R^{15} , $-C(=O)R^{21}$, and $-\text{NHC}(=O)R^{22}$, wherein each $-(C_{1-5} \text{ alkylene})$ is, independently, optionally substituted with 1-5 halide and/or 1-3 unsubstituted $-(C_{1-3} \text{ alkyl})$;

each R^8 is independently selected from the group consisting of H, unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, and unsubstituted $-(C_{1-9} \text{ haloalkyl})$;

each R^9 is independently selected from the group consisting of halide, unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, and unsubstituted $-(C_{1-9} \text{ haloalkyl})$;

each R¹⁰ is independently selected from the group consisting of halide, unsubstituted -(C₁₋₉ alkyl), unsubstituted -(C₂₋₉ alkenyl), unsubstituted -(C₂₋₉ alkynyl), and unsubstituted -(C₁₋₉ haloalkyl);

each R¹¹ is independently selected from the group consisting of H, unsubstituted -(C₁₋₉ alkyl), unsubstituted -(C₂₋₉ alkenyl), unsubstituted -(C₂₋₉ alkynyl), unsubstituted -(C₁₋₉ haloalkyl), -(C₁₋₅ alkylene)_pcarbocyclyl optionally substituted with 1-12 R¹⁶, -heterocyclyl optionally substituted with 1-10 R¹⁷, and -heteroaryl optionally substituted with 1-10 R¹⁸, wherein the -(C₁₋₅ alkylene) is optionally substituted with 1-5 halide and/or 1-3 unsubstituted -(C₁₋₃ alkyl);

each R¹² is -heterocyclyl optionally substituted with 1-10 R¹⁷;

each R¹³ is independently selected from the group consisting of H, unsubstituted -(C₁₋₉ alkyl), unsubstituted -(C₂₋₉ alkenyl), unsubstituted -(C₂₋₉ alkynyl), and unsubstituted -(C₁₋₉ haloalkyl);

each R¹⁴ is independently selected from the group consisting of H, unsubstituted -(C₁₋₉ alkyl), unsubstituted -(C₂₋₉ alkenyl), unsubstituted -(C₂₋₉ alkynyl), unsubstituted -(C₁₋₉ haloalkyl), and -(C₁₋₅ alkylene)_pOR²⁰;

each R¹⁵ is independently selected from the group consisting of halide, unsubstituted -(C₁₋₉ alkyl), unsubstituted -(C₂₋₉ alkenyl), unsubstituted -(C₂₋₉ alkynyl), and unsubstituted -(C₁₋₉ haloalkyl);

each R¹⁶ is independently selected from the group consisting of halide, -OMe, unsubstituted -(C₁₋₉ alkyl), unsubstituted -(C₂₋₉ alkenyl), unsubstituted -(C₂₋₉ alkynyl), and unsubstituted -(C₁₋₉ haloalkyl);

each R¹⁷ is independently selected from the group consisting of halide, unsubstituted -(C₁₋₉ alkyl), unsubstituted -(C₂₋₉ alkenyl), unsubstituted -(C₂₋₉ alkynyl), and unsubstituted -(C₁₋₉ haloalkyl);

each R¹⁸ is independently selected from the group consisting of halide, unsubstituted -(C₁₋₉ alkyl), unsubstituted -(C₂₋₉ alkenyl), unsubstituted -(C₂₋₉ alkynyl), and unsubstituted -(C₁₋₉ haloalkyl);

each R¹⁹ is independently selected from the group consisting of halide, unsubstituted -(C₁₋₉ alkyl), unsubstituted -(C₂₋₉ alkenyl), unsubstituted -(C₂₋₉ alkynyl), and unsubstituted -(C₁₋₉ haloalkyl);

each R²⁰ is independently selected from the group consisting of H, unsubstituted -(C₁₋₉ alkyl), unsubstituted -(C₂₋₉ alkenyl), unsubstituted -(C₂₋₉ alkynyl), and unsubstituted -(C₁₋₉ haloalkyl);

each R^{21} is independently selected from the group consisting of –heterocyclyl optionally substituted with 1-10 R^{17} , $-N(R^{11})_2$ and $-OR^{20}$;

each R^{22} is independently selected from the group consisting of unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, and unsubstituted $-(C_{1-9} \text{ haloalkyl})$;

each R^{23} is independently selected from the group consisting of unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, unsubstituted $-(C_{1-9} \text{ haloalkyl})$, and –carbocyclyl optionally substituted with 1-12 R^{24} ;

each R^{24} is independently selected from the group consisting of halide, unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, and unsubstituted $-(C_{1-9} \text{ haloalkyl})$;

each p is independently 0 or 1; and

wherein each H atom is optionally, independently replaced by 2H (D) (deuterium).

[009] In another embodiment disclosed herein includes a compound having the structure of Formula I:

R^1 is heteroaryl optionally substituted with 1-10 R^3 ;

R^2 is selected from the group consisting of unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, unsubstituted $-(C_{1-9} \text{ haloalkyl})$, $-(C_{1-5} \text{ alkylene})_p OR^4$, $-(C_{1-5} \text{ alkylene})_p$ heterocyclyl optionally substituted with 1-10 R^5 , –heteroaryl optionally substituted with 1-10 R^6 , and $-(C_{1-5} \text{ alkylene})_p$ carbocyclyl optionally substituted with 1-12 R^7 , wherein each $-(C_{1-5} \text{ alkylene})$ is, independently, optionally substituted with 1-5 halide and/or 1-3 unsubstituted $-(C_{1-3} \text{ alkyl})$;

each R^3 is independently selected from the group consisting of halide, unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, unsubstituted $-(C_{1-9} \text{ haloalkyl})$, $-(C_{1-5} \text{ alkylene})_p OR^8$, $-(C_{1-5} \text{ alkylene}) CN$, $-(C_{1-5} \text{ alkylene})_p$ heterocyclyl optionally substituted with 1-10 R^9 , –carbocyclyl optionally substituted with 1-12 R^{10} , $-(C_{1-5} \text{ alkylene})_p$ heteroaryl optionally substituted with 1-10 R^{19} , $-(C_{1-5} \text{ alkylene})_p C(=O)N(R^{11})_2$, and $-C(=O)R^{12}$, wherein each $-(C_{1-5} \text{ alkylene})$ is, independently, optionally substituted with 1-5 halide and/or 1-3 unsubstituted $-(C_{1-3} \text{ alkyl})$;

each R^4 is independently selected from the group consisting of H, unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, and unsubstituted $-(C_{1-9} \text{ haloalkyl})$;

each R^5 is independently selected from the group consisting of halide, unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, unsubstituted $-(C_{1-9} \text{ haloalkyl})$, –heterocyclyl optionally substituted with 1-10 R^{15} , $-(C_{1-5} \text{ alkylene})_p OR^{20}$, $-SO_2R^{22}$, and $-C(=O)R^{23}$,

wherein the $-(C_{1-5} \text{ alkylene})$ is optionally substituted with 1-5 halide and/or 1-3 unsubstituted $-(C_{1-3} \text{ alkyl})$;

alternatively, two R^5 attached to the same carbon atom are taken together to form a carbonyl group;

each R^6 is independently selected from the group consisting of halide, unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, unsubstituted $-(C_{1-9} \text{ haloalkyl})$, and $-\text{OMe}$;

each R^7 is independently selected from the group consisting of halide, unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, unsubstituted $-(C_{1-9} \text{ haloalkyl})$, $-\text{N}(R^{13})_2$, $-(C_{1-5} \text{ alkylene})_p\text{OR}^{14}$, $-(C_{1-5} \text{ alkylene})_p\text{heterocyclyl}$ optionally substituted with 1-10 R^{15} , $-\text{C}(=\text{O})R^{21}$, and $-\text{NH}(=\text{O})R^{22}$, wherein each $-(C_{1-5} \text{ alkylene})$ is, independently, optionally substituted with 1-5 halide and/or 1-3 unsubstituted $-(C_{1-3} \text{ alkyl})$;

each R^8 is independently selected from the group consisting of H, unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, and unsubstituted $-(C_{1-9} \text{ haloalkyl})$;

each R^9 is independently selected from the group consisting of halide, unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, and unsubstituted $-(C_{1-9} \text{ haloalkyl})$;

each R^{10} is independently selected from the group consisting of halide, unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, and unsubstituted $-(C_{1-9} \text{ haloalkyl})$;

each R^{11} is independently selected from the group consisting of H, unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, unsubstituted $-(C_{1-9} \text{ haloalkyl})$, $-(C_{1-5} \text{ alkylene})_p\text{carbocyclyl}$ optionally substituted with 1-12 R^{16} , $-\text{heterocyclyl}$ optionally substituted with 1-10 R^{17} , and $-\text{heteroaryl}$ optionally substituted with 1-10 R^{18} , wherein the $-(C_{1-5} \text{ alkylene})$ is optionally substituted with 1-5 halide and/or 1-3 unsubstituted $-(C_{1-3} \text{ alkyl})$;

each R^{12} is $-\text{heterocyclyl}$ optionally substituted with 1-10 R^{17} ;

each R^{13} is independently selected from the group consisting of H, unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, and unsubstituted $-(C_{1-9} \text{ haloalkyl})$;

each R^{14} is independently selected from the group consisting of H, unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, unsubstituted $-(C_{1-9} \text{ haloalkyl})$, and $-(C_{1-5} \text{ alkylene})_p\text{OR}^{20}$;

each R^{15} is independently selected from the group consisting of halide, unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, and unsubstituted $-(C_{1-9} \text{ haloalkyl})$;

alternatively, two R^{15} attached to the same carbon atom are taken together to form a carbonyl group;

each R^{16} is independently selected from the group consisting of halide, $-\text{OMe}$, unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, and unsubstituted $-(C_{1-9} \text{ haloalkyl})$;

each R^{17} is independently selected from the group consisting of halide, unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, and unsubstituted $-(C_{1-9} \text{ haloalkyl})$;

each R^{18} is independently selected from the group consisting of halide, unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, and unsubstituted $-(C_{1-9} \text{ haloalkyl})$;

each R^{19} is independently selected from the group consisting of halide, unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, and unsubstituted $-(C_{1-9} \text{ haloalkyl})$;

each R^{20} is independently selected from the group consisting of H, unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, and unsubstituted $-(C_{1-9} \text{ haloalkyl})$;

each R^{21} is independently selected from the group consisting of $-\text{heterocyclyl}$ optionally substituted with 1-10 R^{17} , $-\text{N}(R^{11})_2$ and $-\text{OR}^{20}$;

each R^{22} is independently selected from the group consisting of unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, unsubstituted $-(C_{1-9} \text{ haloalkyl})$, and $-(C_{1-5} \text{ alkylene})_p \text{OR}^{20}$;

each R^{23} is independently selected from the group consisting of unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, unsubstituted $-(C_{1-9} \text{ haloalkyl})$, and $-\text{carbocyclyl}$ optionally substituted with 1-12 R^{24} ;

each R^{24} is independently selected from the group consisting of halide, unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, and unsubstituted $-(C_{1-9} \text{ haloalkyl})$;

each p is independently 0 or 1; and

wherein each H atom is optionally, independently replaced by ^2H (D) (deuterium).

[010] Some embodiments include stereoisomers and pharmaceutically acceptable salts of a compound of Formula (I). Some embodiments include pharmaceutically acceptable salts of a compound of Formula (I).

[011] Some embodiments include pro-drugs of a compound of Formula (I).

[012] Some embodiments of the present disclosure include pharmaceutical compositions comprising a compound of Formula (I) and a pharmaceutically acceptable carrier, diluent, or excipient.

[013] Other embodiments disclosed herein include methods of inhibiting DYRK1A by administering to a patient affected by a disorder or disease in which DYRK1A overexpression is implicated, such as Alzheimer's Disease, Amyotrophic Lateral Sclerosis, CDKL5 Deficiency Disorder, Down Syndrome, Frontotemporal Dementia with Parkinsonism-17 (FTDP-17), Lewy body dementia, Parkinson's Disease, Pick's Disease, and additional diseases with pronounced neurodegeneration such as Autism, Dementia, Epilepsy, Huntington's Disease, Multiple Sclerosis; diseases and disorders associated with acquired brain injury such as Chronic Traumatic Encephalopathy, Traumatic Brain Injury, Tumor and Stroke.

[014] Inhibitors of DYRK1A can also be used to treat tauopathies. Tauopathies are neurodegenerative disorders characterized by the deposition of abnormal tau protein in the brain. The spectrum of tau pathologies expands beyond the traditionally discussed disease forms like Pick's disease, progressive supranuclear palsy, corticobasal degeneration, and argyrophilic grain disease. Emerging entities and pathologies include globular glial tauopathies, primary age-related tauopathy, which includes neurofibrillary tangle dementia, chronic traumatic encephalopathy (CTE), frontotemporal lobar degeneration with tau inclusions (FTLD-tau), and aging-related tau astrogliopathy. Clinical symptoms include frontotemporal dementia, corticobasal syndrome, Richardson syndrome, parkinsonism, pure akinesia with gait freezing and, rarely, motor neuron symptoms or cerebellar ataxia (*Handbook of Clinical Neurology* (2018), 145, 355-368 and *Aging Cell* (2019), 18(5), e13000).

[015] Inhibitors of DYRK1A can also be used to treat disorders associated with abnormal folate/methionine metabolism.

[016] Non-limiting examples of diseases which can be treated with the compounds and compositions provided herein include a variety of cancers, diabetes, psoriasis, knee osteoarthritis, tendinopathy, human immunodeficiency virus type 1 (HIV-1), human cytomegalovirus (HCMV), hepatitis C virus (HCV), and herpes simplex virus 1 (HSV-1).

[017] Some embodiments of the present disclosure include methods to prepare compounds of Formula (I).

[018] It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the disclosure, as claimed.

DETAILED DESCRIPTION

[019] Provided herein are compositions and methods for inhibiting DYRK1A.

[020] Some embodiments provided herein relate to a method for treating a disease including, but not limited to, neurological diseases or disorders, cancers, cognitive deficits, knee osteoarthritis, tendinopathy, viral infections, unicellular parasite infections, and motor deficits.

[021] In some embodiments, non-limiting examples of a neurological disease or disorder which can be treated with the compounds and compositions provided herein include, but are not limited to, Alzheimer's disease, amyotrophic lateral sclerosis, Down Syndrome, frontotemporal dementia with Parkinsonism-17 (FTDP-17), Lewy body dementia, Parkinson's disease, Pick's disease tauopathies, and additional diseases with pronounced neurodegeneration such as autism, dementia, epilepsy, Huntington's disease, multiple sclerosis; diseases and disorders associated with acquired brain injury such as Chronic Traumatic Encephalopathy, Traumatic Brain Injury, Tumor, and Stroke.

[022] In some embodiments, non-limiting examples of cancers which can be treated with the compounds and compositions provided herein include solid cancers (e.g., glioblastoma, ovarian, breast, and pancreatic cancers) and leukemias (e.g., acute lymphoblastic leukemia, acute megakaryoblastic leukemia, and chronic myeloid leukemia).

[023] In some embodiments, pharmaceutical compositions are provided that are effective for treatment of a disease of an animal, e.g., a mammal, caused by DYRK1A overexpression. The composition includes a pharmaceutically acceptable carrier and a compound as described herein.

Definitions

[024] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of ordinary skill in the art to which this disclosure belongs. All patents, applications, published applications, and other publications are incorporated by reference in their entirety. In the event that there is a plurality of definitions for a term herein, those in this section prevail unless stated otherwise.

[025] As used herein, "alkyl" means a branched, or straight chain chemical group containing only carbon and hydrogen, such as methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-

butyl, sec-butyl, tert-butyl, n-pentyl, iso-pentyl, sec-pentyl and neo-pentyl. Alkyl groups can either be unsubstituted or substituted with one or more substituents. In some embodiments, alkyl groups include 1 to 9 carbon atoms (for example, 1 to 6 carbon atoms, 1 to 4 carbon atoms, or 1 to 2 carbon atoms).

[026] As used herein, “alkenyl” means a straight or branched chain chemical group containing only carbon and hydrogen and containing at least one carbon-carbon double bond, such as ethenyl, 1-propenyl, 2-propenyl, 2-methyl-1-propenyl, 1-butenyl, 2-butenyl, and the like. In various embodiments, alkenyl groups can either be unsubstituted or substituted with one or more substituents. Typically, alkenyl groups will comprise 2 to 9 carbon atoms (for example, 2 to 6 carbon atoms, 2 to 4 carbon atoms, or 2 carbon atoms).

[027] As used herein, “alkynyl” means a straight or branched chain chemical group containing only carbon and hydrogen and containing at least one carbon-carbon triple bond, such as ethynyl, 1-propynyl, 1-butyne, 2-butyne, and the like. In various embodiments, alkynyl groups can either be unsubstituted or substituted with one or more substituents. Typically, alkynyl groups will comprise 2 to 9 carbon atoms (for example, 2 to 6 carbon atoms, 2 to 4 carbon atoms, or 2 carbon atoms).

[028] As used herein, “alkylene” means a bivalent branched or straight chain chemical group containing only carbon and hydrogen, such as methylene, ethylene, n-propylene, iso-propylene, n-butylene, iso-butylene, sec-butylene, tert-butylene, n-pentylene, iso-pentylene, sec-pentylene and neo-pentylene. Alkylene groups can either be unsubstituted or substituted with one or more substituents. In some embodiments, alkylene groups include 1 to 9 carbon atoms (for example, 1 to 6 carbon atoms, 1 to 4 carbon atoms, or 1 to 2 carbon atoms).

[029] As used herein, “alkenylene” means a bivalent branched or straight chain chemical group containing only carbon and hydrogen and containing at least one carbon-carbon double bond, such as ethenylene, 1-propenylene, 2-propenylene, 2-methyl-1-propenylene, 1-butenylene, 2-butenylene, and the like. In various embodiments, alkenylene groups can either be unsubstituted or substituted with one or more substituents. Typically, alkenylene groups will comprise 2 to 9 carbon atoms (for example, 2 to 6 carbon atoms, 2 to 4 carbon atoms, or 2 carbon atoms).

[030] As used herein, “alkynylene” means a bivalent branched or straight chain chemical group containing only carbon and hydrogen and containing at least one carbon-carbon triple bond, such as ethynylene, 1-propynylene, 1-butyne, 2-butyne, and the like. In various embodiments, alkynylene groups can either be unsubstituted or substituted with one or more

substituents. Typically, alkynylene groups will comprise 2 to 9 carbon atoms (for example, 2 to 6 carbon atoms, 2 to 4 carbon atoms, or 2 carbon atoms).

[031] As used herein, “alkoxy” means an alkyl-O— group in which the alkyl group is as described herein. Exemplary alkoxy groups include methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, s-butoxy, t-butoxy, pentoxy, hexoxy and heptoxy, and also the linear or branched positional isomers thereof.

[032] As used herein, “haloalkoxy” means a haloalkyl-O— group in which the haloalkyl group is as described herein. Exemplary haloalkoxy groups include fluoromethoxy, difluoromethoxy, trifluoromethoxy, and also the linear or branched positional isomers thereof.

[033] As used herein, “carbocyclyl” means a cyclic ring system containing only carbon atoms in the ring system backbone, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cyclohexenyl. Carbocyclyls may include multiple fused rings. Carbocyclyls may have any degree of saturation provided that none of the rings in the ring system are aromatic. Carbocyclyl groups can either be unsubstituted or substituted with one or more substituents. In some embodiments, carbocyclyl groups include 3 to 10 carbon atoms, for example, 3 to 6 carbon atoms.

[034] As used herein, “aryl” means a mono-, bi-, tri- or polycyclic group with only carbon atoms present in the ring backbone having 5 to 14 ring atoms, alternatively 5, 6, 9, or 10 ring atoms; and having 6, 10, or 14 pi electrons shared in a cyclic array; wherein at least one ring in the system is aromatic. Aryl groups can either be unsubstituted or substituted with one or more substituents. Examples of aryl include phenyl, naphthyl, tetrahydronaphthyl, 2,3-dihydro-1H-indenyl, and others. In some embodiments, the aryl is phenyl.

[035] As used herein, “arylalkylene” means an aryl-alkylene- group in which the aryl and alkylene moieties are as previously described. In some embodiments, arylalkylene groups contain a C₁₋₄alkylene moiety. Exemplary arylalkylene groups include benzyl and 2-phenethyl.

[036] As used herein, the term “heteroaryl” means a mono-, bi-, tri- or polycyclic group having 5 to 14 ring atoms, alternatively 5, 6, 9, or 10 ring atoms; and having 6, 10, or 14 pi electrons shared in a cyclic array; wherein at least one ring in the system is aromatic, and at least one ring in the system contains one or more heteroatoms independently selected from the group consisting of N, O, and S. Heteroaryl groups can either be unsubstituted or substituted with one or more substituents. Examples of heteroaryl include thienyl, pyridinyl, furyl, oxazolyl, oxadiazolyl, pyrrolyl, imidazolyl, triazolyl, thiodiazolyl, pyrazolyl, isoxazolyl, thiadiazolyl, pyranyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, thiazolyl, benzothienyl, benzoxadiazolyl, benzofuranyl, benzimidazolyl, benzotriazolyl, cinnoliny, indazolyl, indolyl, isoquinoliny, isothiazolyl,

naphthyridinyl, purinyl, thienopyridinyl, pyrido[2,3-*d*]pyrimidinyl, pyrrolo[2,3-*b*]pyridinyl, quinazoliny, quinolinyl, thieno[2,3-*c*]pyridinyl, pyrazolo[3,4-*b*]pyridinyl, pyrazolo[3,4-*c*]pyridinyl, pyrazolo[4,3-*c*]pyridine, pyrazolo[4,3-*b*]pyridinyl, tetrazolyl, chromane, 2,3-dihydrobenzo[*b*][1,4]dioxine, benzo[*d*][1,3]dioxole, 2,3-dihydrobenzofuran, tetrahydroquinoline, 2,3-dihydrobenzo[*b*][1,4]oxathiine, isoindoline, and others. In some embodiments, the heteroaryl is selected from thienyl, pyridinyl, furyl, pyrazolyl, imidazolyl, isoindolinyl, pyranyl, pyrazinyl, and pyrimidinyl.

[037] As used herein, “halo”, “halide” or “halogen” is a chloro, bromo, fluoro, or iodo atom radical. In some embodiments, a halo is a chloro, bromo or fluoro. For example, a halide can be fluoro.

[038] As used herein, “haloalkyl” means a hydrocarbon substituent, which is a linear or branched alkyl, alkenyl or alkynyl substituted with one or more chloro, bromo, fluoro, and/or iodo atom(s). In some embodiments, a haloalkyl is a fluoroalkyl, wherein one or more of the hydrogen atoms have been substituted by fluoro. In some embodiments, haloalkyls are 1 to 3 carbons in length (e.g., 1 to 2 carbons in length or 1 carbon in length). The term “haloalkylene” means a diradical variant of haloalkyl, and such diradicals may act as spacers between radicals, other atoms, or between a ring and another functional group.

[039] As used herein, “heterocyclyl” means a nonaromatic cyclic ring system comprising at least one heteroatom in the ring system backbone. Heterocyclyls may include multiple fused rings such as bicyclic and spirocyclic heterocyclyls. Heterocyclyls may be substituted or unsubstituted with one or more substituents. In some embodiments, heterocycles have 3-11 members. In six membered monocyclic heterocycles, the heteroatom(s) are selected from one to three of O, N and S, and wherein when the heterocycle is five membered, it can have one or two heteroatoms selected from O, N, and S. Examples of heterocyclyl include azirinyl, aziridinyl, azetidiny, oxetanyl, thietanyl, 1,4,2-dithiazolyl, dihydropyridinyl, 1,3-dioxanyl, 1,4-dioxanyl, 1,3-dioxolanyl, morpholinyl, thiomorpholinyl, piperazinyl, pyranyl, pyrrolidinyl, tetrahydrofuryl, tetrahydropyridinyl, oxazinyl, thiazinyl, thiinyl, thiazolidinyl, isothiazolidinyl, oxazolidinyl, isoxazolidinyl, piperidinyl, pyrazolidinyl, imidazolidinyl, thiomorpholinyl, and others. In some embodiments, the heterocyclyl is selected from azetidiny, morpholinyl, piperazinyl, pyrrolidinyl, and tetrahydropyridinyl.

[040] As used herein, “monocyclic heterocyclyl” means a single nonaromatic cyclic ring comprising at least one heteroatom in the ring system backbone. Heterocyclyls may be substituted or unsubstituted with one or more substituents. In some embodiments, heterocycles have 3-7 members. In six membered monocyclic heterocycles, the heteroatom(s) are selected from

one to three of O, N and S, and wherein when the heterocycle is five membered, it can have one or two heteroatoms selected from O, N, and S. Examples of monocyclic heterocyclyls include aziriny, aziridiny, azetidiny, oxetany, thietany, 1,4,2-dithiazoly, dihydropyridiny, 1,3-dioxany, 1,4-dioxany, 1,3-dioxolany, morpholiny, thiomorpholiny, piperaziny, pyran, pyrrolidiny, tetrahydrofury, tetrahydropyridiny, oxaziny, thiaziny, thiiny, thiazolidiny, isothiazolidiny, oxazolidiny, isoxazolidiny, piperidiny, pyrazolidiny, imidazolidiny, thiomorpholiny, and others.

[041] As used herein, “bicyclic heterocyclyl” means a nonaromatic bicyclic ring system comprising at least one heteroatom in the ring system backbone. Bicyclic heterocyclyls may be substituted or unsubstituted with one or more substituents. In some embodiments, bicyclic heterocycles have 4-11 members with the heteroatom(s) being selected from one to five of O, N and S. Examples of bicyclic heterocyclyls include 2-azabicyclo[1.1.0]butane, 2-azabicyclo[2.1.0]pentane, 2-azabicyclo[1.1.1]pentane, 3-azabicyclo[3.1.0]hexane, 5-azabicyclo[2.1.1]hexane, 3-azabicyclo[3.2.0]heptane, octahydrocyclopenta[*c*]pyrrole, 3-azabicyclo[4.1.0]heptane, 7-azabicyclo[2.2.1]heptane, 6-azabicyclo[3.1.1]heptane, 7-azabicyclo[4.2.0]octane, 2-azabicyclo[2.2.2]octane, and the like.

[042] As used herein, “spirocyclic heterocyclyl” means a nonaromatic bicyclic ring system comprising at least one heteroatom in the ring system backbone and with the rings connected through just one atom. Spirocyclic heterocyclyls may be substituted or unsubstituted with one or more substituents. In some embodiments, spirocyclic heterocycles have 5-11 members with the heteroatom(s) being selected from one to five of O, N and S. Examples of spirocyclic heterocyclyls include 2-azaspiro[2.2]pentane, 4-azaspiro[2.5]octane, 1-azaspiro[3.5]nonane, 2-azaspiro[3.5]nonane, 7-azaspiro[3.5]nonane, 2-azaspiro[4.4]nonane, 6-azaspiro[2.6]nonane, 1,7-diazaspiro[4.5]decane, 2,5-diazaspiro[3.6]decane, and the like.

[043] The term “substituted” refers to moieties having substituents replacing a hydrogen on one or more non-hydrogen atoms of the molecule. It will be understood that “substitution” or “substituted with” includes the implicit proviso that such substitution is in accordance with permitted valence of the substituted atom and the substituent, and that the substitution results in a stable compound, e.g., which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, etc. Substituents can include, for example, $-(C_{1-9} \text{ alkyl})$ optionally substituted with one or more of hydroxyl, $-NH_2$, $-NH(C_{1-3} \text{ alkyl})$, and $-N(C_{1-3} \text{ alkyl})_2$; $-(C_{1-9} \text{ haloalkyl})$; a halide; a hydroxyl; a carbonyl [such as $-C(O)OR$, and $-C(O)R$]; a thiocarbonyl [such as $-C(S)OR$, $-C(O)SR$, and $-C(S)R$]; $-(C_{1-9} \text{ alkoxy})$ optionally substituted with one or more of halide, hydroxyl, $-NH_2$, $-NH(C_{1-3} \text{ alkyl})$, and $-N(C_{1-3} \text{ alkyl})_2$; -

OPO(OH)₂; a phosphonate [such as -PO(OH)₂ and -PO(OR')₂]; -OPO(OR')R''; -NRR'; -C(O)NRR'; -C(NR)NR'R''; -C(NR')R''; a cyano; a nitro; an azido; -SH; -S-R; -OSO₂(OR); a sulfonate [such as -SO₂(OH) and -SO₂(OR)]; -SO₂NR'R''; and -SO₂R; in which each occurrence of R, R' and R'' are independently selected from H; -(C₁₋₉ alkyl); C₆₋₁₀ aryl optionally substituted with 1-3 R'''; 5-10 membered heteroaryl having from 1-4 heteroatoms independently selected from N, O, and S and optionally substituted with 1-3 R'''; C₃₋₇ carbocyclyl optionally substituted with 1-3 R'''; and 3-8 membered heterocyclyl having from 1-4 heteroatoms independently selected from N, O, and S and optionally substituted with 1-3 R'''; wherein each R''' is independently selected from -(C₁₋₆ alkyl), -(C₁₋₆ haloalkyl), a halide (e.g., F), a hydroxyl, -C(O)OR, -C(O)R, -(C₁₋₆ alkoxy), -NRR', -C(O)NRR', and a cyano, in which each occurrence of R and R' is independently selected from H and -(C₁₋₆ alkyl). In some embodiments, the substituent is selected from -(C₁₋₆ alkyl), -(C₁₋₆ haloalkyl), a halide (e.g., F), a hydroxyl, -C(O)OR, -C(O)R, -(C₁₋₆ alkoxy), -NRR', -C(O)NRR', and a cyano, in which each occurrence of R and R' is independently selected from H and -(C₁₋₆ alkyl).

[044] As used herein, when two groups are indicated to be “linked” or “bonded” to form a “ring”, it is to be understood that a bond is formed between the two groups and may involve replacement of a hydrogen atom on one or both groups with the bond, thereby forming a carbocyclyl, heterocyclyl, aryl, or heteroaryl ring. The skilled artisan will recognize that such rings can and are readily formed by routine chemical reactions. In some embodiments, such rings have from 3-7 members, for example, 5 or 6 members.

[045] The skilled artisan will recognize that some chemical structures described herein may be represented on paper by one or more other resonance forms; or may exist in one or more other tautomeric forms, even when kinetically, the artisan recognizes that such tautomeric forms represent only a very small portion of a sample of such compound(s). Such compounds are clearly contemplated within the scope of this disclosure, though such resonance forms or tautomers are not explicitly represented herein.

[046] The compounds provided herein may encompass various stereochemical forms. The compounds also encompass diastereomers as well as optical isomers, e.g., mixtures of enantiomers including racemic mixtures, as well as individual enantiomers and diastereomers, which arise as a consequence of structural asymmetry in certain compounds. Separation of the individual isomers or selective synthesis of the individual isomers is accomplished by application of various methods which are well known to practitioners in the art. Unless otherwise indicated, when a disclosed compound is named or depicted by a structure without specifying the

stereochemistry and has one or more chiral centers, it is understood to represent all possible stereoisomers of the compound.

[047] The present disclosure includes all pharmaceutically acceptable isotopically labeled compounds of Formula I wherein one or more atoms are replaced by atoms having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number which predominates in nature. Examples of isotopes suitable for inclusion in the compounds of the disclosure include, but are not limited to, isotopes of hydrogen, such as ^2H (deuterium) and ^3H (tritium), isotopes of carbon, such as ^{11}C , ^{13}C and ^{14}C , isotopes of chlorine, such as ^{36}Cl , isotopes of fluorine, such as ^{18}F , isotopes of iodine, such as ^{123}I and ^{125}I , isotopes of nitrogen, such as ^{13}N and ^{15}N , isotopes of oxygen, such as ^{15}O , ^{17}O and ^{18}O , isotopes of phosphorus, such as ^{32}P , and isotopes of sulfur, such as ^{35}S .

[048] The term “administration” or “administering” refers to a method of providing a dosage of a compound or pharmaceutical composition to a vertebrate or invertebrate, including a mammal, a bird, a fish, or an amphibian, where the method of administration is, e.g., orally, subcutaneously, intravenously, intralymphatic, intranasally, topically, transdermally, intraperitoneally, intramuscularly, intrapulmonarily, vaginally, rectally, ontologically, neuro-otologically, intraocularly, subconjunctivally, via anterior eye chamber injection, intravitreally, intraperitoneally, intrathecally, intracystically, intrapleurally, via wound irrigation, intrabuccally, intra-abdominally, intra-articularly, intra-aurally, intrabronchially, intracapsularly, intrameningeally, via inhalation, via endotracheal or endobronchial instillation, via direct instillation into pulmonary cavities, intraspinally, intrasynovially, intrathoracically, via thoracostomy irrigation, epidurally, intratympanically, intracisternally, intravascularly, intraventricularly, intraosseously, via irrigation of infected bone, or via application as part of any admixture with a prosthetic device. The method of administration can vary depending on various factors, e.g., the components of the pharmaceutical composition, the site of the disease, the disease involved, and the severity of the disease.

[049] A “diagnostic” as used herein is a compound, method, system, or device that assists in the identification or characterization of a health or disease state. The diagnostic can be used in standard assays as is known in the art.

[050] The term “mammal” is used in its usual biological sense. Thus, it specifically includes humans, cattle, horses, monkeys, dogs, cats, mice, rats, cows, sheep, pigs, goats, and non-human primates, but also includes many other species.

[051] The terms “pharmaceutically acceptable carrier”, “pharmaceutically acceptable diluent” and “pharmaceutically acceptable excipient” include any and all solvents, co-

solvents, complexing agents, dispersion media, coatings, isotonic and absorption delaying agents and the like which are not biologically or otherwise undesirable. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions. In addition, various adjuvants such as are commonly used in the art may be included. These and other such compounds are described in the literature, e.g., in the Merck Index, Merck & Company, Rahway, NJ. Considerations for the inclusion of various components in pharmaceutical compositions are described, e.g., in Gilman *et al.* (Eds.) (2010); Goodman and Gilman's: The Pharmacological Basis of Therapeutics, 12th Ed., The McGraw-Hill Companies.

[052] The term “pharmaceutically acceptable salt” refers to salts that retain the biological effectiveness and properties of the compounds provided herein and, which are not biologically or otherwise undesirable. In many cases, the compounds provided herein are capable of forming acid and/or base salts by virtue of the presence of amino and/or carboxyl groups or groups similar thereto. Many such salts are known in the art, for example, as described in WO 87/05297. Pharmaceutically acceptable acid addition salts can be formed with inorganic acids and organic acids. Inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like. Organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like. Pharmaceutically acceptable base addition salts can be formed with inorganic and organic bases. Inorganic bases from which salts can be derived include, for example, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum, and the like; particularly preferred are the ammonium, potassium, sodium, calcium, and magnesium salts. Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, basic ion exchange resins, and the like, specifically such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, and ethanolamine.

[053] “Patient” as used herein, means a human or a non-human mammal, e.g., a dog, a cat, a mouse, a rat, a cow, a sheep, a pig, a goat, a non-human primate, or a bird, e.g., a chicken, as well as any other vertebrate or invertebrate. In some embodiments, the patient is a human.

[054] A “therapeutically effective amount” of a compound as provided herein is one which is sufficient to achieve the desired physiological effect and may vary according to the nature

and severity of the disease condition, and the potency of the compound. “Therapeutically effective amount” is also intended to include one or more of the compounds of Formula **I** in combination with one or more other agents that are effective to treat the diseases and/or conditions described herein. The combination of compounds can be a synergistic combination. Synergy, as described, for example, by Chou and Talalay, *Advances in Enzyme Regulation* (1984), 22, 27-55, occurs when the effect of the compounds when administered in combination is greater than the additive effect of the compounds when administered alone as a single agent. In general, a synergistic effect is most clearly demonstrated at sub-optimal concentrations of the compounds. It will be appreciated that different concentrations may be employed for prophylaxis than for treatment of an active disease. This amount can further depend upon the patient’s height, weight, sex, age, and medical history.

[055] A therapeutic effect relieves, to some extent, one or more of the symptoms of the disease.

[056] “Treat,” “treatment,” or “treating,” as used herein refers to administering a compound or pharmaceutical composition as provided herein for therapeutic purposes. The term “therapeutic treatment” refers to administering treatment to a patient already suffering from a disease thus causing a therapeutically beneficial effect, such as ameliorating existing symptoms, ameliorating the underlying metabolic causes of symptoms, postponing, or preventing the further development of a disorder, and/or reducing the severity of symptoms that will or are expected to develop.

[057] “Drug-eluting” and/or controlled release as used herein refers to any and all mechanisms, e.g., diffusion, migration, permeation, and/or desorption by which the drug(s) incorporated in the drug-eluting material pass therefrom over time into the surrounding body tissue.

[058] “Drug-eluting material” and/or controlled release material as used herein refers to any natural, synthetic, or semi-synthetic material capable of acquiring and retaining a desired shape or configuration and into which one or more drugs can be incorporated and from which incorporated drug(s) are capable of eluting over time.


[059] “Elutable drug” as used herein refers to any drug or combination of drugs having the ability to pass over time from the drug-eluting material in which it is incorporated into the surrounding areas of the body.

Compounds

[060] The compounds and compositions described herein can be used to inhibit DYRK1A for treating a disorder or disease in which DYRK1A overexpression is implicated, such

as in neurological diseases or disorders, cancers, cognitive deficits, knee osteoarthritis, tendinopathy, viral infections, unicellular parasite infections, and motor deficits.

[061] Some embodiments of the present disclosure include compounds of Formula I:





I

or salts, pharmaceutically acceptable salts, or prodrugs thereof.


[062] In some embodiments of Formula I, R¹ is heteroaryl optionally substituted with 1-10 R³. In some embodiments, R¹ is heteroaryl optionally substituted with 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, or 1 R³.

[063] In some embodiments of Formula I, R¹ is selected from the heteroaryl group consisting of:




and , optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R³.


[064] In some embodiments of Formula I, R¹ is selected from the heteroaryl group consisting of:




[065] In some embodiments of Formula I, R¹ is selected from the heteroaryl group consisting of:



[066] In some embodiments of Formula I, R¹ is selected from the group consisting of:



[067] The compound according to any one of claims 1-3, wherein R¹ is selected from the group consisting of:



[068] In some embodiments of Formula I, R² is selected from the group consisting of unsubstituted -(C₁₋₉ alkyl), unsubstituted -(C₂₋₉ alkenyl), unsubstituted -(C₂₋₉ alkynyl), unsubstituted -(C₁₋₉ haloalkyl), -(C₁₋₃ alkylene)_pOR⁴, -(C₁₋₅ alkylene)_pheterocyclyl optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R⁵, -heteroaryl optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R⁶, and -(C₁₋₅ alkylene)_pcarbocyclyl optionally substituted with 1-12 (e.g., 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-

4, 1-3, 1-2, 1) R^7 , wherein each $-(C_{1-5} \text{ alkylene})$ is, independently, optionally substituted with 1-5 (e.g., 1-4, 1-3, 1-2, 1) halide (e.g., F, Cl, Br, I) and/or 1-3 (e.g., 1-2, 1) unsubstituted $-(C_{1-3} \text{ alkyl})$.

[069] In some embodiments of Formula I, R^2 is selected from the group consisting of unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, unsubstituted $-(C_{1-9} \text{ haloalkyl})$, $-(C_{1-5} \text{ alkylene})_pOR^4$, $-(C_{1-5} \text{ alkylene})_p\text{heterocyclyl}$ optionally substituted with 1-10 R^5 , $-\text{heteroaryl}$ optionally substituted with 1-10 R^6 , and $-(C_{1-5} \text{ alkylene})_p\text{carbocyclyl}$ optionally substituted with 1-12 R^7 , wherein each $-(C_{1-5} \text{ alkylene})$ is, independently, optionally substituted with 1-5 halide and/or 1-3 unsubstituted $-(C_{1-3} \text{ alkyl})$.


[070] In some embodiments of Formula I, R^2 is selected from the group consisting of unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{1-9} \text{ haloalkyl})$, $-(C_{1-5} \text{ alkylene})_p\text{heterocyclyl}$ optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R^5 , $-\text{heteroaryl}$ optionally substituted with 1-10 R^6 , and $-(C_{1-5} \text{ alkylene})_p\text{carbocyclyl}$ optionally substituted with 1-12 (e.g., 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R^7 , wherein each $-(C_{1-5} \text{ alkylene})$ is, independently, optionally substituted with 1-5 (e.g., 1-4, 1-3, 1-2, 1) halide (e.g., F, Cl, Br, I) and/or 1-3 (e.g., 1-2, 1) unsubstituted $-(C_{1-3} \text{ alkyl})$.


[071] In some embodiments of Formula I, R^2 is selected from the group consisting of unsubstituted $-(C_{1-5} \text{ alkyl})$, unsubstituted $-(C_{1-5} \text{ haloalkyl})$, $-(C_{1-2} \text{ alkylene})_p\text{heterocyclyl}$ optionally substituted with 1-3 (e.g., 1-2, 1) R^5 , and $-(C_{1-2} \text{ alkylene})_p\text{carbocyclyl}$ optionally substituted with 1-3 (e.g., 1-2, 1) R^7 , wherein each $-(C_{1-5} \text{ alkylene})$ is, independently, optionally substituted with 1-2 halide.

[072] In some embodiments of Formula I, R^2 is selected from the group consisting of unsubstituted $-(C_{1-5} \text{ alkyl})$, unsubstituted $-(C_{2-5} \text{ alkenyl})$, unsubstituted $-(C_{2-5} \text{ alkynyl})$, unsubstituted $-(C_{1-5} \text{ haloalkyl})$, $-(C_{1-2} \text{ alkylene})_pOR^4$, $-(C_{1-2} \text{ alkylene})_p\text{heterocyclyl}$ optionally substituted with 1-3 R^5 , $-\text{heteroaryl}$ optionally substituted with 1-3 R^6 , and $-(C_{1-2} \text{ alkylene})_p\text{carbocyclyl}$ optionally substituted with 1-3 R^7 , wherein each $-(C_{1-2} \text{ alkylene})$ is, independently, optionally substituted with 1-2 halide.

[073] In some embodiments of Formula I, R^2 is $-(C_{1-2} \text{ alkylene})_p\text{heterocyclyl}$ optionally substituted with 1-3 R^5 , wherein the $-(C_{1-5} \text{ alkylene})$ is optionally substituted with 1-2 halide and wherein the heterocyclyl is selected from the group consisting of oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, azetidiny, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, oxaspiro[3.3]heptanyl, and oxaspiro[3.3]heptanyl.


[074] In some embodiments of Formula I, R^2 is selected from the group consisting






of F, Me, $-\text{CH}_2\text{F}$, $-\text{CHF}_2$, $-\text{CF}_3$, $-\text{CH}_2\text{OH}$, $-\text{CH}_2\text{OMe}$, $-\text{OH}$, $-\text{OMe}$, $-\text{OEt}$, $-\text{OCD}_3$, $-\text{OCF}_3$, $-\text{OCH}_2\text{CH}_2\text{F}$, $-\text{OCH}_2\text{CHF}_2$, $-\text{OCH}_2\text{CF}_3$, $-\text{OCH}_2\text{CH}_2\text{OMe}$, $-\text{OCH}_2\text{CH}_2\text{OH}$, $-\text{NH}_2$, $-\text{NHMe}$, and $-\text{NMe}_2$.

[075] In some embodiments of Formula I, R^2 is selected from the group consisting




[076] In some embodiments of Formula I, R^2 is selected from the group consisting



$-\text{CH}_2\text{CHF}_2$, $-\text{CH}_2\text{CF}_3$, $-\text{CH}_2\text{CH}_2\text{CF}_3$, $-\text{CH}_2\text{CH}_2\text{OMe}$, $-\text{CH}_2\text{CH}_2\text{OH}$, $-\text{C}(=\text{O})\text{Me}$, $-\text{C}(=\text{O})\text{Et}$, $-\text{C}(=\text{O})\text{iPr}$, , and $-\text{SO}_2\text{Me}$; with the proviso that F, $-\text{OH}$, $-\text{OMe}$, $-\text{OEt}$, $-\text{OCD}_3$, and $-\text{OCF}_3$ are not attached to N.

[077] In some embodiments of Formula I, R^2 is selected from the group consisting



, wherein each R^7 is independently selected from the group consisting of F, Me, iBu, $-\text{OH}$, $-\text{OMe}$, $-\text{CH}_2\text{CH}_2\text{F}$, $-\text{CH}_2\text{CHF}_2$, $-\text{CH}_2\text{CF}_3$, $-\text{CH}_2\text{CH}_2\text{CF}_3$, $-\text{CH}_2\text{CH}_2\text{OMe}$, $-\text{CH}_2\text{CH}_2\text{OH}$, $-\text{C}(=\text{O})\text{Me}$, $-\text{C}(=\text{O})\text{Et}$, and $-\text{C}(=\text{O})\text{iPr}$; with the proviso that F, $-\text{OH}$, $-\text{OMe}$ are not attached to N.

[078] In some embodiments of Formula I, R^2 is $-\text{heteroaryl}$ optionally substituted with 1-2 R^6 , wherein the heteroaryl is pyrazolyl.

[079] In some embodiments of Formula I, R^2 is $-(\text{C}_{1-2} \text{ alkylene})_p\text{carbocyclyl}$ optionally substituted with 1-3 R^7 , wherein the $-(\text{C}_{1-5} \text{ alkylene})$ is optionally substituted with 1-2 halide and wherein the carbocyclyl is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and spiro[3.3]heptanyl.

[080] In some embodiments of Formula I, each R^3 is independently selected from the group consisting of halide (e.g., F, Cl, Br, I), unsubstituted $-(\text{C}_{1-9} \text{ alkyl})$, unsubstituted $-(\text{C}_{2-9} \text{ alkenyl})$, unsubstituted $-(\text{C}_{2-9} \text{ alkynyl})$, unsubstituted $-(\text{C}_{1-9} \text{ haloalkyl})$, $-(\text{C}_{1-5} \text{ alkylene})_p\text{OR}^8$, $-\text{heterocyclyl}$ optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R^9 , $-\text{carbocyclyl}$ optionally substituted with 1-12 (e.g., 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R^{10} , $-\text{C}(=\text{O})\text{N}(\text{R}^{11})_2$, and $-\text{C}(=\text{O})\text{R}^{12}$, wherein the $-(\text{C}_{1-5} \text{ alkylene})$ is optionally substituted with 1-5 (e.g., 1-4, 1-3, 1-2, 1) halide (e.g., F, Cl, Br, I) and/or 1-3 (e.g., 1-2, 1) unsubstituted $-(\text{C}_{1-3} \text{ alkyl})$.

[081] In some embodiments of Formula I, each R^3 is independently selected from the group consisting of halide, unsubstituted $-(\text{C}_{1-9} \text{ alkyl})$, unsubstituted $-(\text{C}_{2-9} \text{ alkenyl})$,

unsubstituted $-(C_{2-9} \text{ alkynyl})$, unsubstituted $-(C_{1-9} \text{ haloalkyl})$, $-(C_{1-5} \text{ alkylene})_pOR^8$, $-(C_{1-5} \text{ alkylene})CN$, $-(C_{1-5} \text{ alkylene})_p\text{heterocyclyl}$ optionally substituted with 1-10 R^9 , $-\text{carbocyclyl}$ optionally substituted with 1-12 R^{10} , $-(C_{1-5} \text{ alkylene})_p\text{heteroaryl}$ optionally substituted with 1-10 R^{19} , $-(C_{1-5} \text{ alkylene})_pC(=O)N(R^{11})_2$, and $-C(=O)R^{12}$, wherein each $-(C_{1-5} \text{ alkylene})$ is, independently, optionally substituted with 1-5 halide and/or 1-3 unsubstituted $-(C_{1-3} \text{ alkyl})$.

[082] In some embodiments of Formula I, each R^3 is independently selected from the group consisting of halide (e.g., F, Cl, Br, I), unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{1-9} \text{ haloalkyl})$, $-(C_{1-5} \text{ alkylene})_pOR^8$, $-\text{heterocyclyl}$ optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R^9 , $-\text{carbocyclyl}$ optionally substituted with 1-12 (e.g., 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R^{10} , and $-C(=O)R^{12}$, wherein the $-(C_{1-5} \text{ alkylene})$ is optionally substituted with 1-5 (e.g., 1-4, 1-3, 1-2, 1) halide (e.g., F, Cl, Br, I) and/or 1-3 (e.g., 1-2, 1) unsubstituted $-(C_{1-3} \text{ alkyl})$.

[083] In some embodiments of Formula I, each R^3 is independently selected from the group consisting of halide, unsubstituted $-(C_{1-5} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-5} \text{ alkynyl})$, unsubstituted $-(C_{1-5} \text{ haloalkyl})$, $-(C_{1-4} \text{ alkylene})_pOR^8$, $-(C_{1-2} \text{ alkylene})_pOR^8$, $-(C_{1-4} \text{ alkylene})CN$, $-(C_{1-2} \text{ alkylene})CN$, $-(C_{1-2} \text{ alkylene})_p\text{heterocyclyl}$ optionally substituted with 1-2 R^9 , $-\text{carbocyclyl}$ optionally substituted with 1-2 R^{10} , $-(C_{1-2} \text{ alkylene})_p\text{heteroaryl}$ optionally substituted with 1-2 R^{19} , $-(C_{1-2} \text{ alkylene})_pC(=O)N(R^{11})_2$, and $-C(=O)R^{12}$, wherein each $-(C_{1-2} \text{ alkylene})$ or $-(C_{1-4} \text{ alkylene})$ is, independently, optionally substituted with 1-2 halide.

[084] In some embodiments of Formula I, each R^3 is independently selected from the group consisting of F, Cl, unsubstituted $-(C_{1-5} \text{ alkyl})$, unsubstituted $-(C_{1-5} \text{ haloalkyl})$, $-(C_{1-4} \text{ alkylene})_pOH$, $-(C_{1-2} \text{ alkylene})_pOMe$, $-(C_{1-4} \text{ alkylene})CN$, $-(C_{1-2} \text{ alkylene})CN$, $-(CH_2)_p\text{heterocyclyl}$ optionally substituted with 1-2 R^9 , $-\text{carbocyclyl}$ optionally substituted with 1-2 R^{10} , $-(CH_2)_p\text{heteroaryl}$ optionally substituted with 1-2 R^{19} , $-(CH_2)C(=O)N(Me)_2$, and $-C(=O)R^{12}$, wherein each $-(C_{1-2} \text{ alkylene})$ or $-(C_{1-4} \text{ alkylene})$ is, independently, optionally substituted with 1-2 halide.

[085] In some embodiments of Formula I, each R^3 is independently selected from the group consisting of halide (e.g., F, Cl, Br, I), unsubstituted $-(C_{1-4} \text{ alkyl})$, unsubstituted $-(C_{1-4} \text{ haloalkyl})$, $-\text{heterocyclyl}$ optionally substituted with 1-3 (e.g., 1-2, 1) R^9 , and $-\text{carbocyclyl}$ optionally substituted with 1-3 (e.g., 1-2, 1) R^{10} .

[086] In some embodiments of Formula I, each R^3 is independently selected from the group consisting of halide, unsubstituted $-(C_{1-3} \text{ alkyl})$, unsubstituted $-(C_{1-3} \text{ haloalkyl})$, $-(C_{1-3}$

alkylene)_pOR⁸, –heterocyclyl optionally substituted with 1-2 R⁹, –carbocyclyl optionally substituted with 1-2 R¹⁰, and –C(=O)R¹².

[087] In some embodiments of Formula I, each R³ is independently selected from the group consisting of chloro, methyl, ethyl, isopropyl, 2-fluoroethyl, 2,2-difluoroethyl, methoxy, methoxymethyl, tetrahydropyranyl, difluorocyclobutyl, and (pyrrolidin-1-yl)methanone.

[088] In some embodiments of Formula I, each R⁴ is independently selected from the group consisting of unsubstituted –(C₁₋₉ alkyl), unsubstituted –(C₂₋₉ alkenyl), unsubstituted –(C₂₋₉ alkynyl), and unsubstituted –(C₁₋₉ haloalkyl).

[089] In some embodiments of Formula I, each R⁴ is independently selected from the group consisting of H, unsubstituted –(C₁₋₉ alkyl), unsubstituted –(C₂₋₉ alkenyl), unsubstituted –(C₂₋₉ alkynyl), and unsubstituted –(C₁₋₉ haloalkyl).

[090] In some embodiments of Formula I, each R⁴ is independently selected from the group consisting of H, unsubstituted –(C₁₋₅ alkyl), unsubstituted –(C₂₋₅ alkenyl), unsubstituted –(C₂₋₅ alkynyl), and unsubstituted –(C₁₋₅ haloalkyl).

[091] In some embodiments of Formula I, each R⁴ is independently selected from the group consisting of H, unsubstituted –(C₁₋₃ alkyl), and unsubstituted –(C₁₋₃ haloalkyl).

[092] In some embodiments of Formula I, each R⁵ is independently selected from the group consisting of halide (e.g., F, Cl, Br, I), unsubstituted –(C₁₋₉ alkyl), unsubstituted –(C₂₋₉ alkenyl), unsubstituted –(C₂₋₉ alkynyl), unsubstituted –(C₁₋₉ haloalkyl), and –OMe.

[093] In some embodiments of Formula I, each R⁵ is independently selected from the group consisting of halide, unsubstituted –(C₁₋₉ alkyl), unsubstituted –(C₂₋₉ alkenyl), unsubstituted –(C₂₋₉ alkynyl), unsubstituted –(C₁₋₉ haloalkyl), –heterocyclyl optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R¹⁵, –(C₁₋₅ alkylene)_pOR²⁰, –SO₂R²², and –C(=O)R²³, wherein the –(C₁₋₅ alkylene) is optionally substituted with 1-5 halide and/or 1-3 unsubstituted –(C₁₋₃ alkyl).

[094] In some embodiments of Formula I, each R⁵ is independently selected from the group consisting of F, Cl, unsubstituted –(C₁₋₅ alkyl), unsubstituted –(C₁₋₅ haloalkyl), –heterocyclyl optionally substituted with 1-2 R¹⁵, –(C₁₋₂ alkylene)_pOR²⁰, –SO₂R²², and –C(=O)R²³, wherein the –(C₁₋₂ alkylene) is optionally substituted with 1-2 halide.

[095] In some embodiments of Formula I, each R⁵ is independently selected from the group consisting of F, Cl, unsubstituted –(C₁₋₅ alkyl), unsubstituted –(C₁₋₅ haloalkyl), –heterocyclyl optionally substituted with 1-2 R¹⁵, –OH, –OMe, –SO₂Me, and –C(=O)R²³.

[096] In some embodiments of Formula I, two R⁵ attached to the same carbon atom are taken together to form a carbonyl group.

[0097] In some embodiments of Formula I, each R^6 is independently selected from the group consisting of halide (e.g., F, Cl, Br, I), unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, unsubstituted $-(C_{1-9} \text{ haloalkyl})$, and $-OMe$.

[0098] In some embodiments of Formula I, each R^6 is independently selected from the group consisting of F, Cl, Me, CF_3 , and $-OMe$.

[0099] In some embodiments of Formula I, each R^7 is independently selected from the group consisting of halide (e.g., F, Cl, Br, I), unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, unsubstituted $-(C_{1-9} \text{ haloalkyl})$, $-N(R^{13})_2$, $-(C_{1-5} \text{ alkylene})_pOR^{14}$, and $-\text{heterocyclyl}$ optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R^{15} , wherein $-(C_{1-5} \text{ alkylene})$ is optionally substituted with 1-5 (e.g., 1-4, 1-3, 1-2, 1) halide (e.g., F, Cl, Br, I) and/or 1-3 (e.g., 1-2, 1) unsubstituted $-(C_{1-3} \text{ alkyl})$.

[0100] In some embodiments of Formula I, each R^7 is independently selected from the group consisting of halide, unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, unsubstituted $-(C_{1-9} \text{ haloalkyl})$, $-N(R^{13})_2$, $-(C_{1-5} \text{ alkylene})_pOR^{14}$, $-(C_{1-5} \text{ alkylene})_p\text{heterocyclyl}$ optionally substituted with 1-10 R^{15} , $-C(=O)R^{21}$, and $-NHC(=O)R^{22}$, wherein each $-(C_{1-5} \text{ alkylene})$ is, independently, optionally substituted with 1-5 halide and/or 1-3 unsubstituted $-(C_{1-3} \text{ alkyl})$.

[0101] In some embodiments of Formula I, each R^7 is independently selected from the group consisting of halide, unsubstituted $-(C_{1-5} \text{ alkyl})$, unsubstituted $-(C_{2-5} \text{ alkenyl})$, unsubstituted $-(C_{2-5} \text{ alkynyl})$, unsubstituted $-(C_{1-5} \text{ haloalkyl})$, $-N(R^{13})_2$, $-(C_{1-2} \text{ alkylene})_pOR^{14}$, $-(C_{1-2} \text{ alkylene})_p\text{heterocyclyl}$ optionally substituted with 1-2 R^{15} , $-C(=O)R^{21}$, and $-NHC(=O)R^{22}$, wherein each $-(C_{1-2} \text{ alkylene})$ is, independently, optionally substituted with 1-2 halide.

[0102] In some embodiments of Formula I, each R^8 is independently selected from the group consisting of H, unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, and unsubstituted $-(C_{1-9} \text{ haloalkyl})$.

[0103] In some embodiments of Formula I, each R^9 is independently selected from the group consisting of halide (e.g., F, Cl, Br, I), unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, and unsubstituted $-(C_{1-9} \text{ haloalkyl})$.

[0104] In some embodiments of Formula I, each R^{10} is independently selected from the group consisting of halide (e.g., F, Cl, Br, I), unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, and unsubstituted $-(C_{1-9} \text{ haloalkyl})$.

[0105] In some embodiments of Formula I, each R^{11} is independently selected from the group consisting of H, unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, and unsubstituted $-(C_{1-9} \text{ haloalkyl})$, $-(C_{1-5} \text{ alkylene})_p\text{carbocyclyl}$ optionally

substituted with 1-12 (e.g., 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R¹⁶, –heterocyclyl optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R¹⁷, and –heteroaryl optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R¹⁸, wherein –(C₁₋₅ alkylene) is optionally substituted with 1-5 (e.g., 1-4, 1-3, 1-2, 1) halide (e.g., F, Cl, Br, I) and/or 1-3 (e.g., 1-2, 1) unsubstituted –(C₁₋₃ alkyl).

[0106] In some embodiments of Formula I, each R¹² is –heterocyclyl optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R¹⁷.

[0107] In some embodiments of Formula I, each R¹³ is independently selected from the group consisting of H, unsubstituted –(C₁₋₉ alkyl), unsubstituted –(C₂₋₉ alkenyl), unsubstituted –(C₂₋₉ alkynyl), and unsubstituted –(C₁₋₉ haloalkyl).

[0108] In some embodiments of Formula I, each R¹⁴ is independently selected from the group consisting of H, unsubstituted –(C₁₋₉ alkyl), unsubstituted –(C₂₋₉ alkenyl), unsubstituted –(C₂₋₉ alkynyl), and unsubstituted –(C₁₋₉ haloalkyl).

[0109] In some embodiments of Formula I, each R¹⁴ is independently selected from the group consisting of H, unsubstituted –(C₁₋₉ alkyl), unsubstituted –(C₂₋₉ alkenyl), unsubstituted –(C₂₋₉ alkynyl), unsubstituted –(C₁₋₉ haloalkyl), and –(C₁₋₅ alkylene)_pOR²⁰.

[0110] In some embodiments of Formula I, each R¹⁵ is independently selected from the group consisting of halide (e.g., F, Cl, Br, I), unsubstituted –(C₁₋₉ alkyl), unsubstituted –(C₂₋₉ alkenyl), unsubstituted –(C₂₋₉ alkynyl), and unsubstituted –(C₁₋₉ haloalkyl).

[0111] In some embodiments of Formula I, two R¹⁵ attached to the same carbon atom are taken together to form a carbonyl group.

[0112] In some embodiments of Formula I, each R¹⁶ is independently selected from the group consisting of halide (e.g., F, Cl, Br, I), –OMe, unsubstituted –(C₁₋₉ alkyl), unsubstituted –(C₂₋₉ alkenyl), unsubstituted –(C₂₋₉ alkynyl), and unsubstituted –(C₁₋₉ haloalkyl).

[0113] In some embodiments of Formula I, each R¹⁷ is independently selected from the group consisting of halide (e.g., F, Cl, Br, I), unsubstituted –(C₁₋₉ alkyl), unsubstituted –(C₂₋₉ alkenyl), unsubstituted –(C₂₋₉ alkynyl), and unsubstituted –(C₁₋₉ haloalkyl).

[0114] In some embodiments of Formula I, each R¹⁸ is independently selected from the group consisting of halide (e.g., F, Cl, Br, I), unsubstituted –(C₁₋₉ alkyl), unsubstituted –(C₂₋₉ alkenyl), unsubstituted –(C₂₋₉ alkynyl), and unsubstituted –(C₁₋₉ haloalkyl).

[0115] In some embodiments of Formula I, each R¹⁹ is independently selected from the group consisting of halide (e.g., F, Cl, Br, I), unsubstituted –(C₁₋₉ alkyl), unsubstituted –(C₂₋₉ alkenyl), unsubstituted –(C₂₋₉ alkynyl), and unsubstituted –(C₁₋₉ haloalkyl).

[0116] In some embodiments of Formula I, each R^{20} is independently selected from the group consisting of H, unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, and unsubstituted $-(C_{1-9} \text{ haloalkyl})$.

[0117] In some embodiments of Formula I, each R^{21} is independently selected from the group consisting of $-\text{heterocyclyl}$ optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R^{17} , $-\text{N}(R^{11})_2$ and $-\text{OR}^{20}$.

[0118] In some embodiments of Formula I, each R^{22} is independently selected from the group consisting of unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, and unsubstituted $-(C_{1-9} \text{ haloalkyl})$.

[0119] In some embodiments of Formula I, each R^{22} is independently selected from the group consisting of unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, unsubstituted $-(C_{1-9} \text{ haloalkyl})$, and $-(C_{1-5} \text{ alkylene})_p \text{OR}^{20}$.

[0120] In some embodiments of Formula I, each R^{23} is independently selected from the group consisting of unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, unsubstituted $-(C_{1-9} \text{ haloalkyl})$, and $-\text{carbocyclyl}$ optionally substituted with 1-12 (e.g., 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R^{24} .







[0121] In some embodiments of Formula I, each R^{24} is independently selected from the group consisting of halide (e.g., F, Cl, Br, I), unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, and unsubstituted $-(C_{1-9} \text{ haloalkyl})$.

























[0122] In some embodiments of Formula I, each p is independently 0 or 1.

























[0123] In some embodiments of Formula I, each H atom is optionally, independently replaced by ^2H (D) (deuterium).






















[0124] Illustrative compounds of Formula I are shown in Table 1.



















Table 1.



















1		2		3	
4		5		6	



















7		8		9	
10		11		12	
13		14		15	
16		17		18	
19		20		21	
22		23		24	
25		26		27	
28		29		30	



















31		32		33	
34		35		36	
37		38		39	
40		41		42	
43		44		45	
46		47		48	
49		50		51	
52		53		54	






















55		56		57	
58		59		60	
61		62		63	
64		65		66	
67		68		69	
70		71		72	
73		74		75	

























76		77		78	
79		80		81	
82		83		84	
85		86		87	
88		89		90	
91		92		93	

94		95		96	
97		98		99	
100		101		102	
103		104		105	
106		107		108	
109		110		111	

























112		113		114	
115		116		117	
118		119		120	
121		122		123	
124		125		126	
127		128		129	

























130		131		132	
133		134		135	
136		137		138	
139		140		141	
142		143		144	
145		146		147	

148		149		150	
151		152		153	
154		155		156	
157		158		159	
160		161		162	
163		164		165	
166		167		168	

























169		170		171	
172		173		174	
175		176		177	
178		179		180	
181		182		183	
184		185		186	
187		188		189	
190		191		192	

193		194		195	
196		197		198	
199		200		201	
202		203		204	
205		206		207	
208		209		210	
211		212		213	
214		215		216	

217		218		219	
220		221		222	
223		224		225	
226		227		228	
229		230		231	
232		233		234	
235		236		237	
238		239		240	






















241		242		243	
244		245		246	
247		248		249	
250		251		252	
253		254		255	
256		257		258	
259		260		261	
262		263		264	

265		266		267	
268		269		270	
271		272		273	
274		275		276	
277		278		279	
280		281		282	
283		284		285	
286		287		288	

289		290		291	
292		293		294	
295		296		297	
298		299		300	
301		302		303	
304		305		306	
307		308		309	
310		311		312	

313		314		315	
316		317		318	
319		320		321	
322		323		324	
325		326		327	
328		329		330	
331		332		333	
334		335		336	

337		338		339	
340		341		342	
343		344		345	
346		347		348	
349		350		351	
352		353		354	
355		356		357	
358		359		360	

361		362		363	
364		365		366	
367		368		369	
370		371		372	
373		374		375	
376		377		378	
379		380		381	

382		383		384	
385		386		387	
388		389		390	
391		392		393	
394		395		396	
397		398		399	
400		401		402	
403		404		405	

406		407		408	
409		410		411	
412		413		414	
415		416		417	
418		419		420	
421		422		423	
424		425		426	
427		428		429	

430		431		432	
433		434		435	
436		437		438	
439		440		441	
442		443		444	
445		446		447	
448		449		450	
451		452		453	

454		455		456	
457		458		459	
460		461		462	
463		464		465	
466		467		468	
469		470		471	
472		473		474	
475		476		477	






















478		479		480	
481		482		483	
484		485		486	
487		488		489	
490		491		492	
493		494		495	
496		497		498	
499		500		501	

502		503		504	
505		506		507	
508		509		510	
511		512		513	
514		515		516	
517		518		519	
520		521		522	






















523		524		525	
526		527		528	
529		530		531	
532		533		534	
535		536		537	
538		539		540	
541		542		543	

544		545		546	
547		548		549	
550		551		552	
553		554		555	
556		557		558	
559		560		561	
562		563		564	

565		566		567	
568		569		570	
571		572		573	
574		575		576	
577		578		579	
580		581		582	
583		584		585	






















586		587		588	
589		590		591	
592		593		594	
595		596		597	
598		599		600	
601		602		603	
604		605		606	

607		608		609	
610		611		612	
613		614		615	
616		617		618	
619		620		621	
622		623		624	
625		626		627	

628		629		630	
631		632		633	
634		635		636	
637		638		639	
640		641		642	
643		644		645	
646		647		648	






















649		650		651	
652		653		654	
655		656		657	
658		659		660	
661		662		663	
664		665		666	

667		668		669	
670		671		672	
673		674		675	
676		677		678	
679		680		681	
682		683		684	
685		686		687	






















688		689		690	
691		692		693	
694		695		696	
697		698		699	
700		701		702	
703		704		705	
706		707		708	






















709		710		711	
712		713		714	
715		716		717	
718		719		720	
721		722		723	
724		725		726	
727		728		729	






















730		731		732	
733		734		735	
736		737		738	
739		740		741	
742		743		744	
745		746		747	
748		749		750	

751		752		753	
754		755		756	
757		758		759	
760		761		762	
763		764		765	
766		767		768	
769		770		771	

772		773		774	
775		776		777	
778		779		780	
781		782		783	
784		785		786	
787		788		789	
790		791		792	

793		794		795	
796		797		798	
799		800		801	
802		803		804	
805		806		807	
808		809		810	
811		812		813	

814		815		816	
817		818		819	
820		821		822	
823		824		825	
826		827		828	
829		830		831	
832		833		834	

835		836		837	
838		839		840	
841		842		843	
844		845		846	
847		848		849	
850		851		852	
853		854		855	

856		857		858	
859		860		861	
862		863		864	
865		866		867	
868		869		870	
871		872		873	
874		875		876	

877		878		879	
880		881		882	
883		884		885	
886		887		888	
889		890		891	
892		893		894	
895		896		897	

898		899		900	
901		902		903	
904		905		906	
907		908		909	
910		911		912	
913		914		915	
916		917		918	

919		920		921	
922		923		924	
925		926		927	
928		929		930	
931		932		933	
934		935		936	
937		938		939	






















940		941		942	
943		944		945	
946		947		948	
949		950		951	
952		953		954	
955		956		957	
958		959		960	

961		962		963	
964		965		966	
967		968		969	
970		971		972	
973		974		975	
976		977		978	
979		980		981	



















982		983		984	
985		986		987	
988		989		990	
991		992		993	
994		995		996	
997		998		999	
1000		1001		1002	

1003		1004		1005	
1006		1007		1008	
1009		1010		1011	
1012		1013		1014	
1015		1016		1017	
1018		1019		1020	
1021		1022		1023	

1024		1025		1026	
1027		1028		1029	
1030		1031		1032	
1033		1034		1035	
1036		1037		1038	
1039		1040		1041	
1042		1043		1044	

1045		1046		1047	
1048		1049		1050	
1051		1052		1053	
1054		1055		1056	
1057		1058		1059	
1060		1061		1062	
1063		1064		1065	

1066		1067		1068	
1069		1070		1071	
1072		1073		1074	
1075		1076		1077	
1078		1079		1080	
1081		1082		1083	

1084		1085		1086	
1087		1088		1089	
1090		1091		1092	
1093		1094		1095	
1096		1097		1098	
1099		1100		1101	






















1102		1103		1104	
1105		1106		1107	
1108		1109		1110	
1111		1112		1113	
1114		1115		1116	
1117		1118		1119	
1120		1121		1122	






















1123		1124		1125	
1126		1127		1128	
1129		1130		1131	
1132		1133		1134	
1135		1136		1137	
1138		1139		1140	
1141		1142		1143	

1144		1145		1146	
1147		1148		1149	
1150		1151		1152	
1153		1154		1155	
1156		1157		1158	
1159		1160		1161	
1162		1163		1164	






















1165		1166		1167	
1168		1169		1170	
1171		1172		1173	
1174		1175		1176	
1177		1178		1179	
1180		1181		1182	
1183		1184		1185	






















1186		1187		1188	
1189		1190		1191	
1192		1193		1194	
1195		1196		1197	
1198		1199		1200	
1201		1202		1203	
1204		1205		1206	

























1207		1208		1209	
1210		1211		1212	
1213		1214		1215	
1216		1217		1218	
1219		1220		1221	
1222		1223		1224	
1225		1226		1227	






















1228		1229		1230	
1231		1232		1233	
1234		1235		1236	
1237		1238		1239	
1240		1241		1242	
1243		1244		1245	
1246		1247		1248	






















1249		1250		1251	
1252		1253		1254	
1255		1256		1257	
1258		1259		1260	
1261		1262		1263	
1264		1265		1266	
1267		1268		1269	
1270		1271		1272	

























1273		1274		1275	
1276		1277		1278	
1279		1280		1281	
1282		1283		1284	
1285		1286		1287	
1288		1289		1290	
1291		1292		1293	






















1294		1295		1296	
1297		1298		1299	
1300		1301		1302	
1303		1304		1305	
1306		1307		1308	
1309		1310		1311	
1312		1313		1314	






















1315		1316		1317	
1318		1319		1320	
1321		1322		1323	
1324		1325		1326	
1327		1328		1329	
1330		1331		1332	
1333		1334		1335	
1336		1337		1338	

1339		1340		1341	
1342		1343		1344	
1345		1346		1347	
1348		1349		1350	
1351		1352		1353	
1354		1355		1356	
1357		1358		1359	






















1360		1361		1362	
1363		1364		1365	
1366		1367		1368	
1369		1370		1371	
1372		1373		1374	
1375		1376		1377	
1378		1379		1380	

1381		1382		1383	
1384		1385		1386	
1387		1388		1389	
1390		1391		1392	
1393		1394		1395	
1396		1397		1398	
1399		1400		1401	
1402		1403		1404	






















1405		1406		1407	
1408		1409		1410	
1411		1412		1413	
1414		1415		1416	
1417		1418		1419	
1420		1421		1422	
1423		1424		1425	

1426		1427		1428	
1429		1430		1431	
1432		1433		1434	
1435		1436		1437	
1438		1439		1440	
1441		1442		1443	
1444		1445		1446	






















1447		1448		1449	
1450		1451		1452	
1453		1454		1455	
1456		1457		1458	
1459		1460		1461	
1462		1463		1464	
1465		1466		1467	






















1468		1469		1470	
1471		1472		1473	
1474		1475		1476	
1477		1478		1479	
1480		1481		1482	
1483		1484		1485	
1486		1487		1488	

























1489		1490		1491	
1492		1493		1494	
1495		1496		1497	
1498		1499		1500	
1501		1502		1503	
1504		1505		1506	
1507		1508		1509	






















1510		1511		1512	
1513		1514		1515	
1516		1517		1518	
1519		1520		1521	
1522		1523		1524	
1525		1526		1527	
1528		1529		1530	






















1531		1532		1533	
1534		1535		1536	
1537		1538		1539	
1540		1541		1542	
1543		1544		1545	
1546		1547		1548	
1549		1550		1551	
1552		1553		1554	

























1555		1556		1557	
1558		1559		1560	
1561		1562		1563	
1564		1565		1566	
1567		1568		1569	
1570		1571		1572	
1573		1574		1575	






















1576		1577		1578	
1579		1580		1581	
1582		1583		1584	
1585		1586		1587	
1588		1589		1590	
1591		1592		1593	
1594		1595		1596	






















1597		1598		1599	
1600		1601		1602	
1603		1604		1605	
1606		1607		1608	
1609		1610		1611	
1612		1613		1614	
1615		1616		1617	
1618		1619		1620	






















1621		1622		1623	
1624		1625		1626	
1627		1628		1629	
1630		1631		1632	
1633		1634		1635	
1636		1637		1638	
1639		1640		1641	






















1642		1643		1644	
1645		1646		1647	
1648		1649		1650	
1651		1652		1653	
1654		1655		1656	
1657		1658		1659	
1660		1661		1662	






















1663		1664		1665	
1666		1667		1668	
1669		1670		1671	
1672		1673		1674	
1675		1676		1677	
1678		1679		1680	
1681		1682		1683	
1684		1685		1686	

1687		1688		1689	
1690		1691		1692	
1693		1694		1695	
1696		1697		1698	
1699		1700		1701	
1702		1703		1704	
1705		1706		1707	

1708		1709		1710	
1711		1712		1713	
1714		1715		1716	
1717		1718		1719	
1720		1721		1722	
1723		1724		1725	
1726		1727		1728	

1729		1730		1731	
1732		1733		1734	
1735		1736		1737	
1738		1739		1740	
1741		1742		1743	
1744		1745		1746	
1747		1748		1749	

1750		1751		1752	
1753		1754		1755	
1756		1757		1758	
1759		1760		1761	
1762		1763		1764	
1765		1766		1767	
1768		1769		1770	

1771		1772		1773	
1774		1775		1776	
1777		1778		1779	
1780		1781		1782	
1783		1784		1785	
1786		1787		1788	
1789		1790		1791	

1792		1793		1794	
1795		1796		1797	
1798		1799		1800	
1801		1802		1803	
1804		1805		1806	
1807		1808		1809	
1810		1811		1812	

1813		1814		1815	
1816		1817		1818	
1819		1820		1821	
1822		1823		1824	
1825		1826		1827	
1828		1829		1830	
1831		1832		1833	

1834		1835		1836	
1837		1838		1839	
1840		1841		1842	
1843		1844		1845	
1846		1847		1848	
1849		1850		1851	

1852		1853		1854	
1855		1856		1857	
1858		1859		1860	
1861		1862		1863	
1864		1865		1866	
1867		1868		1869	

1870		1871		1872	
1873		1874		1875	
1876		1877		1878	
1879		1880		1881	
1882		1883		1884	
1885		1886		1887	

1888		1889		1890	
1891		1892		1893	
1894		1895		1896	
1897		1898		1899	
1900		1901		1902	
1903		1904		1905	

1906		1907		1908	
1909		1910		1911	
1912		1913		1914	
1915		1916		1917	
1918		1919		1920	
1921		1922		1923	

1924		1925		1926	
1927		1928		1929	
1930		1931		1932	
1933		1934		1935	
1936		1937		1938	
1939		1940		1941	

1942		1943		1944	
1945		1946		1947	
1948		1949		1950	
1951		1952		1953	
1954		1955		1956	
1957		1958		1959	

1960		1961		1962	
1963		1964		1965	
1966		1967		1968	
1969		1970		1971	
1972		1973		1974	
1975		1976		1977	

1978		1979		1980	
1981		1982		1983	
1984		1985			

Administration and Pharmaceutical Compositions

[0125] Some embodiments include pharmaceutical compositions comprising: (a) a therapeutically effective amount of a compound provided herein, or its corresponding enantiomer, diastereoisomer or tautomer, or pharmaceutically acceptable salt; and (b) a pharmaceutically acceptable carrier.

[0126] The compounds provided herein may also be useful in combination (administered together or sequentially) with other known agents.

[0127] Non-limiting examples of diseases which can be treated with a combination of a compound of Formula (I) and another active agent are colorectal cancer, ovarian cancer, hepatocellular carcinoma, head and neck squamous cell carcinoma, acute lymphoblastic leukemia (ALL), pancreatic cancer, brain tumors, acute megakaryoblastic leukemia (AMKL), and osteoarthritis. For example, a compound of Formula (I) can be combined with one or more chemotherapeutic compounds.

[0128] In some embodiments, hepatocellular carcinoma can be treated with a combination of a compound of Formula (I) and one or more of the following drugs/therapies: sorafenib (Nexavar[®]); regorafenib (Stivarga[®], Regonix[®]), nivolumab (Opdivo[®]); lenvatinib (Lenvima[®]); Pembrolizumab (Keytruda[®]); cabozantinib (Cometriq[®], Cabometyx[®]); 5-fluorouracil (5-FU[®]); ramucirumab (Cyramza[®]); combination of gemcitabine and oxaliplatin (GEMOX). Other therapies that can be performed in combination with a compound of Formula (I) are i) transcatheter

arterial chemoembolization (TACE) in combination with doxorubicin (DOXIL[®]), cisplatin, or mitomycin C (Mitosol[®], Mutamycin[®], Jelmyto[®]); ii) low-dose brachytherapy.

[0129] In some embodiments, head and neck squamous cell carcinoma can be treated with a combination of a compound of Formula (I) and one or more of the following drugs/therapies: TransOral Robotic Surgery (TORS); TORS with radiation therapy; larotrectinib (Vitrakvi[®]); EGFR inhibitors, e.g., erlotinib (Tarceva[®]), osimertinib (Tagrisso[®]), neratinib (Nerlynx[®]), gefitinib (Iressa[®]), cetuximab (Erbix[®]), panitumumab (Vectibix[®]), dacomitinib (Vizimpro[®]), lapatinib (Tykerb[®]), necitumumab (Portrazza), and vandetanib (Caprelsa[®]).

[0130] In some embodiments, acute lymphoblastic leukemia (ALL) can be treated with a combination of a compound of Formula (I) and one or more of the following drugs/therapies: remission induction therapy; consolidation therapy; nelarabine (Arranon[®]); Asparaginase Erwinia Chrysanthemi (Erwinaze[®]); Asparaginase Erwinia Chrysanthemi (Recombinant)-rywn (Rylaze[®]); calaspargase Pegol-mknl (Asparlas[®]); inotuzumab ozogamicin (Besponsa[®]); blinatumomab (Blinicyto[®]); daunorubicin hydrochloride (Cerubidine[®]); clofarabine (Clolar[®]); cyclophosphamide; methotrexate sodium (Trexall[®]); cytarabine (Cytosar-U[®]); dasatinib (Sprycel[®]); dexamethasone; imatinib mesylate (Gleevec[®]); ponatinib hydrochloride (Iclusig[®]); mercaptopurine (Purinethol[®], Purixan[®]); tisagenlecleucel (Kymriah[®]); vincristine sulfate liposome (Marqibo[®]); pegaspargase (Oncaspar[®]); prednisone; daunorubicin hydrochloride (Rubidomycin[®]); and vincristine sulfate.

[0131] In some embodiments, pancreatic cancer can be treated with a combination of a compound of Formula (I) and one or more of the following drugs/therapies: ablation and embolization treatment; gemcitabine (Gemzar[®]); 5-fluorouracil (5-FU[®]); oxaliplatin (Eloxatin[®]); albumin-bound paclitaxel (Abraxane[®]); capecitabine (Xeloda[®]); cisplatin; irinotecan (Camptosar[®]); liposomal Irinotecan (Onivyde[®]); paclitaxel (Taxol[®]), and docetaxel (Taxotere[®]).

[0132] In some embodiments, brain tumors can be treated with a combination of a compound of Formula (I) and one or more of the following drugs/therapies: carmustine can be administered by way of a gliadel wafer; for glioblastoma and high-grade glioma, radiation therapy with daily low-dose temozolomide (Temodar[®]) followed by monthly doses of temozolomide after radiation therapy for 6 months to 1 year; lomustine (Gleostine[®]), procarbazine (Matulane[®]), and vincristine (Vincasar[®]), have been used along with radiation therapy; anti-angiogenesis therapy with bevacizumab (Avastin[®], Mvasi[®]); and targeted therapy using larotrectinib (Vitrakvi[®]).

[0133] In some embodiments, acute megakaryoblastic leukemia (AMKL) can be treated with a combination of a compound of Formula (I) and one or more of the following drugs/therapies: cytarabine (Cytosar-U[®]), etoposide (Vepesid[®]), and anthracycline drugs.

Anthracyclines include daunorubicin (Cerubidine[®]), idarubicin (Idamycin[®]), and mitoxantrone (Novantrone[®]).

[0134] In some embodiments, acute myeloid leukemia (AML) can be treated with a combination of a compound of Formula (I) and one or more of the following drugs/therapies: venetoclax and hypomethylating agents (e.g., decitabine, azacitidine), induction chemotherapy (cytarabine and an anthracycline (e.g., daunorubicin or idarubicin), all-trans-retinoic acid (ATRA) and either arsenic trioxide (ATO) monotherapy or an anthracycline), consolidation therapy (cytarabine).

[0135] In some embodiments, myelodysplastic syndrome (MDS) can be treated with a combination of a compound of Formula (I) and one or more of the following drugs/therapies: 5-azacytidine, decitabine, lenalidomide, and decitabine/cedazuridine (Inqovi[®]).

[0136] In some embodiments, colorectal cancer can be treated with a combination of a compound of Formula (I) and one or more of the following drugs: 5-Fluorouracil (5-FU), which can be administered with the vitamin-like drug leucovorin (also called folinic acid); capecitabine (XELODA[®]), irinotecan (CAMPOSTAR[®]), oxaliplatin (ELOXATIN[®]). Examples of combinations of these drugs which could be further combined with a compound of Formula (I) are FOLFOX (5-FU, leucovorin, and oxaliplatin), FOLFIRI (5-FU, leucovorin, and irinotecan), FOLFOXIRI (leucovorin, 5-FU, oxaliplatin, and irinotecan) and CapeOx (Capecitabine and oxaliplatin). For rectal cancer, chemo with 5-FU or capecitabine combined with radiation may be given before surgery (neoadjuvant treatment).

[0137] In some embodiments, ovarian cancer can be treated with a combination of a compound of Formula (I) and one or more of the following drugs: Topotecan, Liposomal doxorubicin (DOXIL[®]), Gemcitabine (GEMZAR[®]), Cyclophosphamide (CYTOXAN[®]), Vinorelbine (NAVELBINE[®]), Ifosfamide (IFEX[®]), Etoposide (VP-16), Altretamine (HEXALEN[®]), Capecitabine (XELODA[®]), Irinotecan (CPT-11, CAMPTOSAR[®]), Melphalan, Pemetrexed (ALIMTA[®]) and Albumin bound paclitaxel (nab-paclitaxel, ABRAXANE[®]). Examples of combinations of these drugs which could be further combined with a compound of Formula (I) are TIP (paclitaxel [Taxol], ifosfamide, and cisplatin), VeIP (vinblastine, ifosfamide, and cisplatin) and VIP (etoposide [VP-16], ifosfamide, and cisplatin). Ovarian cancer can also be treated with a combination of a compound of Formula (I) and immune checkpoint blockade (ICB) therapy.

[0138] In some embodiments, a compound of Formula (I) can be used to treat cancer in combination with any of the following methods: (a) Hormone therapy such as aromatase inhibitors, LHRH [luteinizing hormone-releasing hormone] analogs and inhibitors, and others; (b)

Ablation or embolization procedures such as radiofrequency ablation (RFA), ethanol (alcohol) ablation, microwave thermotherapy and cryosurgery (cryotherapy); (c) Chemotherapy using alkylating agents such as cisplatin and carboplatin, oxaliplatin, mechlorethamine, cyclophosphamide, chlorambucil and ifosfamide; (d) Chemotherapy using anti-metabolites such as azathioprine and mercaptopurine; (e) Chemotherapy using plant alkaloids and terpenoids such as vinca alkaloids (i.e. Vincristine, Vinblastine, Vinorelbine and Vindesine) and taxanes; (f) Chemotherapy using podophyllotoxin, etoposide, teniposide and docetaxel; (g) Chemotherapy using topoisomerase inhibitors such as irinotecan, topotecan, amsacrine, etoposide, etoposide phosphate, and teniposide; (h) Chemotherapy using cytotoxic antibiotics such as actinomycin, anthracyclines, doxorubicin, daunorubicin, valrubicin, idarubicin, epirubicin, bleomycin, plicamycin and mitomycin; (i) Chemotherapy using tyrosine-kinase inhibitors such as Imatinib mesylate (GLEEVEC[®], also known as STI-571), Gefitinib (Iressa, also known as ZD1839), Erlotinib (marketed as TARCEVA[®]), Bortezomib (VELCADE[®]), tamoxifen, tofacitinib, crizotinib, Bcl-2 inhibitors (e.g. obatoclax, navitoclax (ABT-263), oblimersen (G3139), venetoclax (ABT-199), Gossypol), PARP inhibitors (e.g. Iniparib, Olaparib, Rucaparib, Niraparib, Talazoparib), PI3K inhibitors (e.g. perifosine in a phase III trial), VEGF Receptor 2 inhibitors (e.g. Apatinib), AN-152, (AEZS-108), Braf inhibitors (e.g. vemurafenib, dabrafenib and LGX818), MEK inhibitors (e.g. trametinib and MEK162), CDK inhibitors, (e.g. PD-0332991), salinomycin and Sorafenib; (j) Chemotherapy using monoclonal antibodies such as Rituximab (marketed as MABTHERA[®] or RITUXAN[®]), Trastuzumab (Herceptin also known as ErbB2), Cetuximab (marketed as ERBITUX[®]), and Bevacizumab (marketed as AVASTIN[®]); (k) Chemotherapy using KRAS G12C inhibitors such as sotorasib (Lumakras[®] and Lumykras[®]), adagrasib (MRTX849), and ARS-3248 (Wellspring Biosciences); (l) Chemotherapy using checkpoint inhibitor therapy such as Ipilimumab (Yervoy[®]), Nivolumab (Opdivo[®]), Pembrolizumab (Keytruda[®]), Atezolizumab (Tecentriq[®]), Avelumab (Bavencio), Durvalumab (Imfinzi), Cemiplimab (Libtayo[®]), and Spartalizumab (PDR001); (m) Chemotherapy using antibody-drug conjugates (ADC) such as Gemtuzumab ozogamicin, Brentuximab vedotin, Trastuzumab emtansine, Inotuzumab ozogamicin, Polatuzumab vedotin, Enfortumab vedotin, Trastuzumab deruxtecan, Sacituzumab govitecan, Belantamab mafodotin, Moxetumomab pasudotox, and Loncastuximab tesirine; (n) Chemotherapy using proteasome inhibitors such as carfilzomib, lactacystin, disulfiram, salinosporamide A (marizomib), oprozomib, delanzomib, epoxomicin, MG132, β -hydroxy β -methylbutyric acid (HMB), bortezomib, ixazomib (alone or in combination with lenalidomide and dexamethasone); and (o) radiation therapy.

[0139] In some embodiments, a compound of Formula **I**, can be used to treat diabetes mellitus in combination with any of the following methods: **(a)** injections of insulin; **(b)** biguanides such as metformin (Glucophage), phenformin (DBI), and buformin; **(c)** thiazolidinediones (TZDs) such as rosiglitazone (Avandia), pioglitazone (Actos), and yroglitazone (Rezulin); **(d)** lyn kinase activators such as glimepiride (Amaryl®) and tolimidone (MLR-1023); **(e)** secretagogues such as sulfonylureas (non-limiting examples are acetohexamide, carbutamide, chlorpropamide, glycyclamide (tolcyclamide), metahexamide, tolazamide, tolbutamide, glibenclamide (glyburide), glibornuride, gliclazide, glipizide, gliquidone, glisoxepide, glyclopyramide, and glimepiride) and meglitinides (nonlimiting examples are repaglinide (Prandin), nateglinide (Starlix), and mitiglinide (Glufast)); **(f)** alpha-glucosidase inhibitors such as acarbose (Glucobay, Precose, Prandase), miglitol (Glyset), and voglibose; **(g)** injectable incretin mimetics such as glucagon-like peptide-1 (GLP-1) and gastric inhibitory peptide (glucose-dependent insulintropic peptide, GIP), nonlimiting examples of injectable glucagon-like peptide (GLP) analogs and agonists are exenatide (Exendin-4, marketed as Byetta), liraglutide (Victoza, Saxenda), taspoglutide, lixisenatide (Lyxumia), Semaglutide (Ozempic, Rybelsus), dulaglutide (Trulicity), albiglutide (Tanzeum), nonlimiting examples of dipeptidyl peptidase-4 (DPP-4) inhibitors are sitagliptin (Januvia), vildagliptin (Galvus), saxagliptin (Onglyza), linagliptin (Tradjenta), gemigliptin (Zemiglo), anagliptin (Suiny), teneligliptin (Tenelia), alogliptin (Nesina, Vipidia, Kazano, Vipidomet (with metformin), Oseni, Incresync (with pioglitazone)), trelagliptin (Zafatek, Wedica), omarigliptin (MK-3102), evogliptin (Suganon, Evodine), gosogliptin (Saterex), and dutogliptin; **(h)** injectable amylin analogues such as pramlintide (Symlin); **(i)** glycosurics (SGLT2 inhibitors) such as canagliflozin (Invokana, Sulisent, Prominad), dapagliflozin (Forxiga, Farxiga, Edistride), empagliflozin (Jardiance, Sciampa-M), ertugliflozin (Steglatro), ipragliflozin (Suglat), luseogliflozin (Lusefi), remogliflozin etabonate (pro-drug of remogliflozin), sergliflozin etabonate (GW869682X), sotagliflozin (Zynquista), and tofogliflozin (CSG452).

[0140] In some embodiments, a compound of Formula **(I)** can be used to treat osteoarthritis in combination with any of the following methods: **(d)** injections of a Wnt signaling pathway inhibitor (e.g. lorecivivint); **(a)** Nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, naproxen, aspirin and acetaminophen; **(b)** physical therapy; **(c)** injections of corticosteroid medications; **(d)** injections of hyaluronic acid derivatives (e.g. Hyalgan, Synvisc); **(e)** narcotics, like codeine; **(f)** in combination with braces and/or shoe inserts or any device that can immobilize or support your joint to help you keep pressure off it (e.g., splints, braces, shoe inserts or other medical devices); **(g)** realigning bones (osteotomy); **(h)** joint replacement (arthroplasty); and **(i)** in combination with a chronic pain class.

[0141] In some embodiments, a compound of Formula (I) can be used to treat Alzheimer's disease in combination with aducanumab (AduhelmTM); acetylcholinesterase inhibitors, e.g., tacrine, rivastigmine (Exelon[®]), galantamine (Razadyne[®] and GalantaMindTM), and donepezil (Aricept[®]); and memantine (Axura[®], Ebixa[®], Namenda[®]).

[0142] Administration of the compounds disclosed herein or the pharmaceutically acceptable salts thereof can be via any of the accepted modes of administration, including, but not limited to, orally, subcutaneously, intravenously, intranasally, topically, transdermally, intraperitoneally, intramuscularly, intrapulmonarily, vaginally, rectally, otologically, neuro-otologically, intraocularly, subconjunctivally, via anterior eye chamber injection, intravitreally, intraperitoneally, intrathecally, intracistically, intrapleurally, via wound irrigation, intrabuccally, intra-abdominally, intra-articularly, intra-aurally, intrabronchially, intracapsularly, intrameningeally, via inhalation, via endotracheal or endobronchial instillation, via direct instillation into pulmonary cavities, intraspinally, intrasynovially, intrathoracically, via thoracostomy irrigation, epidurally, intratympanically, intracisternally, intravascularly, intraventricularly, intraosseously, via irrigation of infected bone, or via application as part of any admixture with a prosthetic devices. In some embodiments, the administration method includes oral or parenteral administration.

[0143] Compounds provided herein intended for pharmaceutical use may be administered as crystalline or amorphous products. Pharmaceutically acceptable compositions may include solid, semi-solid, liquid, solutions, colloidal, liposomes, emulsions, suspensions, complexes, coacervates and aerosols. Dosage forms, such as, e.g., tablets, capsules, powders, liquids, suspensions, suppositories, aerosols, implants, controlled release, or the like. They may be obtained, for example, as solid plugs, powders, or films by methods such as precipitation, crystallization, milling, grinding, supercritical fluid processing, coacervation, complex coacervation, encapsulation, emulsification, complexation, freeze drying, spray drying, or evaporative drying. Microwave or radio frequency drying may be used for this purpose. The compounds can also be administered in sustained or controlled release dosage forms, including depot injections, osmotic pumps, pills (tablets and or capsules), transdermal (including electrotransport) patches, implants, and the like, for prolonged and/or timed, pulsed administration at a predetermined rate.

[0144] The compounds can be administered either alone or in combination with a conventional pharmaceutical carrier, excipient, or the like. Pharmaceutically acceptable excipients include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, self-emulsifying drug delivery systems (SEDDS) such as d- α -tocopherol polyethylene glycol 1000

succinate, surfactants used in pharmaceutical dosage forms such as Tweens, poloxamers or other similar polymeric delivery matrices, serum proteins, such as human serum albumin, buffer substances such as phosphates, tris, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium-chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethyl cellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, and wool fat. Cyclodextrins such as α -, β -, and γ -cyclodextrin, or chemically modified derivatives such as hydroxyalkylcyclodextrins, including 2- and 3-hydroxypropyl- β -cyclodextrins, or other solubilized derivatives can also be used to enhance delivery of compounds described herein. Dosage forms or compositions containing a compound as described herein in the range of 0.005% to 100% with the balance made up from non-toxic carrier may be prepared. The contemplated compositions may contain 0.001%-100% of a compound provided herein, in one embodiment 0.1-95%, in another embodiment 75-85%, in a further embodiment 20-80%. Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in this art; for example, see *Remington: The Science and Practice of Pharmacy*, 22nd Edition (Pharmaceutical Press, London, UK. 2012).

[0145] In one embodiment, the compositions will take the form of a unit dosage form such as a pill or tablet and thus the composition may contain, along with a compound provided herein, a diluent such as lactose, sucrose, dicalcium phosphate, or the like; a lubricant such as magnesium stearate or the like; and a binder such as starch, gum acacia, polyvinylpyrrolidone, gelatin, cellulose, cellulose derivatives, or the like. In another solid dosage form, a powder, marume, solution or suspension (*e.g.*, in propylene carbonate, vegetable oils, PEG's, poloxamer 124 or triglycerides) is encapsulated in a capsule (gelatin or cellulose base capsule). Unit dosage forms in which one or more compounds provided herein or additional active agents are physically separated are also contemplated; *e.g.*, capsules with granules (or tablets in a capsule) of each drug; two-layer tablets; two-compartment gel caps, etc. Enteric coated or delayed release oral dosage forms are also contemplated.

[0146] Liquid pharmaceutically administrable compositions can, for example, be prepared by dissolving, dispersing, etc. a compound provided herein and optional pharmaceutical adjuvants in a carrier (*e.g.*, water, saline, aqueous dextrose, glycerol, glycols, ethanol, or the like) to form a solution, colloid, liposome, emulsion, complexes, coacervate or suspension. If desired, the pharmaceutical composition can also contain minor amounts of nontoxic auxiliary substances such as wetting agents, emulsifying agents, co-solvents, solubilizing agents, pH buffering agents

and the like (e.g., sodium acetate, sodium citrate, cyclodextrin derivatives, sorbitan monolaurate, triethanolamine acetate, triethanolamine oleate, and the like).

[0147] In some embodiments, the unit dosage of compounds of Formula (I) is about 0.25 mg/Kg to about 50 mg/Kg in humans.

[0148] In some embodiments, the unit dosage of compounds of Formula (I) is about 0.25 mg/Kg to about 20 mg/Kg in humans.

[0149] In some embodiments, the unit dosage of compounds of Formula (I) is about 0.50 mg/Kg to about 19 mg/Kg in humans.

[0150] In some embodiments, the unit dosage of compounds of Formula (I) is about 0.75 mg/Kg to about 18 mg/Kg in humans.

[0151] In some embodiments, the unit dosage of compounds of Formula (I) is about 1.0 mg/Kg to about 17 mg/Kg in humans.

[0152] In some embodiments, the unit dosage of compounds of Formula (I) is about 1.25 mg/Kg to about 16 mg/Kg in humans.

[0153] In some embodiments, the unit dosage of compounds of Formula (I) is about 1.50 mg/Kg to about 15 mg/Kg in humans.

[0154] In some embodiments, the unit dosage of compounds of Formula (I) is about 1.75 mg/Kg to about 14 mg/Kg in humans.

[0155] In some embodiments, the unit dosage of compounds of Formula (I) is about 2.0 mg/Kg to about 13 mg/Kg in humans.

[0156] In some embodiments, the unit dosage of compounds of Formula (I) is about 3.0 mg/Kg to about 12 mg/Kg in humans.

[0157] In some embodiments, the unit dosage of compounds of Formula (I) is about 4.0 mg/Kg to about 11 mg/Kg in humans.

[0158] In some embodiments, the unit dosage of compounds of Formula (I) is about 5.0 mg/Kg to about 10 mg/Kg in humans.

[0159] In some embodiments, the compositions are provided in unit dosage forms suitable for single administration.

[0160] In some embodiments, the compositions are provided in unit dosage forms suitable for twice a day administration.

[0161] In some embodiments, the compositions are provided in unit dosage forms suitable for three times a day administration.

[0162] Injectables can be prepared in conventional forms, either as liquid solutions, colloid, liposomes, complexes, coacervate or suspensions, as emulsions, or in solid forms suitable

for reconstitution in liquid prior to injection. The percentage of a compound provided herein contained in such parenteral compositions is highly dependent on the specific nature thereof, as well as the activity of the compound and the needs of the patient. However, percentages of active ingredient of 0.01% to 10% in solution are employable and could be higher if the composition is a solid or suspension, which could be subsequently diluted to the above percentages.

[0163] In some embodiments, the composition comprises about 0.1-10% of the active agent in solution.

[0164] In some embodiments, the composition comprises about 0.1-5% of the active agent in solution.

[0165] In some embodiments, the composition comprises about 0.1-4% of the active agent in solution.

[0166] In some embodiments, the composition comprises about 0.15-3% of the active agent in solution.

[0167] In some embodiments, the composition comprises about 0.2-2% of the active agent in solution.

[0168] In some embodiments, the compositions are provided in dosage forms suitable for continuous dosage by intravenous infusion over a period of about 1-96 hours.

[0169] In some embodiments, the compositions are provided in dosage forms suitable for continuous dosage by intravenous infusion over a period of about 1-72 hours.

[0170] In some embodiments, the compositions are provided in dosage forms suitable for continuous dosage by intravenous infusion over a period of about 1-48 hours.

[0171] In some embodiments, the compositions are provided in dosage forms suitable for continuous dosage by intravenous infusion over a period of about 1-24 hours.

[0172] In some embodiments, the compositions are provided in dosage forms suitable for continuous dosage by intravenous infusion over a period of about 1-12 hours.

[0173] In some embodiments, the compositions are provided in dosage forms suitable for continuous dosage by intravenous infusion over a period of about 1-6 hours.

[0174] In some embodiments, these compositions can be administered by intravenous infusion to humans at doses of about 5 mg/m² to about 300 mg/m².

[0175] In some embodiments, these compositions can be administered by intravenous infusion to humans at doses of about 5 mg/m² to about 200 mg/m².

[0176] In some embodiments, these compositions can be administered by intravenous infusion to humans at doses of about 5 mg/m² to about 100 mg/m².

[0177] In some embodiments, these compositions can be administered by intravenous infusion to humans at doses of about 10 mg/m² to about 50 mg/m².

[0178] In some embodiments, these compositions can be administered by intravenous infusion to humans at doses of about 50 mg/m² to about 200 mg/m².

[0179] In some embodiments, these compositions can be administered by intravenous infusion to humans at doses of about 75 mg/m² to about 175 mg/m².

[0180] In some embodiments, these compositions can be administered by intravenous infusion to humans at doses of about 100 mg/m² to about 150 mg/m².

[0181] It is to be noted that concentrations and dosage values may also vary depending on the specific compound and the severity of the condition to be alleviated. It is to be further understood that for any particular patient, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and that the concentration ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed compositions.

[0182] In one embodiment, the compositions can be administered to the respiratory tract (including nasal and pulmonary) e.g., through a nebulizer, metered-dose inhalers, atomizer, mister, aerosol, dry powder inhaler, insufflator, liquid instillation or other suitable device or technique.

[0183] In some embodiments, aerosols intended for delivery to the nasal mucosa are provided for inhalation through the nose. For optimal delivery to the nasal cavities, inhaled particle sizes of about 5 to about 100 microns are useful, with particle sizes of about 10 to about 60 microns being preferred. For nasal delivery, a larger inhaled particle size may be desired to maximize impaction on the nasal mucosa and to minimize or prevent pulmonary deposition of the administered formulation. In some embodiments, aerosols intended for delivery to the lung are provided for inhalation through the nose or the mouth. For delivery to the lung, inhaled aerodynamic particle sizes of about less than 10 µm are useful (e.g., about 1 to about 10 microns). Inhaled particles may be defined as liquid droplets containing dissolved drug, liquid droplets containing suspended drug particles (in cases where the drug is insoluble in the suspending medium), dry particles of pure drug substance, drug substance incorporated with excipients, liposomes, emulsions, colloidal systems, coacervates, aggregates of drug nanoparticles, or dry particles of a diluent which contain embedded drug nanoparticles.

[0184] In some embodiments, compounds of Formula (I) disclosed herein intended for respiratory delivery (either systemic or local) can be administered as aqueous formulations, as

non-aqueous solutions, or suspensions, as suspensions or solutions in halogenated hydrocarbon propellants with or without alcohol, as a colloidal system, as emulsions, coacervates, or as dry powders. Aqueous formulations may be aerosolized by liquid nebulizers employing either hydraulic or ultrasonic atomization or by modified micropump systems (like the soft mist inhalers, the Aerodose[®] or the AERx[®] systems). Propellant-based systems may use suitable pressurized metered-dose inhalers (pMDIs). Dry powders may use dry powder inhaler devices (DPIs), which are capable of dispersing the drug substance effectively. A desired particle size and distribution may be obtained by choosing an appropriate device.

[0185] In some embodiments, the compositions of Formula (I) disclosed herein can be administered to the ear by various methods. For example, a round window catheter (e.g., U.S. Pat. Nos. 6,440,102 and 6,648,873) can be used.

[0186] Alternatively, formulations can be incorporated into a wick for use between the outer and middle ear (e.g., U.S. Pat. No. 6,120,484) or absorbed to collagen sponge or other solid support (e.g., U.S. Pat. No. 4,164,559).

[0187] If desired, formulations of the disclosure can be incorporated into a gel formulation (e.g., U.S. Pat. Nos. 4,474,752 and 6,911,211).

[0188] In some embodiments, compounds of Formula (I) disclosed herein intended for delivery to the ear can be administered via an implanted pump and delivery system through a needle directly into the middle or inner ear (cochlea) or through a cochlear implant stylet electrode channel or alternative prepared drug delivery channel such as but not limited to a needle through temporal bone into the cochlea.

[0189] Other options include delivery via a pump through a thin film coated onto a multichannel electrode or electrode with a specially imbedded drug delivery channel (pathways) carved into the thin film for this purpose. In other embodiments the acidic or basic solid compound of Formula (I) can be delivered from the reservoir of an external or internal implanted pumping system.

[0190] Formulations of the disclosure also can be administered to the ear by intratympanic injection into the middle ear, inner ear, or cochlea (e.g., U.S. Pat. No. 6,377,849 and Ser. No. 11/337,815).

[0191] Intratympanic injection of therapeutic agents is the technique of injecting a therapeutic agent behind the tympanic membrane into the middle and/or inner ear. In one embodiment, the formulations described herein are administered directly onto the round window membrane via transtympanic injection. In another embodiment, the ion channel modulating agent auris-acceptable formulations described herein are administered onto the round window membrane

via a non-transtympanic approach to the inner ear. In additional embodiments, the formulation described herein is administered onto the round window membrane via a surgical approach to the round window membrane comprising modification of the crista fenestrae cochleae.

[0192] In some embodiments, the compounds of Formula (I) are formulated in rectal compositions such as enemas, rectal gels, rectal foams, rectal aerosols, suppositories, jelly suppositories, or retention enemas, containing conventional suppository bases such as cocoa butter or other glycerides, as well as synthetic polymers such as polyvinylpyrrolidone, PEG (like PEG ointments), and the like.

[0193] Suppositories for rectal administration of the drug (either as a solution, colloid, suspension or a complex) can be prepared by mixing a compound provided herein with a suitable non-irritating excipient that is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt or erode/dissolve in the rectum and release the compound. Such materials include cocoa butter, glycerinated gelatin, hydrogenated vegetable oils, poloxamers, mixtures of polyethylene glycols of various molecular weights and fatty acid esters of polyethylene glycol. In suppository forms of the compositions, a low-melting wax such as, but not limited to, a mixture of fatty acid glycerides, optionally in combination with cocoa butter, is first melted.

[0194] Solid compositions can be provided in various different types of dosage forms, depending on the physicochemical properties of the compound provided herein, the desired dissolution rate, cost considerations, and other criteria. In one of the embodiments, the solid composition is a single unit. This implies that one unit dose of the compound is comprised in a single, physically shaped solid form or article. In other words, the solid composition is coherent, which is in contrast to a multiple unit dosage form, in which the units are incoherent.

[0195] Examples of single units which may be used as dosage forms for the solid composition include tablets, such as compressed tablets, film-like units, foil-like units, wafers, lyophilized matrix units, and the like. In one embodiment, the solid composition is a highly porous lyophilized form. Such lyophilizates, sometimes also called wafers or lyophilized tablets, are particularly useful for their rapid disintegration, which also enables the rapid dissolution of the compound.

[0196] On the other hand, for some applications the solid composition may also be formed as a multiple unit dosage form as defined above. Examples of multiple units are powders, granules, microparticles, pellets, mini-tablets, beads, lyophilized powders, and the like. In one embodiment, the solid composition is a lyophilized powder. Such a dispersed lyophilized system comprises a multitude of powder particles, and due to the lyophilization process used in the formation of the powder, each particle has an irregular, porous microstructure through which the

powder is capable of absorbing water very rapidly, resulting in quick dissolution. Effervescent compositions are also contemplated to aid the quick dispersion and absorption of the compound.

[0197] Another type of multiparticulate system which is also capable of achieving rapid drug dissolution is that of powders, granules, or pellets from water-soluble excipients which are coated with a compound provided herein so that the compound is located at the outer surface of the individual particles. In this type of system, the water-soluble low molecular weight excipient may be useful for preparing the cores of such coated particles, which can be subsequently coated with a coating composition comprising the compound and, for example, one or more additional excipients, such as a binder, a pore former, a saccharide, a sugar alcohol, a film-forming polymer, a plasticizer, or other excipients used in pharmaceutical coating compositions.

[0198] Also provided herein are kits. Typically, a kit includes one or more compounds or compositions as described herein. In certain embodiments, a kit can include one or more delivery systems, e.g., for delivering or administering a compound as provided herein, and directions for use of the kit (e.g., instructions for treating a patient). In another embodiment, the kit can include a compound or composition as described herein and a label that indicates that the contents are to be administered to a patient with cancer. In another embodiment, the kit can include a compound or composition as described herein and a label that indicates that the contents are to be administered to a patient with one or more of glioblastoma, ovarian, breast, pancreatic cancers, acute lymphoblastic leukemia, acute megakaryoblastic leukemia, chronic myeloid leukemia, Alzheimer's Disease, Amyotrophic Lateral Sclerosis, CDKL5 Deficiency Disorder, Down Syndrome, Frontotemporal Dementia with Parkinsonism-17 (FTDP-17), Lewy body dementia, Parkinson's Disease, Pick's Disease, Autism, Dementia, Epilepsy, Huntington's Disease, and Multiple Sclerosis.

Methods of Treatment

[0199] The compounds and compositions provided herein can be used as inhibitors of DYRK1A, and thus can be used to treat a variety of disorders and diseases in which over expression of DYRK1A is implicated, such as cancer and neurological conditions/disorders/diseases. Non-limiting examples of diseases which can be treated with the compounds and compositions provided herein include a variety of cancers, Alzheimer's Disease, Amyotrophic Lateral Sclerosis, CDKL5 Deficiency Disorder, Down Syndrome, Frontotemporal Dementia with Parkinsonism-17 (FTDP-17), Lewy body dementia, Parkinson's Disease, Pick's Disease, and additional diseases with pronounced neurodegeneration such as Autism, Dementia, Epilepsy, Huntington's Disease, Multiple Sclerosis; diseases and disorders associated with acquired brain injury such as Chronic

Traumatic Encephalopathy, Traumatic Brain Injury, Tumor, Stroke, tauopathies (e.g., Pick's disease, progressive supranuclear palsy, corticobasal degeneration, argyrophilic grain disease, globular glial tauopathies, primary age-related tauopathy, which includes neurofibrillary tangle dementia, chronic traumatic encephalopathy (CTE), frontotemporal lobar degeneration with tau inclusions (FTLD-tau), and aging-related tau astrogliopathy. Clinical symptoms include frontotemporal dementia, corticobasal syndrome, Richardson syndrome, parkinsonism, pure akinesia with gait freezing and, rarely, motor neuron symptoms or cerebellar ataxia, diabetes, psoriasis, knee osteoarthritis, tendinopathy, human immunodeficiency virus type 1 (HIV-1), human cytomegalovirus (HCMV), hepatitis C virus (HCV), and herpes simplex virus 1 (HSV-1).

[0200] The gene encoding DYRK1A is located on chromosome 21, within the Down syndrome critical region (DSCR), the triploidy of which is responsible for most Down syndrome-associated deficiencies (*FEBS Journal* (2011), 278, 246–256). There is considerable genetical and pharmacological evidence showing that the mere 1.5-fold overexpression of DYRK1A is responsible for most cognitive deficits observed in Down syndrome patients (*Pharmacology & Therapeutics* (2019), 194, 199–221 and *Brain Science* (2018), 8(10), 187). Genetical normalization of DYRK1A levels or pharmacological inhibition of its catalytic activity restores cognitive functions. The development of pharmacological inhibitors of DYRK1A is a major avenue for the treatment of cognitive deficits associated with Down syndrome.

[0201] DYRK1A and DYRK1B are utilized during human cytomegalovirus (HCMV) placental replication. Inhibition of DYRKs prevent replication of various viruses, including hepatitis C virus (HCV), human cytomegalovirus (HCMV), human immunodeficiency virus type 1 (HIV-1), and herpes simplex virus 1 (HSV-1) (*Journal of Virology* (2020), 94(6) and *PLoS ONE* (2015), 10, e0144229).

[0202] There is a growing body of evidence showing that DYRK1A/1B inhibitors induce the proliferation of insulin-producing pancreatic β -cells, making DYRK1A/1B kinases attractive therapeutic targets for β -cell regeneration for both type 1 and type 2 diabetes mellitus and gestational diabetes (*Nature Communications* (2015), 6(8372); *Diabetes* (2016), 65(6), 1660–1671; *JCI Insight* (2020), 5(1), e132594; *Science Translational Medicine* (2020), 12(530); *International Journal of Molecular Sciences* (2021), 22(16), 9083; and *Journal of Medicinal Chemistry* (2021), 64(6), 2901–2922). Other forms of diabetes that may be treated with DYRK inhibitors are maturity onset diabetes of the young (MODY, monogenic diabetes), cases of diabetes that are caused by the body's tissue receptors not responding to insulin, double diabetes (when a type 1 diabetic becomes insulin resistant), diabetes associated with excessive secretion of insulin-antagonistic hormones,

malnutrition-related diabetes mellitus (ICD-10 code E12), and diabetes caused by any genetic mutations (autosomal or mitochondrial) that leads to defects in beta cell function.

[0203] There is abundant literature linking DYRK1A with solid cancers and leukemias (*Pharmacology & Therapeutics* (2015), 151, 87–98; *Cancers* (2020), 12(8), 2106; and *Cellular and Molecular Life Sciences* (2021), 78, 603–619). The most prominent examples are pancreatic cancer (*Gut* (2019), 68(8), 1465–1476 and *Gene* (2020), 758, 144960), brain tumors, glioblastoma (*Journal of Clinical Investigation* (2013), 123(6), 2475–2487), acute megakaryoblastic leukemia (AMKL) (*Journal of Clinical Investigation* (2012), 122(3), 948–962), and acute lymphoblastic leukemia (ALL) (*Journal of Clinical Investigation* (2021), 131(1), e135937). Other cancers linked to DYRK1A are ovarian (*Frontiers in Oncology* (2021), 11, 637193), head and neck squamous cell carcinoma (*Scientific Reports* (2016), 6, 36132), hepatocellular carcinoma (*Cell Death & Disease* (2021), 12, 125), DYRK1A regulates DNA damage response (*Scientific Reports* (2019), 9, 6014 and *Scientific Reports* (2019), 9, 6539). In some situations, DYRK1A appears to function as a tumor-suppressor protein (*Molecular & Cellular Oncology* (2015), 2(1), e970048 and *Nature* (2016), 529, 172–177).

[0204] Other cancers can also be treated with the compounds and compositions described herein.

[0205] More particularly, cancers that may be treated by the compounds, compositions and methods described herein include, but are not limited to, the following:

[0206] 1) Breast cancers, including, for example ER⁺ breast cancer, ER⁻ breast cancer, her2⁻ breast cancer, her2⁺ breast cancer, stromal tumors such as fibroadenomas, phyllodes tumors, and sarcomas, and epithelial tumors such as large duct papillomas; carcinomas of the breast including *in situ* (noninvasive) carcinoma that includes ductal carcinoma *in situ* (including Paget's disease) and lobular carcinoma *in situ*, and invasive (infiltrating) carcinoma including, but not limited to, invasive ductal carcinoma, invasive lobular carcinoma, medullary carcinoma, colloid (mucinous) carcinoma, tubular carcinoma, and invasive papillary carcinoma; chemoresistant breast cancers (TNBC), and miscellaneous malignant neoplasms. Further examples of breast cancers can include luminal A, luminal B, basal A, basal B, and triple negative breast cancer, which is estrogen receptor negative (ER⁻), progesterone receptor negative, and her2 negative (her2⁻). In some embodiments, the breast cancer may have a high risk Oncotype score.

[0207] 2) Cardiac cancers, including, for example sarcoma, e.g., angiosarcoma, fibrosarcoma, rhabdomyosarcoma, and liposarcoma; myxoma; rhabdomyoma; fibroma; lipoma and teratoma.

[0208] 3) Lung cancers, including, for example, bronchogenic carcinoma, e.g., squamous cell, undifferentiated small cell, undifferentiated large cell, and adenocarcinoma; alveolar and bronchiolar carcinoma; bronchial adenoma; sarcoma; lymphoma; chondromatous hamartoma; chemoresistant small cell lung cancer (SCLC), and mesothelioma.

[0209] 4) Gastrointestinal cancer, including, for example, cancers of the esophagus, e.g., squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, and lymphoma; cancers of the stomach, e.g., carcinoma, lymphoma, and leiomyosarcoma; cancers of the pancreas, e.g., ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumors, and vipoma; colon cancers with APC gene mutations; cancers of the small bowel, e.g., adenocarcinoma, lymphoma, carcinoid tumors, Kaposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, and fibroma; cancers of the large bowel, e.g., adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, and leiomyoma.

[0210] 5) Genitourinary tract cancers, including, for example, cancers of the kidney, e.g., adenocarcinoma, Wilm's tumor (nephroblastoma), lymphoma, and leukemia; cancers of the bladder and urethra, e.g., squamous cell carcinoma, transitional cell carcinoma, and adenocarcinoma; cancers of the prostate, e.g., adenocarcinoma, and sarcoma; cancer of the testis, e.g., seminoma, teratoma, embryonal carcinoma, teratocarcinoma, choriocarcinoma, sarcoma, interstitial cell carcinoma, fibroma, fibroadenoma, adenomatoid tumors, and lipoma.

[0211] 6) Liver cancers, including, for example, hepatoma, e.g., hepatocellular carcinoma; cholangiocarcinoma; hepatoblastoma; angiosarcoma; hepatocellular adenoma; and hemangioma.

[0212] 7) Bone cancers, including, for example, osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticulum cell sarcoma), multiple myeloma, malignant giant cell tumor chordoma, osteochondroma (osteocartilaginous exostoses), benign chondroma, chondroblastoma, chondromyxofibroma, osteoid osteoma and giant cell tumors.

[0213] 8) Nervous system cancers, including, for example, cancers of the skull, e.g., osteoma, hemangioma, granuloma, xanthoma, and osteitis deformans; cancers of the meninges, e.g., meningioma, meningiosarcoma, and gliomatosis; cancers of the brain, e.g., astrocytoma, medulloblastoma, glioma, ependymoma, germinoma (pinealoma), glioblastoma multiform, oligodendroglioma, oligodendrocytoma, schwannoma, retinoblastoma, and congenital tumors; and cancers of the spinal cord, e.g., neurofibroma, meningioma, glioma, and sarcoma; pediatric brain cancer, e.g., astrocytoma, medulloblastoma, glioma, ependymoma, germ cell tumors such as

germinomas and non-germinomatous tumors such as teratomas, choriocarcinomas, endodermal sinus tumors (yolk sac tumors), embryonal carcinomas, and mixed tumors.

[0214] 9) Gynecological cancers, including, for example, cancers of the uterus, e.g., endometrial cancers (e.g., carcinoma, endometrioid adenocarcinoma, serous carcinoma, clear cell carcinoma, mucinous carcinomas, mixed or undifferentiated carcinoma (including mixed Müllerian tumor), endometrial stromal sarcoma, squamous cell carcinoma of the endometrium, urothelial carcinoma, endometrial cancer with CTNNB1 mutations); cancers of the cervix, e.g., cervical carcinoma, and pre tumor cervical dysplasia; cancers of the ovaries, e.g., BRCA-mutant ovarian cancer, surface epithelial-stromal tumors (epithelial ovarian cancer (Type 1 (endometrioid, mucinous, clear cell, low grade serous) or Type 2 (poorly differentiated, carcinosarcoma, and high grade serous))), ovarian carcinoma, including serous cystadenocarcinoma, mucinous cystadenocarcinoma, endometrioid tumors, small cell ovarian cancer (small cell ovarian cancer of hypercalcemic type, small cell ovarian cancer of pulmonary type) unclassified carcinoma, granulosa theca cell tumors, Sertoli Leydig cell tumors, dysgerminoma, and malignant teratoma; cancers of the vulva, e.g., squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, and melanoma; cancers of the vagina, e.g., clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma, and embryonal rhabdomyosarcoma; and cancers of the fallopian tubes, e.g., carcinoma, primary fallopian tube cancer; Primary peritoneal cancer (also known as serous surface papillary carcinoma, primary peritoneal carcinoma, extra-ovarian serous carcinoma, primary serous papillary carcinoma, and psammomacarcinoma).

[0215] 10) Hematologic cancers, including, for example, cancers of the blood, e.g., acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndromes (refractory cytopenia with unilineage dysplasia (refractory anemia, refractory neutropenia, and refractory thrombocytopenia), refractory anemia with ring sideroblasts, refractory cytopenia with multilineage dysplasia, refractory anemias with excess blasts I and II, refractory cytopenia of childhood), and myeloproliferative neoplasms, acute lymphoblastic leukemia, chronic lymphocytic leukemia, myeloproliferative diseases, multiple myeloma, myelodysplastic syndrome, myelodysplastic–myeloproliferative diseases, Hodgkin's lymphoma, non-Hodgkin's lymphoma (malignant lymphoma) and Waldenström's macroglobulinemia.

[0216] 11) Skin cancers and skin disorders, including, for example, malignant melanoma and metastatic melanoma, basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, moles dysplastic nevi, lipoma, angioma, dermatofibroma, keloids, and scleroderma.

[0217] 12) Adrenal gland cancers, including, for example, neuroblastoma.

[0218] 13) Soft-tissue sarcomas (STS) such as fibrosarcoma, malignant fibrous histiocytoma, dermatofibrosarcoma, liposarcoma, rhabdomyosarcoma, leiomyosarcoma, hemangiosarcoma, Kaposi's sarcoma, lymphangiosarcoma, synovial sarcoma, malignant peripheral nerve sheath tumors (also called neurofibrosarcomas, malignant schwannomas, and neurogenic sarcomas), neurofibrosarcoma, extraskeletal chondrosarcoma, extraskeletal osteosarcoma, extraskeletal myxoid chondrosarcoma, extraskeletal mesenchymal, embryonal, alveolar soft part sarcoma, and infantile hemangio-pericytoma.

[0219] More particularly, tumors of the central nervous system that may be treated by the compounds, compositions and methods described herein include:

[0220] 1) Astrocytic tumors, e.g., diffuse astrocytoma (fibrillary, protoplasmic, gemistocytic, mixed), anaplastic (malignant) astrocytoma, glioblastoma multiforme (giant cell glioblastoma and gliosarcoma), pilocytic astrocytoma (pilomyxoid astrocytoma), pleomorphic xanthoastrocytoma, subependymal giant cell astrocytoma, and gliomatosis cerebri.

[0221] 2) Oligodendroglial tumors, e.g., oligodendroglioma and anaplastic oligodendroglioma.

[0222] 3) Oligoastrocytic tumors, e.g., oligoastrocytoma and anaplastic oligoastrocytoma.

[0223] 4) Ependymal tumors, e.g., subependymoma, myxopapillary ependymoma, ependymoma, (cellular, papillary, clear cell, tanycytic), and anaplastic (malignant) ependymoma.

[0224] 5) Choroid plexus tumors, e.g., choroid plexus papilloma, atypical choroid plexus papilloma, and choroid plexus carcinoma.

[0225] 6) Neuronal and mixed neuronal-glial tumors, e.g., gangliocytoma, ganglioglioma, dysembryoplastic neuroepithelial tumor (DNET), dysplastic gangliocytoma of the cerebellum (Lhermitte-Duclos), desmoplastic infantile astrocytoma/ganglioglioma, central neurocytoma, anaplastic ganglioglioma, extraventricular neurocytoma, cerebellar liponeurocytoma, Papillary glioneuronal tumor, Rosette-forming glioneuronal tumor of the fourth ventricle, and paraganglioma of the filum terminale.

[0226] 7) Pineal tumors, e.g., pineocytoma, pineoblastoma, papillary tumors of the pineal region, and pineal parenchymal tumor of intermediate differentiation.

[0227] 8) Embryonal tumors, e.g., medulloblastoma (medulloblastoma with extensive nodularity, anaplastic medulloblastoma, desmoplastic, large cell, melanotic, medulloblastoma), medulloepithelioma, supratentorial primitive neuroectodermal tumors, and

primitive neuroectodermal tumors (PNETs) such as neuroblastoma, ganglioneuroblastoma, ependymoblastoma, and atypical teratoid/rhabdoid tumor.

[0228] 9) Neuroblastic tumors, e.g., olfactory (esthesioneuroblastoma), olfactory neuroepithelioma, and neuroblastomas of the adrenal gland and sympathetic nervous system.

[0229] 10) Glial tumors, e.g., astroblastoma, chordoid glioma of the third ventricle, and angiocentric glioma.

[0230] 11) Tumors of cranial and paraspinal nerves, e.g., schwannoma, neurofibroma, Perineurioma, and malignant peripheral nerve sheath tumor.

[0231] 12) Tumors of the meninges such as tumors of meningotheial cells, e.g., meningioma (atypical meningioma and anaplastic meningioma); mesenchymal tumors, e.g., lipoma, angioliipoma, hibernoma, liposarcoma, solitary fibrous tumor, fibrosarcoma, malignant fibrous histiocytoma, leiomyoma, leiomyosarcoma, rhabdomyoma, rhabdomyosarcoma, chondroma, chondrosarcoma, osteoma, osteosarcoma, osteochondroma, haemangioma, epithelioid hemangioendothelioma, haemangiopericytoma, anaplastic haemangiopericytoma, angiosarcoma, Kaposi Sarcoma, and Ewing Sarcoma; primary melanocytic lesions, e.g., diffuse melanocytosis, melanocytoma, malignant melanoma, meningeal melanomatosis; and hemangioblastomas.

[0232] 13) Tumors of the hematopoietic system, e.g., malignant Lymphomas, plasmocytoma, and granulocytic sarcoma.

[0233] 14) Germ cell tumors, e.g., germinoma, embryonal carcinoma, yolk sac tumor, choriocarcinoma, teratoma, and mixed germ cell tumors.

[0234] 15) Tumors of the sellar region, e.g., craniopharyngioma, granular cell tumor, pituicytoma, and spindle cell oncocyoma of the adenohypophysis.

[0235] Cancers may be solid tumors that may or may not be metastatic. Cancers may also occur, as in leukemia, as a diffuse tissue. Thus, the term “tumor cell,” as provided herein, includes a cell afflicted by any one of the above identified disorders.

[0236] A method of treating cancer using a compound or composition as described herein may be combined with existing methods of treating cancers, for example by chemotherapy, irradiation, or surgery (e.g., oophorectomy). In some embodiments, a compound or composition can be administered before, during, or after another anticancer agent or treatment.

[0237] There is mounting evidence for a role of DYRK1A in the onset of Alzheimer's Disease (*Future Medicinal Chemistry* (2016), 8(6), 681–696 and *European Journal of Medicinal Chemistry* (2018), 158, 559-592). DYRK1A phosphorylates key substrates involved in Alzheimer's Disease and dementia: Tau, septin 4, amyloid precursor protein (APP), presenilin 1, neprilysin, Munc18-1, α -synuclein, RCAN1, and β -tubulin. By modulating alternative splicing of

Tau exon 10, DYRK1A favors the production of the 3R-Tau splice isoform (characteristic for DS/AD/tauopathy) over the 4R-Tau isoform (*Journal of Biological Chemistry* (2015), 290, 15219–15237).

[0238] Genome-wide association studies (GWAS) have revealed that DYRK1A is a risk factor for Parkinson's Disease (*The Lancet Neurology* (2019), 18(12), 1091–1102). DYRK1A phosphorylates key factors for Parkinson's Disease such as parkin, septin 4, and α -synuclein. Upregulation of micro-RNAs specific for Parkinson's Disease targets DYRK1A expression. There is further evidence that DYRK1A expression is increased in Parkinson's Disease and in Pick's disease (*Neurobiology of Disease* (2005), 20(2), 392–400).

[0239] The compounds and compositions provided herein can be used as inhibitors and/or modulators of the enzyme DYRK1A, and thus can be used to treat a variety of disorders and diseases associated with tau protein, including, but not limited to, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), down syndrome, frontotemporal dementia (FTD) including FTD with Parkinsonism-17 (FTDP-17), behavioural variant frontotemporal dementia (bvFTD), FTD in patients with motor neuron disease (MND) (typically amyotrophic lateral sclerosis, also called FTD-ALS), corticobasal degeneration (CBD) (also called corticobasal ganglionic degeneration), progressive supranuclear palsy, primary progressive aphasia (PPA), globular glial tauopathy (GGT), myotonic dystrophy type 1 (DM1) (also called Steinert disease), myotonic dystrophy type 2 (DM2) (also called proximal myotonic myopathy), Guam complex, argyrophilic grain disease, dementia pugilistica, post-encephalitic parkinsonism, Lewy body dementia, Parkinson's disease, Pick's disease, and additional diseases with pronounced neurodegeneration such as autism, dementia, epilepsy, Huntington's disease, multiple sclerosis; diseases and disorders associated with acquired brain injury such as chronic traumatic encephalopathy, traumatic brain injury, tumor, and stroke.

[0240] Non-limiting examples of neurological disorders (e.g., neurological conditions and neurological diseases) which can be treated with the compounds and compositions provided herein include Alzheimer's disease, aphasia, apraxia, arachnoiditis, ataxia telangiectasia, attention deficit hyperactivity disorder, auditory processing disorder, autism, alcoholism, Bell's palsy, bipolar disorder, brachial plexus injury, Canavan disease, carpal tunnel syndrome, causalgia, central pain syndrome, central pontine myelinolysis, centronuclear myopathy, cephalic disorder, cerebral aneurysm, cerebral arteriosclerosis, cerebral atrophy, cerebral gigantism, cerebral palsy, cerebral vasculitis, cervical spinal stenosis, Charcot-Marie-Tooth disease, Chiari malformation, chronic fatigue syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP), chronic pain, Coffin–Lowry syndrome, complex regional pain syndrome, compression neuropathy,

congenital facial diplegia, corticobasal degeneration, cranial arteritis, craniosynostosis, Creutzfeldt-Jakob disease, cumulative trauma disorder, Cushing's syndrome, cytomegalic inclusion body disease (CIBD), Dandy-Walker syndrome, Dawson disease, De Morsier's syndrome, Dejerine-Klumpke palsy, Dejerine-Sottas disease, delayed sleep phase syndrome, dementia, dermatomyositis, developmental dyspraxia, diabetic neuropathy, diffuse sclerosis, Dravet syndrome, dysautonomia, dyscalculia, dysgraphia, dyslexia, dystonia, empty sella syndrome, encephalitis, encephalocele, encephalotrigeminal angiomas, encopresis, epilepsy, Erb's palsy, erythromelalgia, essential tremor, Fabry's disease, Fahr's syndrome, familial spastic paralysis, febrile seizure, Fisher syndrome, Friedreich's ataxia, fibromyalgia, Foville's syndrome, Gaucher's disease, Gerstmann's syndrome, giant cell arteritis, giant cell inclusion disease, globoid cell leukodystrophy, gray matter heterotopia, Guillain-Barré syndrome, HTLV-1 associated myelopathy, Hallervorden-Spatz disease, hemifacial spasm, hereditary spastic paraplegia, heredopathia atactica polyneuritiformis, herpes zoster oticus, herpes zoster, Hirayama syndrome, holoprosencephaly, Huntington's disease, hydranencephaly, hydrocephalus, hypercortisolism, hypoxia, immune-mediated encephalomyelitis, inclusion body myositis, incontinentia pigmenti, infantile phytanic acid storage disease, infantile Refsum disease, infantile spasms, inflammatory myopathy, intracranial cyst, intracranial hypertension, Joubert syndrome, Karak syndrome, Kearns-Sayre syndrome, Kennedy disease, Kinsbourne syndrome, Klippel Feil syndrome, Krabbe disease, Kugelberg-Welander disease, kuru, Lafora disease, Lambert-Eaton myasthenic syndrome, Landau-Kleffner syndrome, lateral medullary (Wallenberg) syndrome, Leigh's disease, Lennox-Gastaut syndrome, Lesch-Nyhan syndrome, leukodystrophy, Lewy body dementia, lissencephaly, locked-in syndrome, Lou Gehrig's disease, lumbar disc disease, lumbar spinal stenosis, Lyme disease, Machado-Joseph disease (Spinocerebellar ataxia type 3), macrencephaly, macropsia, megalencephaly, Melkersson-Rosenthal syndrome, Meniere's disease, meningitis, Menkes disease, metachromatic leukodystrophy, microcephaly, micropsia, Miller Fisher syndrome, misophonia, mitochondrial myopathy, Mobius syndrome, monomelic amyotrophy, motor neuron disease, motor skills disorder, Moyamoya disease, mucopolysaccharidoses, multi-infarct dementia, multifocal motor neuropathy, multiple sclerosis, multiple system atrophy, muscular dystrophy, myalgic encephalomyelitis, myasthenia gravis, myelinoclastic diffuse sclerosis, myoclonic Encephalopathy of infants, myoclonus, myopathy, myotubular myopathy, myotonia congenita, narcolepsy, neurofibromatosis, neuroleptic malignant syndrome, lupus erythematosus, neuromyotonia, neuronal ceroid lipofuscinosis, Niemann-Pick disease, O'Sullivan-McLeod syndrome, occipital Neuralgia, occult Spinal Dysraphism Sequence, Ohtahara syndrome, olivopontocerebellar atrophy, opsoclonus myoclonus syndrome, optic neuritis, orthostatic hypotension, palinopsia, paresthesia,

Parkinson's disease, paramyotonia Congenita, paraneoplastic diseases, paroxysmal attacks, Parry-Romberg syndrome, Pelizaeus-Merzbacher disease, periodic paralyses, peripheral neuropathy, photic sneeze reflex, phytanic acid storage disease, Pick's disease, polymicrogyria (PMG), polymyositis, porencephaly, post-polio syndrome, postherpetic neuralgia (PHN), postural hypotension, Prader-Willi syndrome, primary lateral sclerosis, prion diseases, progressive hemifacial atrophy, progressive multifocal leukoencephalopathy, progressive supranuclear palsy, pseudotumor cerebri, Ramsay Hunt syndrome type I, Ramsay Hunt syndrome type II, Ramsay Hunt syndrome type III, Rasmussen's encephalitis, reflex neurovascular dystrophy, Refsum disease, restless legs syndrome, retrovirus-associated myelopathy, Rett syndrome, Reye's syndrome, rhythmic movement disorder, Romberg syndrome, Saint Vitus dance, Sandhoff disease, schizophrenia, Schilder's disease, schizencephaly, sensory integration dysfunction, septo-optic dysplasia, Shy-Drager syndrome, Sjögren's syndrome, snatiation, Sotos syndrome, spasticity, spina bifida, spinal cord tumors, spinal muscular atrophy, spinocerebellar ataxia, Steele-Richardson-Olszewski syndrome, Stiff-person syndrome, stroke, Sturge-Weber syndrome, subacute sclerosing panencephalitis, subcortical arteriosclerotic encephalopathy, superficial siderosis, Sydenham's chorea, syncope, synesthesia, syringomyelia, tarsal tunnel syndrome, tardive dyskinesia, tardive dysphrenia, Tarlov cyst, Tay-Sachs disease, temporal arteritis, tetanus, tethered spinal cord syndrome, Thomsen disease, thoracic outlet syndrome, tic douloureux, Todd's paralysis, Tourette syndrome, toxic encephalopathy, transient ischemic attack, transmissible spongiform encephalopathies, transverse myelitis, tremor, trigeminal neuralgia, tropical spastic paraparesis, trypanosomiasis, tuberous sclerosis, ubisiosis, Von Hippel-Lindau disease (VHL), Viliuisk Encephalomyelitis (VE), Wallenberg's syndrome, Werdnig, Hoffman disease, west syndrome, Williams syndrome, Wilson's disease, and Zellweger syndrome.

[0241] The compounds and compositions may also be useful in the inhibition of the development of invasive cancer, tumor angiogenesis and metastasis.

[0242] In some embodiments, the pharmaceutical composition comprises a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

[0243] In some embodiments, the disorder or disease is cancer.

[0244] In some embodiments, the disorder or disease is metastatic melanoma.

[0245] In some embodiments, the disorder or disease is tendon regeneration.

[0246] In some embodiments, the disorder or disease is diabetes.

[0247] In some embodiments, the disorder or disease is degenerative disc disease.

[0248] In some embodiments, the disorder or disease is osteoarthritis.

[0249] In some embodiments, the disorder or disease is a viral infection.

[0250] In some embodiments, the disorder or disease is a neurological disorder.

[0251] In some embodiments, the disorder or disease is Alzheimer's disease.

[0252] In some embodiments, the disorder or disease is osteoarthritis.

[0253] In some embodiments, the patient is a human.

[0254] In some embodiments, the cancer is chosen from: hepatocellular carcinoma, colon cancer, breast cancer, pancreatic cancer, chronic myeloid leukemia (CML), chronic myelomonocytic leukemia, chronic lymphocytic leukemia (CLL), acute myeloid leukemia, acute lymphocytic leukemia, Hodgkin lymphoma, lymphoma, sarcoma, and ovarian cancer.

[0255] In some embodiments, the cancer is chosen from: lung cancer - non-small cell, lung cancer - small cell, multiple myeloma, nasopharyngeal cancer, neuroblastoma, osteosarcoma, penile cancer, pituitary tumors, prostate cancer, retinoblastoma, synovial sarcoma, rhabdomyosarcoma, salivary gland cancer, skin cancer - basal and squamous cell, skin cancer – melanoma, small intestine cancer, stomach (gastric) cancers, testicular cancer, thymus cancer, thyroid cancer, uterine sarcoma, vaginal cancer, vulvar cancer, laryngeal or hypopharyngeal cancer, kidney cancer, Kaposi sarcoma, gestational trophoblastic disease, gastrointestinal stromal tumor, gastrointestinal carcinoid tumor, gallbladder cancer, eye cancer (melanoma and lymphoma), Ewing tumor, esophagus cancer, endometrial cancer, colorectal cancer, cervical cancer, brain or spinal cord tumor, bone metastasis, bone cancer, bladder cancer, bile duct cancer, anal cancer and adrenal cortical cancer.

[0256] In some embodiments, the cancer is hepatocellular carcinoma; in some embodiments, the cancer is colon cancer; in some embodiments, the cancer is colorectal cancer; in some embodiments, the cancer is breast cancer; in some embodiments, the cancer is pancreatic cancer; in some embodiments, the cancer is chronic myeloid leukemia (CML); in some embodiments, the cancer is chronic myelomonocytic leukemia; in some embodiments, the cancer is chronic lymphocytic leukemia (CLL); in some embodiments, the cancer is acute myeloid leukemia; in some embodiments, the cancer is acute lymphocytic leukemia; in some embodiments, the cancer is Hodgkin lymphoma; in some embodiments, the cancer is lymphoma; in some embodiments, the cancer is sarcoma; in some embodiments, the cancer is ovarian cancer; in some embodiments, the cancer is lung cancer - non-small cell; in some embodiments, the cancer is lung cancer - small cell; in some embodiments, the cancer is multiple myeloma; in some embodiments, the cancer is nasopharyngeal cancer; in some embodiments, the cancer is neuroblastoma; in some embodiments, the cancer is osteosarcoma; in some embodiments, the cancer is penile cancer; in some embodiments, the cancer is pituitary tumors; in some embodiments, the cancer is prostate

cancer; in some embodiments, the cancer is retinoblastoma; in some embodiments, the cancer is rhabdomyosarcoma; in some embodiments, the cancer is salivary gland cancer; in some embodiments, the cancer is skin cancer - basal and squamous cell; in some embodiments, the cancer is skin cancer – melanoma; in some embodiments, the cancer is small intestine cancer; in some embodiments, the cancer is stomach (gastric) cancers; in some embodiments, the cancer is testicular cancer; in some embodiments, the cancer is thymus cancer; in some embodiments, the cancer is thyroid cancer; in some embodiments, the cancer is uterine sarcoma; in some embodiments, the cancer is vaginal cancer; in some embodiments, the cancer is vulvar cancer; in some embodiments, the cancer is Wilms tumor; in some embodiments, the cancer is laryngeal or hypopharyngeal cancer; in some embodiments, the cancer is kidney cancer; in some embodiments, the cancer is Kaposi sarcoma; in some embodiments, the cancer is gestational trophoblastic disease; in some embodiments, the cancer is gastrointestinal stromal tumor; in some embodiments, the cancer is gastrointestinal carcinoid tumor; in some embodiments, the cancer is gallbladder cancer; in some embodiments, the cancer is eye cancer (melanoma and lymphoma); in some embodiments, the cancer is Ewing tumor; in some embodiments, the cancer is esophagus cancer; in some embodiments, the cancer is endometrial cancer; in some embodiments, the cancer is colorectal cancer; in some embodiments, the cancer is cervical cancer; in some embodiments, the cancer is brain or spinal cord tumor; in some embodiments, the cancer is bone metastasis; in some embodiments, the cancer is bone cancer; in some embodiments, the cancer is bladder cancer; in some embodiments, the cancer is bile duct cancer; in some embodiments, the cancer is anal cancer; and in some embodiments, the cancer is adrenal cortical cancer.

[0257] In some embodiments, the disorder or disease is a neurological condition, disorder, or disease, wherein the neurological disease is selected from: Alzheimer's disease, frontotemporal dementias, Parkinson's disease, Huntington's disease, progressive supranuclear palsy, corticobasal degeneration, multiple system atrophy, amyotrophic lateral sclerosis (ALS), inclusion body myositis, autism, degenerative myopathies.

[0258] In some embodiments, the disorder or disease is selected from the group consisting of: Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Down Syndrome, Frontotemporal Dementia with Parkinsonism-17 (FTDP-17), Lewy body dementia, Parkinson's Disease, Pick's Disease, and additional diseases with pronounced neurodegeneration such as Autism, Dementia, Epilepsy, Huntington's Disease, Multiple Sclerosis; diseases and disorders associated with acquired brain injury such as Chronic Traumatic Encephalopathy, Traumatic Brain Injury, Tumor, and Stroke.

[0259] In some embodiments, a compound of Formula (I) inhibits DYRK1A.

[0260] In some embodiments, the method treats a disease or disorder mediated by kinase activity in a patient, the method comprises administering to the patient a therapeutically effective amount of a compound (or compounds) of Formula (I), or a pharmaceutically acceptable salt thereof.

[0261] In some embodiments, the disease or disorder comprises tumor growth, cell proliferation, or angiogenesis.

[0262] In some embodiments, the method inhibits the activity of a protein kinase receptor, the method comprises contacting the receptor with an effective amount of a compound (or compounds) of Formula (I), or a pharmaceutically acceptable salt thereof.

[0263] In some embodiments, the method treats a disease or disorder associated with aberrant cellular proliferation in a patient; the method comprises administering to the patient a therapeutically effective amount of a compound (or compounds) of Formula (I), or a pharmaceutically acceptable salt thereof.

[0264] In some embodiments, the method prevents or reduces abnormal cellular proliferation in a patient; the method comprises administering to the patient a therapeutically effective amount of a compound (or compounds) of Formula (I), or a pharmaceutically acceptable salt thereof.

[0265] In some embodiments, the method treats a disease or disorder associated with aberrant cellular proliferation in a patient, the method comprises administering to the patient a pharmaceutical composition comprising one or more of the compounds of claim 1 in combination with a pharmaceutically acceptable carrier and one or more other agents.

Evaluation of Biological Activity

[0266] The biological activity of the compounds described herein can be tested using any suitable assay known to those of skill in the art. For example, the activity of a compound may be tested using one or more of the test methods outlined below.

[0267] For example, *in vitro* assays for DYRK1A biological activity may be used, e.g., regulation of microtubule-associated protein tau (MAPT/Tau) phosphorylation in neuronal cell lines such as the human SH-SY5Y neuroblastoma cell line. Assays for DYRK1A-regulated level of phosphorylation can include monitoring levels of basal pSer396 Tau, which can be measured, for example, by serial dilutions of a candidate inhibitor composition using a ten micromolar top concentration and detected by ELISA or Western Blotting. An exemplary assay for DYRK-1A-regulated phosphorylation uses the SH-SY5Y cells cultured in a 96 well plate format for a period of time sufficient to stabilize microtubules and Tau phosphorylation, usually at least 2

days, then treated with a 1/3 serial dilution of compounds overnight and lysed. The cell lysate is resolved by SDS PAGE, then transferred to nitrocellulose and probed with an antibody specific for pSer396 Tau. The chemiluminescence signal for HRP-linked antibodies used in western blotting is detected using a Carestream Image Station and blot densitometry for pSer396 and beta-actin are analyzed using ImageJ (NIH).

[0268] In a further example, the activity of a candidate compound can be measured by phosphoTau (Thr212) AlphaLISA by adding the lysate mentioned above onto total Tau-coated plates and detected with a specific pThr212Tau antibody. Colorimetric detection of AlphaLISA signal is performed by EnVision Multilabel Plate Reader (Perkin Elmer).

[0269] To further illustrate this disclosure, the following examples are included. The examples should not, of course, be construed as specifically limiting the disclosure. Variations of these examples within the scope of the claims are within the purview of one skilled in the art and are considered to fall within the scope of the disclosure as described and claimed herein. The reader will recognize that the skilled artisan, armed with the present disclosure, and skill in the art is able to prepare and use the disclosure without exhaustive examples.

EXAMPLES

Compound preparation

[0270] The starting materials used in preparing the compounds of the disclosure are known, made by known methods, or are commercially available. It will be apparent to the skilled artisan that methods for preparing precursors and functionality related to the compounds claimed herein are generally described in the literature. The skilled artisan given the literature and this disclosure is well equipped to prepare any of the compounds.

[0271] It is recognized that the skilled artisan in the art of organic chemistry can readily carry out manipulations without further direction, that is, it is well within the scope and practice of the skilled artisan to carry out these manipulations. These include reduction of carbonyl compounds to their corresponding alcohols, oxidations, acylations, aromatic substitutions, both electrophilic and nucleophilic, etherifications, esterification and saponification and the like. These manipulations are discussed in standard texts such as *March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure* 7th Ed., John Wiley & Sons (2013), Carey and Sundberg, *Advanced Organic Chemistry* 5th Ed., Springer (2007), *Comprehensive Organic Transformations: A Guide to Functional Group Transformations*, 2nd Ed., John Wiley & Sons (1999) (incorporated herein by reference in its entirety) and the like.

[0272] The skilled artisan will readily appreciate that certain reactions are best carried out when other functionality is masked or protected in the molecule, thus avoiding any undesirable side reactions and/or increasing the yield of the reaction. Often the skilled artisan utilizes protecting groups to accomplish such increased yields or to avoid the undesired reactions. These reactions are found in the literature and are also well within the scope of the skilled artisan. Examples of many of these manipulations can be found for example in P. Wuts *Greene's Protective Groups in Organic Synthesis*, 5th Ed., John Wiley & Sons (2014), incorporated herein by reference in its entirety.

[0273] Trademarks used herein are examples only and reflect illustrative materials used at the time of the disclosure. The skilled artisan will recognize that variations in lot, manufacturing processes, and the like, are expected. Hence the examples, and the trademarks used in them are non-limiting, and they are not intended to be limiting, but are merely an illustration of how a skilled artisan may choose to perform one or more of the embodiments of the disclosure.

[0274] (^1H) nuclear magnetic resonance spectra (NMR) were measured in the indicated solvents on a Bruker NMR spectrometer (Avance TM DRX300, 300 MHz for ^1H or Avance TM DRX500, 500 MHz for ^1H) or Varian NMR spectrometer (Mercury 400BB, 400 MHz for ^1H). Peak positions are expressed in parts per million (ppm) downfield from tetramethylsilane. The peak multiplicities are denoted as follows, s, singlet; d, doublet; t, triplet; q, quartet; ABq, AB quartet; quin, quintet; sex, sextet; sep, septet; non, nonet; dd, doublet of doublets; ddd, doublet of doublets of doublets; d/ABq, doublet of AB quartet; dt, doublet of triplets; td, triplet of doublets; dq, doublet of quartets; m, multiplet.

[0275] The following abbreviations have the indicated meanings:

Ac_2O = acetic anhydride

brine = saturated aqueous sodium chloride

$^t\text{BuOK}$ = potassium *tert*-butoxide

CDCl_3 = deuterated chloroform

m-CPBA = meta-chloroperoxybenzoic acid

Cs_2CO_3 = cesium carbonate

DCE = dichloroethane

DCM = dichloromethane

DIPEA = N,N-diisopropylethylamine

DME = dimethoxyethane, or glyme, or monoglyme

DMF = N,N-dimethylformamide

DMPU = N,N'-dimethylpropyleneurea

$\text{DMSO-}d_6$ = deuterated dimethylsulfoxide

ESIMS = electron spray mass spectrometry

EtOAc = ethyl acetate

HATU = 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate

HCl = hydrochloric acid

HOAc = acetic acid

ISCO = Teledyne ISCO, Inc brand CombiFlash[®] Rf 200

KOAc = potassium acetate

LC/MS = Liquid chromatography–mass spectrometry

MeCN = acetonitrile

MeOH = methanol

MgSO₄ = magnesium sulfate

monoglyme = 1,2-dimethoxyethane

MsCl = mesyl chloride or methanesulfonyl chloride

MW = microwave irradiation

NaHCO₃ = sodium bicarbonate

Na(OAc)₃BH = Sodium triacetoxyborohydride

Na₂SO₄ = sodium sulfate

NMR = nuclear magnetic resonance

ON = overnight

PCy₃ = tricyclohexylphosphine

Pd/C = palladium on carbon

Pd₂(dba)₃ = tris(dibenzylideneacetone)dipalladium(0)

Pd(dppf)Cl₂ = 1,1'-bis(diphenylphosphino)ferrocene-palladium(II)dichloride

Pd(OH)₂/C = palladium hydroxide on carbon

prep-TLC = preparative thin layer chromatography

r.t. = room temperature

SM = starting material

T3P = propanephosphonic acid anhydride

TEA = triethylamine

TFA = trifluoroacetic acid


THF = tetrahydrofuran

TLC = thin layer chromatography

[0276] The following example schemes are provided for the guidance of the reader, and collectively represent an example method for making the compounds provided herein. Furthermore, other methods for preparing compounds of the disclosure will be readily apparent to the person of ordinary skill in the art in light of the following reaction schemes and examples. The skilled artisan is thoroughly equipped to prepare these compounds by those methods given the literature and this disclosure. The compound numberings used in the synthetic schemes depicted below are meant for those specific schemes only and should not be construed as or confused with same numberings in other sections of the application. Unless otherwise indicated, all variables are as defined above.

General procedures


[0277] Compounds of Formula I of the present disclosure can be prepared as depicted in Scheme 1.



Scheme 1

[0278] Scheme 1 describes a method for preparation of pyrrolo[2,1-f][1,2,4]triazine derivatives (**VI**) by first coupling the chloride (**I**) with a variety of amines (**II**) to produce bromo pyrrolo[2,1-f][1,2,4]triazine **III**. Formation of a variety of boronic acid pinacol esters by reacting various bromides (**IV**) with bis(pinacolato)diboron followed by Suzuki coupling with bromide (**IV**) produces the final pyrrolo[2,1-f][1,2,4]triazine (**VI**). Alternatively, a variety of commercial boronic acid pinacol esters (**V**) can be directly coupled with bromide (**III**) to produce the final pyrrolo[2,1-f][1,2,4]triazine (**VI**).

[0279] Compounds of Formula I of the present disclosure can also be prepared as depicted in Scheme 2.




Scheme 2

[0280] Scheme 2 describes a method for preparation of pyrrolo[2,1-f][1,2,4]triazine derivatives (VI) by oxidizing sulfide VII to the sulfone VIII. Sulfone VIII can then be coupled with a variety of amines (II) to produce bromo pyrrolo[2,1-f][1,2,4]triazine III followed by Suzuki coupling with a variety of boronic acids (IX) to produce the final pyrrolo[2,1-f][1,2,4]triazine (VI). Alternatively, a variety of boronic acids (IX) can be coupled with sulfone VIII followed by coupling with a variety of amines (II) to produce the final pyrrolo[2,1-f][1,2,4]triazine (VI).

Illustrative Compound Examples

[0281] Preparation of intermediate 6-bromo-1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridine (XV) is depicted below in Scheme 3.



Scheme 3

Step 1

[0282] A mixture of 2,2-difluoroethan-1-amine (XII) (410 mg, 5.02 mmol), 5-bromo-3-fluoro-2-nitropyridine (XI) (commercially available from Ark Pharma Scientific Limited) (1.0 g, 4.53 mmol) and K_2CO_3 (1.38 g, 9.95 mmol) in MeCN (20 mL) was stirred at room temperature for 16 h. The reaction was filtered and concentrated under high vacuum. The residue was taken up in water, stirred for 1 hour and the solids were collected by filtration and dried in vacuo to obtain 5-bromo-N-(2,2-difluoroethyl)-2-nitropyridin-3-amine (XIII) (1.066 g, 3.780 mmol, 83.5% yield) as a yellow solid which was used for next step without purification. ESIMS found for $C_7H_6BrF_2N_3O_2$ m/z 282.0 ($^{79}BrM+H$).

Step 2


[0283] A mixture of 5-bromo-N-(2,2-difluoroethyl)-2-nitropyridin-3-amine (XIII) (1.32 g, 4.69 mmol), Fe (3.07 g, 46.95 mmol) and NH_4Cl (3.77 g, 70.48 mmol) was taken in a mixture of EtOH (18 mL), and water (6 mL) and the mixture was heated to 70°C for 4 h. The reaction mixture was cooled and filtered through Celite®. The filtrates were taken up in EtOAc, washed with water and brine, dried over anhydrous Na_2SO_4 , filtered, and concentrated under

reduced pressure to obtain 5-bromo-N³-(2,2-difluoroethyl)pyridine-2,3-diamine (**XIV**) (630 mg, 2.499 mmol, 53.2% yield) as a grey solid which was used for next reaction without further purification. ESIMS found for C₇H₈BrF₂N₃ *m/z* 252.0 (⁷⁹BrM+H).

Step 3


[0284] A solution of 5-bromo-N³-(2,2-difluoroethyl)pyridine-2,3-diamine (**XIV**) (630 mg, 2.5 mmol) and acetic anhydride (0.28 mL, 2.97 mmol) in HOAc (15 mL) was heated to 120°C for 16 h. The reaction mixture was concentrated, the residue partitioned between EtOAc/1 N NaOH, organics separated, and washed with water and brine. The organics were dried over anhydrous Na₂SO₄, solvents and concentrated under high vacuum. The residue was triturated with diethyl ether, sonicated and the solids were collected by filtration and dried under high vacuo to obtain 6-bromo-1-(2,2-difluoroethyl)-2-methylimidazo[4,5-b]pyridine (**XV**) (325 mg, 1.177 mmol, 47.1% yield) as a grey solid which was used for next step without purification. ESIMS found for C₉H₈BrF₂N₃ *m/z* 276.0 (⁷⁹BrM+H).

[0285] The following intermediates were prepared in accordance with the procedure described in the above Scheme 3.



XVI


[0286] 6-Bromo-1-(3,3-difluorocyclobutyl)-2-methyl-1H-imidazo[4,5-b] pyridine (**XVI**): Grey solid (1.57 g, 6.178 mmol, 68.3% yield). ESIMS found C₁₁H₁₀BrF₂N₃ *m/z* 302.1 (M+H).



XVII

[0287] 6-Bromo-1-(2,2-difluoroethyl)-2-methyl-1H-benzo[d]imidazole (**XVII**): Beige solid (970 mg, 3.526 mmol, 79.0% yield). ESIMS found C₁₀H₉BrF₂N₂ *m/z* 275.0 (M+H).

[0288] Preparation of intermediate 6-bromo-1-isopropyl-2-methyl-1H-imidazo[4,5-b]pyridine (XXII) is depicted below in Scheme 4.



Scheme 4

Step 1

[0289] A mixture of 2-aminopropane (XIX) (0.86 mL, 9.96 mmol), 5-bromo-3-fluoro-2-nitropyridine (XVIII) (2 g, 9.05 mmol) and K_2CO_3 (2.5 g, 18.1 mmol) in MeCN (40 mL) was stirred at room temperature for 16 h. The reaction mixture was added to water (200 mL), stirred for 1 h and the resulting solids were collected by filtration and dried under high vacuo to obtain 5-bromo-N-isopropyl-2-nitropyridin-3-amine (XX) (2.36 g, 9.074 mmol, 100.3% yield) as a yellow solid which was used for next step without purification. ESIMS found for $\text{C}_8\text{H}_{10}\text{BrN}_3\text{O}_2$ m/z 260.0 (M+H).


Step 2

[0290] A mixture of 5-bromo-N-isopropyl-2-nitropyridin-3-amine (XX) (2.35 g, 9.04 mmol) Fe (5.91 g, 90.35 mmol) and NH_4Cl (7.25 g, 135.53 mmol) was taken in a mixture of EtOH (30 mL) and water (10 mL) and the mixture was heated to 70°C for 2 h. The reaction mixture was cooled, filtered through Celite[®], filtrates were taken into EtOAc, washed with water then brine, dried over anhydrous Na_2SO_4 , filtered, and concentrated under reduced pressure to obtain 5-bromo-N³-isopropylpyridine-2,3-diamine (XXI) (2.2 g, 9.561 mmol, 105.8% yield) as a dark brown solid which was used for next step without purification. ESIMS found for $\text{C}_8\text{H}_{12}\text{BrN}_3$ m/z 230.05 (M+H).

Step 3


[0291] A solution of 5-bromo-N³-isopropylpyridine-2,3-diamine (XXI) (2.08 g, 9.04 mmol) and Ac₂O (1.05 mL, 10.84 mmol) in HOAc (20 mL) was heated to 120°C for 16 h. The reaction mixture was concentrated, the residue partitioned between EtOAc/1 N NaOH, organics separated, washed with water and brine. The organics were dried over anhydrous Na₂SO₄, solvents concentrated and dried under high vacuo to give 6-bromo-1-isopropyl-2-methyl-1H-imidazo[4,5-b]pyridine (XXII) (1.57 g, 6.178 mmol, 68.3% yield) as a dark brown solid which was used for next step without purification. ESIMS found for C₁₀H₁₂BrN₃ *m/z* 254.0 (M+H).

[0292] The following intermediates were prepared in accordance with the procedure described in the above Scheme 4.



XXIII


[0293] 6-Bromo-2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-b]pyridine (XXIII): Grey solid (722 mg, 2.438 mmol, 66.3% yield). ESIMS found C₁₂H₁₄BrN₃O *m/z* 296.0 (M+H).



XXIV

[0294] 6-Bromo-1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridine (XXIV): Grey solid (325 mg, 1.177 mmol, 47.1% yield). ESIMS found C₉H₈BrF₂N₃ *m/z* 276.0 (M+H).

[0295] Preparation of intermediate (R)-2-((6-bromo-2-methyl-1H-imidazo[4,5-b]pyridin-1-yl)methyl)-5-(1-fluoroethyl)-1,3,4-oxadiazole (XXXI) is depicted below in Scheme 5.



Scheme 5

Step 1

[0296] A mixture of $tBuOK$ (2.1 g, 18.71 mmol) and 6-bromo-2-methyl-3H-imidazo[4,5-b]pyridine (XXV) (4 g, 18.86 mmol) in THF (40 mL) was stirred at 50°C for 20 minutes. Methyl bromoacetate (XXVI) (1.98 mL, 20.92 mmol) was added to the mixture. The mixture was stirred at 50°C for 1 h. The reaction was stopped with HOAc/water (1/10, 10 mL) at 0°C, and the mixture was diluted with EtOAc (20 mL) and a saturated aqueous $NaHCO_3$ (20 mL). The mixture was concentrated, and the precipitate collected by filtration, and the obtained solid was washed with water and small amount of EtOAc to obtain a light brown compound with two products. The aqueous phase was extracted with $CHCl_3$ (3*50 mL) and combined with the solid and purified by silica gel column chromatography (0→40% 1.7 N NH_3 in MeOH) to produce two sets of fractions containing the correct molecular weight by LC/MS. The least polar fractions were isolated as the byproduct, methyl 2-(6-bromo-2-methyl-3H-imidazo[4,5-b]pyridin-3-yl)acetate (XXVII) methyl (1.48 g, 5.209 mmol, 27.6% yield). 1H NMR (500 MHz, $DMSO-d_6$) δ ppm 2.54 (3 H, s), 3.71 (3 H, s), 5.18 (2 H, s), 8.25 (1 H, d, $J=1.65$ Hz), 8.36 (1 H, d, $J=1.37$ Hz); ESIMS found for $C_{10}H_{10}BrN_3O_2$ m/z 284.0 (M+H). The more polar fractions were isolated as the desired

product, methyl 2-(6-bromo-2-methyl-1H-imidazo[4,5-b]pyridin-1-yl)acetate (**XXVIII**) (2.43 g, 8.55 mmol, 45.3% yield) as an off-white solid. ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 2.51 (3 H, s), 3.72 (3 H, s), 5.27 (2 H, s), 8.33 (1 H, d, *J*=2.19 Hz), 8.41 (1 H, d, *J*=2.19 Hz); ESIMS found for C₁₀H₁₀BrN₃O₂ *m/z* 284.0 (M+H).


Step 2

[0297] A suspension of methyl 2-(6-bromo-2-methylimidazo[4,5-b]pyridin-1-yl)acetate (**XXVIII**) (2.35 g, 8.27 mmol) in EtOH (26 mL)/water (1.3 mL) was stirred at 70°C for 10 min (clear yellow solution). Hydrazine hydrate (3.6 mL, 73.86 mmol) was added to the mixture, and the mixture was stirred at 70°C for 4 h (off-white ppt forms). The reaction was cooled to room temperature and concentrated. The precipitate was collected by filtration and washed with EtOH to obtain 2-(6-bromo-2-methylimidazo[4,5-b]pyridin-1-yl)acetohydrazide (**XXIX**) (1.94 g, 6.828 mmol, 82.6% yield) as an off-white solid. ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 2.53 (3 H, s), 4.36 (2 H, br s), 4.87 (2 H, s), 8.22 (1 H, d, *J*=2.19 Hz), 8.39 (1 H, d, *J*=2.19 Hz), 9.48 (1 H, br s); ESIMS found for C₉H₁₀BrN₃O *m/z* 284.0 (M+H).

Step 3

[0298] (2R)-2-Fluoropropanoic acid (**XXX**) (0.16 g, 1.76 mmol), 2-(6-bromo-2-methylimidazo[4,5-b]pyridin-1-yl)acetohydrazide (**XXIX**) (0.5 g, 1.76 mmol), T3P in EtOAc (1.2 mL, 2.06 mmol) and DIPEA (0.89 mL, 5.11 mmol) were added to butyl acetate (11 mL) at room temperature in a microwave vial. The vial was sealed, and the mixture was stirred at 50°C for 30 minutes, a 2nd batch of T3P in EtOAc (1.2 mL, 2.06 mmol) was added to the mixture, and the resulting mixture was heated to 135°C for 3 h. The reaction was still not complete. A 3rd batch of T3P in EtOAc (0.58 mL, 1 mmol) was added and the mixture was stirred at 135°C for another 3 h. The mixture was cooled, a saturated aqueous NaHCO₃ (30 mL) was then added to the mixture. The liquid layer was extracted with EtOAc (75 mL*3), the organic layer was washed with water and a saturated brine and dried over Na₂SO₄. The organic layer was purified by silica gel column chromatography (0→5% MeOH/CHCl₃) to produce (R)-2-((6-bromo-2-methyl-1H-imidazo[4,5-b]pyridin-1-yl)methyl)-5-(1-fluoroethyl)-1,3,4-oxadiazole (**XXXI**) (430 mg, 1.264 mmol, 71.8% yield) as an off-white solid. ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.71 (3 H, dd, *J*=24.40, 6.60 Hz), 2.62 (3 H, s), 5.99 (1 H, dq, *J*=47.20, 6.60 Hz), 5.95 (2 H, s), 8.38 (1 H, d, *J*=2.19 Hz), 8.45 (1 H, d, *J*=2.19 Hz); ESIMS found for C₁₂H₁₁BrFN₃O *m/z* 340.0 (M+H).

[0299] Preparation of intermediate 5-chloro-3-ethyl-2-methyl-3H-imidazo[4,5-b]pyridine (XXXIII) is depicted below in Scheme 6.




Scheme 6

Step 1


[0300] A mixture of 5-chloro-2-methyl-3H-imidazo[4,5-b]pyridine (XXXII) (commercially available from eNovation Chemicals, LLC) (500 mg, 2.98 mmol), iodoethane (560 mg, 3.58 mmol) and K_2CO_3 (830 mg, 5.97 mmol) in DMF (10 mL) was heated to $70^\circ C$ overnight. The reaction mixture was cooled, solvents concentrated, the residue partitioned between EtOAc/water, the organic layers were separated, washed with brine, dried over anhydrous $MgSO_4$ and the solvents were concentrated under vacuo and dried to obtain 5-chloro-3-ethyl-2-methylimidazo[4,5-b]pyridine (XXXIII) (466 mg, 2.382 mmol, 79.8% yield) as a dark brown solid which was used for next step without purification. ESIMS found for $C_9H_{10}ClN_3$ m/z 196.05 (M+H).

[0301] The following intermediates were prepared in accordance with the procedure described in the above Scheme 6.




XXXIV

[0302] 5-Chloro-3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridine (XXXIV): Beige solid (830 mg, 3.583 mmol, 60.1% yield). ESIMS found $C_9H_8ClF_2N_3$ m/z 232.0 (M+H).




XXXV

[0303] 5-Chloro-3-(2-fluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridine (XXXV): Beige solid (220 mg, 1.030 mmol, 57.5% yield). ESIMS found $C_9H_9ClFN_3$ m/z 214.05 (M+H).




XXXVI

[0304] 5-Chloro-3-(2-methoxyethyl)-2-methyl-3H-imidazo[4,5-b]pyridine (XXXVI): Beige solid (195 mg, 0.864 mmol, 48.3% yield). ESIMS found $C_{10}H_{12}ClN_3O$ m/z 226.1 (M+H).




XXXVII

[0305] 1-(5-Chloro-2-methyl-3H-imidazo[4,5-b]pyridin-3-yl)-2-methylpropan-2-ol (XXXVII): White solid (229.9 mg, 0.959 mmol, 39.7% yield). 1H NMR (499 MHz, DMSO- d_6) δ ppm 1.13 (6 H, s), 2.63 (3 H, s), 4.11 (2 H, s), 4.80 (1 H, s), 7.25 (1 H, d, $J=8.21$ Hz), 7.96 (1 H, d, $J=8.21$ Hz); ESIMS found $C_{11}H_{14}ClN_3O$ m/z 240.1 (M+H).




XXXVIII

[0306] 5-Chloro-3-isobutyl-2-methyl-3H-imidazo[4,5-b]pyridine (XXXVIII): White solid (206.8 mg, 0.925 mmol, 38.7% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 0.87 (6 H, d, *J*=6.57 Hz), 2.22 (1 H, dquin, *J*=13.89, 7.07, 7.07, 7.07, 7.07 Hz), 2.58 (3 H, s), 4.01 (2 H, d, *J*=7.67 Hz), 7.26 (1 H, d, *J*=8.21 Hz), 7.98 (1 H, d, *J*=8.21 Hz); ESIMS found C₁₁H₁₄ClN₃ *m/z* 224.1 (M+H).




XXXIX

[0307] 5-Chloro-2-methyl-3-(2,2,2-trifluoroethyl)-3H-imidazo[4,5-b]pyridine (XXXIX): Beige solid (372 mg, 1.490 mmol, 50.0% yield). ESIMS found C₉H₇ClF₃N₃ *m/z* 250.0 (M+H).




XL

[0308] 5-Chloro-2-methyl-3-(oxetan-3-ylmethyl)-3H-imidazo[4,5-b]pyridine (XL): Light brown solid (289.7 mg, 1.219 mmol, 40.4% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 2.59 (3 H, s), 3.43 - 3.56 (1 H, m), 4.47 (2 H, t, *J*=6.02 Hz), 4.52 (2 H, d, *J*=7.67 Hz), 4.62 (2 H, dd, *J*=7.67, 6.02 Hz), 7.27 (1 H, d, *J*=8.21 Hz), 7.98 (1 H, d, *J*=8.21 Hz); ESIMS found C₁₁H₁₂ClN₃O *m/z* 238.1 (M+H).




XLI



[0309] *tert*-Butyl 3-((5-chloro-2-methyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl)azetidine-1-carboxylate (**XLI**): Off-white amorphous solid (532.6 mg, 1.581 mmol, 52.1% yield). ESIMS found $C_{16}H_{21}ClN_4O_2$ m/z 337.1 (M+H).

**XLI**

[0310] 2-(5-Chloro-2-methyl-3H-imidazo[4,5-b]pyridin-3-yl)-N,N-dimethylacetamide (**XLII**): Off-white solid (474.4 mg, 1.877 mmol, 62.6% yield). ESIMS found $C_{11}H_{13}ClN_4O$ m/z 253.1 (M+H).


**XLII**

[0311] 3-(5-Chloro-2-methyl-3H-imidazo[4,5-b]pyridin-3-yl)-2,2-dimethylpropanenitrile (**XLIII**): Off-white amorphous solid (59.1 mg, 0.238 mmol, 7.9% yield). ESIMS found $C_{12}H_{13}ClN_4$ m/z 249.1 (M+H).

**XLIV****XLV**

[0312] An inseparable mixture of 5-bromo-1-(2,2-difluoroethyl)-2-methylimidazo[4,5-b]pyrazine (**XLIV**) and 5-bromo-3-(2,2-difluoroethyl)-2-methylimidazo[4,5-b]pyrazine (**XLV**) (556 mg, 2.007 mmol, 40.7% yield) as a brown solid. ESIMS found $C_8H_7BrF_2N_4$ m/z 277.0 (M+H). Used as a mixture for the synthesis of compounds 1970 and 1971. Final compounds were separated by chiral supercritical fluid chromatography (SFC).

[0313] Preparation of intermediate 6-bromo-1-(2,2-difluoroethyl)-1H-benzo[d][1,2,3]triazole (XLIX) is depicted below in Scheme 7.



Scheme 7

Step 1


[0314] A solution of 4-bromo-2-fluoro-1-nitrobenzene (XLVI) (20.0 g, 98.03 mmol) in THF (500.0 mL) was cooled to 0°C. Cs₂CO₃ (63.9 g, 196.06 mmol) was added, 2,2-difluoroethan-1-amine (XLVII) (36.6 g, 183.81 mmol) was added at 0°C. The reaction was warmed to 40°C for 16 h. The reaction mixture was extracted with EtOAc (500 mL x 3). The combined organics were washed with brine (500 mL x 3). The combined organic layers were dried with Na₂SO₄, filtered, and concentrated to give the crude product. The crude was purified by column chromatography on silica gel (10→20% EtOAc/petroleum ether) to give 5-bromo-N-(2,2-difluoroethyl)-2-nitroaniline (XLVIII) (23 g, 81.83 mmol, 83.5% yield) as a yellow solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 3.99 (tdd, *J* = 15.6, 6.6, 3.8 Hz, 2H), 6.29 (tt, *J* = 55.4, 3.7 Hz, 1H), 6.96 (dd, *J* = 9.2, 2.0 Hz, 1H), 7.51 (d, *J* = 1.6 Hz, 1H), 8.05 (d, *J* = 9.2 Hz, 1H), 8.33 (t, *J* = 6.4 Hz, 1H); ESIMS found for C₈H₇BrF₂N₂O₂ *m/z* 280.9 (M+H).

Step 2

[0315] To a solution of 5-bromo-N-(2,2-difluoroethyl)-2-nitroaniline (XLVIII) (12.0 g, 42.86 mmol) in HOAc/HCl (500/50 mL) was added Fe (30.0 g, 428.62 mmol). The reaction mixture was stirred at 50°C for 30 minutes, then cooled to room temperature and filtered. NaNO₂ (3.0 g, 53.58 mmol) in water (20 mL) was then added dropwise into above acid solution at 0°C. The reaction solution was stirred for 1 h at 0°C. The reaction mixture was concentrated to dryness, the reaction mixture was poured into EtOAc (300 mL) and H₂O (300 mL). The pH was adjusted >7 with NaHCO₃. The reaction mixture was extracted with EtOAc (500 mL x 3). The combined organics were washed with brine (500 mL x 3). The organic layers was concentrated, dried over Na₂SO₄, filtered, and concentrated to give the crude. The crude was purified by column chromatography on silica gel (10→50% EtOAc/petroleum ether) to give 6-bromo-1-(2,2-

difluoroethyl)-1H-benzo[d][1,2,3]triazole (**XLIX**) (5 g, 19.08 mmol, 44.5%) as a brown solid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 5.41 – 5.29 (m, 2H), 6.61 (tt, $J = 54.2, 3.2$ Hz, 1H), 7.60 (dd, $J = 8.8, 1.7$ Hz, 1H), 8.08 (d, $J = 8.8$ Hz, 1H), 8.31 (d, $J = 1.0$ Hz, 1H); ESIMS found for $\text{C}_8\text{H}_6\text{BrF}_2\text{N}_3$ m/z 261.9 (M+H).

[0316] Preparation of intermediate (6-bromoimidazo[1,2-a]pyridin-3-yl)(pyrrolidin-1-yl)methanone (**LII**) is depicted below in Scheme 8.




Scheme 8

Step 1

[0317] A mixture of 6-bromoimidazo[1,2-a]pyridine-3-carboxylic acid (**L**) (0.5 g, 2.07 mmol), DIPEA (0.9 mL, 5.17 mmol) and HATU (0.79 g, 2.07 mmol) in DMF (4 mL) was stirred for 5 min. Pyrrolidine (**LI**) (0.32 mL, 3.18 mmol) was then added, and the reaction mixture was continued to stir at room temperature for 4 h. The solvent were concentrated, the residue partitioned between EtOAc and saturated aqueous NaHCO_3 , the organic layer was separated, washed with water and brine. The organic layer was dried over anhydrous Na_2SO_4 , concentrated and dried under high vacuo to obtain (6-bromoimidazo[1,2-a]pyridin-3-yl)-pyrrolidin-1-ylmethanone (**LII**) (577 mg, 1.962 mmol, 94.6% yield) as a beige solid. ESIMS found for $\text{C}_{12}\text{H}_{12}\text{BrN}_3\text{O}$ m/z 294.0 (M+H).

[0318] Preparation of intermediate imidazo[1,2-a]pyrimidin-6-ylboronic acid (LV) is depicted below in Scheme 9.




Scheme 9

Step 1

[0319] A mixture of 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-amine (LIII) (1 g, 4.52 mmol) and chloroacetaldehyde (LIV) (0.92 mL, 5.39 mmol) was dissolved in 1,4-dioxane (20 mL) and heated to 110°C over the weekend. The reaction mixture was cooled, and the solids were collected by filtration and dried under high vacuo to obtain imidazo[1,2-a]pyrimidin-6-ylboronic acid (LV) (650 mg, 3.989 mmol, 88.2% yield) as a brown solid which was used for next step without purification. ESIMS found for $C_6H_6BN_3O_2$ m/z 164.1 (M+H).

[0320] Preparation of intermediate 6-bromo-3-methylimidazo[1,2-a]pyrimidine (LX) is depicted below in Scheme 10.



Scheme 10

Step 1


[0321] To a mixture of propionaldehyde (LVI) (5 g, 70 mmol) in Et_2O (150 mL) was added 5,5-dibromopyrimidine-2,4,6(1H,3H,5H)-trione (LVII) (9.91 g, 35 mmol) and the resulting mixture was stirred at room temperature for 16 h. After completion, the mixture was washed by

petroleum ether (80 mL x 2). The organic layer was filtered and concentrated to give 2-bromopropanal (**LVIII**) (2.0 g, 14.6 mmol, 20.9% yield) as a yellow oil.

Step 2

[0322] To a solution of 2-bromopropanal (**LVIII**) (0.7 g, 5.11 mol) in DMF (20 mL) was added 5-bromopyrimidin-2-amine (**LIX**) (0.97 g, 5.56 mmol) at room temperature under Ar. The mixture was stirred at 100°C for 16 h. After completion, the mixture was diluted with EtOAc and washed with brine (20 mL x 3). The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated. The crude residue was purified by silica gel column chromatography (0%→20% EtOAc/petroleum ether) to give 6-bromo-3-methylimidazo[1,2-a]pyrimidine (**LX**) (80 mg, 0.377 mmol, 7.4% yield) as a white solid. ESIMS found for C₇H₆BrN₃ *m/z* 212.1 (M+H).


[0323] The following intermediate was prepared in accordance with the procedure described in the above Scheme 10.



LXI

[0324] 6-Bromo-3-ethylimidazo[1,2-a]pyrimidine (**LXI**): White solid (200 mg, 0.885 mmol, 19.1% yield). ESIMS found C₈H₈BrN₃ *m/z* 226.0 (M+H).

[0325] Preparation of intermediate *cis*-4-(methoxy-*d*₃)cyclohexan-1-amine (**LXVII**) is depicted below in Scheme 11.



Scheme 11

Step 1

[0326] To a solution of *cis*-4-aminocyclohexan-1-ol (**LXII**) (5 g, 32.9 mmol), (bromomethyl)benzene (**LXIII**) (11.25 g, 65.8 mmol) in MeCN (80 mL) was added K₂CO₃ (13.64 g, 98.7 mmol). The mixture was stirred at 70°C for 5 h. The reaction mixture was concentrated under reduced pressure to remove MeCN. The mixture was diluted with EtOAc and then extracted with EtOAc (100 mL x 3) and H₂O. The combined organic layers were concentrated, and the crude residue was purified by silica gel column chromatography (0%→30% EtOAc/petroleum ether) to give the *cis*-4-(dibenzylamino)cyclohexan-1-ol (**LIV**) (8.0 g, 27.08 mmol, 82.3% yield) as a white solid. ESIMS found for C₂₀H₂₅NO *m/z* 296.4 (M+H).

Step 2


[0327] To a solution of *cis*-4-(dibenzylamino)cyclohexan-1-ol (**LIV**) (8.0 g, 27.08 mmol) in DMPU (80 mL) was added slowly NaH (5.98 g, 149.7 mmol) under nitrogen atmosphere with continuous stirring. The reaction mixture was stirred at room temperature for 1 h. Then iodomethane-*d*₃ (**LXV**) (10.85 g, 74.86 mmol) was added at room temperature over a period of 10 min. After complete addition, the reaction mixture was stirred at 50°C for 16 h. The reaction mixture was then quenched with saturated aqueous NH₄Cl (300 mL) and stirred for 10 min. The mixture was diluted with EtOAc and then extracted with EtOAc (300 mL x 3) and H₂O. The crude residue was purified by silica gel column chromatography (0%→20% EtOAc/petroleum ether) to yield *cis*-N,N-dibenzyl-4-(methoxy-*d*₃)cyclohexan-1-amine (**LXVI**) (6 g, 19.202 mmol, 70.9% yield) as a colorless oil. ESIMS found for C₂₁H₂₄D₃NO *m/z* 313.0 (M+H).

Step 3

[0328] To a solution of *cis*-N,N-dibenzyl-4-(methoxy-*d*₃)cyclohexan-1-amine (**LXVI**) (200 mg, 0.64 mmol) in EtOH (5 mL) was added Pd(OH)₂/C (50 mg) and Pd/C (50 mg). The mixture was stirred at room temperature for 16 h. The mixture was filtered through Celite[®] and washed with EtOH. The reaction mixture was concentrated under reduced pressure to give the *cis*-4-(methoxy-*d*₃)cyclohexan-1-amine (**LXVII**) (76.4 mg, 0.578 mmol, 90.3% yield) as a colorless oil. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.51 – 1.40 (m, 4H), 1.67 – 1.56 (m, 4H), 1.86 (td, *J* =


9.8, 4.6 Hz, 2H), 2.71 (tt, $J = 10.8, 5.4$ Hz, 1H), 3.34 (td, $J = 4.8, 2.4$ Hz, 1H); ESIMS found for $C_7H_{12}D_3NO$ m/z 133.0 (M+H).

[0329] The following intermediates were prepared in accordance with the procedure described in the above Scheme 11.




LXVIII

[0330] 2-((*cis*-4-Aminocyclohexyl)oxy)ethan-1-ol (LXVIII): Colorless oil (0.5 g, 3.14 mmol, 67.4% yield). ESIMS found for $C_8H_{17}NO_2$ m/z 160. (M+H).




LXIX

[0331] *cis*-4-(2-Methoxyethoxy)cyclohexan-1-amine (LXIX): Colorless oil (1.5 g, 8.65 mmol, 76.6% yield). ESIMS found for $C_9H_{19}NO_2$ m/z 174.1 (M+H).




LXX

[0332] *cis*-4-(2,2-Difluoroethoxy)cyclohexan-1-amine (LXX): White solid (1.352 g, 7.54 mmol, 90.3% yield). ESIMS found for $C_8H_{15}F_2NO$ m/z 180.1 (M+H).



LXXI


[0333] *cis*-4-Ethoxycyclohexan-1-amine (LXXI): Colorless oil (2 g, 13.96 mmol, 64.4% yield). 1H NMR (400 MHz, $CDCl_3$) δ 1.19 (t, $J = 7.0$ Hz, 3H), 1.49 – 1.44 (m, 6H), 1.62 – 1.55 (m, 2H), 1.86 – 1.79 (m, 2H), 2.4 – 2.723 (m, 1H), 3.49 – 3.41 (m, 3H).



LXXII

[0334] *cis*-3-(2-Methoxyethoxy)cyclobutan-1-amine (LXXII): Colorless oil. 1H NMR (400 MHz, $DMSO-d_6$) δ 1.51 (dd, $J = 13.4, 5.2$ Hz, 2H), 2.49 – 2.40 (m, 2H), 2.89 – 2.75 (m, 1H), 3.23 (s, 3H), 3.37 – 3.35 (m, 3H), 3.47 (s, 2H), 3.54 – 3.48 (m, 1H).

[0335] Preparation of intermediate *cis*-4-(difluoromethoxy)cyclohexan-1-amine (LXXV) is depicted below in Scheme 12.



Scheme 12


Step 1

[0336] To a solution of *cis*-4-(dibenzylamino)cyclohexan-1-ol (LXIV) (50 mg, 0.170 mmol), CuI (6.5 mg, 0.034 mmol) in MeCN (5 mL) and heated to 45°C under nitrogen atmosphere for 5 min. To this mixture was added a solution of 2,2-difluoro-2-(fluorosulfonyl)acetic acid (LXXIII) (60 mg, 0.339 mmol) in (2 mL) MeCN over 10 min. Then the mixture was stirred at 45°C for 1 h. Volatile components were then removed via evaporation and the residue was diluted with EtOAc (100 mL) and 100 mL of a 1:1 mixture of water and saturated aqueous NaHCO₃. The resulting biphasic mixture containing solids was filtered through a sintered glass Buchner funnel. The filtrate layers were separated, and the aqueous layer was extracted with EtOAc (50 mL). The combined EtOAc layers were washed with 50 mL of a 1:1 mixture of brine and water, dried over anhydrous MgSO₄, filtered, and concentrated to an oil. The crude oil was purified by silica gel chromatography (0→30% EtOAc/hexanes). Product containing fractions were combined and concentrated to afford the *cis*-N,N-dibenzyl-4-(difluoromethoxy)cyclohexan-1-amine (LXXIV) (25 mg, 0.072 mmol, 42.3% yield) as an oil that solidified to an off-white solid. ESIMS found for C₂₁H₂₅F₂NO *m/z* 346.1 (M+H).

Step 2

[0337] To a solution of *cis*-N,N-dibenzyl-4-(difluoromethoxy)cyclohexan-1-amine (LXXIV) (2.8 g, 8.11 mmol) in THF (60 mL) was added Pd (OH)₂/C (1.4 g) and Pd/C (1.4 g). The mixture was stirred at room temperature for 16 h. The mixture was filtered through Celite® and washed with THF. The reaction mixture was concentrated under reduced pressure to afford *cis*-4-(difluoromethoxy)cyclohexan-1-amine (LXXV) (1.05 g, 6.36 mmol, 78.4% yield) as a colorless oil. ESIMS found for C₇H₁₃F₂NO *m/z* 166.1 (M+H).

[0338] Preparation of intermediate 1-(3,3,3-trifluoropropyl)piperidin-4-amine (LXXIX) is depicted below in Scheme 13.



Scheme 13


Step 1

[0339] *tert*-Butyl piperidin-4-ylcarbamate (LXXVI) (Commercially available from Combi-Blocks Inc.) (1 g, 4.99 mmol) and K_2CO_3 (1.73 g, 12.52 mmol) were dissolved in DMF (15 mL) and 1-iodo-3,3,3-trifluoropropane (LXXVII) (878 μL , 7.49 mmol) was added and the reaction was stirred at room temperature for 16 h. The reaction mixture was poured in EtOAc, and the aqueous layer was separated. The aqueous layer was extracted with EtOAc ($\times 3$) and then the combined organic layers were acidified to pH 4.5 with 1 M citric acid. The organic layer was washed three times with small volumes of water to remove unreacted SM. Sufficient amounts of the product remained in the organic layer which was dried using anhydrous MgSO_4 and reduced in vacuo to give the product *tert*-butyl N-[1-(3,3,3-trifluoropropyl)piperidin-4-yl]carbamate (LXXVIII) (861 mg, 2.906 mmol, 58.2% yield) as a white solid. ESIMS found for $\text{C}_{13}\text{H}_{23}\text{F}_3\text{N}_2\text{O}_2$ m/z 297.2 (M+H).

Step 2

[0340] *tert*-Butyl N-[1-(3,3,3-trifluoropropyl)piperidin-4-yl]carbamate (LXXVIII) (200 mg, 0.670 mmol) was dissolved in DCE (3.2 mL) and TFA (800 μL , 10.38 mmol) was added and the reaction was stirred at room temperature for 30 m. The reaction mixture was blown dry and excess TFA removed by high vacuum to give the crude intermediate 1-(3,3,3-trifluoropropyl)piperidin-4-amine (LXXIX) (209 mg, 0.674 mmol, 99.8% yield) as a white semi-solid which was used without further purification. ESIMS found for $\text{C}_8\text{H}_{15}\text{F}_3\text{N}_2$ m/z 197.1 (M+H).

[0341] Preparation of intermediate N-(*trans*-4-aminocyclohexyl)acetamide (LXXXII) is depicted below in Scheme 14.




Scheme 14

Step 1

[0342] To a stirring solution of *tert*-butyl N-(4-aminocyclohexyl)carbamate (LXXX) (Commercially available from Combi-Blocks Inc.) (0.6 g, 2.8 mmol) in DCM (6 mL) was added TEA (1.2 mL, 8.61 mmol). Acetyl chloride (LXXXI) (0.22 mL, 3.09 mmol) was then slowly, and the reaction mixture was stirred at room temperature for 16 h. The solvent was removed, and the crude material was dissolved in EtOAc, washed with 1 M NaOH, brine, and dried over anhydrous MgSO₄ and finally concentrated. The product was dissolved in EtOH (2 mL) and 4 M HCl (1 mL). The solution was stirred at room temperature for 2 h before evaporating to dryness to give the HCl salt of N-(4-aminocyclohexyl)acetamide (LXXXII) (480 mg, 2.49 mmol, 89.0% yield) as a white solid. ESIMS found for C₈H₁₆N₂O *m/z* 157.05 (M+H).

[0343] Preparation of intermediate *cis*-4-amino-N,N-dimethylcyclohexane-1-carboxamide (LXXXIV) is depicted below in Scheme 15.




Scheme 15

Step 1

[0344] To a stirring solution of 4-(*tert*-butoxycarbonylamino)cyclohexanecarboxylic acid (LXXXIII) (Commercially available from Combi-Blocks Inc.) (0.3 g, 1.23 mmol) in DMF (6 mL) was added DIPEA (0.65 mL, 3.73 mmol) and HATU (0.7 g, 1.85 mmol). Reaction was stirred for 5 min at room temperature. Dimethylamine (0.92 mL, 1.84 mmol) was added, and reaction was heated to 90°C for 16 h. The reaction was concentrated and dissolved in EtOH (2 mL) and 4 M HCl in dioxane (1 mL). The mixture was stirred for 2 h at room temperature, concentrated under vacuum to yield the HCl salt of 4-amino-N,N-dimethylcyclohexane-1-carboxamide (LXXXIV) (280 mg,

1.355 mmol, 109.9% yield) as a light brown viscous solid. ESIMS found for $C_9H_{18}N_2O$ m/z 171.15 (M+H).

[0345] The following intermediate was prepared in accordance with the procedure described in the above Scheme 15.




LXXXV

[0346] *trans*-4-Amino-N,N-dimethylcyclohexane-1-carboxamide (LXXXV): Light brown viscous solid (290 mg, 1.403 mmol, 113.8% yield). ESIMS found for $C_9H_{18}N_2O$ m/z 171.1 (M+H).

Example 1.

[0347] Preparation of N-(cyclopropylmethyl)-5-(imidazo[1,2-a]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine (16) is depicted below in Scheme 16.



Scheme 16

Step 1

[0348] To a solution of 5-bromo-2-(methylthio)pyrrolo[2,1-f][1,2,4]triazine (**VII**) (commercially available from Combi-Blocks Inc.) (4.0 g, 15.59 mmol) in DCM (80 mL) was added *m*-CPBA (3.22 g, 18.66 mmol) at 0°C. The mixture was stirred at room temperature for 16 h. The reaction mixture was quenched with saturated aqueous NaS₂O₃ at 0°C, diluted with H₂O (50 mL) and extracted with EtOAc (200 mL). The combined organic layers were concentrated to give the residue. The aqueous phase was concentrated, washed with DCM/MeOH (200 mL/ 10 mL), filtered to give a residue. The combined residue was purified by reverse phase chromatography (C18-I, Regular C18 20-40 μm, 120 g, 40→45% MeCN/0.1% formic acid in H₂O) to afford 5-bromo-2-(methylsulfinyl)pyrrolo[2,1-f][1,2,4]triazine (**VIII**) (1.5 g, 5.767 mmol, 37%) as a yellow solid. ¹H NMR (400 MHz, CDCl₃) δ 3.01 (s, 3H), 7.10 (d, J = 2.8 Hz, 1H), 7.97 (d, J = 2.7 Hz, 1H), 8.93 (s, 1H); ESIMS found for C₇H₆BrN₃OS *m/z* 261.9 (⁸¹BrM+H).

Step 2

[0349] A solution of 5-bromo-2-(methylsulfinyl)pyrrolo[2,1-f][1,2,4]triazine (**VIII**) (400 mg, 1.55 mmol), imidazo[1,2-a]pyridin-6-ylboronic acid (**LXXXVI**) (commercially available from Synthonix Corporation) (301.2 mg, 1.86 mmol), PCy₃ (86.8 mg, 0.31 mmol), Pd₂(dba)₃ (141.8 mg, 0.155 mmol) and K₃PO₄ (657.2 mg, 3.1 mmol) in 1,4-dioxane/H₂O (6 mL/2 mL) was irradiated with microwave at 120°C for 0.5 h under N₂. The reaction mixture was diluted with H₂O (30 mL) and extracted with EtOAc (60 mL). The combined organic layers were concentrated to give the residue. The residue was purified by reverse phase chromatography (C18-I, Regular C18, 20-40 μm, 120 g, 50% MeCN/0.1% formic acid in H₂O) to afford the product 5-(imidazo[1,2-a]pyridin-6-yl)-2-(methylsulfinyl)pyrrolo[2,1-f][1,2,4]triazine (**LXXXVII**) (240 mg, 0.807 mmol, 52.1% yield) as a yellow solid. ESIMS found for C₁₄H₁₁N₅OS *m/z* 298. (M+H).


Step 3

[0350] A solution of 5-(imidazo[1,2-a]pyridin-6-yl)-2-(methylsulfinyl)pyrrolo[2,1-f][1,2,4]triazine (**LXXXVII**) (58 mg, 0.185 mmol), cyclopropylmethanamine (**LXXXVIII**) (40.0 mg, 0.555 mmol) and DIPEA (71.8 mg, 0.555 mmol) in DME (2 mL) was irradiated with microwave at 180°C for 1 h. The reaction mixture was diluted with H₂O (30 mL) and extracted with EtOAc (60 mL). The combined organic layers were concentrated to give the residue. The residue was purified by preparative HPLC (Sunfire C18 21.2*250 mm*10 μm, 18→20%

MeCN/0.1% formic acid in H₂O) to afford N-(cyclopropylmethyl)-5-(imidazo[1,2-a]pyridin-6-yl)pyrrolo[2,1-f][1,2,4] triazin-2-amine (**16**) (5.16 mg, 0.017 mmol, 9.2% yield) as a yellow solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 0.19 - 0.28 (2 H, m), 0.40 - 0.50 (2 H, m), 1.07 - 1.17 (1 H, m), 3.09 (2 H, t, *J*=6.24 Hz), 6.96 (1 H, d, *J*=2.57 Hz), 7.04 (1 H, t, *J*=5.81 Hz), 7.53 - 7.65 (2 H, m), 7.58 (1 H, d, *J*=1.10 Hz), 7.71 (1 H, dd, *J*=2.45, 0.61 Hz), 7.95 (1 H, s), 8.92 (1 H, dd, *J*=1.65, 1.04 Hz), 9.12 (1 H, s); ESIMS found for C₁₇H₁₆N₆ *m/z* 305.3 (M+1).

Example 2.

[0351] Preparation of (R)-5-(imidazo[1,2-a]pyrimidin-6-yl)-N-(1,1,1-trifluoropropan-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine (**219**) is depicted below in Scheme 17.



Scheme 17

Step 1

[0352] (R)-1,1,1-Trifluoropropan-2-amine (**LXXXIX**) (433.7 mg, 0.29 mmol) and Cs₂CO₃ (945.4 mg, 2.9 mmol) were dissolved in DMSO (2 mL) and stirred for 30 min. To this mixture was added 5-bromo-2-(methylsulfinyl)pyrrolo[2,1-f][1,2,4]triazine (**VIII**) (150 mg, 0.58 mmol) and pyridine (229.39 mg, 2.9 mmol). The resulting mixture was sealed and irradiated with microwave at 180°C for 1.5 h. The reaction mixture was then cooled to room temperature and diluted with EtOAc (30 mL). The solution was washed with water (30 mL), and the aqueous portion was extracted with EtOAc (30 mL). The combined organic extracts were washed with brine (30 mL) and dried over anhydrous MgSO₄, filtrated, and concentrated in vacuo to afford the crude product which was purified by pre-TLC (16.7% EtOAc/petroleum ether) to give (R)-5-bromo-N-(1,1,1-trifluoropropan-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine (**XC**) (58 mg, 0.187 mmol, 64.5% yield) as a yellow solid. ESIMS found for C₉H₈BrF₃N₄ *m/z* 309.0 (⁷⁹BrM+H).


Step 2

[0353] Performed using procedure shown in Example 3, Scheme 18, Step 2 to yield (R)-5-(Imidazo[1,2-a]pyrimidin-6-yl)-N-(1,1,1-trifluoropropan-2-yl)pyrrolo [2,1-f][1,2,4]triazin-

2-amine (**219**) (20.91 mg, 0.060 mmol) as a yellow solid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ ppm 1.37 (3 H, d, $J=7.00$ Hz), 4.66 - 4.82 (1 H, m), 7.15 (1 H, d, $J=2.50$ Hz), 7.60 (1 H, d, $J=9.13$ Hz), 7.75 (1 H, d, $J=1.13$ Hz), 7.84 (1 H, d, $J=2.63$ Hz), 7.90 (1 H, d, $J=1.25$ Hz), 8.90 (1 H, d, $J=2.50$ Hz), 9.24 (1 H, s), 9.33 (1 H, d, $J=2.50$ Hz); ESIMS found for $\text{C}_{15}\text{H}_{12}\text{F}_3\text{N}_7$ m/z 348.1 ($\text{M}+1$).

Example 3.

[0354] Preparation of 5-(imidazo[1,2-a]pyrimidin-6-yl)-N-(tetrahydro-2H-pyran-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine (**280**) is depicted below in Scheme 18.



Scheme 18

Step 1

[0355] A solution of 5-bromo-2-(methylsulfinyl)pyrrolo[2,1-f][1,2,4]triazine (**VIII**) (150 mg, 0.58 mmol), tetrahydro-2H-pyran-4-amine (**XCI**) (293.3 mg, 2.9 mmol), and pyridine (225 μL , 2.9 mmol) in DMSO (3 mL) was sealed and irradiated with microwave at 180°C for 1.5 h. The reaction mixture was then cooled to room temperature and diluted with EtOAc (30 mL). The solution was washed with water (30 x 3 mL), and the aqueous portion was extracted with EtOAc (30 x 3 mL). The combined organic extracts were washed with brine (30 x 3 mL) and dried over anhydrous Na_2SO_4 , filtrated, and concentrated in vacuo to afford the crude residue. The residue was purified by pre-TLC (20% EtOAc/petroleum ether) to afford 5-bromo-N-(tetrahydro-2H-pyran-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine (**XCI**) (220 mg, 0.740 mmol, >100% yield) as a yellow solid. ESIMS found for $\text{C}_{11}\text{H}_{13}\text{BrN}_4\text{O}$ m/z 297.0 ($^{79}\text{BrM}+\text{H}$).

Step 2


[0356] A solution of 5-bromo-N-(tetrahydro-2H-pyran-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine (**XCI**) (190 mg, 0.64 mmol), imidazo[1,2-a]pyrimidin-6-ylboronic acid (**LV**) (1.04 g, 6.4 mmol), PCy_3 (71.8 mg, 0.26 mmol), $\text{Pd}_2(\text{dba})_3$ (117.1 mg, 0.13 mmol) and K_3PO_4 (407.6 mg, 1.92 mmol) in dioxane/water (12 mL, 3:1 ratio) was sealed and irradiated with

microwave at 120°C for 30 min. The reaction mixture was then cooled to room temperature and diluted with EtOAc (30 x 3 mL). The solution was washed with water (30 x 3 mL), and the aqueous portion was extracted with EtOAc (30 x 3 mL). The combined organic extracts were washed with brine (30 x 3 mL) and dried over anhydrous Na₂SO₄, filtrated, and concentrated in vacuo to afford the crude which was purified by pre-TLC (6.25% MeOH/DCM→50% EtOAc/petroleum ether) to produce

5-(imidazo[1,2-a]pyrimidin-6-yl)-N-(tetrahydro-2H-pyran-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine (**280**) (25.1 mg, 0.075 mmol, 11.7% yield) as a yellow solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.45 - 1.61 (2 H, m), 1.90 (2 H, br dd, *J*=12.51, 2.00 Hz), 3.35 - 3.43 (2 H, m), 3.72 - 3.83 (1 H, m), 3.84 - 3.93 (2 H, m), 7.01 (1 H, d, *J*=7.75 Hz), 7.06 (1 H, d, *J*=2.50 Hz), 7.74 (2 H, dd, *J*=4.13, 1.88 Hz), 7.89 (1 H, d, *J*=1.25 Hz), 8.88 (1 H, d, *J*=2.50 Hz), 9.16 (1 H, s), 9.29 (1 H, d, *J*=2.50 Hz); ESIMS found for C₁₇H₁₇N₇O *m/z* 336.1 (M+1).

Example 4.

[0357] Preparation of 5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(2-fluoro-2-methylpropyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine (**642**) is depicted below in Scheme 19.



Scheme 19

Step 1

[0358] A mixture of 2-fluoro-2-methylpropan-1-amine hydrochloride (**XCIII**) (290 mg, 2.26 mmol), 5-bromo-2-chloropyrrolo[2,1-f][1,2,4]triazine (**I**) (commercially available from Advanced ChemBlocks Inc.) (350 mg, 1.51 mmol) and DIPEA (1.2 mL, 6.89 mmol) in 1,4-dioxane (4 mL) was heated to 110°C for 16 h. The reaction mixture was concentrated, the residue partitioned between CHCl₃/water, the organic layer was separated, washed with brine solution, dried over anhydrous Na₂SO₄, and the solvents concentrated and dried under high vacuo to obtain crude 5-

bromo-N-(2-fluoro-2-methylpropyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine (**XCIV**) (435 mg, 1.52 mmol, 100.6% yield) which was used for next step without purification. ESIMS found for $C_{10}H_{12}BrFN_4$ m/z 287.0 ($^{79}BrM+H$).


Steps 2-3

[0359] A mixture of 6-bromo-1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridine (**XV**) (100 mg, 0.370 mmol), bis(pinacolato)diboron (100 mg, 0.400 mmol), KOAc (110 mg, 1.1 mmol) and Pd(dppf)Cl₂ (100 mg, 0.020 mmol) was taken in monoglyme (1.5 mL) and N₂ was purged into the mixture for 2 min and the vial was sealed and heated to 95°C overnight. LCMS showed the completion of reaction and the formation of boronic acid.

[0360] To the mixture was added 5-bromo-N-(2-fluoro-2-methylpropyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine (**XCIV**) (70 mg, 0.240 mmol), Pd(dppf)Cl₂ (100 mg, 0.020 mmol) and 2 N solution of K₃PO₄ (0.37 mL, 0.750 mmol), N₂ was purged for 2 min and the mixture was heated to 95°C for 5 h. The organics were separated, absorbed on silica gel, and was purified by ISCO (0→6%7 N NH₃ MeOH/CHCl₃). The pure fractions were combined, triturated with diethyl ether, sonicated and the solids were collected by filtration to obtain 5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(2-fluoro-2-methylpropyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine (**642**) (37 mg, 0.092 mmol, 37.6% yield) as a yellow solid. ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.38 (6 H, d, *J*=21.40 Hz), 2.63 (3 H, s), 3.49 (2 H, dd, *J*=19.30, 6.43 Hz), 4.91 (2 H, td, *J*=15.88, 3.01 Hz), 6.53 (1 H, tt, *J*=54.40, 3.20 Hz), 7.01 (1 H, d, *J*=2.74 Hz), 7.03 (1 H, t, *J*=6.43 Hz), 7.73 (1 H, d, *J*=2.46 Hz), 8.25 (1 H, d, *J*=1.92 Hz), 8.67 (1 H, d, *J*=1.92 Hz), 9.14 (1 H, s); ESIMS found for C₁₉H₂₀F₃N₇ m/z 404.2 (M+1).

Example 5.

[0361] Preparation of N-(2-isobutyl-2-azaspiro[3.3]heptan-6-yl)-5-(quinolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine (**1771**) is depicted below in Scheme 20.



Scheme 20

Step 1

[0362] A mixture of DIPEA (0.79 mL, 4.52 mmol), 5-bromo-2-chloropyrrolo[2,1-f][1,2,4]triazine (**I**) (commercially available from Advanced ChemBlocks Inc.) (350 mg, 1.51 mmol) and *tert*-butyl 6-amino-2-azaspiro[3.3]heptane-2-carboxylate (**XCV**) (480 mg, 2.26 mmol) in 1,4-dioxane (4 mL) was heated to 110°C for 16 h. The reaction mixture was concentrated, the residue partitioned between DCM/water, organic layer separated, washed with brine solution, dried over anhydrous Na₂SO₄, solvents concentrated and dried under high vacuo to obtain crude *tert*-butyl 6-((5-bromopyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-2-azaspiro[3.3]heptane-2-carboxylate (**XCVI**) (630 mg, 1.54 mmol, 102.5% yield) which was used in the next step without purification. ESIMS found for C₁₇H₂₂BrN₅O₂ *m/z* 352.1 (M+H⁺-^tBu).

Step 2

[0363] A mixture of *tert*-butyl 6-((5-bromopyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-2-azaspiro[3.3]heptane-2-carboxylate (**XCVI**) (620 mg, 1.51 mmol), 2 N aqueous solution of K₃PO₄ (4.44 mL, 8.88 mmol), and Pd(dppf)Cl₂ (60 g, 0.080 mmol) was taken in 1,4-dioxane (8 mL) and quinoline-6-boronic acid (**XCVII**) (520 mg, 3.01 mmol) was added. The reaction mixture was purged with N₂ gas for 5 min, the vial was sealed and heated at 95°C overnight. The solvents were added to saturated aqueous NaHCO₃, solids were collected by filtration and the crude was

purified by ISCO (4% 7 N NH₃ MeOH in CHCl₃) to produce *tert*-butyl 6-((5-(quinolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-2-azaspiro[3.3]heptane-2-carboxylate (**XCVIII**) (588 mg, 1.29 mmol, 85.5% yield) as a yellow solid. ESIMS found for C₂₆H₂₈N₆O₂ *m/z* 457.3 (M+H).

Step 3


[0364] To a stirred solution of *tert*-butyl 6-((5-(quinolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-2-azaspiro[3.3]heptane-2-carboxylate (**XCVIII**) (590 mg, 1.29 mmol) in DCM (10 mL) was added TFA (3.8 mL, 49.3 mmol) and the mixture was stirred at room temperature for 3 h. The mixture was concentrated and basified with 2 N NH₃ solution in MeOH and purified via column chromatography (0→8% 7 N NH₃ in MeOH/CHCl₃) to yield 5-(quinolin-6-yl)-N-(2-azaspiro[3.3]heptan-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine (**XCIX**) (410 mg, 1.15 mmol, 89.3% yield) as a yellow solid. ESIMS found for C₂₁H₂₀N₆ *m/z* 357.2 (M+H).

Step 4

[0365] To a stirring solution of 5-(quinolin-6-yl)-N-(2-azaspiro[3.3]heptan-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine (**XCIX**) (100 mg, 0.280 mmol) in DCE (1 mL) and EtOH (0.125 mL) was added isobutyraldehyde (**C**) (0.26 mL, 2.81 mmol). Reaction mixture was allowed to stir for 30min and NaBH(OAc)₃ (150 mg, 0.700 mmol) was added. Reaction mixture was allowed to stir at room temperature for 16 h. Quenched reaction with saturated aqueous NaHCO₃. Extracted with DCM. Washed organics with brine and dried over MgSO₄. Concentrated. Purified via column chromatography. (100% CHCl₃ => 6% 7 N NH₃ in MeOH/CHCl₃) to afford 5-(imidazo[1,2-a]pyrimidin-6-yl)-N-(*cis*-4-(trifluoromethoxy) cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine (**1771**) (20 mg, 0.048 mmol, 18.2% yield) as a brown solid. ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.62 - 1.71 (2 H, m), 1.71 - 1.80 (2 H, m), 1.80 - 1.88 (2 H, m), 1.95 (2 H, br dd, *J*=9.03, 4.65 Hz), 3.65 - 3.77 (1 H, m), 4.57 - 4.65 (1 H, m), 7.02 (1 H, d, *J*=7.12 Hz), 7.07 (1 H, d, *J*=2.74 Hz), 7.73 - 7.76 (2 H, m), 7.89 (1 H, d, *J*=1.09 Hz), 8.88 (1 H, d, *J*=2.74 Hz), 9.16 (1 H, s), 9.30 (1 H, d, *J*=2.74 Hz); ESIMS found for C₁₉H₁₈F₃N₇O *m/z* 418.2 (M+1).

Example 6.

[0366] Preparation of 5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*cis*-4-(morpholinomethyl)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine (**1842**) is depicted below in Scheme 21.



Scheme 21

Step 1

[0367] A mixture of 5-bromo-2-chloropyrrolo[2,1-f][1,2,4]triazine (**I**) (commercially available from Advanced ChemBlocks Inc.) (200 mg, 0.860 mmol), (*cis*-4-aminocyclohexyl)methanol HCl salt (**CI**) (commercially available from Combi-Blocks Inc.) (215 mg, 1.3 mmol) and DIPEA (0.44 mL, 2.53 mmol) in DMSO (1 mL) was heated to 110°C for 16 h. The reaction mixture was concentrated. The residue was purified by silica gel column chromatography (0→100% EtOAc/Hexanes) to produce (*cis*-4-((5-bromopyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclohexyl)methanol (**CII**) (203.9 mg, 0.627 mmol, 72.9% yield) as a tan solid. ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.42 - 1.51 (5 H, m), 1.53 - 1.60 (2 H, m), 1.66 - 1.74 (2 H, m), 3.30 (2 H, t, *J*=5.75 Hz), 3.70 - 3.80 (1 H, m), 4.37 (1 H, t, *J*=5.34 Hz), 6.73 (1 H, d, *J*=2.46 Hz), 6.82 (1 H, d, *J*=7.12 Hz), 7.66 (1 H, d, *J*=2.74 Hz), 8.69 (1 H, s); ESIMS found for C₁₃H₁₇BrN₄O *m/z* 325.0 (M+H).

Step 2

[0368] To a solution of (*cis*-4-((5-bromopyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclohexyl)methanol (**CII**) (180 mg, 0.550 mmol) in DCM (4 mL) at 0°C was added MsCl (43 μL, 0.560 mmol) and TEA (231 μL, 1.66 mmol). The reaction was allowed to warm to room temperature and stir for 2 h. The reaction evaporated onto Celite[®] and purified by silica gel column chromatography (0→100% EtOAc/Hexanes) to produce ((*cis*-4-((5-bromopyrrolo[2,1-

f[1,2,4]triazin-2-yl)amino)cyclohexyl)methyl methanesulfonate (**CIII**) (182 mg, 0.451 mmol, 81.5% yield) as an off-white solid. ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.53 (4 H, q, *J*=5.75 Hz), 1.56 - 1.64 (2 H, m), 1.77 (2 H, br dd, *J*=12.73, 5.06 Hz), 1.80 - 1.86 (1 H, m), 3.17 (3 H, s), 3.75 - 3.85 (1 H, m), 4.10 (2 H, d, *J*=7.12 Hz), 6.74 (1 H, d, *J*=2.74 Hz), 6.87 (1 H, d, *J*=7.12 Hz), 7.63 - 7.70 (1 H, m), 8.71 (1 H, s); ESIMS found for C₁₄H₁₉BrN₄O₃S *m/z* 403.1 (M+H).

Step 3


[0369] A solution of ((*cis*-4-((5-bromopyrrolo[2,1-*f*][1,2,4]triazin-2-yl)amino)cyclohexyl) methyl methanesulfonate (**CIII**) (60 mg, 0.150 mmol) in morpholine (1 mL, 11.59 mmol) was heated to 80°C for 20 h. The solvent was removed under reduced pressure and the residue was purified by silica gel column chromatography (0 to 5% MeOH/CHCl₃) to produce 5-bromo-N-(*cis*-4-(morpholinomethyl) cyclohexyl)pyrrolo[2,1-*f*][1,2,4]triazin-2-amine (**CIV**) (73 mg, 0.185 mmol, 124.4% yield) as an off-white solid. ESIMS found for C₁₇H₂₄BrN₅O *m/z* 394.1 (M+H).

Steps 4-5

[0370] 5-Chloro-3-(2,2-difluoroethyl)-2-methylimidazo[4,5-*b*]pyridine (**XXXIV**) (50 mg, 0.220 mmol), Pd(dppf)Cl₂ (17 mg, 0.020 mmol), bis(pinacolato)diboron (82 mg, 0.320 mmol) and KOAc (63 mg, 0.640 mmol) were suspended in dioxane (4 mL). The reaction was degassed with N₂ before stirred at 90°C for 5 h. The reaction was cooled to room temperature before adding 5-bromo-N-(*cis*-4-(morpholinomethyl)cyclohexyl)pyrrolo[2,1-*f*][1,2,4]triazin-2-amine (**CIV**) (73 mg, 0.190 mmol), an aqueous solution of Na₂CO₃ (0.69 mL, 0.650 mmol), Pd(dppf)Cl₂ (17 mg, 0.020 mmol), and monoglyme (4 mL). The reaction was heated to 90°C for 16 h. The reaction evaporated onto Celite[®] and purified by silica gel column chromatography (0→50% MeOH/CHCl₃) to afford 5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-*b*]pyridin-5-yl)-N-(*cis*-4-(morpholinomethyl)cyclohexyl)pyrrolo[2,1-*f*][1,2,4]triazin-2-amine (**1842**) (38 mg, 0.074 mmol, 34.5% yield) as a light brown solid. ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.42 - 1.56 (4 H, m), 1.56 - 1.65 (2 H, m), 1.65 - 1.76 (3 H, m), 2.18 (2 H, br d, *J*=7.12 Hz), 2.32 (4 H, br s), 2.61 (3 H, s), 3.57 (4 H, br t, *J*=4.24 Hz), 3.76 - 3.85 (1 H, m), 4.83 (2 H, td, *J*=15.81, 2.33 Hz), 6.55 (1 H, tt, *J*=54.60, 3.00 Hz), 6.67 (1 H, d, *J*=7.39 Hz), 7.22 (1 H, d, *J*=2.46 Hz), 7.64 (1 H, d, *J*=2.74 Hz), 7.72 (1 H, d, *J*=8.49 Hz), 7.95 (1 H, d, *J*=8.49 Hz), 9.70 (1 H, s); ESIMS found for C₂₆H₃₂F₂N₈O *m/z* 511.3 (M+1).

Example 7.

[0371] Preparation of azetidin-1-yl(*cis*-4-((5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-*b*]pyridin-5-yl)pyrrolo[2,1-*f*][1,2,4]triazin-2-yl)amino)cyclohexyl)methanone (1896) is depicted below in Scheme 22.



Scheme 22

Step 1

[0372] A mixture of DIPEA (1.35 mL, 7.75 mmol), 5-bromo-2-chloropyrrolo[2,1-*f*][1,2,4]triazine (**I**) (commercially available from Advanced ChemBlocks Inc.) (600 mg, 2.58 mmol) and methyl 4-aminocyclohexane-1-carboxylate (**CV**) (commercially available from Combi-Blocks Inc.) (490 mg, 3.1 mmol) in 1,4-dioxane (10 mL) was heated to 110°C for 16 h. The reaction was concentrated and purified via column chromatography (0→2% MeOH/CHCl₃) (12 g of silica gel) to yield methyl 4-[(5-bromopyrrolo[2,1-*f*][1,2,4]triazin-2-yl)amino]cyclohexane-1-carboxylate (**CVI**) (729 mg, 2.064 mmol, 80.0% yield) as a light brown viscous solid. ESIMS found for C₁₄H₁₇BrN₄O₂ *m/z* 353.1 (M-¹Bu+H).

Steps 2-3

[0373] To a microwave vial was added 5-chloro-3-(2,2-difluoroethyl)-2-methylimidazo[4,5-*b*]pyridine (**XXXIV**) (720 mg, 3.1 mmol), bis(pinacolato)diboron (1.05 g, 4.13 mmol), KOAc (0.91 g, 9.29 mmol), and Pd(dppf)Cl₂ (0.13 g, 0.15 mmol) in 1,4-dioxane (15 mL). The reaction mixture was heated to 90°C for 16 h before adding methyl 4-[(5-bromopyrrolo[2,1-

f[1,2,4]triazin-2-yl]amino]cyclohexane-1-carboxylate (**CVI**) (730 mg, 2.06 mmol), a 2 N aqueous solution of K_3PO_4 (3.3 mL, 6.6 mmol), and $Pd(dppf)Cl_2$ (130 mg, 0.15 mmol). The reaction was stirred at 90°C for an additional 8 h. The reaction was concentrated and purified via column chromatography (0→8% MeOH/ $CHCl_3$) (24 g of silica gel) to give methyl 4-[[5-[3-(2,2-difluoroethyl)-2-methylimidazo[4,5-b]pyridin-5-yl]pyrrolo[2,1-f][1,2,4]triazin-2-yl]amino]cyclohexane-1-carboxylate (**CVII**) (765 mg, 1.629 mmol, 78.9% yield) as an amber viscous solid. ESIMS found for $C_{23}H_{25}F_2N_7O_2$ m/z 470.2 (M+H).

Step 4

[0374] Methyl 4-[[5-[3-(2,2-difluoroethyl)-2-methylimidazo[4,5-b]pyridin-5-yl]pyrrolo[2,1-f][1,2,4]triazin-2-yl]amino]cyclohexane-1-carboxylate (**CVII**) (729 mg, 1.55 mmol) to a mixture of water (3 mL) and THF (12 mL) followed by LiOH (1.4 mL, 2.8 mmol). The reaction was stirred at room temperature for 16 h. Concentrated HCl (2.9 mL, 2.9 mmol) was added to neutralize the reaction. The reaction mixture was stripped evaporated onto Celite®, and the sample was purified by reverse phase C18 silica gel (0→20% MeCN/water (containing 0.1% formic acid)). The fractions containing compound were lyophilized (frozen at -78°C) to produce 4-[[5-[3-(2,2-difluoroethyl)-2-methylimidazo[4,5-b]pyridin-5-yl]pyrrolo[2,1-f][1,2,4]triazin-2-yl]amino]cyclohexane-1-carboxylic acid (**CVIII**) (450 mg, 0.988 mmol, 63.6% yield) as an orange-brown solid. ESIMS found for $C_{22}H_{23}F_2N_7O_2$ m/z 456.2 (M+H).


Step 5

[0375] To a stirring solution of 4-[[5-[3-(2,2-difluoroethyl)-2-methylimidazo[4,5-b]pyridin-5-yl]pyrrolo[2,1-f][1,2,4]triazin-2-yl]amino]cyclohexane-1-carboxylic acid (**CVIII**) (50 mg, 0.1 mmol) in DCM (1 mL) was added DIPEA (0.07 mL, 0.4 mmol) and HATU (60 mg, 0.15 mmol). The reaction was stirred at room temperature for 5 min. Azetidine hydrochloride (**CIX**) (20 mg, 0.2 mmol) was then added and the reaction was stirred at room temperature for 16 h. The reaction was concentrated and purified via column chromatography (0→8 % 7 N NH_3 in MeOH/Chloroform) (8 g of silica gel) to afford azetidin-1-yl(*cis*-4-((5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclohexyl)methanone (**1896**) (7 mg, 0.014 mmol, 14.3% yield) as a yellow solid. 1H NMR (499 MHz, $DMSO-d_6$) δ ppm 1.42 - 1.50 (2 H, m), 1.57 - 1.66 (2 H, m), 1.73 - 1.83 (2 H, m), 1.92 (2 H, dt, $J=6.64, 3.39$ Hz), 2.13 - 2.22 (2 H, m), 2.31 (1 H, tt, $J=8.62, 4.11$ Hz), 2.61 (3 H, s), 3.75 - 3.80 (1 H, m), 3.82 (2 H, t, $J=7.67$ Hz), 4.15 (2 H, t, $J=7.53$ Hz), 4.83 (2 H, td, $J=15.95, 2.60$ Hz), 6.55 (1 H, tt, $J=54.60, 3.00$ Hz), 6.77 (1 H, d, $J=6.30$ Hz), 7.22 (1 H, d, $J=2.74$ Hz), 7.64 (1

H, d, $J=2.46$ Hz), 7.72 (1 H, d, $J=8.21$ Hz), 7.95 (1 H, d, $J=8.21$ Hz), 9.70 (1 H, s); ESIMS found for $C_{23}H_{26}F_2N_8O$ m/z 495.3 ($M+1$).

Example 8.

[0376] Preparation of 1-(7-((5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-2-azaspiro[3.5]nonan-2-yl)ethan-1-one (1899) is depicted below in Scheme 23.



Scheme 23

Step 1

[0377] A mixture of 5-bromo-2-chloropyrrolo[2,1-f][1,2,4]triazine (I) (commercially available from Advanced ChemBlocks Inc.) (200 mg, 0.860 mmol), *tert*-butyl 7-amino-2-azaspiro[3.5]nonane-2-carboxylate (CX) (commercially available from A2B Chem LLC) (311.9 mg, 1.3 mmol) and DIPEA (0.44 mL, 2.53 mmol) in DMSO (1 mL) was heated to 110°C for 16 h. The reaction mixture was concentrated under high vacuum. The residue was purified by silica gel column chromatography (0→100% EtOAc/hexanes) to produce *tert*-butyl 7-((5-bromopyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-2-azaspiro[3.5]nonane-2-carboxylate (CXI) (2.185 mg, 0.501 mmol, 58.2% yield) as a tan solid. ESIMS found for $C_{19}H_{26}BrN_5O_2$ m/z 380.1 ($M-^tBu+H$).

Steps 2-3

[0378] 5-Chloro-3-(2,2-difluoroethyl)-2-methylimidazo[4,5-b]pyridine (XXXVI) (100 mg, 0.430 mmol), Pd(dppf)Cl₂ (35 mg, 0.040 mmol), bis(pinacolato)diboron (164 mg, 0.650 mmol), and KOAc (127 mg, 1.29 mmol) were suspended in dioxane (4 mL). The reaction was degassed with N₂ before stirred at 90°C for 5 h. The reaction was cooled to room temperature before adding *tert*-butyl 7-((5-bromopyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-2-azaspiro[3.5]nonane-2-carboxylate (CXI) (124 mg, 0.280 mmol), an aqueous solution of Na₂CO₃ (1.3 mL, 1.3 mmol), Pd(dppf)Cl₂ (35 mg, 0.040 mmol), and DME (4 mL). The reaction was heated to 90°C for 16 h. The reaction evaporated onto Celite[®] and purified by silica gel column chromatography (0→50% MeOH/CHCl₃) to yield *tert*-butyl 7-((5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-2-azaspiro[3.5]nonane-2-carboxylate (CXII) (133 mg, 0.241 mmol, 55.7% yield) as a yellow solid. ESIMS found for C₂₈H₃₄F₂N₈O₂ *m/z* 553.3 (M+H).

Step 4

[0379] *tert*-Butyl 7-((5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-2-azaspiro[3.5]nonane-2-carboxylate (CXII) (133 mg, 0.240 mmol) was added to TFA (1 mL, 12.98 mmol) in DCE (4 mL) and stirred at room temperature for 1 h. The solvent was removed, and the residue was purified by silica gel column chromatography (0→10% 7 N NH₃ in MeOH/CHCl₃) to produce 5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(2-azaspiro[3.5]nonan-7-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine (CXIII) (112 mg, 0.248 mmol, 102.8% yield) as a light-yellow solid. ESIMS found for C₂₃H₂₆F₂N₈ *m/z* 453.2 (M+H).


Step 5

[0380] To a solution of 5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(2-azaspiro[3.5]nonan-7-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine (CXIII) (55 mg, 0.120 mmol) in DMF (1.2 mL) was added HOAc (8 μL, 0.140 mmol) followed by HATU (60 mg, 0.160 mmol) and DIPEA (64 μL, 0.370 mmol). The solution was stirred at room temperature for 16 h. Water (40 mL) was added, and the solution was extracted with EtOAc. The reaction evaporated onto Celite[®] and purified by silica gel column chromatography (0→100% EtOAc/hexanes). The compound was still not pure by NMR. The crude product was dissolved in DCM and washed with saturated aqueous NaHCO₃ and then re-purified using silica gel column chromatography (0→100% EtOAc/hexanes) to afford 1-(7-((5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-

yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-2-azaspiro[3.5]nonan-2-yl)ethan-1-one (**1899**) (33 mg, 0.067 mmol, 54.9% yield) as a yellow solid. ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.27 - 1.41 (2 H, m), 1.50 - 1.62 (2 H, m), 1.73 - 1.79 (3 H, m), 1.88 (4 H, br d, *J*=10.13 Hz), 2.60 (3 H, s), 3.45 - 3.55 (2 H, m), 3.55 - 3.66 (1 H, m), 3.70 - 3.85 (2 H, m), 4.77 - 4.90 (2 H, m), 6.55 (1 H, tt, *J*=54.60, 3.00 Hz), 6.74 (1 H, dd, *J*=12.05, 7.94 Hz), 7.23 (1 H, d, *J*=2.74 Hz), 7.65 (1 H, t, *J*=3.01 Hz), 7.72 (1 H, d, *J*=8.21 Hz), 7.95 (1 H, d, *J*=8.21 Hz), 9.69 (1 H, s); ESIMS found for C₂₅H₂₈F₂N₈O *m/z* 495.25 (M+1).

Example 9.

[0381] Preparation of 5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-((3R,4S)-3-fluoro-1-isobutylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine (**1909**) is depicted below in Scheme 24.



Scheme 24

Step 1

[0382] To a solution of 5-bromo-2-chloropyrrolo[2,1-f][1,2,4]triazine (**I**) (commercially available from Advanced ChemBlocks Inc.) (200 mg, 0.860 mmol) and *tert*-butyl (3R,4S)-4-amino-3-fluoropiperidine-1-carboxylate (**CXIV**) (commercially available from Sunshine Chemlab, Inc.) (282 mg, 1.29 mmol) in DMSO (1 mL) was added DIPEA (450 μL, 2.58

mmol). The reaction was stirred at 120°C for 16 h. The reaction mixture was then added to water and EtOAc and the organic layer was separated. The aqueous layer was extracted with EtOAc (×3) and the combined organic layers were washed with brine, dried (MgSO₄), and reduced in vacuo to give the crude product *tert*-butyl (3R,4S)-4-((5-bromopyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-3-fluoropiperidine-1-carboxylate (**CXV**) (457 mg, 1.103 mmol, 128% yield) as a fluffy brown solid which was used without further purification. ESIMS found for C₁₆H₂₁BrFN₅O₂ *m/z* 358.1 (M-^tBu+H).

Step 2

[0383] To a solution of *tert*-butyl (3R,4S)-4-((5-bromopyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-3-fluoropiperidine-1-carboxylate (**CXV**) (356 mg, 0.860 mmol) in DCE (2.7 mL) was added TFA (300 µL, 3.89 mmol). The reaction was stirred at room temperature for 3 h. The reaction mixture was blown dry and excess TFA removed by high vacuum to give the crude intermediate 5-bromo-N-((3R,4S)-3-fluoropiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine (**CXVI**) (270 mg, 0.859 mmol, 100% yield) as a brown semi-solid which was used without further purification. ESIMS found for C₁₁H₁₃BrFN₅ *m/z* 314.0 (M+H).

Step 3

[0384] To a solution of 5-bromo-N-((3R,4S)-3-fluoropiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine (**CXVI**) (135 mg, 0.430 mmol) in MeOH (3 mL) was added HOAc (50 µL, 0.870 mmol) and isobutyraldehyde (**CXVII**) (78 µL, 0.850 mmol). The reaction was stirred at room temperature for 20 minutes. NaBH(OAc)₃ (228 mg, 1.08 mmol) was added, and the reaction was stirred for 10 minutes. LCMS showed partial conversion therefore NaBH(OAc)₃ (228 mg, 1.08 mmol) was added in 5 minutes intervals until LCMS confirmed completion (3 additions). The reaction evaporated onto Celite[®] and purified by reverse phase chromatography (0→20% MeCN/0.1% formic acid in H₂O) to give 5-bromo-N-((3R,4S)-3-fluoro-1-isobutylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine (**CXVIII**) (33 mg, 0.089 mmol, 20.7% yield) as a brown semi-solid. ESIMS found for C₁₅H₂₁BrFN₅ *m/z* 370.1 (M+H).

Step 4

[0385] 5-Chloro-3-(2,2-difluoroethyl)-2-methylimidazo[4,5-b]pyridine (**XXXIV**) (1 g, 4.32 mmol), bis(pinacolato)diboron (1.75 g, 6.89 mmol), Pd(dppf)Cl₂ (176 mg, 0.220 mmol) and KOAc (1.28 g, 13.04 mmol) were dissolved in dry DMF (30 mL) and the reaction was sonicated and degassed with Ar for 5 minutes. The reaction was stirred at 100°C for 16 h. The reaction


mixture was cooled and reduced in vacuo to give a black solid. The crude product was purified by a C18Aq reverse phase column chromatography (0→11% MeCN/0.1% formic acid in H₂O). Appropriate fractions were collected and evaporated under high vacuum to produce (3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)boronic acid (**CXIX**) (543 mg, 2.253 mmol, 52.2% yield) as a fluffy yellow solid which was stored in -20°C. ESIMS found for C₉H₁₀BF₂N₃O₂ *m/z* 242.1 (M+H).

Step 5

[0386] To a suspension of 5-Bromo-N-((3R,4S)-3-fluoro-1-isobutylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine (**CXVIII**) (32 mg, 0.090 mmol), (3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)boronic acid (**CXIX**) (31 mg, 0.130 mmol) and Pd(dppf)Cl₂ (3 mg, 0 mmol) in dioxane (1.5 mL) was added an aqueous solution of Na₂CO₃ (274 μL, 0.260 mmol). The reaction was sonicated and degassed for 5 minutes with Ar and then heated 100°C for 16 h. The reaction mixture was purified by column chromatography (0→10% 7.0 M NH₃ in MeOH/CHCl₃). The compound was further purified by reverse phase chromatography (0→17% MeCN/0.1% formic acid in H₂O). Appropriate fractions were collected and added to saturated aqueous NaHCO₃ and extracted with DCM (×3). The combined organic layers were washed with brine, dried (MgSO₄) and reduced in vacuo to afford 5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-((3R,4S)-3-fluoro-1-isobutylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine (**1909**) (15 mg, 0.031 mmol, 35.7% yield) as a yellow solid. ¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 0.86 (6 H, br d, *J*=6.31 Hz), 1.66 - 1.82 (2 H, m), 1.88 - 1.99 (1 H, m), 2.00 - 2.11 (3 H, m), 2.12 - 2.27 (1 H, m), 2.61 (3 H, s), 2.80 - 2.91 (1 H, m), 3.05 - 3.17 (1 H, m), 3.73 - 3.92 (1 H, m), 4.84 (2 H, td, *J*=15.85, 2.61 Hz), 4.94 (1 H, br s), 6.55 (1 H, tt, *J*=54.60, 3.00 Hz), 6.86 (1 H, br d, *J*=7.68 Hz), 7.26 (1 H, d, *J*=2.47 Hz), 7.66 (1 H, d, *J*=2.47 Hz), 7.74 (1 H, d, *J*=8.51 Hz), 7.96 (1 H, d, *J*=8.51 Hz), 9.73 (1 H, s); ESIMS found for C₂₄H₂₉F₃N₈ *m/z* 487.3 (M+1).

Example 10.

[0387] Preparation of 5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-((3S,4R)-4-fluoro-1-(oxetan-3-yl)pyrrolidin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine (**1944**) is depicted below in Scheme 25.



Scheme 25

Step 1

[0388] 5-bromo-2-chloropyrrolo[2,1-f][1,2,4]triazine (**I**) (commercially available from Advanced ChemBlocks Inc.) (1.5 g, 6.45 mmol), [3-(2,2-difluoroethyl)-2-methylimidazo[4,5-b]pyridin-5-yl]boronic acid (**CXX**) (1.63 g, 6.78 mmol), Pd(OAc)₂ (45 mg, 0.2 mmol) and QPhos (270 mg, 0.38 mmol) were dissolved in dry 1,4-dioxane (35 mL) and purged with Ar for 5 min. A 2 N aqueous solution of K₃PO₄ (6.45 mL, 12.9 mmol) was added and the reaction was purged with Ar for a further 2 min. The reaction was then heated to 80°C for 30 min. To the reaction mixture was added to DCM and aqueous saturated NH₄Cl solution was added, and the organic layer was separated. The aqueous layer was extracted with DCM (×3), and the combined organic layers were dried (anhydrous MgSO₄) and reduced in vacuo to give an orange solid. The crude product was purified by column chromatography (0→100% EtOAc/hexanes) followed by (0→6% 7.0 M NH₃ in MeOH/CHCl₃). Appropriate fractions were combined and reduced in vacuo to give an orange solid. The solid was triturated with MeOH and filtered, washing with MeOH. The product 5-(2-chloropyrrolo[2,1-f][1,2,4]triazin-5-yl)-3-(2,2-difluoroethyl)-2-methylimidazo[4,5-b]pyridine (1.79 g, 5.133 mmol, 79.5% yield) was collected as a yellow solid. The filtrate was reduced in vacuo to give additional 5-(2-chloropyrrolo[2,1-f][1,2,4]triazin-5-yl)-3-(2,2-difluoroethyl)-2-methylimidazo[4,5-b]pyridine (**CXXI**) (481 mg, 1.379 mmol, 21.4% yield)

as an orange solid (60% pure) and was used without further purification. ESIMS found for $C_{15}H_{11}ClF_2N_6$ m/z 349.1 (M+H).

Step 2

[0389] 5-(2-chloropyrrolo[2,1-f][1,2,4]triazin-5-yl)-3-(2,2-difluoroethyl)-2-methylimidazo [4,5-b]pyridine (**CXXI**) (150 mg, 0.43 mmol) and *tert*-butyl (3*S*,4*R*)-3-amino-4-fluoropyrrolidine-1-carboxylate (**CXXII**) (114 mg, 0.56 mmol) were dissolved in DMSO (1 mL) and DIPEA (150 μ L, 0.86 mmol) was added and the reaction was stirred at 120°C for 24 h. The reaction mixture was added to water and EtOAc and the organic layer was separated. The aqueous layer was extracted with EtOAc ($\times 3$) and the combined organic layers were washed with brine, dried (anhydrous $MgSO_4$), and reduced in vacuo to give the crude product *tert*-butyl (3*S*,4*R*)-3-((5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-4-fluoropyrrolidine-1-carboxylate (**CXXIII**) (222 mg, 0.430 mmol, 99.9% yield), assuming quantitative yield, as a brown semi-solid which was used without further purification. ESIMS found for $C_{24}H_{27}F_3N_8O_2$ m/z 517.3 (M+H).

Step 3

[0390] *tert*-Butyl (3*S*,4*R*)-3-((5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-4-fluoropyrrolidine-1-carboxylate (**CXXIII**) (222 mg, 0.43 mmol) was dissolved in DCE (4.5 mL) and the reaction was cooled to 0°C. TFA (0.50 mL) was added and the reaction was stirred at room temperature for 16 h. The reaction mixture was evaporated, and the crude product was purified by column chromatography (0 $\rightarrow$ 2% 7.0 M NH_3 in MeOH/ $CHCl_3$) to give 5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-((3*S*,4*R*)-4-fluoropyrrolidin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine (**CXXIV**) (138 mg, 0.331 mmol, 77.1% yield) as a yellow semi-solid. ESIMS found for $C_{19}H_{19}F_3N_8$ m/z 417.2 (M+H).


Step 4

[0391] In a solution of 5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-((3*S*,4*R*)-4-fluoropyrrolidin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine (**CXXIV**) (138 mg, 0.33 mmol) in EtOH (3 mL) was added HOAc (95 μ L, 1.66 mmol) and oxetan-3-one (**CXXV**) (97 μ L, 1.66 mmol). The reaction was stirred at room temperature for 10 min. $NaH(OAc)_2$ (105 mg, 0.5 mmol) was added and the reaction was stirred at room temperature for another 20 min. LCMS showed minor product formation, therefore, the reaction was heated to 65°C for 30 min. LCMS

showed more conversion. Additional oxetan-3-one (**CXXV**) (97 μ L, 1.66 mmol) and HOAc (95 μ L, 1.66 mmol) were added and stirred at room temperature for 5 min. NaH(OAc)₂ (105 mg, 0.5 mmol) was added and stirred at 65°C for 1 h. Subsequent rounds of reagents were added until no more conversion was observed (~90%) and therefore the reaction was stopped. The reaction mixture was loaded on Celite[®] and purified by column chromatography (0→6% 7.0 M NH₃ in MeOH/CHCl₃). The product was further purified by HPLC (0→35% MeCN/H₂O (containing 0.1% formic acid)). Appropriate fractions were collected and neutralized with aqueous saturated NaHCO₃ and extracted with DCM (×2). The combined organic layers were dried (anhydrous MgSO₄) and reduced in vacuo to afford 5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-((3S,4R)-4-fluoro-1-(oxetan-3-yl)pyrrolidin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine (**1944**) (80 mg, 0.169 mmol, 51.1% yield) as a yellow solid. ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 2.61 (3 H, s), 2.71 (1 H, t, *J*=9.17 Hz), 2.80 (1 H, dd, *J*=28.50, 11.20 Hz), 3.04 (1 H, t, *J*=8.21 Hz), 3.17 (1 H, ddd, *J*=33.45, 12.05, 4.40 Hz), 3.80 (1 H, quin, *J*=6.16 Hz), 4.23 - 4.40 (1 H, m), 4.48 (2 H, t, *J*=5.89 Hz), 4.60 (2 H, t, *J*=6.57 Hz), 4.84 (2 H, td, *J*=16.02, 2.74 Hz), 5.26 (1 H, dt, *J*=56.25, 3.55 Hz), 6.56 (1 H, tt, *J*=54.50, 3.00 Hz), 7.06 (1 H, d, *J*=7.94 Hz), 7.28 (1 H, d, *J*=2.74 Hz), 7.69 (1 H, d, *J*=2.46 Hz), 7.75 (1 H, d, *J*=8.49 Hz), 7.96 (1 H, d, *J*=8.21 Hz), 9.74 (1 H, s); ESIMS found for C₂₂H₂₃F₃N₈O *m/z* 473.3 (M+1).

Example 11.

[0392] Preparation of 5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(piperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine (**1916**) and (4,4-difluorocyclohexyl)(4-((5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)piperidin-1-yl)methanone (**1953**) is depicted below in Scheme 26.



Scheme 26

Step 1

[0393] A mixture of DIPEA (1.6 mL, 9.19 mmol), 5-bromo-2-chloropyrrolo[2,1-f][1,2,4]triazine (**I**) (commercially available from Advanced ChemBlocks Inc.) (530 mg, 2.26 mmol) and 4-amino-1-Boc-piperidine (**CXXVI**) (commercially available from Combi-Blocks Inc.) (540 mg, 2.71 mmol) in 1,4-dioxane (10 mL) was heated to 110°C for 16 h. The reaction was concentrated and dissolved in DCM, washed with water, brine, dried over anhydrous MgSO_4 , filtered, and concentrated to produce *tert*-butyl 4-[(5-bromopyrrolo[2,1-f][1,2,4]triazin-2-yl)amino]piperidine-1-carboxylate (**CXXVII**) (940 mg, 2.372 mmol, 105.0% yield) as a light brown viscous solid. Carried forward to the next step without further purification. ESIMS found for $\text{C}_{16}\text{H}_{22}\text{BrN}_5\text{O}_2$ m/z 396.1 ($\text{M}+\text{H}$).

Steps 2-3

[0394] To a microwave vial was added 5-chloro-3-(2,2-difluoroethyl)-2-methylimidazo[4,5-b]pyridine (**XXXIV**) (350 mg, 1.51 mmol), bis(pinacolato)diboron (510 mg, 2.02 mmol), KOAc (450 mg, 4.54 mmol), and $\text{Pd}(\text{dppf})\text{Cl}_2$ (60 mg, 0.08 mmol) in 1,4-dioxane (5 mL). The reaction mixture was heated to 90°C for 16 h. *tert*-Butyl 4-[(5-bromopyrrolo[2,1-f][1,2,4]triazin-2-yl)amino]piperidine-1-carboxylate (**CXXVII**) (400 mg, 1.01 mmol), a 2 N aqueous solution of K_3PO_4 (1.6 mL, 3.2 mmol), and $\text{Pd}(\text{dppf})\text{Cl}_2$ (60 mg, 0.08 mmol) was added

and stirred for 90°C for an additional 8 h. The reaction was concentrated and purified via column chromatography. (0→8 % MeOH/CHCl₃) (12 g of silica gel) to yield *tert*-butyl 4-[[5-[3-(2,2-difluoroethyl)-2-methylimidazo[4,5-*b*]pyridin-5-yl]pyrrolo[2,1-*f*][1,2,4]triazin-2-yl]amino]piperidine-1-carboxylate (**CXXVIII**) (470 mg, 0.917 mmol, 90.8% yield) as an amber viscous solid. ESIMS found for C₂₅H₃₀F₂N₈O₂ *m/z* 513.3 (M+H).

Step 4

[0395] To a solution of *tert*-butyl 4-[[5-[3-(2,2-difluoroethyl)-2-methylimidazo[4,5-*b*]pyridin-5-yl]pyrrolo[2,1-*f*][1,2,4]triazin-2-yl]amino]piperidine-1-carboxylate (**CXXVIII**) (470 mg, 0.92 mmol) in DCM (5 mL) was added TFA (0.7 mL, 9.09 mmol). The reaction mixture was stirred at room temperature for 3 h. The reaction was concentrated and basified with a NH₄ solution (7 N) in MeOH and then purified via column chromatography (0→10% 7 N NH₃ in MeOH/CHCl₃) (12 g of silica gel) to give 5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-*b*]pyridin-5-yl)-N-(piperidin-4-yl)pyrrolo[2,1-*f*][1,2,4]triazin-2-amine (**1916**) (220 mg, 0.533 mmol, 58.2% yield) as a yellow solid. ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.36 (2 H, qd, *J*=11.59, 3.83 Hz), 1.88 (2 H, br d, *J*=9.86 Hz), 2.51 - 2.55 (2 H, m), 2.60 (3 H, s), 2.96 (2 H, br d, *J*=12.32 Hz), 3.59 - 3.72 (1 H, m), 4.83 (2 H, td, *J*=15.95, 2.60 Hz), 6.55 (1 H, tt, *J*=54.60, 3.00 Hz), 6.80 (1 H, d, *J*=7.94 Hz), 7.22 (1 H, d, *J*=2.74 Hz), 7.64 (1 H, d, *J*=2.46 Hz), 7.72 (1 H, d, *J*=8.49 Hz), 7.95 (1 H, d, *J*=8.21 Hz), 9.69 (1 H, s); ESIMS found for C₂₀H₂₂F₂N₈ *m/z* 413.2 (M+1).


Step 5

[0396] To a solution of 5-[3-(2,2-difluoroethyl)-2-methylimidazo[4,5-*b*]pyridin-5-yl]-N-piperidin-4-ylpyrrolo[2,1-*f*][1,2,4]triazin-2-amine (**1916**) (30 mg, 0.07 mmol) in DCM (1 mL) was added DIPEA (40 μL, 0.24 mmol) and HATU (40 mg, 0.11 mmol). The reaction was allowed to stir at room temperature for 5 min. 4,4-Difluorocyclohexanecarboxylic acid (**CXXIX**) (10 mg, 0.09 mmol) was then added and reaction was heated to 90°C for 16 h. The reaction was concentrated and purified via column chromatography (0→8% 7 N NH₃ in MeOH/CHCl₃) (8 g of silica gel) to afford (4,4-difluorocyclohexyl)(4-((5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-*b*]pyridin-5-yl)pyrrolo[2,1-*f*][1,2,4]triazin-2-yl)amino)piperidin-1-yl)methanone (**1953**) (18 mg, 0.032 mmol, 44.3% yield) as a yellow solid. ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.30 - 1.39 (1 H, m), 1.41 - 1.51 (1 H, m), 1.53 - 1.67 (2 H, m), 1.73 (2 H, br d, *J*=13.14 Hz), 1.81 - 1.92 (1 H, m), 1.92 - 1.98 (2 H, m), 1.98 - 2.12 (3 H, m), 2.61 (3 H, s), 2.74 - 2.81 (1 H, m), 2.84 (1 H, br t, *J*=11.23 Hz), 3.20 (1 H, br t, *J*=11.91 Hz), 3.82 - 3.94 (1 H, m), 3.99 (1 H, br d, *J*=13.42 Hz), 4.31 (1 H, br d, *J*=12.59 Hz), 4.83 (2 H, td, *J*=16.02, 2.74 Hz), 6.55 (1 H, tt, *J*=54.50, 3.00

Hz), 6.91 (1 H, d, $J=7.94$ Hz), 7.24 (1 H, d, $J=2.74$ Hz), 7.66 (1 H, d, $J=2.74$ Hz), 7.73 (1 H, d, $J=8.49$ Hz), 7.95 (1 H, d, $J=8.49$ Hz), 9.71 (1 H, s); ESIMS found for $C_{27}H_{30}F_4N_8O$ m/z 559.3 ($M+1$).

Example 12.

[0397] Preparation of N-((1*r*,3*r*)-1-methyl-3-((5-(quinoxalin-6-yl)pyrrolo[2,1-*f*][1,2,4]triazin-2-yl)amino)cyclobutyl)acetamide (1981) is depicted below in Scheme 27.



Scheme 27

Step 1

[0398] To a microwave vial of 5-bromo-2-chloropyrrolo[2,1-*f*][1,2,4]triazine (I) (commercially available from Advanced ChemBlocks Inc.) (500 mg, 2.15 mmol) in 1,4-dioxane (10 mL) was added DIPEA (1.12 mL, 6.43 mmol) and *trans-tert*-butyl N-(3-amino-1-methylcyclobutyl)carbamate (CXXX) (commercially available from PharmaBlock (USA), Inc.) (544 mg, 2.72 mmol). Reaction vial was capped and heated to 110°C for 16 h. The reaction was concentrated and purified via column chromatography (0→8% 7 N NH_3 in MeOH/ $CHCl_3$) (8 g of silica gel) to give *tert*-butyl N-[3-[(5-bromopyrrolo[2,1-*f*][1,2,4]triazin-2-yl)amino]-1-methylcyclobutyl]carbamate (CXXXI) (266 mg, 0.671 mmol, 31.2% yield) as a light-yellow solid. ESIMS found for $C_{16}H_{22}BrN_5O_2$ m/z 396.1 ($M-^tBu+H$).

Steps 2

[0399] To a stirred solution of *tert*-butyl N-[3-[(5-bromopyrrolo[2,1-f][1,2,4]triazin-2-yl)amino]-1-methylcyclobutyl]carbamate (**CXXXI**) (266 mg, 0.67 mmol) in DCM (1 mL) was added TFA (1.6 mL, 20.77 mmol). The mixture was stirred at room temperature for 1 h, concentrated and the residue was purified by ISCO (0→8% 7 N NH₃ MeOH/CHCl₃). The pure fractions were collected, concentrated under reduced pressure, and dried under high vacuo to obtain 3-N-(5-bromopyrrolo[2,1-f][1,2,4]triazin-2-yl)-1-methylcyclobutane-1,3-diamine (**CXXXII**) (126 mg, 0.425 mmol, 63.4% yield) as a dark yellow solid. ESIMS found for C₁₁H₁₄BrN₅ *m/z* 296.05 (M+H).

Step 3


[0400] To a solution of HOAc (37 μL, 0.65 mmol), HATU (243 mg, 0.64 mmol) in DMF (200 μL) was added DIPEA (220 μL, 1.26 mmol). The mixture was stirred for 5 min then, 3-N-(5-bromopyrrolo[2,1-f][1,2,4]triazin-2-yl)-1-methylcyclobutane-1,3-diamine (**CXXXII**) (146 mg, 0.49 mmol) in DMF (300 μL) was added and the reaction mixture was stirred at room temperature for 16 h. Water (10 mL) was added, and the solution was extracted with EtOAc. The organics were separated, concentrated, absorbed on silica gel, and purified by ISCO (0→100% 7 N NH₃ in MeOH/CHCl₃). The pure fractions were concentrated and dried under high vacuo to obtain N-[3-[(5-bromopyrrolo[2,1-f][1,2,4]triazin-2-yl)amino]-1-methylcyclobutyl]acetamide (**CXXXIII**) (130 mg, 0.384 mmol, 78.0% yield) as a dark yellow solid. ESIMS found for C₁₃H₁₆BrN₅O *m/z* 338.1 (M+H).

Step 4

[0401] A mixture of *trans*-N-[3-[(5-bromopyrrolo[2,1-f][1,2,4]triazin-2-yl)amino]-1-methylcyclobutyl]acetamide (**CXXXIII**) (30 mg, 0.09 mmol), 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinoxaline (**CXXXIV**) (commercially available from AmBeed, Inc.) (27.3 mg, 0.11 mmol), Pd(dppf)Cl₂ (3.7 mg, 0.0045 mmol), and a 2 N aqueous solution of K₃PO₄ (130 μL, 0.26 mmol), in 1,4-dioxane (5 mL) was purged with N₂ gas for 5 min. The mixture was stirred and irradiated with microwave at 110°C for 30 min. The reaction mixture was cooled, and organic layer was separated, concentrated and purified via column chromatography (0→7% 7 N NH₃ in MeOH/CHCl₃) (8 g of silica gel) to afford N-((1*r*,3*r*)-1-methyl-3-((5-(quinoxalin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclobutyl)acetamide (**1981**) (14 mg, 0.036 mmol, 40.7% yield) as a yellow solid. ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.37 (3 H, s), 1.82 (3 H, s), 1.90 - 2.01 (2 H, m), 2.66 (2 H, ddd, *J*=10.27, 7.94, 2.60 Hz), 4.20 (1 H, sxt, *J*=7.72 Hz), 7.19 (1 H, d, *J*=2.74 Hz),

7.36 (1 H, d, $J=7.12$ Hz), 7.75 (1 H, d, $J=2.46$ Hz), 7.96 (1 H, s), 8.13 (1 H, d, $J=8.76$ Hz), 8.23 (1 H, dd, $J=8.76$, 1.92 Hz), 8.31 (1 H, d, $J=2.19$ Hz), 8.90 (1 H, d, $J=1.92$ Hz), 8.95 (1 H, d, $J=1.92$ Hz), 9.19 (1 H, s); ESIMS found for $C_{21}H_{21}N_7O$ m/z 388.2 (M+1).


[0402] The following compounds were prepared in accordance with the procedures described in the above Schemes 1-27.



2

[0403] 5-(Imidazo[1,2-a]pyridin-6-yl)-N-isobutylpyrrolo[2,1-f][1,2,4]triazin-2-amine **2**.


[0404] Yellow solid (40.14 mg, 0.131 mmol). 1H NMR (400 MHz, DMSO- d_6) δ ppm 0.92 (6 H, d, $J=6.60$ Hz), 1.95 (1 H, dquin, $J=13.49$, 6.75, 6.75, 6.75, 6.75 Hz), 3.03 (2 H, dd, $J=6.85$, 5.99 Hz), 6.94 (1 H, d, $J=2.57$ Hz), 7.00 (1 H, t, $J=5.75$ Hz), 7.53 - 7.58 (1 H, m), 7.58 (1 H, d, $J=1.22$ Hz), 7.60 - 7.65 (1 H, m), 7.70 (1 H, dd, $J=2.57$, 0.61 Hz), 7.94 (1 H, d, $J=0.73$ Hz), 8.91 (1 H, dd, $J=1.71$, 1.10 Hz), 9.10 (1 H, s); ESIMS found for $C_{17}H_{18}N_6$ m/z 307.2 (M+1).



3

[0405] N-(2-Fluoro-2-methylpropyl)-5-(imidazo[1,2-a]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **3**.


[0406] Pale yellow solid (16 mg, 0.049 mmol, 38.3% yield). 1H NMR (499 MHz, DMSO- d_6) δ ppm 1.37 (6 H, d, $J=21.40$ Hz), 3.48 (2 H, dd, $J=19.16$, 6.57 Hz), 6.98 (1 H, d, $J=2.46$ Hz), 7.05 (1 H, t, $J=6.43$ Hz), 7.54 - 7.58 (1 H, m), 7.59 (1 H, d, $J=1.09$ Hz), 7.61 - 7.64 (1 H, m), 7.72 (1 H, d, $J=2.46$ Hz), 7.95 (1 H, s), 8.89 - 8.96 (1 H, m), 9.14 (1 H, s); ESIMS found for $C_{17}H_{17}FN_6$ m/z 325.2 (M+1).



4

[0407] N-(2,2-Difluoropropyl)-5-(imidazo[1,2-a]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine 4.


[0408] Yellow solid (9.31 mg, 0.028 mmol). ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ ppm 1.66 (3 H, t, $J=19.01$ Hz), 3.72 (2 H, td, $J=13.75$, 6.72 Hz), 7.01 (1 H, d, $J=2.57$ Hz), 7.33 (1 H, t, $J=6.66$ Hz), 7.55 - 7.66 (2 H, m), 7.59 (1 H, s), 7.76 (1 H, d, $J=2.45$ Hz), 7.95 (1 H, s), 8.93 (1 H, s), 9.17 (1 H, s); ESIMS found for $\text{C}_{16}\text{H}_{14}\text{F}_2\text{N}_6$ m/z 329.1 ($\text{M}+1$).



9

[0409] 5-(Imidazo[1,2-a]pyridin-6-yl)-N-(2-methoxyethyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine 9.

[0410] Yellow solid (55.95 mg, 0.181 mmol). ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ ppm 3.28 (3 H, s), 3.36 - 3.38 (2 H, m), 3.50 - 3.54 (2 H, m), 6.91 (1 H, br t, $J=5.69$ Hz), 6.96 (1 H, d, $J=2.57$ Hz), 7.54 - 7.65 (2 H, m), 7.58 (1 H, s), 7.72 (1 H, d, $J=2.32$ Hz), 7.94 (1 H, s), 8.91 (1 H, s), 9.12 (1 H, s); ESIMS found for $\text{C}_{16}\text{H}_{16}\text{N}_6\text{O}$ m/z 309.1 ($\text{M}+1$).




11

[0411] 5-(Imidazo[1,2-a]pyridin-6-yl)-N-(2-isopropoxyethyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine 11.


[0412] Yellow solid (30.8 mg, 0.092 mmol). ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ ppm 1.10 (6 H, d, $J=6.13$ Hz), 3.34 - 3.38 (2 H, m), 3.55 (2 H, t, $J=6.19$ Hz), 3.57 - 3.63 (1 H, m), 6.84 (1 H, t, $J=5.75$ Hz), 6.97 (1 H, d, $J=2.50$ Hz), 7.53 - 7.65 (2 H, m), 7.58 (1 H, d, $J=1.00$ Hz), 7.73

(1 H, d, $J=2.50$ Hz), 7.94 (1 H, s), 8.92 (1 H, s), 9.12 (1 H, s); ESIMS found for $C_{18}H_{20}N_6O$ m/z 337.1 (M+1).

**12**


[0413] 5-(Imidazo[1,2-a]pyridin-6-yl)-N-((1-methylcyclopropyl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **12**.

[0414] Yellow solid (13.6 mg, 0.043 mmol). 1H NMR (400 MHz, $DMSO-d_6$) δ ppm 0.22 - 0.30 (2 H, m), 0.48 - 0.54 (2 H, m), 1.11 (3 H, s), 3.17 (2 H, d, $J=5.88$ Hz), 6.91 - 6.99 (2 H, m), 7.53 - 7.64 (2 H, m), 7.58 (1 H, d, $J=0.88$ Hz), 7.69 (1 H, d, $J=2.50$ Hz), 7.94 (1 H, s), 8.92 (1 H, s), 9.12 (1 H, s); ESIMS found for $C_{18}H_{18}N_6$ m/z 319.1 (M+1).

**16**


[0415] N-(Cyclopropylmethyl)-5-(imidazo[1,2-a]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **16**.

[0416] Yellow solid (5.16 mg, 0.017 mmol). 1H NMR (400 MHz, $DMSO-d_6$) δ ppm 0.19 - 0.28 (2 H, m), 0.40 - 0.50 (2 H, m), 1.07 - 1.17 (1 H, m), 3.09 (2 H, t, $J=6.24$ Hz), 6.96 (1 H, d, $J=2.57$ Hz), 7.04 (1 H, t, $J=5.81$ Hz), 7.53 - 7.65 (2 H, m), 7.58 (1 H, d, $J=1.10$ Hz), 7.71 (1 H, dd, $J=2.45, 0.61$ Hz), 7.95 (1 H, s), 8.92 (1 H, dd, $J=1.65, 1.04$ Hz), 9.12 (1 H, s); ESIMS found for $C_{17}H_{16}N_6$ m/z 305.3 (M+1).

**20**


[0417] 5-(Imidazo[1,2-a]pyridin-6-yl)-N-(oxetan-3-ylmethyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **20**.

[0418] Yellow solid (14.48 mg, 0.045 mmol). ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ ppm 3.26 (1 H, br s), 3.51 (2 H, br s), 4.36 (2 H, br s), 4.66 (2 H, br s), 6.96 (1 H, br s), 7.16 (1 H, br s), 7.59 (3 H, br d, $J=8.31$ Hz), 7.73 (1 H, br s), 7.94 (1 H, br s), 8.91 (1 H, br s), 9.12 (1 H, br s); ESIMS found for $\text{C}_{17}\text{H}_{16}\text{N}_6\text{O}$ m/z 321.0 ($\text{M}+1$).

**21**


[0419] 5-(Imidazo[1,2-a]pyridin-6-yl)-N-((tetrahydrofuran-2-yl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **21**.

[0420] Yellow solid (36.87 mg, 0.110 mmol). ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ ppm 1.56 - 1.70 (1 H, m), 1.74 - 1.89 (2 H, m), 1.90 - 2.01 (1 H, m), 3.15 - 3.26 (1 H, m), 3.29 - 3.38 (1 H, m), 3.58 - 3.70 (1 H, m), 3.74 - 3.85 (1 H, m), 4.08 (1 H, quin, $J=6.36$ Hz), 6.92 (1 H, t, $J=5.99$ Hz), 6.96 (1 H, d, $J=2.57$ Hz), 7.54 - 7.64 (2 H, m), 7.58 (1 H, d, $J=0.98$ Hz), 7.72 (1 H, d, $J=2.45$ Hz), 7.94 (1 H, s), 8.92 (1 H, s), 9.12 (1 H, s); ESIMS found for $\text{C}_{18}\text{H}_{18}\text{N}_6\text{O}$ m/z 335.4 ($\text{M}+1$).

**23**


[0421] N-(3,3-Difluorocyclobutyl)-5-(imidazo[1,2-a]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **23**.

[0422] Yellow solid (4.61 mg, 0.014 mmol). ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ ppm 2.57 - 2.77 (2 H, m), 2.91 - 3.07 (2 H, m), 3.99 - 4.13 (1 H, m), 7.00 (1 H, d, $J=2.57$ Hz), 7.52 - 7.65 (3 H, m), 7.59 (1 H, d, $J=1.10$ Hz), 7.76 (1 H, d, $J=2.57$ Hz), 7.95 (1 H, s), 8.93 (1 H, s), 9.17 (1 H, s); ESIMS found for $\text{C}_{17}\text{H}_{14}\text{F}_2\text{N}_6$ m/z 341.0 ($\text{M}+1$).

**26**

[0423] 5-(Imidazo[1,2-a]pyridin-6-yl)-N-(*cis*-3-methoxycyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **26**.


[0424] Yellow solid (37.9 mg, 0.113 mmol). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.78 - 1.91 (2 H, m), 2.60 - 2.72 (2 H, m), 3.14 (3 H, s), 3.62 (1 H, quin, *J*=7.09 Hz), 3.78 (1 H, sxt, *J*=7.85 Hz), 6.96 (1 H, d, *J*=2.45 Hz), 7.28 (1 H, d, *J*=7.34 Hz), 7.53 - 7.64 (3 H, m), 7.70 (1 H, d, *J*=2.57 Hz), 7.94 (1 H, s), 8.92 (1 H, s), 9.12 (1 H, s); ESIMS found for C₁₈H₁₈N₆O *m/z* 335.4 (M+1).



43

[0425] N-(4,4-Difluorocyclohexyl)-5-(imidazo[1,2-a]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **43**.


[0426] Yellow solid (52.2 mg, 0.142 mmol). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.64 (2 H, q, *J*=11.25 Hz), 1.82 - 2.03 (4 H, m), 2.04 - 2.17 (2 H, m), 3.72 - 3.88 (1 H, m), 6.97 (1 H, d, *J*=2.57 Hz), 7.02 (1 H, d, *J*=7.58 Hz), 7.54 - 7.65 (2 H, m), 7.59 (1 H, s), 7.72 (1 H, d, *J*=2.45 Hz), 7.95 (1 H, s), 8.92 (1 H, s), 9.13 (1 H, s); ESIMS found for C₁₉H₁₈F₂N₆ *m/z* 369.1 (M+1).



64

[0427] 5-(Imidazo[1,2-a]pyridin-6-yl)-N-(1-methylazetidin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **64**.


[0428] Yellow solid (1.93 mg, 0.006 mmol). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 2.25 (3 H, s), 2.91 (2 H, t, *J*=7.21 Hz), 3.57 - 3.64 (2 H, m), 4.22 (1 H, sxt, *J*=6.80 Hz), 6.97 (1 H, d, *J*=2.57 Hz), 7.43 (1 H, d, *J*=6.85 Hz), 7.54 - 7.64 (2 H, m), 7.58 (1 H, d, *J*=0.98 Hz), 7.72 (1 H, d, *J*=2.08 Hz), 7.94 (1 H, s), 8.92 (1 H, s), 9.14 (1 H, s); ESIMS found for C₁₇H₁₇N₇ *m/z* 320.0 (M+1).



65

[0429] 5-(Imidazo[1,2-a]pyridin-6-yl)-N-(oxetan-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **65**.


[0430] Yellow solid (28.58 mg, 0.093 mmol). ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ ppm 4.55 (2 H, s), 4.74 - 4.85 (3 H, m), 6.99 (1 H, d, $J=2.50$ Hz), 7.54 - 7.65 (2 H, m), 7.59 (1 H, s), 7.72 (1 H, d, $J=2.50$ Hz), 7.76 (1 H, br d, $J=5.38$ Hz), 7.94 (1 H, s), 8.93 (1 H, s), 9.17 (1 H, s); ESIMS found for $\text{C}_{16}\text{H}_{14}\text{N}_6\text{O}$ m/z 307.2 ($\text{M}+1$).



66

[0431] 5-(Imidazo[1,2-a]pyridin-6-yl)-N-(1-methylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **66**.

[0432] Yellow solid (38.32 mg, 0.110 mmol). ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ ppm 1.53 (2 H, qd, $J=11.59, 3.61$ Hz), 1.86 - 2.00 (4 H, m), 2.16 (3 H, s), 2.75 (2 H, br d, $J=11.62$ Hz), 3.47 - 3.61 (1 H, m), 6.85 (1 H, d, $J=7.83$ Hz), 6.95 (1 H, d, $J=2.57$ Hz), 7.53 - 7.64 (2 H, m), 7.58 (1 H, d, $J=1.10$ Hz), 7.71 (1 H, d, $J=2.08$ Hz), 7.94 (1 H, s), 8.88 - 8.94 (1 H, m), 9.12 (1 H, s); ESIMS found for $\text{C}_{19}\text{H}_{21}\text{N}_7$ m/z 348.1 ($\text{M}+1$).




67

[0433] 5-(Imidazo[1,2-a]pyridin-6-yl)-N-(tetrahydro-2H-pyran-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **67**.

[0434] Yellow solid (7.97 mg, 0.024 mmol). ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ ppm 1.46 - 1.63 (2 H, m), 1.91 (2 H, br d, $J=11.13$ Hz), 3.40 (2 H, br t, $J=10.82$ Hz), 3.73 - 3.84 (1 H,


m), 3.89 (2 H, br d, $J=11.37$ Hz), 6.91 - 7.01 (2 H, m), 7.54 - 7.66 (3 H, m), 7.71 (1 H, d, $J=2.20$ Hz), 7.95 (1 H, s), 8.91 (1 H, s), 9.13 (1 H, s); ESIMS found for $C_{18}H_{18}N_6O$ m/z 335.1 (M+1).



74

[0435] (6-(2-((2-Fluoro-2-methylpropyl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)imidazo[1,2-a]pyridin-3-yl)(pyrrolidin-1-yl)methanone **74**.


[0436] Yellow solid (21 mg, 0.050 mmol, 22.0% yield). 1H NMR (499 MHz, DMSO- d_6) δ ppm 1.38 (6 H, d, $J=21.40$ Hz), 1.91 (2 H, br s), 1.95 (2 H, br s), 3.49 (2 H, dd, $J=19.16$, 6.30 Hz), 3.58 (2 H, br s), 3.81 (2 H, br s), 6.99 (1 H, d, $J=2.46$ Hz), 7.08 (1 H, t, $J=6.43$ Hz), 7.74 (1 H, d, $J=2.46$ Hz), 7.77 - 7.86 (2 H, m), 8.22 (1 H, s), 9.03 (1 H, s), 9.65 (1 H, t, $J=1.37$ Hz); ESIMS found for $C_{22}H_{24}FN_7O$ m/z 422.2 (M+1).



145

[0437] N-(2-Fluoro-2-methylpropyl)-5-(imidazo[1,2-b]pyridazin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **145**.


[0438] Light brown solid (18 mg, 0.055 mmol, 21.2% yield). 1H NMR (499 MHz, DMSO- d_6) δ ppm 1.38 (6 H, d, $J=21.40$ Hz), 3.49 (2 H, dd, $J=19.03$, 6.43 Hz), 7.25 (1 H, t, $J=6.43$ Hz), 7.41 (1 H, d, $J=2.74$ Hz), 7.73 - 7.78 (3 H, m), 8.13 (1 H, d, $J=9.58$ Hz), 8.35 (1 H, s), 9.58 (1 H, s); ESIMS found for $C_{16}H_{16}FN_7$ m/z 326.1 (M+1).



214


[0439] 5-(Imidazo[1,2-a]pyrimidin-6-yl)-N-isopropylpyrrolo[2,1-f][1,2,4]triazin-2-amine **214**.

[0440] Yellow solid (12.01 mg, 0.041 mmol). ^1H NMR (400 MHz, $\text{DMSO-}d_6$) δ ppm 1.19 (6 H, d, $J=6.50$ Hz), 3.82 - 3.97 (1 H, m), 6.84 (1 H, d, $J=7.88$ Hz), 7.05 (1 H, d, $J=2.63$ Hz), 7.74 (2 H, d, $J=1.50$ Hz), 7.89 (1 H, d, $J=1.13$ Hz), 8.88 (1 H, d, $J=2.50$ Hz), 9.14 (1 H, s), 9.29 (1 H, d, $J=2.38$ Hz); ESIMS found for $\text{C}_{15}\text{H}_{15}\text{N}_7$ m/z 294.1 ($\text{M}+1$).

**215**


[0441] 5-(Imidazo[1,2-a]pyrimidin-6-yl)-N-isobutylpyrrolo[2,1-f][1,2,4]triazin-2-amine **215**.

[0442] Yellow solid (25.06 mg, 0.082 mmol). ^1H NMR (400 MHz, $\text{DMSO-}d_6$) δ ppm 0.92 (6 H, d, $J=6.50$ Hz), 1.95 (1 H, dquin, $J=13.30$, 6.65, 6.65, 6.65, 6.65 Hz), 3.03 (2 H, br t, $J=6.25$ Hz), 7.00 - 7.09 (2 H, m), 7.74 (2 H, br s), 7.89 (1 H, s), 8.88 (1 H, s), 9.14 (1 H, s), 9.29 (1 H, s); ESIMS found for $\text{C}_{16}\text{H}_{17}\text{N}_7$ m/z 308.0 ($\text{M}+1$).

**216**


[0443] N-(2-Fluoro-2-methylpropyl)-5-(imidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **216**.

[0444] Yellow solid (102 mg, 0.314 mmol, 20.0% yield). ^1H NMR (500 MHz, $\text{DMSO-}d_6$) δ ppm 1.37 (6 H, d, $J=21.40$ Hz), 3.48 (2 H, dd, $J=18.94$, 6.31 Hz), 7.09 (1 H, d, $J=2.74$ Hz), 7.11 (1 H, t, $J=6.45$ Hz), 7.74 (1 H, d, $J=1.37$ Hz), 7.75 - 7.77 (1 H, m), 7.89 (1 H, d, $J=1.37$ Hz), 8.89 (1 H, d, $J=2.47$ Hz), 9.18 (1 H, d, $J=0.82$ Hz), 9.31 (1 H, d, $J=2.74$ Hz); ESIMS found for $\text{C}_{16}\text{H}_{16}\text{FN}_7$ m/z 326.1 ($\text{M}+1$).

**218**

[0445] 5-(Imidazo[1,2-a]pyrimidin-6-yl)-N-(2,2,2-trifluoroethyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **218**.


[0446] Yellow solid (8.99 mg, 0.027 mmol). ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ ppm 4.03 - 4.17 (2 H, m), 7.16 (1 H, d, $J=2.63$ Hz), 7.65 (1 H, t, $J=7.00$ Hz), 7.75 (1 H, d, $J=1.25$ Hz), 7.86 (1 H, d, $J=2.63$ Hz), 7.90 (1 H, d, $J=1.25$ Hz), 8.90 (1 H, d, $J=2.50$ Hz), 9.25 (1 H, s), 9.33 (1 H, d, $J=2.63$ Hz); ESIMS found for $\text{C}_{14}\text{H}_{10}\text{F}_3\text{N}_7$ m/z 334.1 ($\text{M}+1$).



219

[0447] (R)-5-(Imidazo[1,2-a]pyrimidin-6-yl)-N-(1,1,1-trifluoropropan-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **219**.


[0448] Yellow solid (20.91 mg, 0.060 mmol). ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ ppm 1.37 (3 H, d, $J=7.00$ Hz), 4.66 - 4.82 (1 H, m), 7.15 (1 H, d, $J=2.50$ Hz), 7.60 (1 H, d, $J=9.13$ Hz), 7.75 (1 H, d, $J=1.13$ Hz), 7.84 (1 H, d, $J=2.63$ Hz), 7.90 (1 H, d, $J=1.25$ Hz), 8.90 (1 H, d, $J=2.50$ Hz), 9.24 (1 H, s), 9.33 (1 H, d, $J=2.50$ Hz); ESIMS found for $\text{C}_{15}\text{H}_{12}\text{F}_3\text{N}_7$ m/z 348.1 ($\text{M}+1$).



220

[0449] 5-(Imidazo[1,2-a]pyrimidin-6-yl)-N-(3,3,3-trifluoropropyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **220**.


[0450] Yellow solid (12.8 mg, 0.037 mmol). ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ ppm 2.55 - 2.71 (2 H, m), 3.47 (2 H, q, $J=6.70$ Hz), 7.10 (1 H, d, $J=2.63$ Hz), 7.19 (1 H, t, $J=5.69$ Hz), 7.74 (1 H, s), 7.80 (1 H, d, $J=2.50$ Hz), 7.89 (1 H, d, $J=0.88$ Hz), 8.89 (1 H, d, $J=2.50$ Hz), 9.18 (1 H, s), 9.31 (1 H, d, $J=2.50$ Hz); ESIMS found for $\text{C}_{15}\text{H}_{12}\text{F}_3\text{N}_7$ m/z 348.0 ($\text{M}+1$).



221

[0451] 5-(Imidazo[1,2-a]pyrimidin-6-yl)-N-(3,3,3-trifluoro-2,2-dimethylpropyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **221**.


[0452] Pale yellow solid (29 mg, 0.077 mmol, 26.0% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.16 (6 H, s), 3.48 (2 H, d, *J*=6.57 Hz), 7.10 (1 H, d, *J*=2.74 Hz), 7.13 (1 H, t, *J*=6.57 Hz), 7.75 (1 H, d, *J*=1.09 Hz), 7.78 (1 H, d, *J*=2.74 Hz), 7.90 (1 H, d, *J*=1.09 Hz), 8.89 (1 H, d, *J*=2.19 Hz), 9.20 (1 H, s), 9.31 (1 H, d, *J*=2.19 Hz); ESIMS found for C₁₇H₁₆F₃N₇ *m/z* 376.2 (M+1).



223

[0453] (R)-5-(Imidazo[1,2-a]pyrimidin-6-yl)-N-(1-methoxypropan-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **223**.


[0454] Yellow solid (28.36 mg, 0.088 mmol). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.17 (3 H, d, *J*=6.63 Hz), 3.26 - 3.32 (1 H, m), 3.28 (3 H, s), 3.43 - 3.48 (1 H, m), 3.94 - 4.09 (1 H, m), 6.79 (1 H, d, *J*=8.25 Hz), 7.07 (1 H, d, *J*=2.50 Hz), 7.74 (1 H, br s), 7.75 (1 H, d, *J*=2.50 Hz), 7.89 (1 H, s), 8.88 (1 H, d, *J*=2.50 Hz), 9.16 (1 H, s), 9.30 (1 H, d, *J*=2.38 Hz); ESIMS found for C₁₆H₁₇N₇O *m/z* 324.0 (M+1).



225


[0455] 5-(Imidazo[1,2-a]pyrimidin-6-yl)-N-((1-methylcyclopropyl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **225**.

[0456] Pale yellow solid (43 mg, 0.135 mmol, 37.9% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 0.23 - 0.30 (2 H, m), 0.47 - 0.54 (2 H, m), 1.11 (3 H, s), 3.17 (2 H, d, *J*=6.02 Hz), 7.00 (1 H, t, *J*=5.75 Hz), 7.06 (1 H, d, *J*=2.74 Hz), 7.73 (1 H, d, *J*=2.19 Hz), 7.74 (1 H, d, *J*=1.10 Hz), 7.89 (1 H, d, *J*=1.10 Hz), 8.88 (1 H, d, *J*=2.19 Hz), 9.16 (1 H, s), 9.30 (1 H, d, *J*=2.74 Hz); ESIMS found for C₁₇H₁₇N₇ *m/z* 320.2 (M+1).

**226**


[0457] 5-(Imidazo[1,2-a]pyrimidin-6-yl)-N-((1-(trifluoromethyl)cyclopropyl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **226**.

[0458] Pale yellow solid (27 mg, 0.072 mmol, 24.2% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 0.88 - 0.94 (2 H, m), 0.94 - 1.01 (2 H, m), 3.63 (2 H, d, *J*=6.57 Hz), 7.10 (1 H, d, *J*=2.74 Hz), 7.14 (1 H, t, *J*=6.30 Hz), 7.74 (1 H, d, *J*=1.09 Hz), 7.78 (1 H, d, *J*=2.19 Hz), 7.89 (1 H, d, *J*=1.64 Hz), 8.89 (1 H, d, *J*=2.74 Hz), 9.19 (1 H, s), 9.31 (1 H, d, *J*=2.74 Hz); ESIMS found for C₁₇H₁₄F₃N₇ *m/z* 374.1 (M+1).

**227**


[0459] N-((1-Fluorocyclobutyl)methyl)-5-(imidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **227**.

[0460] Pale yellow solid (30 mg, 0.089 mmol, 26.6% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.48 - 1.63 (1 H, m), 1.71 - 1.84 (1 H, m), 2.14 - 2.24 (2 H, m), 2.25 - 2.32 (2 H, m), 3.57 - 3.68 (2 H, m), 7.09 (1 H, d, *J*=2.74 Hz), 7.16 (1 H, t, *J*=6.30 Hz), 7.74 (1 H, d, *J*=1.64 Hz), 7.77 (1 H, d, *J*=2.74 Hz), 7.89 (1 H, d, *J*=1.09 Hz), 8.89 (1 H, d, *J*=2.74 Hz), 9.19 (1 H, s), 9.31 (1 H, d, *J*=2.74 Hz); ESIMS found for C₁₇H₁₆FN₇ *m/z* 338.2 (M+1).

**228**


[0461] N-((3-Fluorooxetan-3-yl)methyl)-5-(imidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **228**.

[0462] Yellow solid (26 mg, 0.077 mmol, 33.0% yield). ^1H NMR (499 MHz, $\text{DMSO-}d_6$) δ ppm 3.80 (2 H, dd, $J=19.71, 6.02$ Hz), 4.61 - 4.77 (4 H, m), 7.11 (1 H, d, $J=2.19$ Hz), 7.37 (1 H, t, $J=6.30$ Hz), 7.75 (1 H, d, $J=1.10$ Hz), 7.80 (1 H, d, $J=2.19$ Hz), 7.90 (1 H, d, $J=1.10$ Hz), 8.89 (1 H, d, $J=2.74$ Hz), 9.20 (1 H, s), 9.32 (1 H, d, $J=2.74$ Hz); ESIMS found for $\text{C}_{16}\text{H}_{14}\text{FN}_7\text{O}$ m/z 340.1 ($\text{M}+1$).

**229**


[0463] N-(Cyclopropylmethyl)-5-(imidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **229**.

[0464] Yellow solid (11.82 mg, 0.039 mmol). ^1H NMR (400 MHz, $\text{DMSO-}d_6$) δ ppm 0.21 - 0.29 (2 H, m), 0.41 - 0.50 (2 H, m), 1.08 - 1.21 (1 H, m), 3.10 (2 H, t, $J=6.25$ Hz), 7.05 - 7.11 (2 H, m), 7.75 (2 H, dd, $J=3.56, 1.94$ Hz), 7.89 (1 H, d, $J=1.13$ Hz), 8.88 (1 H, d, $J=2.50$ Hz), 9.16 (1 H, s), 9.30 (1 H, d, $J=2.50$ Hz); ESIMS found for $\text{C}_{16}\text{H}_{15}\text{N}_7$ m/z 306.1 ($\text{M}+1$).

**230**


[0465] (S)-N-(1-Cyclopropylethyl)-5-(imidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **230**.

[0466] Yellow solid (28.31 mg, 0.089 mmol). ^1H NMR (400 MHz, $\text{DMSO-}d_6$) δ ppm 0.15 - 0.24 (1 H, m), 0.31 - 0.51 (3 H, m), 0.97 - 1.09 (1 H, m), 1.24 (3 H, d, $J=6.63$ Hz), 3.35 (1 H, br d, $J=4.38$ Hz), 7.05 (1 H, br d, $J=3.25$ Hz), 7.18 (1 H, d, $J=2.63$ Hz), 7.78 (1 H, d, $J=2.50$ Hz), 8.17 (1 H, d, $J=2.25$ Hz), 8.25 (1 H, d, $J=2.13$ Hz), 9.22 (1 H, s), 9.37 (1 H, d, $J=2.25$ Hz), 9.61 (1 H, d, $J=2.38$ Hz); ESIMS found for $\text{C}_{17}\text{H}_{17}\text{N}_7$ m/z 320.2 ($\text{M}+1$).

**231**

[0467] (R)-N-(1-Cyclopropylethyl)-5-(imidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **231**.


[0468] Yellow solid (21.29 mg, 0.067 mmol). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 0.14 - 0.24 (1 H, m), 0.31 - 0.50 (3 H, m), 0.96 - 1.08 (1 H, m), 1.23 (3 H, d, *J*=6.50 Hz), 6.90 (1 H, d, *J*=8.38 Hz), 7.05 (1 H, d, *J*=2.50 Hz), 7.71 (1 H, d, *J*=2.38 Hz), 7.74 (1 H, s), 7.89 (1 H, s), 8.88 (1 H, d, *J*=2.50 Hz), 9.14 (1 H, s), 9.29 (1 H, d, *J*=2.50 Hz); ESIMS found for C₁₇H₁₇N₇ *m/z* 320.1 (M+1).



232

[0469] N-(2-Cyclopropyl-2,2-difluoroethyl)-5-(imidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **232**.


[0470] Yellow solid (3 mg, 0.008 mmol, 4.1% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 0.55 - 0.60 (4 H, m), 1.41 - 1.55 (1 H, m), 3.82 (2 H, td, *J*=13.96, 6.57 Hz), 7.12 (1 H, d, *J*=2.19 Hz), 7.36 (1 H, t, *J*=6.57 Hz), 7.75 (1 H, d, *J*=1.10 Hz), 7.80 (1 H, d, *J*=2.19 Hz), 7.89 (1 H, d, *J*=1.64 Hz), 8.90 (1 H, d, *J*=2.74 Hz), 9.21 (1 H, s), 9.32 (1 H, d, *J*=2.74 Hz); ESIMS found for C₁₇H₁₅F₂N₇ *m/z* 356.1 (M+1).



235


[0471] N-Cyclobutyl-5-(imidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **235**.

[0472] Yellow solid (11.92 mg, 0.039 mmol). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.60 - 1.76 (2 H, m), 1.92 - 2.06 (2 H, m), 2.22 - 2.35 (2 H, m), 4.18 (1 H, dt, *J*=15.99, 7.96 Hz), 7.23 (1 H, d, *J*=2.57 Hz), 7.81 (1 H, d, *J*=2.57 Hz), 8.28 - 8.35 (2 H, m), 9.29 (1 H, s), 9.44 (1 H, d, *J*=2.32 Hz), 9.82 (1 H, d, *J*=2.20 Hz); ESIMS found for C₁₆H₁₅N₇ *m/z* 306.2 (M+1).

**236**


[0473] N-(3,3-Difluorocyclobutyl)-5-(imidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **236**.

[0474] Yellow solid (10.03 mg, 0.029 mmol). ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ ppm 2.58 - 2.75 (2 H, m), 2.92 - 3.06 (2 H, m), 4.01 - 4.13 (1 H, m), 7.11 (1 H, d, $J=2.38$ Hz), 7.58 (1 H, d, $J=6.25$ Hz), 7.74 (1 H, s), 7.79 (1 H, d, $J=2.38$ Hz), 7.89 (1 H, s), 8.88 (1 H, d, $J=2.25$ Hz), 9.20 (1 H, s), 9.31 (1 H, d, $J=2.25$ Hz); ESIMS found for $\text{C}_{16}\text{H}_{13}\text{F}_2\text{N}_7$ m/z 342.0 ($\text{M}+1$).

**237**

[0475] N-(3,3-Dimethylcyclobutyl)-5-(imidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **237**.


[0476] Yellow solid (9.7 mg, 0.029 mmol). ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ ppm 1.11 (3 H, s), 1.16 (3 H, s), 1.77 - 1.89 (2 H, m), 2.16 (2 H, ddd, $J=9.14, 7.92, 2.51$ Hz), 4.16 (1 H, dt, $J=16.11, 8.02$ Hz), 7.22 (1 H, d, $J=2.69$ Hz), 7.83 (1 H, d, $J=2.57$ Hz), 8.27 (1 H, d, $J=2.20$ Hz), 8.32 (1 H, d, $J=2.20$ Hz), 9.26 (1 H, s), 9.43 (1 H, d, $J=2.32$ Hz), 9.76 (1 H, d, $J=2.20$ Hz); ESIMS found for $\text{C}_{18}\text{H}_{19}\text{N}_7$ m/z 334.2 ($\text{M}+1$).

**239**

[0477] 5-(Imidazo[1,2-a]pyrimidin-6-yl)-N-(*cis*-3-methoxycyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **239**.


[0478] Yellow solid (3.11 mg, 0.009 mmol). ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ ppm 1.78 - 1.90 (2 H, m), 2.66 (2 H, dtd, $J=9.06, 6.66, 6.66, 2.81$ Hz), 3.14 (3 H, s), 3.56 - 3.68 (1 H, m), 3.78 (1 H, dq, $J=15.59, 7.93$ Hz), 7.08 (1 H, d, $J=2.57$ Hz), 7.32 (1 H, d, $J=7.34$ Hz), 7.69 -

7.77 (2 H, m), 7.89 (1 H, d, $J=1.34$ Hz), 8.88 (1 H, d, $J=2.45$ Hz), 9.16 (1 H, s), 9.30 (1 H, d, $J=2.57$ Hz); ESIMS found for $C_{17}H_{17}N_7O$ m/z 336.1 ($M+1$).

**240**


[0479] 5-(Imidazo[1,2-a]pyrimidin-6-yl)-N-(*trans*-3-methoxycyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **240**.

[0480] Yellow solid (9.17 mg, 0.027 mmol). 1H NMR (400 MHz, $DMSO-d_6$) δ ppm 2.18 - 2.34 (4 H, m), 3.16 (3 H, s), 3.98 - 4.03 (1 H, m), 4.15 - 4.25 (1 H, m), 7.17 (1 H, d, $J=2.63$ Hz), 7.47 (1 H, br d, $J=6.00$ Hz), 7.81 (1 H, d, $J=2.50$ Hz), 8.10 - 8.14 (2 H, m), 9.21 (1 H, s), 9.25 (1 H, d, $J=2.25$ Hz), 9.54 (1 H, d, $J=2.38$ Hz); ESIMS found for $C_{17}H_{17}N_7O$ m/z 336.1 ($M+1$).

**242**


[0481] N-(*cis*-3-Ethoxycyclobutyl)-5-(imidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **242**.

[0482] Brown solid (20 mg, 0.057 mmol, 11.9% yield). 1H NMR (499 MHz, $DMSO-d_6$) δ ppm 1.10 (3 H, t, $J=6.84$ Hz), 1.80 - 1.92 (2 H, m), 2.66 (2 H, dtd, $J=8.90$, 6.78, 6.78, 2.74 Hz), 3.33 - 3.38 (2 H, m), 3.66 - 3.73 (1 H, m), 3.73 - 3.83 (1 H, m), 7.07 (1 H, d, $J=2.74$ Hz), 7.31 (1 H, d, $J=7.12$ Hz), 7.72 - 7.75 (2 H, m), 7.89 (1 H, d, $J=1.10$ Hz), 8.88 (1 H, d, $J=2.19$ Hz), 9.15 (1 H, s), 9.30 (1 H, d, $J=2.19$ Hz); ESIMS found for $C_{18}H_{19}N_7O$ m/z 350.15 ($M+1$).

**244**


[0483] 5-(Imidazo[1,2-a]pyrimidin-6-yl)-N-(*cis*-3-(2-methoxyethoxy)cyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **244**.

[0484] Tan solid (12 mg, 0.032 mmol, 5.4% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.82 - 1.93 (2 H, m), 2.62 - 2.71 (2 H, m), 3.25 (3 H, s), 3.42 (4 H, s), 3.68 - 3.84 (2 H, m), 7.07 (1 H, d, *J*=2.19 Hz), 7.32 (1 H, d, *J*=7.12 Hz), 7.74 (1 H, d, *J*=4.38 Hz), 7.74 (1 H, s), 7.89 (1 H, d, *J*=1.64 Hz), 8.88 (1 H, d, *J*=2.19 Hz), 9.16 (1 H, s), 9.30 (1 H, d, *J*=2.74 Hz); ESIMS found for C₁₉H₂₁N₇O₂ *m/z* 380.2 (M+1).

**256**


[0485] N-(4,4-Difluorocyclohexyl)-5-(imidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **256**.

[0486] Pale yellow solid (67 mg, 0.1814 mmol, 23.3% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.57 - 1.71 (2 H, m), 1.85 - 2.04 (4 H, m), 2.04 - 2.15 (2 H, m), 3.74 - 3.86 (1 H, m), 7.06 (1 H, d, *J*=8.21 Hz), 7.08 (1 H, d, *J*=2.74 Hz), 7.74 (1 H, d, *J*=1.64 Hz), 7.76 (1 H, d, *J*=2.74 Hz), 7.89 (1 H, d, *J*=1.64 Hz), 8.89 (1 H, d, *J*=2.19 Hz), 9.17 (1 H, s), 9.30 (1 H, d, *J*=2.74 Hz); ESIMS found for C₁₈H₁₇F₂N₇ *m/z* 370.1 (M+1).

**258**


[0487] (1s,4s)-4-((5-(Imidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclohexan-1-ol **258**.

[0488] Yellow solid (37 mg, 0.102 mmol, 33.1% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.12 (3 H, s), 1.37 (2 H, td, *J*=13.00, 4.11 Hz), 1.58 (2 H, br d, *J*=12.05 Hz), 1.61 - 1.69 (2 H, m), 1.69 - 1.75 (2 H, m), 3.45 - 3.57 (1 H, m), 4.02 (1 H, s), 6.84 (1 H, d, *J*=8.21 Hz), 7.04 (1 H, d, *J*=2.74 Hz), 7.73 (1 H, d, *J*=2.74 Hz), 7.74 (1 H, d, *J*=1.10 Hz), 7.89 (1 H, d, *J*=1.10 Hz), 8.88 (1 H, d, *J*=2.19 Hz), 9.14 (1 H, s), 9.29 (1 H, d, *J*=2.74 Hz); ESIMS found for C₁₉H₂₁N₇O *m/z* 364.2 (M+1).

**259**


[0489] 5-(Imidazo[1,2-a]pyrimidin-6-yl)-N-(*cis*-4-methoxycyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **259**.

[0490] Beige solid (5 mg, 0.014 mmol, 4.5% yield). ^1H NMR (499 MHz, $\text{DMSO}-d_6$) δ ppm 1.42 - 1.55 (2 H, m), 1.56 - 1.65 (2 H, m), 1.66 - 1.76 (2 H, m), 1.80 - 1.91 (2 H, m), 3.22 (3 H, s), 3.33 - 3.37 (1 H, m), 3.59 - 3.68 (1 H, m), 6.89 (1 H, d, $J=7.67$ Hz), 7.05 (1 H, q, $J=2.19$ Hz), 7.71 - 7.75 (2 H, m), 7.89 (1 H, d, $J=1.64$ Hz), 8.88 (1 H, d, $J=2.19$ Hz), 9.14 (1 H, s), 9.29 (1 H, d, $J=2.19$ Hz); ESIMS found for $\text{C}_{19}\text{H}_{21}\text{N}_7\text{O}$ m/z 364.2 ($M+1$).

**260**

[0491] 5-(Imidazo[1,2-a]pyrimidin-6-yl)-N-(*trans*-4-methoxycyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **260**.


[0492] Yellow solid (16.56 mg, 0.046 mmol). ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ ppm 1.14 - 1.27 (2 H, m), 1.27 - 1.41 (2 H, m), 1.95 - 2.08 (4 H, m), 3.13 (1 H, tt, $J=10.06$, 3.45 Hz), 3.24 (3 H, s), 3.51 - 3.63 (1 H, m), 6.88 (1 H, d, $J=7.95$ Hz), 7.06 (1 H, d, $J=2.57$ Hz), 7.74 (1 H, d, $J=1.34$ Hz), 7.76 (1 H, d, $J=2.08$ Hz), 7.89 (1 H, d, $J=1.34$ Hz), 8.88 (1 H, d, $J=2.57$ Hz), 9.15 (1 H, s), 9.29 (1 H, d, $J=2.45$ Hz); ESIMS found for $\text{C}_{19}\text{H}_{21}\text{N}_7\text{O}$ m/z 364.2 ($M+1$).

**263**

[0493] N-(*cis*-4-Ethoxycyclohexyl)-5-(imidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **263**.

[0494] Tan solid (44 mg, 0.117 mmol, 26.4% yield). ^1H NMR (499 MHz, $\text{DMSO}-d_6$) δ ppm 1.12 (3 H, t, $J=7.12$ Hz), 1.43 - 1.56 (2 H, m), 1.58 - 1.75 (4 H, m), 1.77 - 1.87 (2 H, m),


3.42 (2 H, q, $J=7.12$ Hz), 3.44 - 3.47 (1 H, m), 3.59 - 3.69 (1 H, m), 6.88 (1 H, d, $J=7.67$ Hz), 7.05 (1 H, d, $J=2.74$ Hz), 7.74 (1 H, d, $J=3.85$ Hz), 7.74 (1 H, s), 7.89 (1 H, d, $J=1.64$ Hz), 8.88 (1 H, d, $J=2.19$ Hz), 9.14 (1 H, s), 9.29 (1 H, d, $J=2.19$ Hz); ESIMS found for $C_{20}H_{23}N_7O$ m/z 378.2 (M+1).



265

[0495] 5-(Imidazo[1,2-a]pyrimidin-6-yl)-N-(*cis*-4-(2-methoxyethoxy)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **265**.


[0496] Yellow solid (18 mg, 0.044 mmol, 12.8% yield). 1H NMR (499 MHz, DMSO- d_6) δ ppm 1.44 - 1.57 (2 H, m), 1.60 - 1.75 (4 H, m), 1.78 - 1.88 (2 H, m), 3.27 (3 H, s), 3.43 - 3.46 (2 H, m), 3.46 - 3.49 (1 H, m), 3.49 - 3.52 (2 H, m), 3.58 - 3.69 (1 H, m), 6.91 (1 H, d, $J=7.67$ Hz), 7.05 (1 H, d, $J=2.74$ Hz), 7.73 - 7.75 (2 H, m), 7.89 (1 H, d, $J=1.10$ Hz), 8.88 (1 H, d, $J=2.74$ Hz), 9.15 (1 H, s), 9.29 (1 H, d, $J=2.74$ Hz); ESIMS found for $C_{21}H_{25}N_7O_2$ m/z 408.2 (M+1).



279

[0497] 5-(Imidazo[1,2-a]pyrimidin-6-yl)-N-(1-methylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **279**.


[0498] Yellow solid (18 mg, 0.052 mmol, 16.0% yield). 1H NMR (499 MHz, DMSO- d_6) δ ppm 1.47 - 1.60 (2 H, m), 1.90 (2 H, br d, $J=9.86$ Hz), 1.96 (2 H, br t, $J=11.50$ Hz), 2.17 (3 H, s), 2.75 (2 H, br d, $J=12.05$ Hz), 3.48 - 3.59 (1 H, m), 6.90 (1 H, d, $J=7.67$ Hz), 7.06 (1 H, d, $J=2.74$ Hz), 7.74 (1 H, d, $J=1.64$ Hz), 7.75 (1 H, d, $J=2.19$ Hz), 7.89 (1 H, d, $J=1.64$ Hz), 8.88 (1 H, d, $J=2.74$ Hz), 9.16 (1 H, s), 9.30 (1 H, d, $J=2.74$ Hz); ESIMS found for $C_{19}H_{20}N_8$ m/z 349.2 (M+1).



280

[0499] 5-(Imidazo[1,2-a]pyrimidin-6-yl)-N-(tetrahydro-2H-pyran-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **280**.


[0500] Yellow solid (54.78 mg, 0.163 mmol). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.45 - 1.61 (2 H, m), 1.90 (2 H, br dd, *J*=12.51, 2.00 Hz), 3.35 - 3.43 (2 H, m), 3.72 - 3.83 (1 H, m), 3.84 - 3.93 (2 H, m), 7.01 (1 H, d, *J*=7.75 Hz), 7.06 (1 H, d, *J*=2.50 Hz), 7.74 (2 H, dd, *J*=4.13, 1.88 Hz), 7.89 (1 H, d, *J*=1.25 Hz), 8.88 (1 H, d, *J*=2.50 Hz), 9.16 (1 H, s), 9.29 (1 H, d, *J*=2.50 Hz); ESIMS found for C₁₇H₁₇N₇O *m/z* 336.1 (M+1).



281

[0501] N-(6,6-Difluorospiro[3.3]heptan-2-yl)-5-(imidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **281**.


[0502] Beige solid (33 mg, 0.087 mmol, 29.7% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 2.12 - 2.21 (2 H, m), 2.45 - 2.49 (2 H, m), 2.58 (2 H, br t, *J*=12.59 Hz), 2.65 - 2.76 (2 H, m), 4.13 (1 H, sxt, *J*=7.78 Hz), 7.07 (1 H, d, *J*=2.74 Hz), 7.34 (1 H, d, *J*=7.12 Hz), 7.74 (1 H, d, *J*=1.64 Hz), 7.76 (1 H, d, *J*=2.74 Hz), 7.89 (1 H, d, *J*=1.10 Hz), 8.88 (1 H, d, *J*=2.19 Hz), 9.16 (1 H, s), 9.30 (1 H, d, *J*=2.74 Hz); ESIMS found for C₁₉H₁₇F₂N₇ *m/z* 382.2 (M+1).



282

[0503] 5-(Imidazo[1,2-a]pyrimidin-6-yl)-N-(2-oxaspiro[3.3]heptan-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **282**.


[0504] Light brown solid (11 mg, 0.032 mmol, 10.9% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 2.12 - 2.22 (2 H, m), 2.58 - 2.67 (2 H, m), 3.99 (1 H, sxt, *J*=7.67 Hz), 4.52 (2 H, s), 4.64 (2 H, s), 7.07 (1 H, d, *J*=2.74 Hz), 7.29 (1 H, d, *J*=6.57 Hz), 7.72 - 7.76 (2 H, m), 7.89 (1 H, d, *J*=1.64 Hz), 8.88 (1 H, d, *J*=2.74 Hz), 9.15 (1 H, s), 9.30 (1 H, d, *J*=2.19 Hz); ESIMS found for C₁₈H₁₇N₇O *m/z* 348.2 (M+1).



283

[0505] 5-(Imidazo[1,2-a]pyrimidin-6-yl)-N-(2-methyl-2-azaspiro[3.3]heptan-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **283**.


[0506] Yellow solid (5 mg, 0.014 mmol, 12.0% yield). ^1H NMR (499 MHz, DMSO- d_6) δ ppm 2.03 - 2.10 (2 H, m), 2.16 (3 H, s), 2.45 (2 H, ddd, $J=9.72, 7.26, 2.74$ Hz), 3.04 (2 H, s), 3.16 (2 H, s), 4.03 (1 H, sxt, $J=7.67$ Hz), 7.07 (1 H, d, $J=2.74$ Hz), 7.27 (1 H, d, $J=7.12$ Hz), 7.74 (1 H, d, $J=1.64$ Hz), 7.75 (1 H, d, $J=2.74$ Hz), 7.89 (1 H, d, $J=1.09$ Hz), 8.88 (1 H, d, $J=2.74$ Hz), 9.14 (1 H, s), 9.29 (1 H, d, $J=2.19$ Hz); ESIMS found for $\text{C}_{19}\text{H}_{20}\text{N}_8$ m/z 361.2 ($M+1$).



287

[0507] 5-(3-Chloroimidazo[1,2-a]pyrimidin-6-yl)-N-(2-fluoro-2-methylpropyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **287**.

[0508] Yellow solid (16 mg, 0.045 mmol, 18.2% yield). ^1H NMR (499 MHz, DMSO- d_6) δ ppm 1.38 (6 H, d, $J=21.40$ Hz), 3.49 (2 H, dd, $J=19.16, 6.30$ Hz), 7.11 - 7.15 (2 H, m), 7.77 (1 H, d, $J=2.19$ Hz), 7.89 (1 H, s), 8.95 (2 H, q, $J=2.28$ Hz), 9.15 (1 H, s); ESIMS found for $\text{C}_{16}\text{H}_{15}\text{ClFN}_7$ m/z 360.1 ($M+1$).




358

[0509] N-(2-Fluoro-2-methylpropyl)-5-(3-methylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **358**.

[0510] Yellow solid (10.71 mg, 0.032 mmol). ^1H NMR (400 MHz, DMSO- d_6) δ ppm 1.33 (6 H, d, $J=21.40$ Hz), 2.46 (2 H, br s), 3.44 (2 H, dd, $J=19.20, 6.32$ Hz), 6.98 - 7.08 (2 H, m),


7.49 (1 H, s), 7.71 (1 H, d, $J=2.50$ Hz), 8.77 (1 H, d, $J=2.25$ Hz), 8.86 (1 H, d, $J=2.13$ Hz), 9.14 (1 H, s); ESIMS found for $C_{17}H_{18}FN_7$ m/z 340.1 (M+1).



398

[0511] N-(4,4-Difluorocyclohexyl)-5-(3-methylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **398**.


[0512] Yellow solid (2.1 mg, 0.005 mmol). 1H NMR (400 MHz, DMSO- d_6) δ ppm 1.58 - 1.72 (2 H, m), 1.86 - 2.04 (4 H, m), 2.09 (2 H, br d, $J=7.38$ Hz), 2.54 (3 H, s), 3.76 - 3.89 (1 H, m), 7.01 (1 H, br d, $J=7.63$ Hz), 7.07 (1 H, d, $J=2.38$ Hz), 7.53 (1 H, s), 7.75 (1 H, d, $J=2.38$ Hz), 8.81 (1 H, d, $J=2.25$ Hz), 8.89 (1 H, d, $J=2.13$ Hz), 9.18 (1 H, s); ESIMS found for $C_{19}H_{19}F_2N_7$ m/z 384.2 (M+1).



429

[0513] 5-(3-Ethylimidazo[1,2-a]pyrimidin-6-yl)-N-(2-fluoro-2-methylpropyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **429**.


[0514] Yellow solid (11.07 mg, 0.031 mmol). 1H NMR (400 MHz, DMSO- d_6) δ ppm 1.31 - 1.37 (3 H, m), 1.37 (6 H, d, $J=21.40$ Hz), 2.98 (2 H, q, $J=7.50$ Hz), 3.49 (2 H, br dd, $J=19.20$, 6.32 Hz), 7.03 - 7.12 (2 H, m), 7.55 (1 H, s), 7.76 (1 H, d, $J=2.25$ Hz), 8.82 (1 H, d, $J=2.25$ Hz), 8.94 (1 H, d, $J=2.38$ Hz), 9.15 (1 H, s); ESIMS found for $C_{18}H_{20}FN_7$ m/z 354.3 (M+1).



500


[0515] 5-(4-Fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)-N-(2-fluoro-2-methylpropyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **500**.

[0516] Yellow solid (34 mg, 0.085 mmol, 49.0% yield). ^1H NMR (499 MHz, DMSO- d_6) δ ppm 1.37 (6 H, d, $J=21.40$ Hz), 1.59 (6 H, d, $J=6.84$ Hz), 2.60 (3 H, s), 3.48 (2 H, dd, $J=19.16$, 6.57 Hz), 4.83 (1 H, dt, $J=13.89$, 6.88 Hz), 6.96 - 7.01 (2 H, m), 7.24 (1 H, dd, $J=11.77$, 1.10 Hz), 7.63 (1 H, d, $J=1.10$ Hz), 7.68 (1 H, d, $J=2.46$ Hz), 8.98 (1 H, s); ESIMS found for $\text{C}_{21}\text{H}_{24}\text{F}_2\text{N}_6$ m/z 399.2 (M+1).

**571**


[0517] N-(2-Fluoro-2-methylpropyl)-5-(1-isopropyl-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **571**.

[0518] Yellow solid (39 mg, 0.102 mmol, 39.1% yield). ^1H NMR (499 MHz, DMSO- d_6) δ ppm 1.38 (6 H, d, $J=21.40$ Hz), 1.60 (6 H, d, $J=6.84$ Hz), 2.64 (3 H, s), 3.49 (2 H, dd, $J=19.30$, 6.43 Hz), 4.76 - 4.90 (1 H, m), 6.99 - 7.04 (2 H, m), 7.72 (1 H, d, $J=2.46$ Hz), 8.22 (1 H, d, $J=1.92$ Hz), 8.60 (1 H, d, $J=2.19$ Hz), 8.99 (1 H, s); ESIMS found for $\text{C}_{20}\text{H}_{24}\text{FN}_7$ m/z 382.2 (M+1).

**642**


[0519] 5-(1-(2,2-Difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(2-fluoro-2-methylpropyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **642**.

[0520] Yellow solid (37 mg, 0.092 mmol, 37.6% yield). ^1H NMR (499 MHz, DMSO- d_6) δ ppm 1.38 (6 H, d, $J=21.40$ Hz), 2.63 (3 H, s), 3.49 (2 H, dd, $J=19.30$, 6.43 Hz), 4.91 (2 H, td, $J=15.88$, 3.01 Hz), 6.53 (1 H, tt, $J=54.40$, 3.20 Hz), 7.01 (1 H, d, $J=2.74$ Hz), 7.03 (1 H, t, $J=6.43$ Hz), 7.73 (1 H, d, $J=2.46$ Hz), 8.25 (1 H, d, $J=1.92$ Hz), 8.67 (1 H, d, $J=1.92$ Hz), 9.14 (1 H, s); ESIMS found for $\text{C}_{19}\text{H}_{20}\text{F}_3\text{N}_7$ m/z 404.2 (M+1).

**682**


[0521] N-(4,4-Difluorocyclohexyl)-5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **682**.

[0522] Yellowish brown solid (8 mg, 0.018 mmol, 5.9% yield). ^1H NMR (499 MHz, $\text{DMSO}-d_6$) δ ppm 1.56 - 1.70 (2 H, m), 1.87 - 2.03 (4 H, m), 2.03 - 2.16 (2 H, m), 2.63 (3 H, s), 3.76 - 3.86 (1 H, m), 4.90 (2 H, td, $J=15.88, 2.74$ Hz), 6.53 (1 H, tt, $J=54.60, 3.00$ Hz), 6.98 (1 H, d, $J=8.21$ Hz), 7.00 (1 H, d, $J=2.74$ Hz), 7.73 (1 H, d, $J=2.74$ Hz), 8.24 (1 H, d, $J=2.19$ Hz), 8.66 (1 H, d, $J=2.19$ Hz), 9.13 (1 H, s); ESIMS found for $\text{C}_{21}\text{H}_{21}\text{F}_4\text{N}_7$ m/z 448.2 ($\text{M}+1$).

**683**


[0523] *cis*-4-((5-(1-(2,2-Difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclohexan-1-ol **683**.

[0524] Light brown solid (6 mg, 0.014 mmol, 4.4% yield). ^1H NMR (499 MHz, $\text{DMSO}-d_6$) δ ppm 1.45 - 1.57 (2 H, m), 1.61 - 1.69 (4 H, m), 1.70 - 1.81 (2 H, m), 2.62 (3 H, s), 3.57 - 3.68 (1 H, m), 3.74 (1 H, br d, $J=2.46$ Hz), 4.35 (1 H, d, $J=3.01$ Hz), 4.90 (2 H, td, $J=15.95, 2.87$ Hz), 6.53 (1 H, tt, $J=54.60, 3.00$ Hz), 6.76 (1 H, d, $J=7.67$ Hz), 6.97 (1 H, d, $J=2.46$ Hz), 7.71 (1 H, d, $J=2.46$ Hz), 8.23 (1 H, d, $J=2.19$ Hz), 8.66 (1 H, d, $J=1.92$ Hz), 9.10 (1 H, s); ESIMS found for $\text{C}_{21}\text{H}_{23}\text{F}_2\text{N}_7\text{O}$ m/z 428.2 ($\text{M}+1$).

**684**


[0525] *cis*-4-((5-(1-(2,2-Difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclohexan-1-ol **684**.

[0526] Dark yellow solid (16 mg, 0.036 mmol, 11.8% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.13 (3 H, s), 1.37 (2 H, td, *J*=13.14, 4.38 Hz), 1.59 (2 H, br d, *J*=12.05 Hz), 1.62 - 1.70 (2 H, m), 1.70 - 1.76 (2 H, m), 2.62 (3 H, s), 3.47 - 3.60 (1 H, m), 4.01 (1 H, s), 4.90 (2 H, td, *J*=15.74, 3.01 Hz), 6.52 (1 H, tt, *J*=54.40, 3.00 Hz), 6.74 (1 H, d, *J*=7.67 Hz), 6.96 (1 H, d, *J*=2.74 Hz), 7.69 (1 H, d, *J*=2.74 Hz), 8.22 (1 H, d, *J*=2.19 Hz), 8.65 (1 H, d, *J*=2.19 Hz), 9.09 (1 H, s); ESIMS found for C₂₂H₂₅F₂N₇O *m/z* 442.2 (M+1).

**685**

[0527] 5-(1-(2,2-Difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*cis*-4-methoxycyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **685**.


[0528] Light brown solid (46 mg, 0.104 mmol, 33.9% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.44 - 1.53 (2 H, m), 1.55 - 1.65 (2 H, m), 1.66 - 1.74 (2 H, m), 1.82 - 1.90 (2 H, m), 2.62 (3 H, s), 3.22 (3 H, s), 3.35 (1 H, br d, *J*=2.19 Hz), 3.60 - 3.72 (1 H, m), 4.90 (2 H, td, *J*=15.88, 2.74 Hz), 6.52 (1 H, tt, *J*=54.60, 3.00 Hz), 6.80 (1 H, d, *J*=7.94 Hz), 6.97 (1 H, d, *J*=2.74 Hz), 7.71 (1 H, d, *J*=2.19 Hz), 8.23 (1 H, d, *J*=1.92 Hz), 8.66 (1 H, d, *J*=2.19 Hz), 9.10 (1 H, s); ESIMS found for C₂₂H₂₅F₂N₇O *m/z* 442.2 (M+1).

**686**

[0529] 5-(1-(2,2-Difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*trans*-4-methoxycyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **686**.

[0530] Light brown solid (42 mg, 0.095 mmol, 30.9% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.14 - 1.26 (2 H, m), 1.27 - 1.38 (2 H, m), 1.95 - 2.09 (4 H, m), 2.62 (3 H, s), 3.13 (1 H, tt, *J*=10.13, 3.42 Hz), 3.25 (3 H, s), 3.51 - 3.64 (1 H, m), 4.90 (2 H, td, *J*=15.81, 2.60 Hz), 6.52 (1 H, tt, *J*=54.60, 3.00 Hz), 6.79 (1 H, d, *J*=8.21 Hz), 6.98 (1 H, d, *J*=2.46 Hz), 7.73 (1


H, d, $J=2.46$ Hz), 8.23 (1 H, d, $J=1.64$ Hz), 8.66 (1 H, d, $J=1.92$ Hz), 9.11 (1 H, s); ESIMS found for $C_{22}H_{25}F_2N_7O$ m/z 442.2 (M+1).



687

[0531] 5-(1-(2,2-Difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*cis*-4-(difluoromethoxy)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **687**.


[0532] Light brown solid (7 mg, 0.015 mmol, 5.3% yield). 1H NMR (499 MHz, DMSO- d_6) δ ppm 1.60 - 1.72 (4 H, m), 1.73 - 1.82 (2 H, m), 1.88 (2 H, dt, $J=9.31$, 4.65 Hz), 2.63 (3 H, s), 3.64 - 3.76 (1 H, m), 4.29 (1 H, br s), 4.90 (2 H, td, $J=15.88$, 2.74 Hz), 6.53 (1 H, tt, $J=54.60$, 3.00 Hz), 6.73 (1 H, t, $J=76.80$ Hz), 6.90 (1 H, d, $J=7.67$ Hz), 6.98 (1 H, d, $J=2.19$ Hz), 7.71 (1 H, d, $J=2.19$ Hz), 8.23 (1 H, d, $J=2.19$ Hz), 8.66 (1 H, d, $J=2.19$ Hz), 9.11 (1 H, s); ESIMS found for $C_{22}H_{23}F_4N_7O$ m/z 478.2 (M+1).



691

[0533] 5-(1-(2,2-Difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*cis*-4-(2-methoxyethoxy)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **691**.


[0534] Yellow solid (23 mg, 0.047 mmol, 17.5% yield). 1H NMR (499 MHz, DMSO- d_6) δ ppm 1.45 - 1.57 (2 H, m), 1.59 - 1.75 (4 H, m), 1.79 - 1.89 (2 H, m), 2.62 (3 H, s), 3.27 (3 H, s), 3.43 - 3.47 (2 H, m), 3.47 - 3.49 (1 H, m), 3.49 - 3.52 (2 H, m), 3.59 - 3.70 (1 H, m), 4.90 (2 H, td, $J=15.81$, 2.87 Hz), 6.53 (1 H, tt, $J=54.60$, 3.00 Hz), 6.81 (1 H, d, $J=7.67$ Hz), 6.97 (1 H, d, $J=2.46$ Hz), 7.71 (1 H, d, $J=2.46$ Hz), 8.23 (1 H, d, $J=1.92$ Hz), 8.66 (1 H, d, $J=2.19$ Hz), 9.10 (1 H, s); ESIMS found for $C_{24}H_{29}F_2N_7O_2$ m/z 486.2 (M+1).



692

[0535] 5-(1-(2,2-Difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*trans*-4-(2-methoxyethoxy)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **692**.


[0536] Dark yellow solid (25 mg, 0.052 mmol, 19.0% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.18 - 1.39 (4 H, m), 2.01 (4 H, br dd, *J*=10.40, 2.20 Hz), 2.62 (3 H, s), 3.21 - 3.28 (1 H, m), 3.25 (2 H, s), 3.42 (2 H, t, *J*=4.90 Hz), 3.54 (2 H, t, *J*=4.90 Hz), 3.55 - 3.62 (1 H, m), 4.84 - 4.97 (2 H, m), 6.52 (1 H, tt, *J*=54.60, 3.00 Hz), 6.77 (1 H, d, *J*=8.21 Hz), 6.98 (1 H, d, *J*=2.74 Hz), 7.73 (1 H, d, *J*=2.74 Hz), 8.23 (1 H, d, *J*=1.64 Hz), 8.66 (1 H, d, *J*=2.19 Hz), 9.11 (1 H, s); ESIMS found for C₂₄H₂₉F₂N₇O₂ *m/z* 486.2 (M+1).



706

[0537] 5-(1-(2,2-Difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(tetrahydro-2H-pyran-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **706**.


[0538] Light brown solid (8 mg, 0.019 mmol, 5.8% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.45 - 1.59 (2 H, m), 1.91 (2 H, br dd, *J*=12.59, 2.19 Hz), 2.63 (3 H, s), 3.41 (2 H, td, *J*=11.64, 1.92 Hz), 3.75 - 3.85 (1 H, m), 3.86 - 3.94 (2 H, m), 4.90 (2 H, td, *J*=15.88, 2.74 Hz), 6.52 (1 H, tt, *J*=54.60, 3.00 Hz), 6.91 (1 H, d, *J*=7.67 Hz), 6.99 (1 H, d, *J*=2.74 Hz), 7.73 (1 H, d, *J*=2.19 Hz), 8.23 (1 H, d, *J*=2.19 Hz), 8.66 (1 H, d, *J*=1.64 Hz), 9.12 (1 H, s); ESIMS found for C₂₀H₂₁F₂N₇O *m/z* 414.2 (M+1).



713


[0539] 5-(1-(3,3-Difluorocyclobutyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(2-fluoro-2-methylpropyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **713**.

[0540] Yellow solid (45 mg, 0.105 mmol, 43.0% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.38 (6 H, d, *J*=21.40 Hz), 2.64 (3 H, s), 3.35 - 3.43 (2 H, m), 3.48 (2 H, dd, *J*=19.30, 6.43 Hz), 3.53 - 3.64 (2 H, m), 5.04 - 5.17 (1 H, m), 6.99 - 7.06 (2 H, m), 7.73 (1 H, d, *J*=2.46 Hz), 8.04 (1 H, d, *J*=1.92 Hz), 8.66 (1 H, d, *J*=1.92 Hz), 9.10 (1 H, s); ESIMS found for C₂₁H₂₂F₃N₇ *m/z* 430.2 (M+1).

**784**


[0541] N-(2-Fluoro-2-methylpropyl)-5-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **784**.

[0542] Yellow solid (19 mg, 0.045 mmol, 19.8% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.38 (6 H, d, *J*=21.40 Hz), 1.87 (2 H, br dd, *J*=12.32, 2.46 Hz), 2.44 (2 H, qd, *J*=12.37, 4.52 Hz), 2.68 (3 H, s), 3.49 (2 H, dd, *J*=19.30, 6.43 Hz), 3.54 - 3.62 (2 H, m), 4.04 (2 H, br dd, *J*=11.23, 4.11 Hz), 4.68 (1 H, tt, *J*=12.22, 4.21 Hz), 7.01 (1 H, t, *J*=6.43 Hz), 7.04 (1 H, d, *J*=2.46 Hz), 7.73 (1 H, d, *J*=2.46 Hz), 8.18 (1 H, d, *J*=1.92 Hz), 8.61 (1 H, d, *J*=1.92 Hz), 9.01 (1 H, s); ESIMS found for C₂₂H₂₆FN₇O *m/z* 424.2 (M+1).

**855**


[0543] 5-(2,3-Dimethyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(2-fluoro-2-methylpropyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **855**.

[0544] Yellow solid ((16 mg, 0.045 mmol, 18.6% yield). ¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 1.38 (6 H, d, *J*=21.40 Hz), 2.58 (3 H, s), 3.49 (2 H, dd, *J*=19.35, 6.45 Hz), 3.82 (3 H, s), 7.02 (1 H, t, *J*=6.45 Hz), 7.24 (1 H, d, *J*=2.74 Hz), 7.65 (1 H, d, *J*=2.74 Hz), 7.69 (1 H, d, *J*=8.51 Hz), 7.90 (1 H, d, *J*=8.23 Hz), 9.76 (1 H, s); ESIMS found for C₁₈H₂₀FN₇ *m/z* 354.2 (M+1).

**926**


[0545] 5-(3-Ethyl-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(2-fluoro-2-methylpropyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **926**.

[0546] Yellow solid (13 mg, 0.035 mmol, 13.5% yield). ^1H NMR (499 MHz, DMSO- d_6) δ ppm 1.38 (6 H, d, $J=21.40$ Hz), 1.41 (3 H, t, $J=7.10$ Hz), 2.60 (3 H, s), 3.49 (2 H, dd, $J=19.71$, 6.57 Hz), 4.33 (2 H, q, $J=7.12$ Hz), 7.01 (1 H, t, $J=6.30$ Hz), 7.24 (1 H, d, $J=2.74$ Hz), 7.66 (1 H, d, $J=2.19$ Hz), 7.69 (1 H, d, $J=8.21$ Hz), 7.91 (1 H, d, $J=8.21$ Hz), 9.71 (1 H, s); ESIMS found for $\text{C}_{19}\text{H}_{22}\text{FN}_7$ m/z 368.2 (M+1).

**1037**


[0547] N-(4,4-Difluorocyclohexyl)-5-(3-(2-fluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1037**.

[0548] Yellow solid (19 mg, 0.044 mmol, 19.5% yield). ^1H NMR (499 MHz, DMSO- d_6) δ ppm 1.58 - 1.72 (2 H, m), 1.86 - 2.03 (4 H, m), 2.03 - 2.16 (2 H, m), 2.59 (3 H, s), 3.76 - 3.90 (1 H, m), 4.66 (2 H, dt, $J=27.40$, 4.80 Hz), 4.87 (2 H, dt, $J=47.20$, 4.90 Hz), 6.92 (1 H, d, $J=7.67$ Hz), 7.23 (1 H, d, $J=2.74$ Hz), 7.65 (1 H, d, $J=2.74$ Hz), 7.71 (1 H, d, $J=8.21$ Hz), 7.93 (1 H, d, $J=8.21$ Hz), 9.67 (1 H, s); ESIMS found for $\text{C}_{21}\text{H}_{22}\text{F}_3\text{N}_7$ m/z 430.2 (M+1).

**1068**


[0549] N-(2-Fluoro-2-methylpropyl)-5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1068**.

[0550] Yellow solid (86 mg, 0.213 mmol, 38.3% yield). ^1H NMR (499 MHz, $\text{DMSO-}d_6$) δ ppm 1.38 (6 H, d, $J=21.40$ Hz), 2.61 (3 H, s), 3.50 (2 H, dd, $J=19.44, 6.30$ Hz), 4.84 (2 H, td, $J=16.02, 3.01$ Hz), 6.56 (1 H, tt, $J=54.90, 3.20$ Hz), 7.01 (1 H, t, $J=6.30$ Hz), 7.25 (1 H, d, $J=2.74$ Hz), 7.65 (1 H, d, $J=2.74$ Hz), 7.73 (1 H, d, $J=8.21$ Hz), 7.95 (1 H, d, $J=8.21$ Hz), 9.72 (1 H, s); ESIMS found for $\text{C}_{19}\text{H}_{20}\text{F}_3\text{N}_7$ m/z 404.2 ($\text{M}+1$).

**1088**


[0551] N-(3,3-Difluorocyclobutyl)-5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1088**.

[0552] Yellow solid (13 mg, 0.031 mmol, 12.5% yield). ^1H NMR (499 MHz, $\text{DMSO-}d_6$) δ ppm 2.61 (3 H, s), 2.63 - 2.74 (2 H, m), 2.95 - 3.04 (2 H, m), 4.02 - 4.15 (1 H, m), 4.84 (2 H, td, $J=16.02, 3.01$ Hz), 6.55 (1 H, tt, $J=54.40, 2.90$ Hz), 7.28 (1 H, d, $J=2.74$ Hz), 7.46 (1 H, d, $J=6.02$ Hz), 7.70 (1 H, d, $J=2.74$ Hz), 7.74 (1 H, d, $J=8.21$ Hz), 7.96 (1 H, d, $J=8.21$ Hz), 9.74 (1 H, s); ESIMS found for $\text{C}_{19}\text{H}_{17}\text{F}_4\text{N}_7$ m/z 420.15 ($\text{M}+1$).

**1091**


[0553] 5-(3-(2,2-Difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*cis*-3-methoxycyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1091**.

[0554] Yellow solid (5 mg, 0.012 mmol, 4.8% yield). ^1H NMR (499 MHz, $\text{DMSO-}d_6$) δ ppm 1.80 - 1.94 (2 H, m), 2.62 - 2.72 (2 H, m), 3.15 (3 H, s), 3.59 - 3.67 (1 H, m), 3.76 - 3.88 (1 H, m), 4.83 (2 H, td, $J=16.02, 3.01$ Hz), 6.55 (1 H, tt, $J=54.50, 3.10$ Hz), 7.20 (1 H, d, $J=7.12$ Hz), 7.24 (1 H, d, $J=2.74$ Hz), 7.63 (1 H, d, $J=2.74$ Hz), 7.73 (1 H, d, $J=8.21$ Hz), 7.95 (1 H, d, $J=8.21$ Hz), 9.70 (1 H, s); ESIMS found for $\text{C}_{20}\text{H}_{21}\text{F}_2\text{N}_7\text{O}$ m/z 414.2 ($\text{M}+1$).

**1108**


[0555] N-(4,4-Difluorocyclohexyl)-5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1108**.

[0556] Yellow solid (35 mg, 0.078 mmol, 25.8% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.57 - 1.72 (2 H, m), 1.86 - 2.03 (4 H, m), 2.03 - 2.15 (2 H, m), 3.77 - 3.88 (1 H, m), 4.83 (2 H, td, *J*=16.02, 3.01 Hz), 6.55 (1 H, tt, *J*=54.90, 3.30 Hz), 6.95 (1 H, d, *J*=7.67 Hz), 7.24 (1 H, d, *J*=2.74 Hz), 7.65 (1 H, d, *J*=2.74 Hz), 7.73 (1 H, d, *J*=8.76 Hz), 7.95 (1 H, d, *J*=8.21 Hz), 9.71 (1 H, s); ESIMS found for C₂₁H₂₁F₄N₇ *m/z* 448.2 (*M*+1).

**1109**


[0557] *cis*-4-((5-(3-(2,2-Difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclohexan-1-ol **1109**.

[0558] Yellow solid (9 mg, 0.021 mmol, 6.5% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.47 - 1.56 (2 H, m), 1.61 - 1.70 (4 H, m), 1.71 - 1.80 (2 H, m), 2.61 (3 H, s), 3.56 - 3.69 (1 H, m), 3.74 (1 H, br d, *J*=1.64 Hz), 4.36 (1 H, d, *J*=2.74 Hz), 4.83 (2 H, td, *J*=16.02, 3.01 Hz), 6.55 (1 H, tt, *J*=54.50, 3.00 Hz), 6.74 (1 H, d, *J*=7.67 Hz), 7.21 (1 H, d, *J*=2.74 Hz), 7.63 (1 H, d, *J*=2.74 Hz), 7.72 (1 H, d, *J*=8.76 Hz), 7.95 (1 H, d, *J*=8.21 Hz), 9.69 (1 H, s); ESIMS found for C₂₁H₂₃F₂N₇O *m/z* 428.2 (*M*+1).

**1110**

[0559] (1s,4s)-4-((5-(3-(2,2-Difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4] triazin-2-yl)amino)-1-methylcyclohexan-1-ol **1110**.


[0560] Pale yellow solid (70 mg, 0.159 mmol, 51.6% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.13 (3 H, s), 1.37 (2 H, td, *J*=13.00, 4.65 Hz), 1.59 (2 H, br d, *J*=12.59 Hz), 1.63 - 1.76 (4 H, m), 2.60 (3 H, s), 3.48 - 3.60 (1 H, m), 4.02 (1 H, s), 4.83 (2 H, td, *J*=16.02, 3.01 Hz), 6.55 (1 H, tt, *J*=54.85, 3.30 Hz), 6.72 (1 H, d, *J*=8.21 Hz), 7.21 (1 H, d, *J*=2.74 Hz), 7.62 (1 H, d, *J*=2.19 Hz), 7.72 (1 H, d, *J*=8.21 Hz), 7.94 (1 H, d, *J*=8.21 Hz), 9.69 (1 H, s); ESIMS found for C₂₂H₂₅F₂N₇O *m/z* 442.2 (M+1).



1111

[0561] 5-(3-(2,2-Difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*cis*-4-methoxycyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1111**.

[0562] Pale yellow solid (50 mg, 0.113 mmol, 36.8% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.45 - 1.55 (2 H, m), 1.56 - 1.66 (2 H, m), 1.66 - 1.74 (2 H, m), 1.80 - 1.91 (2 H, m), 2.61 (3 H, s), 3.23 (3 H, s), 3.33 - 3.39 (1 H, m), 3.60 - 3.72 (1 H, m), 4.83 (2 H, td, *J*=16.15, 2.74 Hz), 6.55 (1 H, tt, *J*=54.50, 3.30 Hz), 6.76 (1 H, d, *J*=8.21 Hz), 7.21 (1 H, d, *J*=2.74 Hz), 7.63 (1 H, d, *J*=2.74 Hz), 7.72 (1 H, d, *J*=8.21 Hz), 7.94 (1 H, d, *J*=8.21 Hz), 9.69 (1 H, s); ESIMS found for C₂₂H₂₅F₂N₇O *m/z* 442.2 (M+1).




1113

[0563] N-(*cis*-4-(Difluoromethoxy)cyclohexyl)-5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1113**.

[0564] Yellow solid (32 mg, 0.067 mmol, 24.2% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.59 - 1.73 (4 H, m), 1.74 - 1.83 (2 H, m), 1.88 (2 H, dt, *J*=9.38, 4.76 Hz), 2.61 (3 H, s), 3.71 (1 H, dt, *J*=7.80, 3.76 Hz), 4.30 (1 H, br s), 4.83 (2 H, td, *J*=15.95, 2.87 Hz), 6.55 (1 H, tt, *J*=54.60, 3.00 Hz), 6.73 (1 H, t, *J*=77.05 Hz), 6.88 (2 H, d, *J*=7.12 Hz), 7.22 (1 H, d, *J*=2.46 Hz),


7.64 (1 H, d, $J=2.46$ Hz), 7.72 (1 H, d, $J=8.21$ Hz), 7.95 (1 H, d, $J=8.49$ Hz), 9.70 (1 H, s); ESIMS found for $C_{22}H_{23}F_4N_7O$ m/z 478.2 (M+1).



1115

[0565] N-(*cis*-4-Ethoxycyclohexyl)-5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1115**.


[0566] Yellow solid (54 mg, 0.119 mmol, 53.6% yield). 1H NMR (499 MHz, DMSO- d_6) δ ppm 1.13 (3 H, t, $J=6.84$ Hz), 1.45 - 1.57 (2 H, m), 1.59 - 1.75 (4 H, m), 1.78 - 1.88 (2 H, m), 2.60 (3 H, s), 3.42 (2 H, q, $J=7.12$ Hz), 3.45 - 3.48 (1 H, m), 3.62 - 3.72 (1 H, m), 4.83 (2 H, td, $J=16.02$, 3.01 Hz), 6.55 (1 H, tt, $J=54.85$, 2.75 Hz), 6.77 (1 H, d, $J=7.67$ Hz), 7.21 (1 H, d, $J=2.74$ Hz), 7.63 (1 H, d, $J=2.74$ Hz), 7.72 (1 H, d, $J=8.21$ Hz), 7.94 (1 H, d, $J=8.21$ Hz), 9.69 (1 H, s); ESIMS found for $C_{23}H_{27}F_2N_7O$ m/z 456.25 (M+1).



1117

[0567] 5-(3-(2,2-Difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*cis*-4-(2-methoxyethoxy)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1117**.


[0568] Yellow solid (44 mg, 0.091 mmol, 44.6% yield). 1H NMR (499 MHz, DMSO- d_6) δ ppm 1.46 - 1.57 (2 H, m), 1.59 - 1.75 (4 H, m), 1.79 - 1.88 (2 H, m), 2.61 (3 H, s), 3.27 (3 H, s), 3.44 - 3.47 (2 H, m), 3.47 - 3.49 (1 H, m), 3.49 - 3.52 (2 H, m), 3.61 - 3.71 (1 H, m), 4.83 (2 H, td, $J=16.02$, 3.01 Hz), 6.55 (1 H, tt, $J=54.90$, 3.30 Hz), 6.79 (1 H, d, $J=7.67$ Hz), 7.22 (1 H, d, $J=2.74$ Hz), 7.63 (1 H, d, $J=2.74$ Hz), 7.72 (1 H, d, $J=8.21$ Hz), 7.95 (1 H, d, $J=8.21$ Hz), 9.69 (1 H, s); ESIMS found for $C_{24}H_{29}F_2N_7O_2$ m/z 486.2 (M+1).



1118

[0569] 5-(3-(2,2-Difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*trans*-4-(2-methoxyethoxy)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1118**.


[0570] Yellow solid (12 mg, 0.025 mmol, 12.2% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.17 - 1.41 (4 H, m), 2.01 (4 H, br dd, *J*=9.58, 2.46 Hz), 2.61 (3 H, s), 3.22 - 3.29 (1 H, m), 3.25 (3 H, s), 3.41 - 3.44 (2 H, m), 3.52 - 3.55 (2 H, m), 3.56 - 3.63 (1 H, m), 4.83 (2 H, td, *J*=16.02, 3.01 Hz), 6.55 (1 H, tt, *J*=54.60, 3.00 Hz), 6.75 (1 H, d, *J*=8.21 Hz), 7.22 (1 H, d, *J*=2.74 Hz), 7.66 (1 H, d, *J*=2.74 Hz), 7.72 (1 H, d, *J*=8.21 Hz), 7.95 (1 H, d, *J*=8.21 Hz), 9.69 (1 H, s); ESIMS found for C₂₄H₂₉F₂N₇O₂ *m/z* 486.2 (M+1).



1125

[0571] 5-(3-(2,2-Difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*cis*-4-morpholinocyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1125**.


[0572] Brown solid (65.0 mg, 0.131 mmol, 30.3% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.46 - 1.55 (2 H, m), 1.55 - 1.63 (2 H, m), 1.74 - 1.89 (4 H, m), 2.14 - 2.21 (1 H, m), 2.44 (4 H, br s), 2.61 (3 H, s), 3.58 (4 H, t, *J*=4.52 Hz), 3.75 - 3.83 (1 H, m), 4.83 (2 H, td, *J*=16.02, 3.01 Hz), 6.55 (1 H, tt, *J*=54.60, 3.30 Hz), 6.81 (1 H, d, *J*=7.12 Hz), 7.22 (1 H, d, *J*=2.74 Hz), 7.64 (1 H, d, *J*=2.46 Hz), 7.72 (1 H, d, *J*=8.49 Hz), 7.95 (1 H, d, *J*=8.21 Hz), 9.70 (1 H, s); ESIMS found for C₂₅H₃₀F₂N₈O *m/z* 497.3 (M+1).



1131

[0573] 5-(3-(2,2-Difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(1-methylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1131**.


[0574] Yellow solid (62 mg, 0.145 mmol, 45.1% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.50 - 1.66 (2 H, m), 1.88 - 1.99 (2 H, m), 2.10 (2 H, br t, *J*=10.95 Hz), 2.23 (3 H, s), 2.61 (3 H, s), 2.83 (2 H, br d, *J*=12.05 Hz), 3.54 - 3.65 (1 H, m), 4.83 (2 H, td, *J*=16.02, 3.01 Hz), 6.55 (1 H, tt, *J*=54.60, 3.00 Hz), 6.82 (1 H, d, *J*=7.67 Hz), 7.23 (1 H, d, *J*=2.74 Hz), 7.65 (1 H, d, *J*=2.19 Hz), 7.72 (1 H, d, *J*=8.21 Hz), 7.95 (1 H, d, *J*=8.21 Hz), 9.70 (1 H, s); ESIMS found for C₂₁H₂₄F₂N₈ *m/z* 427.2 (M+1).



1132

[0575] 5-(3-(2,2-Difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(tetrahydro-2H-pyran-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1132**.

[0576] Yellow solid (46.0 mg, 0.111 mmol, 33.1% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.47 - 1.62 (2 H, m), 1.91 (2 H, br dd, *J*=12.59, 2.19 Hz), 2.61 (3 H, s), 3.41 (2 H, td, *J*=11.64, 1.92 Hz), 3.76 - 3.85 (1 H, m), 3.86 - 3.93 (2 H, m), 4.83 (2 H, td, *J*=16.02, 3.01 Hz), 6.55 (1 H, tt, *J*=54.40, 3.20 Hz), 6.89 (1 H, d, *J*=8.21 Hz), 7.23 (1 H, d, *J*=2.74 Hz), 7.66 (1 H, d, *J*=2.74 Hz), 7.73 (1 H, d, *J*=8.76 Hz), 7.95 (1 H, d, *J*=8.21 Hz), 9.71 (1 H, s); ESIMS found for C₂₀H₂₁F₂N₇O *m/z* 414.2 (M+1).




1179

[0577] N-(4,4-Difluorocyclohexyl)-5-(3-(2-methoxyethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1179**.


[0578] Yellow solid (20 mg, 0.045 mmol, 20.0% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.56 - 1.73 (2 H, m), 1.87 - 2.04 (4 H, m), 2.04 - 2.15 (2 H, m), 2.59 (3 H, s), 3.25 (3 H, s), 3.77 (2 H, t, *J*=5.48 Hz), 3.80 - 3.88 (1 H, m), 4.47 (2 H, t, *J*=5.48 Hz), 6.95 (1 H, d, *J*=7.67

Hz), 7.23 (1 H, d, $J=2.74$ Hz), 7.65 (1 H, d, $J=2.74$ Hz), 7.69 (1 H, d, $J=8.21$ Hz), 7.91 (1 H, d, $J=8.76$ Hz), 9.70 (1 H, s); ESIMS found for $C_{22}H_{25}F_2N_7O$ m/z 442.2 (M+1).

**1210**


[0579] N-(2-Fluoro-2-methylpropyl)-5-(1-methyl-1H-benzod[1,2,3]triazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1210**.

[0580] Yellow solid (47 mg, 0.139 mmol, 53.0% yield). 1H NMR (499 MHz, DMSO- d_6) δ ppm 1.38 (6 H, d, $J=21.40$ Hz), 3.49 (2 H, dd, $J=19.16$, 6.30 Hz), 4.36 (3 H, s), 7.08 (1 H, s), 7.06 (1 H, d, $J=2.46$ Hz), 7.70 - 7.75 (2 H, m), 8.05 (1 H, d, $J=8.76$ Hz), 8.07 (1 H, s), 9.23 (1 H, s); ESIMS found for $C_{17}H_{18}FN_7$ m/z 340.15 (M+1).

**1281**


[0581] N-(2-Fluoro-2-methylpropyl)-5-(quinolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1281**.

[0582] Yellow solid (19.6 mg, 0.058 mmol). 1H NMR (400 MHz, DMSO- d_6) δ ppm 1.39 (6 H, d, $J=21.40$ Hz), 3.49 (2 H, dd, $J=19.20$, 6.32 Hz), 7.07 (1 H, t, $J=6.38$ Hz), 7.11 (1 H, d, $J=2.63$ Hz), 7.54 (1 H, dd, $J=8.25$, 4.13 Hz), 7.74 (1 H, d, $J=2.50$ Hz), 8.03 - 8.13 (2 H, m), 8.30 (1 H, d, $J=1.75$ Hz), 8.40 - 8.47 (1 H, m), 8.86 (1 H, dd, $J=4.19$, 1.56 Hz), 9.25 (1 H, s); ESIMS found for $C_{19}H_{18}FN_5$ m/z 336.2 (M+1).

**1309**


[0583] N-(*cis*-3-(2-Methoxyethoxy)cyclobutyl)-5-(quinolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1309**.

[0584] Yellow solid (48.0 mg, 0.123 mmol, 35.0% yield). ^1H NMR (499 MHz, $\text{DMSO-}d_6$) δ ppm 1.81 - 1.94 (2 H, m), 2.61 - 2.73 (2 H, m), 3.25 (3 H, s), 3.40 - 3.45 (4 H, m), 3.69 - 3.76 (1 H, m), 3.76 - 3.84 (1 H, m), 7.09 (1 H, d, $J=2.74$ Hz), 7.30 (1 H, d, $J=7.67$ Hz), 7.54 (1 H, dd, $J=8.49$, 4.11 Hz), 7.72 (1 H, d, $J=2.19$ Hz), 8.03 - 8.07 (1 H, m), 8.08 - 8.12 (1 H, m), 8.28 (1 H, d, $J=2.19$ Hz), 8.43 (1 H, dd, $J=8.21$, 1.64 Hz), 8.86 (1 H, dd, $J=4.38$, 1.64 Hz), 9.23 (1 H, s); ESIMS found for $\text{C}_{22}\text{H}_{23}\text{N}_5\text{O}_2$ m/z 390.2 ($\text{M}+1$).

**1322**


[0585] *cis*-4-((5-(Quinolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclohexan-1-ol **1322**.

[0586] Tan solid (11 mg, 0.031 mmol, 9.5% yield). ^1H NMR (499 MHz, $\text{DMSO-}d_6$) δ ppm 1.45 - 1.57 (2 H, m), 1.61 - 1.71 (4 H, m), 1.71 - 1.82 (2 H, m), 3.57 - 3.67 (1 H, m), 3.74 (1 H, br d, $J=2.19$ Hz), 4.36 (1 H, d, $J=2.74$ Hz), 6.82 (1 H, d, $J=7.67$ Hz), 7.07 (1 H, d, $J=2.19$ Hz), 7.54 (1 H, dd, $J=8.49$, 4.11 Hz), 7.72 (1 H, d, $J=2.19$ Hz), 8.03 - 8.07 (1 H, m), 8.08 - 8.12 (1 H, m), 8.28 (1 H, d, $J=2.19$ Hz), 8.39 - 8.46 (1 H, m), 8.85 (1 H, dd, $J=4.38$, 1.64 Hz), 9.22 (1 H, s); ESIMS found for $\text{C}_{21}\text{H}_{21}\text{N}_5\text{O}$ m/z 360.2 ($\text{M}+1$).

**1323**


[0587] (1*s*,4*s*)-1-Methyl-4-((5-(quinolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclohexan-1-ol **1323**.

[0588] Yellow solid (8 mg, 0.021 mmol, 5.1% yield). ^1H NMR (499 MHz, $\text{DMSO-}d_6$) δ ppm 1.13 (3 H, s), 1.37 (2 H, td, $J=13.14$, 4.38 Hz), 1.59 (2 H, br d, $J=12.05$ Hz), 1.63 - 1.76 (4 H, m), 3.46 - 3.59 (1 H, m), 4.01 (1 H, s), 6.80 (1 H, d, $J=7.67$ Hz), 7.07 (1 H, d, $J=2.74$ Hz), 7.49 - 7.58 (1 H, m), 7.71 (1 H, d, $J=2.19$ Hz), 8.03 - 8.07 (1 H, m), 8.08 - 8.12 (1 H, m), 8.28 (1 H, d, $J=2.19$ Hz), 8.42 (1 H, dd, $J=8.49$, 1.37 Hz), 8.85 (1 H, dd, $J=3.83$, 1.64 Hz), 9.21 (1 H, s); ESIMS found for $\text{C}_{22}\text{H}_{23}\text{N}_5\text{O}$ m/z 374.2 ($\text{M}+1$).

**1332**


[0589] *cis*-N¹-(5-(Quinolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclohexane-1,4-diamine **1332**.

[0590] Yellow solid (335 mg, 0.935 mmol, 79.7% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.48 - 1.56 (4 H, m), 1.58 - 1.66 (2 H, m), 1.74 - 1.88 (2 H, m), 2.79 - 2.89 (1 H, m), 3.68 (1 H, tq, *J*=7.39, 3.65 Hz), 6.72 (1 H, d, *J*=7.12 Hz), 7.08 (1 H, d, *J*=2.19 Hz), 7.54 (1 H, dd, *J*=8.21, 4.38 Hz), 7.73 (1 H, d, *J*=2.19 Hz), 8.03 - 8.07 (1 H, m), 8.08 - 8.12 (1 H, m), 8.28 (1 H, d, *J*=2.19 Hz), 8.43 (1 H, dd, *J*=8.49, 1.37 Hz), 8.86 (1 H, dd, *J*=4.38, 1.64 Hz), 9.22 (1 H, s); ESIMS found for C₂₁H₂₂N₆ *m/z* 359.2 (M+1).

**1336**


[0591] *cis*-N¹,N¹-Dimethyl-N⁴-(5-(quinolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclohexane-1,4-diamine **1336**.

[0592] Yellow solid (22 mg, 0.057 mmol, 35.2% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.48 (2 H, td, *J*=8.35, 4.11 Hz), 1.60 (2 H, ddd, *J*=12.46, 8.35, 3.83 Hz), 1.71 - 1.89 (4 H, m), 2.02 - 2.11 (1 H, m), 2.17 (6 H, s), 3.72 - 3.83 (1 H, m), 6.86 (1 H, d, *J*=7.12 Hz), 7.07 (1 H, d, *J*=2.19 Hz), 7.54 (1 H, dd, *J*=8.21, 3.83 Hz), 7.73 (1 H, d, *J*=2.74 Hz), 8.04 - 8.07 (1 H, m), 8.08 - 8.12 (1 H, m), 8.28 (1 H, d, *J*=2.19 Hz), 8.39 - 8.47 (1 H, m), 8.86 (1 H, dd, *J*=3.83, 1.64 Hz), 9.22 (1 H, s); ESIMS found for C₂₃H₂₆N₆ *m/z* 387.3 (M+1).

**1348**

[0593] N-(2-Methyl-2-azaspiro[3.3]heptan-6-yl)-5-(quinolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1348**.


[0594] Yellow solid (19 mg, 0.051 mmol, 18.3% yield). ^1H NMR (499 MHz, DMSO- d_6) δ ppm 2.03 - 2.12 (2 H, m), 2.16 (3 H, s), 2.42 - 2.49 (2 H, m), 3.06 (2 H, s), 3.17 (2 H, s), 4.05 (1 H, sxt, $J=7.78$ Hz), 7.09 (1 H, d, $J=2.19$ Hz), 7.24 (1 H, d, $J=7.12$ Hz), 7.54 (1 H, dd, $J=8.21$, 4.38 Hz), 7.74 (1 H, d, $J=2.19$ Hz), 8.03 - 8.06 (1 H, m), 8.08 - 8.11 (1 H, m), 8.28 (1 H, d, $J=2.19$ Hz), 8.42 (1 H, dd, $J=8.49$, 1.37 Hz), 8.86 (1 H, dd, $J=3.83$, 1.64 Hz), 9.22 (1 H, s); ESIMS found for $\text{C}_{22}\text{H}_{22}\text{N}_6$ m/z 371.1 (M+1).



1352

[0595] N-(2-Fluoro-2-methylpropyl)-5-(quinoxalin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1352**.


[0596] Yellow solid (38.22 mg, 0.114 mmol). ^1H NMR (400 MHz, DMSO- d_6) δ ppm 1.39 (6 H, d, $J=21.40$ Hz), 3.49 (2 H, dd, $J=19.20$, 6.44 Hz), 7.14 (1 H, t, $J=6.44$ Hz), 7.20 (1 H, d, $J=2.50$ Hz), 7.77 (1 H, d, $J=2.38$ Hz), 8.14 (1 H, d, $J=8.76$ Hz), 8.24 (1 H, dd, $J=8.82$, 1.69 Hz), 8.32 (1 H, d, $J=1.75$ Hz), 8.90 (1 H, d, $J=1.63$ Hz), 8.96 (1 H, d, $J=1.50$ Hz), 9.22 (1 H, s); ESIMS found for $\text{C}_{18}\text{H}_{17}\text{FN}_6$ m/z 337.1 (M+1).



1375


[0597] N-(*cis*-3-Methoxycyclobutyl)-5-(quinoxalin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1375**.

[0598] Yellow solid (32 mg, 0.092 mmol, 36.6% yield). ^1H NMR (499 MHz, DMSO- d_6) δ ppm 1.80 - 1.91 (2 H, m), 2.61 - 2.72 (2 H, m), 3.15 (3 H, s), 3.58 - 3.69 (1 H, m), 3.73 - 3.86 (1 H, m), 7.19 (1 H, d, $J=2.74$ Hz), 7.36 (1 H, d, $J=7.67$ Hz), 7.75 (1 H, d, $J=1.64$ Hz), 8.13 (1 H, d, $J=8.76$ Hz), 8.23 (1 H, dd, $J=8.76$, 1.64 Hz), 8.31 (1 H, d, $J=1.64$ Hz), 8.90 (1 H, d, $J=1.64$ Hz), 8.95 (1 H, d, $J=1.64$ Hz), 9.19 (1 H, s); ESIMS found for $\text{C}_{19}\text{H}_{18}\text{N}_6\text{O}$ m/z 347.2 (M+1).

**1376**


[0599] N-(*trans*-3-Methoxycyclobutyl)-5-(quinoxalin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1376**.

[0600] Yellow solid (28.54 mg, 0.082 mmol, % yield). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 2.18 - 2.35 (4 H, m), 3.16 (3 H, s), 3.96 - 4.07 (1 H, m), 4.16 - 4.27 (1 H, m), 7.19 (1 H, d, *J*=2.57 Hz), 7.78 (1 H, d, *J*=2.57 Hz), 8.09 - 8.17 (1 H, m), 8.19 - 8.26 (1 H, m), 8.30 (1 H, d, *J*=1.71 Hz), 8.89 (1 H, d, *J*=1.71 Hz), 8.95 (1 H, d, *J*=1.71 Hz), 9.20 (1 H, s); ESIMS found for C₁₉H₁₈N₆O *m/z* 347.1 (*M* + 1).

**1377**


[0601] N-(*trans*-3-(Methoxymethyl)cyclobutyl)-5-(quinoxalin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1377**.

[0602] Yellow solid (37 mg, 0.103 mmol, 42.6% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 2.07 - 2.18 (4 H, m), 2.39 - 2.47 (1 H, m), 3.29 (3 H, s), 3.41 (2 H, d, *J*=7.12 Hz), 4.25 (1 H, sxt, *J*=7.34 Hz), 7.18 (1 H, d, *J*=2.74 Hz), 7.39 (1 H, d, *J*=7.12 Hz), 7.77 (1 H, d, *J*=2.19 Hz), 8.13 (1 H, d, *J*=8.76 Hz), 8.23 (1 H, dd, *J*=8.49, 1.92 Hz), 8.31 (1 H, d, *J*=2.19 Hz), 8.89 (1 H, d, *J*=2.19 Hz), 8.95 (1 H, d, *J*=1.64 Hz), 9.19 (1 H, s); ESIMS found for C₂₀H₂₀N₆O *m/z* 361.2 (*M*+1).

**1392**


[0603] N-(4,4-Difluorocyclohexyl)-5-(quinoxalin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1392**.

[0604] Yellow solid (26 mg, 0.068 mmol, 30.2% yield). ^1H NMR (499 MHz, $\text{DMSO-}d_6$) δ ppm 1.59 - 1.71 (2 H, m), 1.86 - 2.04 (4 H, m), 2.04 - 2.16 (2 H, m), 3.76 - 3.88 (1 H, m), 7.11 (1 H, d, $J=7.67$ Hz), 7.19 (1 H, d, $J=2.74$ Hz), 7.77 (1 H, d, $J=2.19$ Hz), 8.13 (1 H, d, $J=8.76$ Hz), 8.23 (1 H, dd, $J=8.76$, 2.19 Hz), 8.32 (1 H, d, $J=2.19$ Hz), 8.90 (1 H, d, $J=1.64$ Hz), 8.95 (1 H, d, $J=1.64$ Hz), 9.21 (1 H, s); ESIMS found for $\text{C}_{20}\text{H}_{18}\text{F}_2\text{N}_6$ m/z 381.2 ($\text{M}+1$).

**1393**


[0605] *cis*-4-((5-(Quinoxalin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclohexan-1-ol **1393**.

[0606] Beige solid (7 mg, 0.019 mmol, 6.0% yield). ^1H NMR (499 MHz, $\text{DMSO-}d_6$) δ ppm 1.44 - 1.56 (2 H, m), 1.61 - 1.71 (4 H, m), 1.71 - 1.82 (2 H, m), 3.57 - 3.67 (1 H, m), 3.74 (1 H, br d, $J=2.19$ Hz), 4.36 (1 H, d, $J=2.74$ Hz), 6.89 (1 H, d, $J=7.67$ Hz), 7.17 (1 H, d, $J=2.74$ Hz), 7.75 (1 H, d, $J=2.74$ Hz), 8.13 (1 H, d, $J=8.76$ Hz), 8.23 (1 H, dd, $J=8.76$, 2.19 Hz), 8.31 (1 H, d, $J=2.19$ Hz), 8.89 (1 H, d, $J=2.19$ Hz), 8.95 (1 H, d, $J=1.64$ Hz), 9.18 (1 H, s); ESIMS found for $\text{C}_{20}\text{H}_{20}\text{N}_6\text{O}$ m/z 361.2 ($\text{M}+1$).

**1394**


[0607] (1s,4s)-1-Methyl-4-((5-(quinoxalin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclohexan-1-ol **1394**.

[0608] Yellow solid (30 mg, 0.080 mmol, 19.0% yield). ^1H NMR (499 MHz, $\text{DMSO-}d_6$) δ ppm 1.13 (3 H, s), 1.37 (2 H, td, $J=12.87$, 4.38 Hz), 1.59 (2 H, br d, $J=12.05$ Hz), 1.63 - 1.76 (4 H, m), 3.46 - 3.59 (1 H, m), 4.02 (1 H, s), 6.87 (1 H, d, $J=8.21$ Hz), 7.16 (1 H, d, $J=2.74$ Hz), 7.74 (1 H, d, $J=2.74$ Hz), 8.12 (1 H, d, $J=8.76$ Hz), 8.22 (1 H, dd, $J=8.76$, 2.19 Hz), 8.30 (1 H, d, $J=1.64$ Hz), 8.89 (1 H, d, $J=1.64$ Hz), 8.95 (1 H, d, $J=1.64$ Hz), 9.17 (1 H, s); ESIMS found for $\text{C}_{21}\text{H}_{22}\text{N}_6\text{O}$ m/z 375.2 ($\text{M}+1$).

**1395**


[0609] N-(*cis*-4-Methoxycyclohexyl)-5-(quinoxalin-6-yl)pyrrolo[2,1-*f*][1,2,4]triazin-2-amine **1395**.

[0610] Yellow solid (62 mg, 0.166 mmol, 39.9% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.46 - 1.55 (2 H, m), 1.56 - 1.67 (2 H, m), 1.67 - 1.75 (2 H, m), 1.81 - 1.90 (2 H, m), 3.23 (3 H, s), 3.33 - 3.37 (1 H, m), 3.59 - 3.71 (1 H, m), 6.93 (1 H, d, *J*=7.67 Hz), 7.17 (1 H, d, *J*=2.74 Hz), 7.75 (1 H, d, *J*=2.74 Hz), 8.13 (1 H, d, *J*=8.76 Hz), 8.23 (1 H, dd, *J*=8.76, 2.19 Hz), 8.31 (1 H, d, *J*=1.64 Hz), 8.89 (1 H, d, *J*=2.19 Hz), 8.95 (1 H, d, *J*=1.64 Hz), 9.18 (1 H, s); ESIMS found for C₂₁H₂₂N₆O *m/z* 375.2 (M+1).

**1418**


[0611] 5-(Quinoxalin-6-yl)-N-(2-oxaspiro[3.3]heptan-6-yl)pyrrolo[2,1-*f*][1,2,4]triazin-2-amine **1418**.

[0612] Pale yellow solid (26 mg, 0.073 mmol, 24.9% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 2.13 - 2.23 (2 H, m), 2.59 - 2.68 (2 H, m), 4.01 (1 H, sxt, *J*=7.67 Hz), 4.52 (2 H, s), 4.64 (2 H, s), 7.19 (1 H, d, *J*=2.19 Hz), 7.33 (1 H, d, *J*=7.12 Hz), 7.76 (1 H, d, *J*=2.19 Hz), 8.13 (1 H, d, *J*=8.76 Hz), 8.20 - 8.26 (1 H, m), 8.31 (1 H, d, *J*=2.19 Hz), 8.90 (1 H, d, *J*=1.64 Hz), 8.95 (1 H, d, *J*=2.19 Hz), 9.19 (1 H, s); ESIMS found for C₂₀H₁₈N₆O *m/z* 359.2 (M+1).

**1423**

[0613] N-(2-Fluoro-2-methylpropyl)-5-(4-methoxyquinazolin-6-yl)pyrrolo[2,1-*f*][1,2,4]triazin-2-amine **1423**.


[0614] Yellow solid (52.33 mg, 0.143 mmol). ^1H NMR (400 MHz, $\text{DMSO-}d_6$) δ ppm 1.38 (6 H, d, $J=21.40$ Hz), 3.49 (2 H, dd, $J=19.20$, 6.40 Hz), 4.18 (3 H, s), 7.10 - 7.14 (1 H, m), 7.11 (1 H, d, $J=2.63$ Hz), 7.75 (1 H, d, $J=2.50$ Hz), 7.97 (1 H, d, $J=9.63$ Hz), 8.27 - 8.31 (1 H, m), 8.28 (1 H, s), 8.79 (1 H, s), 9.11 (1 H, s); ESIMS found for $\text{C}_{19}\text{H}_{19}\text{FN}_6\text{O}$ m/z 367.2 ($\text{M}+1$).



1520

[0615] N-(*cis*-3-Ethoxycyclobutyl)-5-(1,8-naphthyridin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1520**.


[0616] Beige solid (62 mg, 0.172 mmol, 53.5% yield). ^1H NMR (499 MHz, $\text{DMSO-}d_6$) δ ppm 1.11 (3 H, t, $J=6.84$ Hz), 1.81 - 1.95 (2 H, m), 2.61 - 2.73 (2 H, m), 3.35 (2 H, q, $J=7.12$ Hz), 3.66 - 3.74 (1 H, m), 3.75 - 3.85 (1 H, m), 7.24 (1 H, d, $J=2.74$ Hz), 7.35 (1 H, d, $J=7.67$ Hz), 7.66 (1 H, dd, $J=8.21$, 4.38 Hz), 7.77 (1 H, d, $J=2.74$ Hz), 8.52 (1 H, dd, $J=8.21$, 2.19 Hz), 8.74 (1 H, d, $J=2.19$ Hz), 9.03 (1 H, dd, $J=4.11$, 1.92 Hz), 9.29 (1 H, s), 9.45 (1 H, d, $J=2.74$ Hz); ESIMS found for $\text{C}_{20}\text{H}_{20}\text{N}_6\text{O}$ m/z 361.2 ($\text{M}+1$).



1522


[0617] N-(*cis*-3-(2-Methoxyethoxy)cyclobutyl)-5-(1,8-naphthyridin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1522**.

[0618] Light brown solid (51 mg, 0.131 mmol, 44.6% yield). ^1H NMR (499 MHz, $\text{DMSO-}d_6$) δ ppm 1.81 - 1.94 (2 H, m), 2.61 - 2.73 (2 H, m), 3.25 (3 H, s), 3.40 - 3.46 (1 H, m), 3.43 (3 H, s), 3.70 - 3.76 (1 H, m), 3.76 - 3.83 (1 H, m), 7.24 (1 H, d, $J=2.74$ Hz), 7.36 (1 H, d, $J=7.67$ Hz), 7.64 - 7.70 (1 H, m), 7.77 (1 H, d, $J=2.74$ Hz), 8.52 (1 H, dd, $J=8.21$, 1.64 Hz), 8.74 (1 H, d, $J=2.74$ Hz), 9.00 - 9.07 (1 H, m), 9.29 (1 H, s), 9.45 (1 H, d, $J=2.19$ Hz); ESIMS found for $\text{C}_{21}\text{H}_{22}\text{N}_6\text{O}_2$ m/z 391.2 ($\text{M}+1$).

**1535**


[0619] *cis*-4-((5-(1,8-Naphthyridin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclohexan-1-ol **1535**.

[0620] Light orange solid (4.0 mg, 0.011 mmol, 62.5% yield). ^1H NMR (499 MHz, DMSO- d_6) δ ppm 1.44 - 1.58 (2 H, m), 1.62 - 1.71 (4 H, m), 1.71 - 1.81 (2 H, m), 3.56 - 3.69 (2 H, m), 3.75 (1 H, br s), 4.36 (1 H, br s), 6.90 (1 H, d, $J=7.67$ Hz), 7.22 (1 H, d, $J=2.74$ Hz), 7.61 - 7.71 (1 H, m), 7.77 (1 H, d, $J=2.74$ Hz), 8.52 (1 H, dd, $J=8.21$, 2.19 Hz), 8.74 (1 H, d, $J=2.74$ Hz), 9.03 (1 H, dd, $J=4.38$, 2.19 Hz), 9.28 (1 H, s), 9.45 (1 H, d, $J=2.74$ Hz); ESIMS found for $\text{C}_{20}\text{H}_{20}\text{N}_6\text{O}$ m/z 361.1 (M+1).

**1536**


[0621] (1*s*,4*s*)-4-((5-(1,8-Naphthyridin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclohexan-1-ol **1536**.

[0622] Beige solid (7 mg, 0.019 mmol, 4.1% yield). ^1H NMR (499 MHz, DMSO- d_6) δ ppm 1.13 (3 H, s), 1.37 (2 H, td, $J=12.87$, 4.38 Hz), 1.59 (2 H, br d, $J=12.05$ Hz), 1.63 - 1.76 (4 H, m), 3.46 - 3.59 (1 H, m), 4.02 (1 H, s), 6.88 (1 H, d, $J=7.67$ Hz), 7.21 (1 H, d, $J=2.74$ Hz), 7.65 (1 H, dd, $J=7.94$, 4.11 Hz), 7.76 (1 H, d, $J=2.74$ Hz), 8.51 (1 H, dd, $J=8.21$, 1.64 Hz), 8.73 (1 H, d, $J=2.74$ Hz), 9.03 (1 H, dd, $J=4.11$, 1.92 Hz), 9.27 (1 H, s), 9.45 (1 H, d, $J=2.74$ Hz); ESIMS found for $\text{C}_{21}\text{H}_{22}\text{N}_6\text{O}$ m/z 375.2 (M+1).

**1537**

[0623] N-(*cis*-4-Methoxycyclohexyl)-5-(1,8-naphthyridin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1537**.


[0624] Pale yellow solid (18 mg, 0.048 mmol, 15.6% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.46 - 1.56 (2 H, m), 1.57 - 1.67 (2 H, m), 1.67 - 1.76 (2 H, m), 1.81 - 1.91 (2 H, m), 3.23 (3 H, s), 3.34 - 3.39 (1 H, m), 3.60 - 3.72 (1 H, m), 6.93 (1 H, d, *J*=7.67 Hz), 7.22 (1 H, d, *J*=2.74 Hz), 7.66 (1 H, dd, *J*=7.94, 4.11 Hz), 7.77 (1 H, d, *J*=2.74 Hz), 8.52 (1 H, dd, *J*=7.94, 1.92 Hz), 8.74 (1 H, d, *J*=2.74 Hz), 9.03 (1 H, dd, *J*=4.11, 1.92 Hz), 9.28 (1 H, s), 9.45 (1 H, d, *J*=2.74 Hz); ESIMS found for C₂₁H₂₂N₆O *m/z* 375.2 (M+1).



1541

[0625] N-(*cis*-4-Ethoxycyclohexyl)-5-(1,8-naphthyridin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1541**.

[0626] Light brown solid (61 mg, 0.157 mmol, 61.2% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.13 (3 H, t, *J*=6.84 Hz), 1.44 - 1.57 (2 H, m), 1.60 - 1.75 (4 H, m), 1.78 - 1.88 (2 H, m), 3.42 (2 H, q, *J*=6.75 Hz), 3.45 - 3.48 (1 H, m), 3.58 - 3.71 (1 H, m), 6.93 (1 H, d, *J*=7.67 Hz), 7.22 (1 H, d, *J*=2.74 Hz), 7.65 (1 H, dd, *J*=7.94, 4.11 Hz), 7.77 (1 H, d, *J*=2.74 Hz), 8.51 (1 H, dd, *J*=8.21, 1.64 Hz), 8.73 (1 H, d, *J*=2.74 Hz), 9.03 (1 H, dd, *J*=4.11, 1.92 Hz), 9.28 (1 H, s), 9.45 (1 H, d, *J*=2.74 Hz); ESIMS found for C₂₂H₂₄N₆O *m/z* 389.2 (M+1).




1543

[0627] N-(*cis*-4-(2-Methoxyethoxy)cyclohexyl)-5-(1,8-naphthyridin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1543**


[0628] Dark yellow solid (85 mg, 0.203 mmol, 50.0% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.45 - 1.57 (2 H, m), 1.59 - 1.76 (4 H, m), 1.79 - 1.90 (2 H, m), 3.27 (3 H, s), 3.44 - 3.46 (2 H, m), 3.47 - 3.49 (1 H, m), 3.49 - 3.52 (2 H, m), 3.65 (1 H, qt, *J*=8.53, 4.45 Hz), 6.94 (1 H, d, *J*=7.67 Hz), 7.22 (1 H, d, *J*=2.74 Hz), 7.65 (1 H, dd, *J*=8.21, 4.38 Hz), 7.77 (1 H, d,

$J=2.74$ Hz), 8.51 (1 H, dd, $J=8.21$, 1.64 Hz), 8.73 (1 H, d, $J=2.74$ Hz), 9.03 (1 H, dd, $J=4.11$, 1.92 Hz), 9.28 (1 H, s), 9.45 (1 H, d, $J=2.74$ Hz); ESIMS found for $C_{23}H_{26}N_6O_2$ m/z 419.2 (M+1).

**1544**


[0629] N-(*trans*-4-(2-Methoxyethoxy)cyclohexyl)-5-(1,8-naphthyridin-3-yl)pyrrolo [2,1-f][1,2,4]triazin-2-amine **1544**.

[0630] Light brown solid (16 mg, 0.038 mmol, 23.5% yield). 1H NMR (499 MHz, DMSO- d_6) δ ppm 1.17 - 1.40 (4 H, m), 2.02 (4 H, br d, $J=9.31$ Hz), 3.22 - 3.28 (1 H, m), 3.25 (3 H, s), 3.43 (2 H, dd, $J=5.75$, 4.11 Hz), 3.54 (2 H, dd, $J=5.48$, 3.83 Hz), 3.56 - 3.62 (1 H, m), 6.92 (1 H, d, $J=7.67$ Hz), 7.23 (1 H, d, $J=2.74$ Hz), 7.61 - 7.69 (1 H, m), 7.80 (1 H, d, $J=2.74$ Hz), 8.52 (1 H, dd, $J=8.21$, 2.19 Hz), 8.74 (1 H, d, $J=2.19$ Hz), 9.03 (1 H, dd, $J=4.11$, 1.92 Hz), 9.29 (1 H, s), 9.45 (1 H, d, $J=2.19$ Hz); ESIMS found for $C_{23}H_{26}N_6O_2$ m/z 419.3 (M+1).

**1551**


[0631] N-(*cis*-4-Morpholinocyclohexyl)-5-(1,8-naphthyridin-3-yl)pyrrolo[2,1-f] [1,2,4]triazin-2-amine **1551**.

[0632] Yellow solid (25 mg, 0.058 mmol, 41.8% yield). 1H NMR (499 MHz, DMSO- d_6) δ ppm 1.47 - 1.56 (2 H, m), 1.56 - 1.64 (2 H, m), 1.75 - 1.82 (2 H, m), 1.82 - 1.90 (2 H, m), 2.12 - 2.23 (1 H, m), 2.45 (4 H, br s), 3.59 (4 H, t, $J=4.38$ Hz), 3.76 - 3.85 (1 H, m), 6.95 (1 H, d, $J=7.12$ Hz), 7.22 (1 H, d, $J=2.74$ Hz), 7.66 (1 H, dd, $J=7.94$, 4.11 Hz), 7.78 (1 H, d, $J=2.74$ Hz), 8.52 (1 H, dd, $J=7.94$, 1.92 Hz), 8.74 (1 H, d, $J=2.74$ Hz), 9.03 (1 H, dd, $J=4.11$, 1.92 Hz), 9.29 (1 H, s), 9.46 (1 H, d, $J=2.74$ Hz); ESIMS found for $C_{24}H_{27}N_7O$ m/z 430.3 (M+1).

**1557**

[0633] N-(1-Methylpiperidin-4-yl)-5-(1,8-naphthyridin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1557**.


[0634] Light brown solid (50 mg, 0.139 mmol, 28.8% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.13 (3 H, t, *J*=6.84 Hz), 1.44 - 1.57 (2 H, m), 1.60 - 1.75 (4 H, m), 1.78 - 1.88 (2 H, m), 3.42 (2 H, q, *J*=6.75 Hz), 3.45 - 3.48 (1 H, m), 3.58 - 3.71 (1 H, m), 6.93 (1 H, d, *J*=7.67 Hz), 7.22 (1 H, d, *J*=2.74 Hz), 7.65 (1 H, dd, *J*=7.94, 4.11 Hz), 7.77 (1 H, d, *J*=2.74 Hz), 8.51 (1 H, dd, *J*=8.21, 1.64 Hz), 8.73 (1 H, d, *J*=2.74 Hz), 9.03 (1 H, dd, *J*=4.11, 1.92 Hz), 9.28 (1 H, s), 9.45 (1 H, d, *J*=2.74 Hz); ESIMS found for C₂₀H₂₁N₇ *m/z* 360.2 (M+1).



1720

[0635] *cis*-3-((5-(3-(2,2-Difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclobutan-1-ol **1720**.

[0636] Pale yellow solid (43 mg, 0.108 mmol, 44.2% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.79 - 1.89 (2 H, m), 2.59 - 2.66 (2 H, m), 2.62 (3 H, s), 3.67 (1 H, dq, *J*=14.89, 7.54 Hz), 3.82 - 3.92 (1 H, m), 4.85 (2 H, td, *J*=15.88, 2.46 Hz), 6.55 (1 H, tt, *J*=54.60, 3.00 Hz), 7.16 (1 H, br d, *J*=7.12 Hz), 7.24 (1 H, d, *J*=2.74 Hz), 7.63 (1 H, d, *J*=2.46 Hz), 7.74 (1 H, d, *J*=8.49 Hz), 7.96 (1 H, d, *J*=8.21 Hz), 9.69 (1 H, s); ESIMS found for C₁₉H₁₉F₂N₇O *m/z* 400.2 (M+1).




1723

[0637] *cis*-3-((5-(Quinolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclobutan-1-ol **1723**.

[0638] Yellow solid (14 mg, 0.042 mmol, 11.4% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.79 - 1.90 (2 H, m), 2.58 - 2.68 (2 H, m), 3.60 - 3.72 (1 H, m), 3.8 - 3.93 (1 H, m), 5.06 (1 H, br d, *J*=4.38 Hz), 7.09 (1 H, d, *J*=2.74 Hz), 7.24 (1 H, d, *J*=7.12 Hz), 7.54 (1 H, dd, *J*=8.21, 4.38 Hz), 7.71 (1 H, d, *J*=2.19 Hz), 8.03 - 8.07 (1 H, m), 8.08 - 8.12 (1 H, m), 8.28 (1 H, d, *J*=2.19


Hz), 8.43 (1 H, dd, $J=8.49, 1.37$ Hz), 8.86 (1 H, dd, $J=4.38, 1.64$ Hz), 9.22 (1 H, s); ESIMS found for $C_{19}H_{17}N_5O$ m/z 332.2 (M+1).



1724

[0639] *cis*-3-((5-(Quinoxalin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino) cyclobutan-1-ol **1724**.


[0640] Yellow solid (16 mg, 0.048 mmol, 13.0% yield). 1H NMR (499 MHz, DMSO- d_6) δ ppm 1.79 - 1.89 (2 H, m), 2.58 - 2.69 (2 H, m), 3.61 - 3.72 (1 H, m), 3.82 - 3.93 (1 H, m), 5.06 (1 H, d, $J=6.02$ Hz), 7.18 (1 H, d, $J=2.74$ Hz), 7.30 (1 H, d, $J=7.12$ Hz), 7.74 (1 H, d, $J=2.74$ Hz), 8.13 (1 H, d, $J=8.76$ Hz), 8.23 (1 H, dd, $J=8.76, 2.19$ Hz), 8.31 (1 H, d, $J=1.64$ Hz), 8.90 (1 H, d, $J=1.64$ Hz), 8.95 (1 H, d, $J=2.19$ Hz), 9.19 (1 H, s); ESIMS found for $C_{18}H_{16}N_6O$ m/z 333.2 (M+1).



1732

[0641] 5-(Imidazo[1,2-a]pyrimidin-6-yl)-N-(2-azaspiro[3.3]heptan-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1732**.


[0642] Light yellow solid (90 mg, 0.260 mmol, 71.2% yield). 1H NMR (499 MHz, DMSO- d_6) δ ppm 2.17 - 2.27 (2 H, m), 2.60 - 2.70 (2 H, m), 3.95 (2 H, s), 4.00 - 4.10 (1 H, m), 4.05 (2 H, br s), 7.09 (1 H, d, $J=2.74$ Hz), 7.33 (1 H, d, $J=6.57$ Hz), 7.73 (1 H, d, $J=2.19$ Hz), 7.75 (1 H, d, $J=1.10$ Hz), 7.90 (1 H, d, $J=1.10$ Hz), 8.89 (1 H, d, $J=2.74$ Hz), 9.17 (1 H, s), 9.31 (1 H, d, $J=2.74$ Hz); ESIMS found for $C_{18}H_{18}N_8$ m/z 347.2 (M+1).



1747

[0643] 5-(Quinolin-6-yl)-N-(2-azaspiro[3.3]heptan-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1747**.


[0644] Yellow solid (45 mg, 0.126 mmol, 25.1% yield). ^1H NMR (499 MHz, DMSO- d_6) δ ppm 2.17 - 2.28 (2 H, m), 2.60 - 2.70 (2 H, m), 3.94 (2 H, s), 4.05 - 4.11 (1 H, m), 7.11 (1 H, d, $J=2.74$ Hz), 7.31 (1 H, d, $J=7.12$ Hz), 7.54 (1 H, dd, $J=8.21$, 3.83 Hz), 7.71 (1 H, d, $J=2.74$ Hz), 8.04 - 8.07 (1 H, m), 8.08 - 8.12 (1 H, m), 8.28 (1 H, d, $J=1.64$ Hz), 8.43 (1 H, dd, $J=8.21$, 1.09 Hz), 8.86 (1 H, dd, $J=4.38$, 1.64 Hz), 9.23 (1 H, s); ESIMS found for $\text{C}_{21}\text{H}_{20}\text{N}_6$ m/z 357.2 ($\text{M}+1$).



1756

[0645] 5-(Imidazo[1,2-a]pyrimidin-6-yl)-N-(2-isobutyl-2-azaspiro[3.3]heptan-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1756**.

[0646] Yellow solid (20 mg, 0.050 mmol, 43.0% yield). ^1H NMR (499 MHz, DMSO- d_6) δ ppm 0.82 (6 H, d, $J=6.57$ Hz), 1.48 (1 H, dq, $J=13.48$, 6.76, 6.76, 6.76, 6.76 Hz), 1.57 - 1.58 (1 H, m), 2.04 - 2.11 (2 H, m), 2.11 (2 H, d, $J=7.12$ Hz), 2.45 (2 H, ddd, $J=9.72$, 7.26, 2.74 Hz), 3.03 (2 H, s), 3.15 (2 H, s), 4.04 (1 H, sxt, $J=7.67$ Hz), 7.07 (1 H, d, $J=2.19$ Hz), 7.27 (1 H, d, $J=7.12$ Hz), 7.74 (1 H, d, $J=1.64$ Hz), 7.75 (1 H, d, $J=2.74$ Hz), 7.89 (1 H, d, $J=1.09$ Hz), 8.88 (1 H, d, $J=2.74$ Hz), 9.14 (1 H, s), 9.29 (1 H, d, $J=2.74$ Hz); ESIMS found for $\text{C}_{22}\text{H}_{26}\text{N}_8$ m/z 403.2 ($\text{M}+1$).




1771

[0647] N-(2-Isobutyl-2-azaspiro[3.3]heptan-6-yl)-5-(quinolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1771**.

[0648] Yellow solid (60 mg, 0.145 mmol, 51.8% yield). ^1H NMR (499 MHz, DMSO- d_6) δ ppm 0.82 (6 H, d, $J=7.12$ Hz), 1.48 (1 H, dq, $J=13.48$, 6.62, 6.62, 6.62, 6.62 Hz), 2.06 - 2.10 (2 H, m), 2.11 (2 H, d, $J=6.57$ Hz), 2.46 (2 H, ddd, $J=9.72$, 7.26, 2.74 Hz), 3.03 (2 H, s), 3.15 (2 H, s), 4.05 (1 H, sxt, $J=7.78$ Hz), 7.09 (1 H, d, $J=2.74$ Hz), 7.24 (1 H, d, $J=7.12$ Hz), 7.50 - 7.58 (1 H, m), 7.73 (1 H, d, $J=2.19$ Hz), 8.03 - 8.06 (1 H, m), 8.08 - 8.12 (1 H, m), 8.28 (1 H, d, $J=2.19$ Hz).


Hz), 8.42 (1 H, dd, $J=8.49, 1.37$ Hz), 8.85 (1 H, dd, $J=4.38, 1.64$ Hz), 9.22 (1 H, s); ESIMS found for $C_{25}H_{28}N_6$ m/z 413.25 (M+1).



1780

[0649] 5-(Imidazo[1,2-a]pyrimidin-6-yl)-N-(*cis*-4-(trifluoromethoxy)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1780**.


[0650] Brown solid (20 mg, 0.048 mmol, 18.2% yield). 1H NMR (499 MHz, DMSO- d_6) δ ppm 1.62 - 1.71 (2 H, m), 1.71 - 1.80 (2 H, m), 1.80 - 1.88 (2 H, m), 1.95 (2 H, br dd, $J=9.03, 4.65$ Hz), 3.65 - 3.77 (1 H, m), 4.57 - 4.65 (1 H, m), 7.02 (1 H, d, $J=7.12$ Hz), 7.07 (1 H, d, $J=2.74$ Hz), 7.73 - 7.76 (2 H, m), 7.89 (1 H, d, $J=1.09$ Hz), 8.88 (1 H, d, $J=2.74$ Hz), 9.16 (1 H, s), 9.30 (1 H, d, $J=2.74$ Hz); ESIMS found for $C_{19}H_{18}F_3N_7O$ m/z 418.2 (M+1).



1786

[0651] 5-(1-(2,2-Difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*cis*-4-(trifluoromethoxy) cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1786**.


[0652] Light brown solid (35 mg, 0.071 mmol, 26.8% yield). 1H NMR (499 MHz, DMSO- d_6) δ ppm 1.62 - 1.71 (2 H, m), 1.72 - 1.80 (2 H, m), 1.81 - 1.88 (2 H, m), 1.91 - 2.01 (2 H, m), 2.63 (3 H, s), 3.67 - 3.79 (1 H, m), 4.56 - 4.66 (1 H, m), 4.90 (2 H, td, $J=15.81, 2.87$ Hz), 6.53 (1 H, tt, $J=54.60, 3.00$ Hz), 6.93 (1 H, d, $J=7.94$ Hz), 6.98 (1 H, d, $J=2.46$ Hz), 7.71 (1 H, d, $J=2.46$ Hz), 8.23 (1 H, d, $J=1.92$ Hz), 8.66 (1 H, d, $J=2.19$ Hz), 9.12 (1 H, s); ESIMS found for $C_{22}H_{22}F_5N_7O$ m/z 496.2 (M+1).



1792

[0653] 5-(3-(2,2-Difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*cis*-4-(trifluoromethoxy)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1792**.


[0654] Pale yellow solid (33 mg, 0.067 mmol, 21.7% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.61 - 1.71 (2 H, m), 1.72 - 1.80 (2 H, m), 1.81 - 1.88 (2 H, m), 1.92 - 2.00 (2 H, m), 2.61 (3 H, s), 3.67 - 3.81 (1 H, m), 4.56 - 4.66 (1 H, m), 4.83 (2 H, td, *J*=16.02, 3.01 Hz), 6.55 (1 H, tt, *J*=54.85, 3.30 Hz), 6.90 (1 H, d, *J*=7.67 Hz), 7.23 (1 H, d, *J*=2.19 Hz), 7.64 (1 H, d, *J*=2.74 Hz), 7.73 (1 H, d, *J*=8.21 Hz), 7.95 (1 H, d, *J*=8.21 Hz), 9.71 (1 H, s); ESIMS found for C₂₂H₂₂F₅N₇O *m/z* 496.2 (M+1).



1798

[0655] 5-(1,8-Naphthyridin-3-yl)-N-(*cis*-4-(trifluoromethoxy)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1798**.

[0656] Yellow solid (13 mg, 0.030 mmol, 9.2% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.62 - 1.72 (2 H, m), 1.73 - 1.81 (2 H, m), 1.81 - 1.89 (2 H, m), 1.96 (2 H, br dd, *J*=9.03, 4.65 Hz), 3.66 - 3.79 (1 H, m), 4.56 - 4.66 (1 H, m), 7.06 (1 H, d, *J*=7.67 Hz), 7.23 (1 H, d, *J*=2.74 Hz), 7.66 (1 H, dd, *J*=7.94, 4.11 Hz), 7.78 (1 H, d, *J*=2.19 Hz), 8.52 (1 H, dd, *J*=8.21, 2.19 Hz), 8.74 (1 H, d, *J*=2.74 Hz), 9.03 (1 H, dd, *J*=4.38, 2.19 Hz), 9.30 (1 H, s), 9.45 (1 H, d, *J*=2.74 Hz); ESIMS found for C₂₁H₁₉F₃N₆O *m/z* 429.15 (M+1).




1801

[0657] N-(2-Fluoro-2-methylpropyl)-5-(3-isopropyl-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1801**.


[0658] Yellow solid (24 mg, 0.063 mmol, 21.3% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.38 (6 H, d, *J*=21.20 Hz), 1.72 (6 H, d, *J*=6.84 Hz), 2.61 (3 H, s), 3.49 (2 H, dd, *J*=19.30, 6.43 Hz), 4.84 (1 H, spt, *J*=6.80 Hz), 7.02 (1 H, t, *J*=6.30 Hz), 7.24 (1 H, d, *J*=2.74 Hz), 7.66 (1 H,

d, $J=2.74$ Hz), 7.69 (1 H, d, $J=8.49$ Hz), 7.89 (1 H, d, $J=8.21$ Hz), 9.66 (1 H, s); ESIMS found for $C_{20}H_{24}FN_7$ m/z 382.2 (M+1).

**1802**


[0659] 5-(Imidazo[1,2-a]pyrimidin-6-yl)-N-(*cis*-4-(methoxy- d_3)cyclohexyl)pyrrolo[2,1-f][1,2,4] triazin-2-amine **1802**.

[0660] Pale yellow solid (61 mg, 0.167 mmol, 54.6% yield). 1H NMR (499 MHz, DMSO- d_6) δ ppm 1.45 - 1.54 (2 H, m), 1.56 - 1.65 (2 H, m), 1.66 - 1.74 (2 H, m), 1.80 - 1.88 (2 H, m), 3.33 - 3.36 (1 H, m), 3.58 - 3.69 (1 H, m), 6.89 (1 H, d, $J=7.67$ Hz), 7.05 (1 H, d, $J=2.74$ Hz), 7.69 - 7.78 (2 H, m), 7.89 (1 H, d, $J=1.64$ Hz), 8.88 (1 H, d, $J=2.74$ Hz), 9.14 (1 H, s), 9.29 (1 H, d, $J=2.74$ Hz); ESIMS found for $C_{19}H_{18}[2H_3]N_7O$ m/z 367.2 (M+1).

**1803**

[0661] 5-(3-(2,2-Difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*cis*-4-(methoxy- d_3) cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1803**.


[0662] Pale yellow solid (50 mg, 0.113 mmol, 36.9% yield). 1H NMR (499 MHz, DMSO- d_6) δ ppm 1.45 - 1.55 (2 H, m), 1.56 - 1.66 (2 H, m), 1.66 - 1.74 (2 H, m), 1.81 - 1.89 (2 H, m), 2.60 (3 H, s), 3.33 - 3.37 (1 H, m), 3.59 - 3.74 (1 H, m), 4.83 (2 H, td, $J=16.02, 3.01$ Hz), 6.55 (1 H, tt, $J=54.85, 3.30$ Hz), 6.77 (1 H, d, $J=7.67$ Hz), 7.21 (1 H, d, $J=2.74$ Hz), 7.63 (1 H, d, $J=2.19$ Hz), 7.72 (1 H, d, $J=8.21$ Hz), 7.94 (1 H, d, $J=8.76$ Hz), 9.69 (1 H, s); ESIMS found for $C_{22}H_{22}[2H_3]F_2N_7O$ m/z 445.2 (M+1).



1813

[0663] *cis*-3-((5-(1-(2,2-Difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclobutan-1-ol **1813**.


[0664] Olive green solid (8 mg, 0.019 mmol, 5.8% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.28 (3 H, s), 1.97 - 2.08 (2 H, m), 2.32 - 2.43 (2 H, m), 2.62 (3 H, s), 3.73 (1 H, dq, *J*=15.06, 7.57 Hz), 4.85 - 4.95 (2 H, m), 4.94 (1 H, s), 6.52 (1 H, tt, *J*=54.60, 3.00 Hz), 6.98 (1 H, d, *J*=2.19 Hz), 7.17 (1 H, br d, *J*=6.57 Hz), 7.73 (1 H, d, *J*=2.19 Hz), 8.23 (1 H, d, *J*=1.64 Hz), 8.65 (1 H, d, *J*=1.64 Hz), 9.10 (1 H, s); ESIMS found for C₂₀H₂₁F₂N₇O *m/z* 414.2 (M+1).



1819

[0665] *cis*-3-((5-(3-(2,2-Difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclobutan-1-ol **1819**.

[0666] Olive green solid (13 mg, 0.031 mmol, 12.5% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.28 (3 H, s), 2.03 (2 H, td, *J*=9.03, 2.19 Hz), 2.33 - 2.42 (2 H, m), 2.61 (3 H, s), 3.74 (1 H, dq, *J*=15.33, 7.67 Hz), 4.83 (2 H, td, *J*=15.88, 2.74 Hz), 4.95 (1 H, s), 6.55 (1 H, tt, *J*=54.60, 3.00 Hz), 7.14 (1 H, d, *J*=7.12 Hz), 7.23 (1 H, d, *J*=2.74 Hz), 7.65 (1 H, d, *J*=2.74 Hz), 7.72 (1 H, d, *J*=8.21 Hz), 7.95 (1 H, d, *J*=8.21 Hz), 9.69 (1 H, s); ESIMS found for C₂₀H₂₁F₂N₇O *m/z* 414.2 (M+1).




1825

[0667] *cis*-3-((5-(1,8-Naphthyridin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclobutan-1-ol **1825**.

[0668] Brownish orange solid (6 mg, 0.017 mmol, 5.1% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.28 (3 H, s), 1.98 - 2.09 (2 H, m), 2.33 - 2.43 (2 H, m), 3.68 - 3.80 (1 H, m), 4.95 (1 H, br s), 7.23 (1 H, d, *J*=2.74 Hz), 7.31 (1 H, d, *J*=6.57 Hz), 7.66 (1 H, dd, *J*=8.21, 4.38 Hz), 7.79 (1 H, d, *J*=2.74 Hz), 8.52 (1 H, dd, *J*=8.21, 1.64 Hz), 8.74 (1 H, d, *J*=2.74 Hz), 9.03 (1


H, dd, $J=4.38, 2.19$ Hz), 9.28 (1 H, s), 9.45 (1 H, d, $J=2.74$ Hz); ESIMS found for $C_{19}H_{18}N_6O$ m/z 347. (M+1).



1828

[0669] *trans*-4-((5-(Imidazo[1,2-a]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclohexan-1-ol **1828**.


[0670] Beige solid (22 mg, 0.061 mmol, 24.7% yield). 1H NMR (499 MHz, DMSO- d_6) δ ppm 1.14 (3 H, s), 1.36 - 1.53 (4 H, m), 1.57 - 1.66 (2 H, m), 1.81 - 1.95 (2 H, m), 3.64 (1 H, br dd, $J=7.80, 3.97$ Hz), 4.24 (1 H, br s), 6.77 (1 H, d, $J=7.94$ Hz), 6.94 (1 H, d, $J=2.46$ Hz), 7.54 - 7.57 (1 H, m), 7.58 (1 H, d, $J=0.82$ Hz), 7.60 - 7.64 (1 H, m), 7.72 (1 H, d, $J=2.46$ Hz), 7.94 (1 H, s), 8.91 (1 H, s), 9.11 (1 H, s); ESIMS found for $C_{20}H_{22}N_6O$ m/z 363.2 (M+1).



1829

[0671] *cis*-4-((5-(3-Isobutyl-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclohexan-1-ol **1829**.


[0672] Yellow solid (18.4 mg, 0.042 mmol, 21.6% yield). 1H NMR (499 MHz, DMSO- d_6) δ ppm 0.95 (6 H, d, $J=6.57$ Hz), 1.13 (3 H, s), 1.37 (2 H, td, $J=12.87, 3.83$ Hz), 1.58 (2 H, br d, $J=12.05$ Hz), 1.63 - 1.68 (2 H, m), 1.69 - 1.76 (2 H, m), 2.25 - 2.39 (1 H, m), 2.58 (3 H, s), 3.45 - 3.58 (2 H, m), 4.01 (1 H, s), 4.10 (2 H, br d, $J=7.67$ Hz), 6.81 (1 H, br d, $J=7.67$ Hz), 7.20 (1 H, d, $J=2.74$ Hz), 7.62 (1 H, d, $J=2.74$ Hz), 7.68 (1 H, d, $J=8.21$ Hz), 7.90 (1 H, d, $J=8.76$ Hz), 9.70 (1 H, s); ESIMS found for $C_{24}H_{31}N_7O$ m/z 434.3 (M+1).



1830

[0673] (R)-2-((5-(3-(2,2-Difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)propan-1-ol **1830**.


[0674] Pale yellow solid (30 mg, 0.077 mmol, 37.5% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.17 (3 H, d, *J*=6.57 Hz), 2.61 (3 H, s), 3.37 (1 H, dt, *J*=10.54, 6.09 Hz), 3.52 (1 H, dt, *J*=10.47, 5.30 Hz), 3.78 - 3.92 (1 H, m), 4.71 (1 H, t, *J*=5.61 Hz), 4.83 (2 H, td, *J*=16.02, 2.74 Hz), 6.55 (1 H, tt, *J*=54.60, 3.00 Hz), 6.53 (1 H, d, *J*=8.21 Hz), 7.23 (1 H, d, *J*=2.46 Hz), 7.64 (1 H, d, *J*=2.46 Hz), 7.73 (1 H, d, *J*=8.49 Hz), 7.95 (1 H, d, *J*=8.21 Hz), 9.70 (1 H, s); ESIMS found for C₁₈H₁₉F₂N₇O *m/z* 388.2 (M+1).



1831

[0675] (R)-1-((5-(3-(2,2-Difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)propan-2-ol **1831**.

[0676] Light yellow solid (54 mg, 0.139 mmol, 46.7% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.11 (3 H, d, *J*=6.30 Hz), 2.61 (3 H, s), 3.18 (2 H, t, *J*=6.02 Hz), 3.83 - 3.95 (1 H, m), 4.72 (1 H, d, *J*=4.65 Hz), 4.84 (2 H, td, *J*=16.08, 2.87 Hz), 6.55 (1 H, tt, *J*=54.60, 3.00 Hz), 6.71 (1 H, t, *J*=5.89 Hz), 7.24 (1 H, d, *J*=2.46 Hz), 7.65 (1 H, d, *J*=2.46 Hz), 7.73 (1 H, d, *J*=8.21 Hz), 7.95 (1 H, d, *J*=8.21 Hz), 9.70 (1 H, s); ESIMS found for C₁₈H₁₉F₂N₇O *m/z* 388.2 (M+1).




1832

[0677] (S)-1-((5-(3-(2,2-Difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)propan-2-ol **1832**.

[0678] Light yellow solid (48 mg, 0.124 mmol, 38.6% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.11 (3 H, d, *J*=6.30 Hz), 2.61 (3 H, s), 3.17 (2 H, t, *J*=6.16 Hz), 3.83 - 3.95 (1 H, m), 4.72 (1 H, d, *J*=4.93 Hz), 4.84 (2 H, td, *J*=16.02, 2.74 Hz), 6.55 (1 H, tt, *J*=54.60, 3.00 Hz),


6.71 (1 H, t, $J=5.89$ Hz), 7.24 (1 H, d, $J=2.74$ Hz), 7.65 (1 H, d, $J=2.46$ Hz), 7.73 (1 H, d, $J=8.21$ Hz), 7.95 (1 H, d, $J=8.21$ Hz), 9.70 (1 H, s); ESIMS found for $C_{18}H_{19}F_2N_7O$ m/z 388.15 (M+1).



1833

[0679] 1-((5-(3-(2,2-Difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-2-methylpropan-2-ol **1833**.


[0680] Light yellow solid (43 mg, 0.107 mmol, 30.9% yield). 1H NMR (499 MHz, DMSO- d_6) δ ppm 1.17 (6 H, s), 2.61 (3 H, s), 3.24 (2 H, d, $J=6.02$ Hz), 4.56 (1 H, s), 4.84 (2 H, td, $J=15.95, 2.87$ Hz), 6.43 (1 H, t, $J=6.02$ Hz), 6.55 (1 H, tt, $J=54.60, 3.00$ Hz), 7.24 (1 H, d, $J=2.46$ Hz), 7.65 (1 H, d, $J=2.46$ Hz), 7.73 (1 H, d, $J=8.49$ Hz), 7.95 (1 H, d, $J=8.21$ Hz), 9.71 (1 H, s); ESIMS found for $C_{19}H_{21}F_2N_7O$ m/z 402.2 (M+1).



1834


[0681] (*cis*-3-((5-(3-(2,2-Difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclobutyl)methanol **1834**.

[0682] Light yellow solid (50 mg, 0.121 mmol, 44.9% yield). 1H NMR (499 MHz, DMSO- d_6) δ ppm 1.66 - 1.76 (2 H, m), 2.03 - 2.15 (1 H, m), 2.30 - 2.40 (2 H, m), 2.60 (3 H, s), 3.38 (2 H, t, $J=5.61$ Hz), 4.02 - 4.11 (1 H, m), 4.48 (1 H, t, $J=5.34$ Hz), 4.83 (2 H, td, $J=15.95, 2.87$ Hz), 6.55 (1 H, tt, $J=54.60, 3.00$ Hz), 7.11 (1 H, d, $J=7.39$ Hz), 7.23 (1 H, d, $J=2.74$ Hz), 7.63 (1 H, d, $J=2.46$ Hz), 7.72 (1 H, d, $J=8.21$ Hz), 7.95 (1 H, d, $J=8.49$ Hz), 9.69 (1 H, s); ESIMS found for $C_{20}H_{21}F_2N_7O$ m/z 414.2 (M+1).

**1835**


[0683] *trans*-3-((5-(3-(2,2-Difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclobutan-1-ol **1835**.

[0684] Light yellow solid (40 mg, 0.097 mmol, 45.6% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.29 (3 H, s), 1.96 - 2.04 (2 H, m), 2.30 - 2.38 (2 H, m), 2.61 (3 H, s), 3.07 (1 H, s), 4.26 (1 H, sxt, *J*=7.39 Hz), 4.83 (2 H, td, *J*=15.88, 2.74 Hz), 6.55 (1 H, tt, *J*=54.60, 3.00 Hz), 7.15 (1 H, d, *J*=6.84 Hz), 7.23 (1 H, d, *J*=2.74 Hz), 7.65 (1 H, d, *J*=2.46 Hz), 7.73 (1 H, d, *J*=8.49 Hz), 7.95 (1 H, d, *J*=8.49 Hz), 9.69 (1 H, s); ESIMS found for C₂₀H₂₁F₂N₇O *m/z* 414.2 (M+1).

**1836**


[0685] 5-(3-(2,2-Difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(7-methyl-7-azaspiro[3.5]nonan-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1836**.

[0686] Yellow solid (44 mg, 0.086 mmol, 97.1% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.54 (2 H, t, *J*=5.48 Hz), 1.61 (2 H, br t, *J*=5.20 Hz), 1.74 (2 H, br dd, *J*=11.50, 8.21 Hz), 2.16 (3 H, s), 2.13 - 2.39 (4 H, m), 2.23 (2 H, br t, *J*=9.86 Hz), 2.60 (3 H, s), 4.16 (1 H, dq, *J*=15.50, 7.79 Hz), 4.83 (2 H, td, *J*=16.02, 2.74 Hz), 6.55 (1 H, tt, *J*=54.60, 3.00 Hz), 7.17 (1 H, d, *J*=7.39 Hz), 7.23 (1 H, d, *J*=2.46 Hz), 7.65 (1 H, d, *J*=2.46 Hz), 7.72 (1 H, d, *J*=8.49 Hz), 7.95 (1 H, d, *J*=8.49 Hz), 9.69 (1 H, s); ESIMS found for C₂₄H₂₈F₂N₈ *m/z* 467.25 (M+1).

**1837**


[0687] (*cis*-4-((5-(3-(2,2-Difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclohexyl)methanol **1837**.

[0688] Light yellow solid (226 mg, 0.512 mmol, 59.3% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.43 - 1.55 (5 H, m), 1.56 - 1.65 (2 H, m), 1.68 - 1.78 (2 H, m), 2.61 (3 H, s), 3.29 - 3.33 (2 H, m), 3.76 - 3.86 (1 H, m), 4.39 (1 H, t, *J*=5.34 Hz), 4.82 (2 H, td, *J*=15.95, 2.87 Hz), 6.55 (1 H, tt, *J*=54.60, 3.00 Hz), 6.68 (1 H, d, *J*=7.39 Hz), 7.22 (1 H, d, *J*=2.46 Hz), 7.64 (1 H, d, *J*=2.46 Hz), 7.72 (1 H, d, *J*=8.21 Hz), 7.95 (1 H, d, *J*=8.21 Hz), 9.70 (1 H, s); ESIMS found for C₂₂H₂₅F₂N₇O *m/z* 442.2 (M+1).

**1838**

[0689] N-(*cis*-4-(2,2-Difluoroethoxy)cyclohexyl)-5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1838**.


[0690] Yellow solid (20 mg, 0.041 mmol, 20.4% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.51 - 1.60 (2 H, m), 1.60 - 1.68 (2 H, m), 1.68 - 1.75 (2 H, m), 1.81 - 1.92 (2 H, m), 2.61 (3 H, s), 3.57 - 3.62 (1 H, m), 3.63 - 3.71 (1 H, m), 3.67 (2 H, td, *J*=15.33, 3.83 Hz), 4.83 (2 H, td, *J*=16.02, 3.01 Hz), 6.13 (1 H, tt, *J*=55.12, 3.85 Hz), 6.55 (1 H, tt, *J*=54.60, 3.00 Hz), 6.81 (1 H, d, *J*=7.67 Hz), 7.22 (1 H, d, *J*=2.19 Hz), 7.63 (1 H, d, *J*=2.74 Hz), 7.72 (1 H, d, *J*=8.21 Hz), 7.95 (1 H, d, *J*=8.21 Hz), 9.70 (1 H, s); ESIMS found for C₂₃H₂₅F₄N₇O *m/z* 492.2 (M+1).

**1839**

[0691] 2-((*cis*-4-((5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclohexyl)oxy)ethan-1-ol **1839**.

[0692] Yellow solid (4 mg, 0.009 mmol, 4.0% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.47 - 1.56 (2 H, m), 1.62 - 1.73 (4 H, m), 1.80 - 1.88 (2 H, m), 2.61 (3 H, s), 3.41 (2 H, t, *J*=5.48 Hz), 3.49 (1 H, br d, *J*=2.74 Hz), 3.51 (2 H, t, *J*=5.50 Hz), 3.66 (1 H, td, *J*=8.21, 4.38 Hz), 4.52 (1 H, br s), 4.77 - 4.91 (2 H, m), 6.55 (2 H, tt, *J*=54.60, 3.00 Hz), 6.76 (1 H, d, *J*=7.67 Hz),


7.22 (1 H, d, $J=2.74$ Hz), 7.63 (1 H, d, $J=2.74$ Hz), 7.72 (1 H, d, $J=8.21$ Hz), 7.95 (1 H, d, $J=8.21$ Hz), 9.69 (1 H, s); ESIMS found for $C_{23}H_{27}F_2N_7O_2$ m/z 472.2 (M+1).



1840

[0693] *trans*-4-((5-(3-(2,2-Difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclohexan-1-ol **1840**.


[0694] Brownish orange solid (9 mg, 0.020 mmol, 6.6% yield). 1H NMR (499 MHz, DMSO- d_6) δ ppm 1.15 (3 H, s), 1.38 - 1.54 (4 H, m), 1.57 - 1.66 (2 H, m), 1.84 - 1.94 (2 H, m), 2.61 (3 H, s), 3.66 (1 H, dt, $J=7.87, 3.87$ Hz), 4.23 (1 H, s), 4.83 (2 H, td, $J=15.95, 2.87$ Hz), 6.55 (2 H, tt, $J=54.60, 3.00$ Hz), 6.71 (1 H, d, $J=7.94$ Hz), 7.22 (1 H, d, $J=2.74$ Hz), 7.65 (1 H, d, $J=2.46$ Hz), 7.72 (1 H, d, $J=8.49$ Hz), 7.95 (1 H, d, $J=8.49$ Hz), 9.69 (1 H, s); ESIMS found for $C_{22}H_{25}F_2N_7O$ m/z 442.2 (M+1).



1841


[0695] 5-(3-(2,2-Difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*cis*-4-((4-methylpiperazin-1-yl)methyl)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1841**.

[0696] Light brown solid (24 mg, 0.046 mmol, 21.2% yield). 1H NMR (499 MHz, DMSO- d_6) δ ppm 1.40 - 1.54 (4 H, m), 1.55 - 1.63 (2 H, m), 1.64 - 1.75 (3 H, m), 2.14 (3 H, s), 2.17 (2 H, d, $J=7.39$ Hz), 2.19 - 2.44 (8 H, m), 2.61 (3 H, s), 3.81 (1 H, br d, $J=2.74$ Hz), 4.82 (2 H, td, $J=15.88, 2.74$ Hz), 6.55 (1 H, tt, $J=54.60, 3.00$ Hz), 6.66 (1 H, d, $J=7.39$ Hz), 7.22 (1 H, d, $J=2.74$ Hz), 7.64 (1 H, d, $J=2.74$ Hz), 7.72 (1 H, d, $J=8.49$ Hz), 7.95 (1 H, d, $J=8.21$ Hz), 9.70 (1 H, s); ESIMS found for $C_{27}H_{35}F_2N_9$ m/z 524.35 (M+1).

**1842**


[0697] 5-(3-(2,2-Difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*cis*-4-(morpholinomethyl)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1842**.

[0698] Light brown solid (38 mg, 0.074 mmol, 34.5% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.42 - 1.56 (4 H, m), 1.56 - 1.65 (2 H, m), 1.65 - 1.76 (3 H, m), 2.18 (2 H, br d, *J*=7.12 Hz), 2.32 (4 H, br s), 2.61 (3 H, s), 3.57 (4 H, br t, *J*=4.24 Hz), 3.76 - 3.85 (1 H, m), 4.83 (2 H, td, *J*=15.81, 2.33 Hz), 6.55 (1 H, tt, *J*=54.60, 3.00 Hz), 6.67 (1 H, d, *J*=7.39 Hz), 7.22 (1 H, d, *J*=2.46 Hz), 7.64 (1 H, d, *J*=2.74 Hz), 7.72 (1 H, d, *J*=8.49 Hz), 7.95 (1 H, d, *J*=8.49 Hz), 9.70 (1 H, s); ESIMS found for C₂₆H₃₂F₂N₈O *m/z* 511.3 (M+1).

**1843**


[0699] Ethyl *cis*-4-((5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclohexane-1-carboxylate **1843**.

[0700] Yellow solid (22 mg, 0.046 mmol, 8.6% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.20 (3 H, t, *J*=7.12 Hz), 1.55 - 1.68 (4 H, m), 1.71 - 1.80 (2 H, m), 1.92 - 2.04 (2 H, m), 2.51 - 2.56 (1 H, m), 2.61 (3 H, s), 3.72 (1 H, br s), 4.09 (2 H, q, *J*=7.12 Hz), 4.83 (2 H, td, *J*=15.95, 2.87 Hz), 6.55 (1 H, tt, *J*=54.60, 3.00 Hz), 6.80 (1 H, d, *J*=7.39 Hz), 7.22 (1 H, d, *J*=2.74 Hz), 7.64 (1 H, d, *J*=2.46 Hz), 7.72 (1 H, d, *J*=8.49 Hz), 7.95 (1 H, d, *J*=8.49 Hz), 9.70 (1 H, s); ESIMS found for C₂₄H₂₇F₂N₇O₂ *m/z* 484.2 (M+1).

**1844**


[0701] N-(*trans*-4-((5-(3-(2,2-Difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclohexyl)acetamide **1844**.

[0702] Yellow solid (7 mg, 0.015 mmol, 8.1% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.20 - 1.30 (2 H, m), 1.31 - 1.42 (2 H, m), 1.79 (3 H, s), 1.83 (2 H, br d, *J*=10.95 Hz), 2.01 (2 H, br d, *J*=11.23 Hz), 2.61 (3 H, s), 3.46 - 3.53 (1 H, m), 3.54 - 3.61 (1 H, m), 4.83 (2 H, br t, *J*=15.74 Hz), 6.55 (1 H, tt, *J*=54.60, 3.00 Hz), 6.76 (1 H, d, *J*=7.94 Hz), 7.22 (1 H, d, *J*=2.46 Hz), 7.66 (1 H, d, *J*=2.19 Hz), 7.70 - 7.77 (2 H, m), 7.95 (1 H, d, *J*=8.49 Hz), 9.69 (1 H, s); ESIMS found for C₂₃H₂₆F₂N₈O *m/z* 469.2 (M+1).

**1845**

[0703] *cis*-4-((5-(3-(2,2-Difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-N,N-dimethylcyclohexane-1-carboxamide **1845**.


[0704] Yellow solid (55 mg, 0.114 mmol, 41.7% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.43 - 1.53 (2 H, m), 1.59 - 1.69 (2 H, m), 1.72 - 1.86 (2 H, m), 1.92 - 2.04 (2 H, m), 2.61 (3 H, s), 2.65 - 2.73 (1 H, m), 2.81 (3 H, s), 3.01 (3 H, s), 3.83 (1 H, br d, *J*=4.11 Hz), 4.75 - 4.91 (2 H, m), 6.55 (1 H, tt, *J*=54.60, 3.00 Hz), 6.76 (1 H, d, *J*=6.02 Hz), 7.22 (1 H, d, *J*=2.46 Hz), 7.64 (1 H, d, *J*=2.46 Hz), 7.72 (1 H, d, *J*=8.49 Hz), 7.95 (1 H, d, *J*=8.21 Hz), 9.71 (1 H, s); ESIMS found for C₂₄H₂₈F₂N₈O *m/z* 483.3 (M+1).

**1846**

[0705] 5-(3-(2,2-Difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(2-methyl-2-azaspiro[3.5]nonan-7-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1846**.

[0706] Yellow solid (35 mg, 0.075 mmol, 61.7% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.23 - 1.36 (2 H, m), 1.41 - 1.52 (2 H, m), 1.81 - 1.90 (4 H, m), 2.23 (3 H, s), 2.60 (3 H, s), 2.87 (2 H, s), 2.94 (2 H, s), 3.50 - 3.60 (1 H, m), 4.83 (2 H, td, *J*=16.02, 3.01 Hz), 6.55 (1 H, tt, *J*=54.60, 3.00 Hz), 6.69 (1 H, d, *J*=7.94 Hz), 7.22 (1 H, d, *J*=2.74 Hz), 7.64 (1 H, d, *J*=2.46 Hz),


7.72 (1 H, d, $J=8.49$ Hz), 7.94 (1 H, d, $J=8.21$ Hz), 9.69 (1 H, s); ESIMS found for $C_{24}H_{28}F_2N_8$ m/z 467.2 (M+1).



1847

[0707] 5-(3-(2,2-Difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(1,4-dioxaspiro[4.5]decan-8-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1847**.


[0708] Yellow solid (78 mg, 0.166 mmol, 48.9% yield). 1H NMR (499 MHz, $DMSO-d_6$) δ ppm 1.52 - 1.66 (4 H, m), 1.69 - 1.77 (2 H, m), 1.89 - 1.96 (2 H, m), 2.60 (3 H, s), 3.64 - 3.75 (1 H, m), 3.83 - 3.90 (4 H, m), 4.83 (2 H, td, $J=15.88$, 2.74 Hz), 6.55 (1 H, tt, $J=54.60$, 3.00 Hz), 6.84 (1 H, d, $J=7.94$ Hz), 7.22 (1 H, d, $J=2.46$ Hz), 7.65 (1 H, d, $J=2.74$ Hz), 7.72 (1 H, d, $J=8.49$ Hz), 7.95 (1 H, d, $J=8.21$ Hz), 9.69 (1 H, s); ESIMS found for $C_{23}H_{25}F_2N_7O_2$ m/z 470.25 (M+1).



1848


[0709] 5-(3-(2,2-Difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-((4-methylmorpholin-2-yl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1848**.

[0710] Dark yellow solid (46 mg, 0.104 mmol, 44.6% yield). 1H NMR (499 MHz, $DMSO-d_6$) δ ppm 1.71 - 1.81 (1 H, m), 1.98 (1 H, td, $J=11.23$, 3.29 Hz), 2.17 (3 H, s), 2.55 - 2.59 (1 H, m), 2.61 (3 H, s), 2.77 (1 H, br d, $J=11.23$ Hz), 3.18 - 3.27 (1 H, m), 3.30 - 3.37 (1 H, m), 3.50 (1 H, td, $J=11.16$, 2.33 Hz), 3.67 - 3.75 (1 H, m), 3.79 (1 H, dt, $J=9.72$, 1.44 Hz), 4.84 (2 H, td, $J=16.08$, 2.87 Hz), 6.55 (1 H, tt, $J=54.60$, 3.00 Hz), 6.91 (1 H, t, $J=6.02$ Hz), 7.25 (1 H, d, $J=2.74$ Hz), 7.67 (1 H, d, $J=2.74$ Hz), 7.73 (1 H, d, $J=8.49$ Hz), 7.95 (1 H, d, $J=8.21$ Hz), 9.71 (1 H, s); ESIMS found for $C_{21}H_{24}F_2N_8O$ m/z 443.2 (M+1).

**1849**


[0711] 5-(3-(2,2-Difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(1-(2-fluoroethyl)piperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1849**.

[0712] Yellow solid (2.4 mg, 0.005 mmol, 2.4% yield). ^1H NMR (499 MHz, DMSO- d_6) δ ppm 1.47 - 1.62 (2 H, m), 1.92 (2 H, br d, $J=10.95$ Hz), 2.07 - 2.19 (2 H, m), 2.62 (2 H, dt, $J=28.25, 4.90$ Hz), 2.61 (3 H, s), 2.89 (2 H, br d, $J=11.77$ Hz), 3.54 - 3.67 (1 H, m), 4.53 (2 H, dt, $J=48.00, 5.00$ Hz), 4.83 (2 H, td, $J=15.95, 2.60$ Hz), 6.55 (1 H, tt, $J=54.60, 3.00$ Hz), 6.82 (1 H, d, $J=7.94$ Hz), 7.23 (1 H, d, $J=2.74$ Hz), 7.65 (1 H, d, $J=2.46$ Hz), 7.73 (1 H, d, $J=8.21$ Hz), 7.95 (1 H, d, $J=8.49$ Hz), 9.70 (1 H, s); ESIMS found for $\text{C}_{22}\text{H}_{25}\text{F}_3\text{N}_8$ m/z 459.3 (M+1).

**1850**

[0713] 5-(3-(2,2-Difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(1-(2,2-difluoroethyl)piperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1850**.


[0714] Yellow solid (32 mg, 0.067 mmol, 28.1% yield). ^1H NMR (499 MHz, DMSO- d_6) δ ppm 1.49 - 1.62 (2 H, m), 1.91 (2 H, br d, $J=10.68$ Hz), 2.27 (2 H, br t, $J=10.13$ Hz), 2.61 (3 H, s), 2.68 - 2.81 (2 H, m), 2.91 (2 H, br d, $J=8.76$ Hz), 3.60 (1 H, br d, $J=4.11$ Hz), 4.83 (2 H, td, $J=16.02, 2.74$ Hz), 6.14 (1 H, tt, $J=55.12, 3.85$ Hz), 6.55 (1 H, tt, $J=54.60, 3.00$ Hz), 6.57 - 6.63 (1 H, m), 6.82 (1 H, br d, $J=6.84$ Hz), 7.23 (1 H, d, $J=2.46$ Hz), 7.65 (1 H, d, $J=2.74$ Hz), 7.73 (1 H, d, $J=8.21$ Hz), 7.95 (1 H, d, $J=8.49$ Hz), 9.70 (1 H, s); ESIMS found for $\text{C}_{22}\text{H}_{24}\text{F}_4\text{N}_8$ m/z 477.2 (M+1).

**257**

1851

[0715] 5-(3-(2,2-Difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(1-(3,3,3-trifluoropropyl)piperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1851**.


[0716] Yellow solid (7 mg, 0.014 mmol, 10.8% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.46 - 1.60 (2 H, m), 1.87 - 1.97 (2 H, m), 2.02 - 2.12 (2 H, m), 2.40 - 2.48 (2 H, m), 2.51 - 2.56 (2 H, m), 2.61 (3 H, s), 2.88 (2 H, br d, *J*=11.50 Hz), 3.55 - 3.67 (1 H, m), 4.83 (2 H, td, *J*=16.02, 2.74 Hz), 6.55 (1 H, tt, *J*=54.60, 3.00 Hz), 6.82 (1 H, d, *J*=7.94 Hz), 7.23 (1 H, d, *J*=2.74 Hz), 7.65 (1 H, d, *J*=2.46 Hz), 7.72 (1 H, d, *J*=8.49 Hz), 7.95 (1 H, d, *J*=8.21 Hz), 9.70 (1 H, s); ESIMS found for C₂₃H₂₅F₅N₈ *m/z* 509.2 (M+1).



1852

[0717] 2-(4-((5-(3-(2,2-Difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)piperidin-1-yl)ethan-1-ol **1852**.

[0718] Light brown solid (13 mg, 0.029 mmol, 12.9% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.47 - 1.61 (2 H, m), 1.91 (2 H, br d, *J*=10.95 Hz), 2.08 (2 H, br s), 2.33 - 2.44 (2 H, m), 2.61 (3 H, s), 2.88 (2 H, br d, *J*=10.68 Hz), 3.44 - 3.53 (2 H, m), 3.54 - 3.66 (1 H, m), 4.38 (1 H, br s), 4.83 (2 H, td, *J*=15.95, 2.87 Hz), 6.55 (1 H, tt, *J*=54.60, 3.00 Hz), 6.81 (1 H, br d, *J*=7.94 Hz), 7.23 (1 H, d, *J*=2.74 Hz), 7.65 (1 H, d, *J*=2.74 Hz), 7.72 (1 H, d, *J*=8.49 Hz), 7.95 (1 H, d, *J*=8.21 Hz), 9.69 (1 H, s); ESIMS found for C₂₂H₂₆F₂N₈O *m/z* 457.2 (M+1).




1853

[0719] 5-(3-(2,2-Difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-((3*S*,4*R*)-3-fluoro-1-methylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1853**.

[0720] Yellow solid (2 mg, 0.005 mmol, 3.7% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.68 - 1.75 (1 H, m), 1.93 (1 H, qd, *J*=12.14, 3.56 Hz), 2.03 - 2.10 (1 H, m), 2.12 - 2.25


(1 H, m), 2.19 (3 H, s), 2.61 (3 H, s), 2.81 (1 H, br d, $J=12.32$ Hz), 3.01 - 3.10 (1 H, m), 3.70 - 3.87 (1 H, m), 4.79 - 4.97 (2 H, m), 4.84 (1 H, br d, $J=3.01$ Hz), 6.55 (1 H, tt, $J=54.60, 3.00$ Hz), 6.86 (1 H, d, $J=7.94$ Hz), 7.26 (1 H, d, $J=2.74$ Hz), 7.66 (1 H, d, $J=2.74$ Hz), 7.74 (1 H, d, $J=8.49$ Hz), 7.95 (1 H, d, $J=8.49$ Hz), 9.73 (1 H, s); ESIMS found for $C_{21}H_{23}F_3N_8$ m/z 445.2 ($M+1$).



1854

[0721] 5-(3-(2,2-Difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-((3R,4R)-3-fluoro-1-methylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1854**.


[0722] Yellow solid (2.5 mg, 0.006 mmol, 4.6% yield). 1H NMR (499 MHz, DMSO- d_6) δ ppm 1.48 - 1.62 (1 H, m), 1.94 - 2.05 (2 H, m), 2.08 (1 H, dt, $J=9.92, 5.03$ Hz), 2.24 (3 H, s), 2.61 (3 H, s), 2.71 (1 H, br d, $J=11.22$ Hz), 3.05 - 3.12 (1 H, m), 3.77 - 3.92 (1 H, m), 4.59 (1 H, dtd, $J=49.90, 9.24, 9.24, 4.52$ Hz), 4.84 (2 H, td, $J=16.02, 2.74$ Hz), 6.55 (1 H, tt, $J=54.60, 3.00$ Hz), 7.04 (1 H, d, $J=8.76$ Hz), 7.25 (1 H, d, $J=2.46$ Hz), 7.67 (1 H, d, $J=2.74$ Hz), 7.74 (1 H, d, $J=8.49$ Hz), 7.95 (1 H, d, $J=8.49$ Hz), 9.71 (1 H, s); ESIMS found for $C_{21}H_{23}F_3N_8$ m/z 445.2 ($M+1$).



1855


[0723] 5-(3-(2,2-Difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-((3S,4S)-3-fluoro-1-methylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1855**.

[0724] Yellow solid (4 mg, 0.009 mmol, 7.4% yield). 1H NMR (499 MHz, DMSO- d_6) δ ppm 1.49 - 1.62 (1 H, m), 1.94 - 2.05 (2 H, m), 2.05 - 2.12 (1 H, m), 2.24 (3 H, s), 2.61 (3 H, s), 2.71 (1 H, br d, $J=11.22$ Hz), 3.06 - 3.11 (1 H, m), 3.78 - 3.91 (1 H, m), 4.59 (1 H, dtd, $J=49.65, 9.31, 9.31, 4.65$ Hz), 4.84 (2 H, td, $J=16.02, 2.74$ Hz), 6.55 (1 H, tt, $J=54.60, 3.00$ Hz), 7.03 (1 H, d, $J=8.49$ Hz), 7.25 (1 H, d, $J=2.74$ Hz), 7.67 (1 H, d, $J=2.46$ Hz), 7.73 (1 H, d, $J=8.21$ Hz), 7.95 (1 H, d, $J=8.21$ Hz), 9.71 (1 H, s); ESIMS found for $C_{21}H_{23}F_3N_8$ m/z 445.2 ($M+1$).

**1856**


[0725] 5-(3-(2,2-Difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-((3R,4S)-3-fluoro-1-methylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1856**.

[0726] Yellow solid (4 mg, 0.009 mmol, 8.4% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.67 - 1.78 (1 H, m), 1.93 (1 H, qd, *J*=12.18, 3.70 Hz), 2.04 - 2.12 (1 H, m), 2.13 - 2.26 (1 H, m), 2.20 (3 H, s), 2.61 (3 H, s), 2.81 (1 H, br d, *J*=11.23 Hz), 3.01 - 3.12 (1 H, m), 3.71 - 3.89 (1 H, m), 4.80 - 4.97 (2 H, m), 4.84 (1 H, d, *J*=3.01 Hz), 6.55 (1 H, tt, *J*=54.60, 3.00 Hz), 6.86 (1 H, d, *J*=7.94 Hz), 7.26 (1 H, d, *J*=2.74 Hz), 7.66 (1 H, d, *J*=2.46 Hz), 7.74 (1 H, d, *J*=8.49 Hz), 7.96 (1 H, d, *J*=8.21 Hz), 9.73 (1 H, s); ESIMS found for C₂₁H₂₃F₃N₈ *m/z* 445.2 (M+1).

**1857**


[0727] 1-(4-((5-(3-(2,2-Difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)piperidin-1-yl)ethan-1-one **1857**.

[0728] Yellow solid (5 mg, 0.011 mmol, 3.7% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.30 - 1.40 (1 H, m), 1.41 - 1.52 (1 H, m), 1.89 - 1.96 (1 H, m), 1.99 (1 H, br d, *J*=12.87 Hz), 2.02 (3 H, s), 2.61 (3 H, s), 2.73 - 2.84 (1 H, m), 3.12 - 3.23 (1 H, m), 3.79 - 3.84 (1 H, m), 3.84 - 3.90 (1 H, m), 4.28 (1 H, br d, *J*=13.96 Hz), 4.83 (2 H, td, *J*=16.02, 3.01 Hz), 6.55 (2 H, tt, *J*=54.60, 3.00 Hz), 6.91 (1 H, d, *J*=7.94 Hz), 7.24 (1 H, d, *J*=2.74 Hz), 7.66 (1 H, d, *J*=2.74 Hz), 7.73 (1 H, d, *J*=8.49 Hz), 7.95 (1 H, d, *J*=8.21 Hz), 9.71 (1 H, s); ESIMS found for C₂₂H₂₄F₂N₈O *m/z* 455.2 (M+1).

**1858**


[0729] 1-(4-((5-(3-(2,2-Difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)piperidin-1-yl)propan-1-one **1858**.

[0730] Light orange solid (5 mg, 0.011 mmol, 37.2% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.00 (3 H, t, *J*=7.39 Hz), 1.30 - 1.39 (1 H, m), 1.39 - 1.49 (1 H, m), 1.88 - 2.03 (2 H, m), 2.33 (2 H, q, *J*=7.39 Hz), 2.61 (3 H, s), 2.77 (1 H, br t, *J*=11.23 Hz), 3.14 (1 H, br t, *J*=11.64 Hz), 3.81 - 3.91 (2 H, m), 4.30 (1 H, br d, *J*=12.59 Hz), 4.83 (2 H, td, *J*=15.95, 2.87 Hz), 6.55 (1 H, tt, *J*=54.60, 3.00 Hz), 6.90 (1 H, d, *J*=7.94 Hz), 7.24 (1 H, d, *J*=2.74 Hz), 7.66 (1 H, d, *J*=2.74 Hz), 7.73 (1 H, d, *J*=8.21 Hz), 7.95 (1 H, d, *J*=8.49 Hz), 9.71 (1 H, s); ESIMS found for C₂₃H₂₆F₂N₈O *m/z* 469.2 (M+1).

**1859**


[0731] 1-(4-((5-(3-(2,2-Difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)piperidin-1-yl)-2-methylpropan-1-one **1859**.

[0732] Yellow solid (5 mg, 0.010 mmol, 5.1% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 0.98 - 1.04 (6 H, m), 1.28 - 1.39 (1 H, m), 1.40 - 1.50 (1 H, m), 1.94 (1 H, br d, *J*=10.95 Hz), 2.01 (1 H, br d, *J*=11.50 Hz), 2.61 (3 H, s), 2.72 - 2.80 (1 H, m), 2.87 - 2.94 (1 H, m), 3.18 (1 H, br t, *J*=11.64 Hz), 3.81 - 3.90 (1 H, m), 3.95 (1 H, br d, *J*=13.96 Hz), 4.28 - 4.39 (1 H, m), 4.83 (2 H, td, *J*=15.95, 2.60 Hz), 6.55 (2 H, tt, *J*=54.60, 3.00 Hz), 6.89 (1 H, d, *J*=7.94 Hz), 7.24 (1 H, d, *J*=2.74 Hz), 7.66 (1 H, d, *J*=2.74 Hz), 7.73 (1 H, d, *J*=8.21 Hz), 7.95 (1 H, d, *J*=8.21 Hz), 9.71 (1 H, s); ESIMS found for C₂₄H₂₈F₂N₈O *m/z* 483.2 (M+1).

**1860**


[0733] Cyclopropyl(4-((5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)piperidin-1-yl)methanone **1860**.

[0734] Yellow solid (19 mg, 0.040 mmol, 14.4% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 0.65 - 0.78 (4 H, m), 1.30 - 1.41 (1 H, m), 1.43 - 1.54 (1 H, m), 1.90 - 1.97 (1 H, m), 1.97 - 2.07 (2 H, m), 2.61 (3 H, s), 2.75 - 2.86 (1 H, m), 3.21 - 3.29 (1 H, m), 3.84 - 3.97 (1 H, m), 4.18 - 4.34 (2 H, m), 4.83 (2 H, td, *J*=15.95, 3.15 Hz), 6.55 (1 H, tt, *J*=54.60, 3.00 Hz), 6.91 (1 H, d, *J*=7.94 Hz), 7.24 (1 H, d, *J*=2.74 Hz), 7.67 (1 H, d, *J*=2.46 Hz), 7.73 (1 H, d, *J*=8.21 Hz), 7.95 (1 H, d, *J*=8.21 Hz), 9.71 (1 H, s); ESIMS found for C₂₄H₂₆F₂N₈O *m/z* 481.2 (M+1).

**1861**


[0735] 5-(3-(2,2-Difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(1-(methylsulfonyl)piperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1861**.

[0736] Off-white solid (58 mg, 0.118 mmol, 55.3% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.53 - 1.67 (2 H, m), 1.98 - 2.09 (2 H, m), 2.61 (3 H, s), 2.87 - 2.94 (2 H, m), 2.89 (3 H, s), 3.51 - 3.59 (2 H, m), 3.72 - 3.83 (1 H, m), 4.83 (2 H, td, *J*=16.08, 2.87 Hz), 6.55 (2 H, tt, *J*=54.60, 3.00 Hz), 6.97 (1 H, d, *J*=7.94 Hz), 7.25 (1 H, d, *J*=2.46 Hz), 7.65 (1 H, d, *J*=2.74 Hz), 7.74 (1 H, d, *J*=8.21 Hz), 7.95 (1 H, d, *J*=8.21 Hz), 9.72 (1 H, s); ESIMS found for C₂₁H₂₄F₂N₈O₂S *m/z* 491.2 (M+1).

**1862**


[0737] 5-(3-(2,2-Difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(1-(oxetan-3-yl)piperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1862**.

[0738] Yellow solid (31 mg, 0.066 mmol, 28.8% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.49 - 1.62 (2 H, m), 1.88 (2 H, br t, *J*=11.64 Hz), 1.93 (2 H, br d, *J*=12.32 Hz), 2.61 (3 H, s), 2.69 (2 H, br d, *J*=11.22 Hz), 3.39 (1 H, quin, *J*=6.43 Hz), 3.55 - 3.68 (1 H, m), 4.42 (2 H, t, *J*=6.02 Hz), 4.53 (2 H, t, *J*=6.57 Hz), 4.83 (2 H, td, *J*=15.95, 2.87 Hz), 6.55 (1 H, tt, *J*=54.60, 3.00 Hz), 6.85 (1 H, d, *J*=7.94 Hz), 7.23 (1 H, d, *J*=2.74 Hz), 7.65 (1 H, d, *J*=2.46 Hz), 7.72 (1 H, d, *J*=8.49 Hz), 7.95 (1 H, d, *J*=8.49 Hz), 9.70 (1 H, s); ESIMS found for C₂₃H₂₆F₂N₈O *m/z* 469.25 (M+1).

**1863**

[0739] (R)-5-(3-(2,2-Difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(tetrahydro-2H-pyran-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1863**.


[0740] Off-white solid (48 mg, 0.116 mmol, 53.1% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.50 - 1.65 (2 H, m), 1.67 - 1.78 (1 H, m), 1.95 - 2.05 (1 H, m), 2.61 (3 H, s), 3.14 (1 H, dd, *J*=10.40, 9.31 Hz), 3.27 - 3.32 (1 H, m), 3.72 - 3.83 (2 H, m), 3.90 - 4.01 (1 H, m), 4.83 (2 H, td, *J*=16.08, 2.87 Hz), 6.55 (1 H, tt, *J*=54.60, 3.00 Hz), 6.81 (1 H, d, *J*=7.94 Hz), 7.25 (1 H, d, *J*=2.74 Hz), 7.68 (1 H, d, *J*=2.46 Hz), 7.73 (1 H, d, *J*=8.49 Hz), 7.95 (1 H, d, *J*=8.49 Hz), 9.71 (1 H, s); ESIMS found for C₂₀H₂₁F₂N₇O *m/z* 414.2 (M+1).

**1864**

[0741] (S)-5-(3-(2,2-Difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(tetrahydro-2H-pyran-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1864**.


[0742] Off-white solid (59 mg, 0.143 mmol, 77.1% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.50 - 1.64 (2 H, m), 1.68 - 1.77 (1 H, m), 1.96 - 2.05 (1 H, m), 2.61 (3 H, s), 3.14 (1 H, dd, *J*=10.68, 9.31 Hz), 3.27 - 3.32 (1 H, m), 3.71 - 3.82 (2 H, m), 3.90 - 3.99 (1 H, m),

4.83 (2 H, td, $J=16.02, 3.01$ Hz), 6.55 (1 H, tt, $J=54.60, 3.00$ Hz), 6.81 (1 H, d, $J=7.94$ Hz), 7.25 (1 H, d, $J=2.74$ Hz), 7.67 (1 H, d, $J=2.46$ Hz), 7.73 (1 H, d, $J=8.49$ Hz), 7.95 (1 H, d, $J=8.21$ Hz), 9.71 (1 H, s); ESIMS found for $C_{20}H_{21}F_2N_7O$ m/z 414.2 (M+1).

**1865**


[0743] (3R,4R)-4-((5-(3-(2,2-Difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)tetrahydro-2H-pyran-3-ol **1865**.

[0744] Yellow solid (116 mg, 0.270 mmol, 84.6% yield). 1H NMR (499 MHz, DMSO- d_6) δ ppm 1.67 (1 H, br dd, $J=13.28, 3.15$ Hz), 1.84 - 2.00 (1 H, m), 2.61 (3 H, s), 3.42 (1 H, td, $J=11.36, 2.19$ Hz), 3.49 (1 H, dd, $J=11.77, 1.37$ Hz), 3.76 (1 H, dd, $J=11.77, 3.01$ Hz), 3.79 - 3.85 (2 H, m), 3.89 (1 H, ddt, $J=11.05, 7.43, 3.90, 3.90$ Hz), 4.84 (2 H, td, $J=15.95, 2.87$ Hz), 4.95 (1 H, d, $J=4.93$ Hz), 6.20 (1 H, d, $J=7.94$ Hz), 6.55 (1 H, tt, $J=54.60, 3.00$ Hz), 7.25 (1 H, d, $J=2.74$ Hz), 7.67 (1 H, d, $J=2.46$ Hz), 7.73 (1 H, d, $J=8.21$ Hz), 7.95 (1 H, d, $J=8.21$ Hz), 9.73 (1 H, s); ESIMS found for $C_{20}H_{21}F_2N_7O_2$ m/z 430.2 (M+1).

**1866**


[0745] (3S,4R)-4-((5-(3-(2,2-Difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)tetrahydro-2H-pyran-3-ol **1866**.

[0746] Yellow solid (70 mg, 0.163 mmol, 78.5% yield). 1H NMR (499 MHz, DMSO- d_6) δ ppm 1.44 - 1.58 (1 H, m), 1.98 - 2.09 (1 H, m), 2.61 (3 H, s), 3.07 (1 H, dd, $J=10.95, 9.86$ Hz), 3.34 - 3.39 (1 H, m), 3.45 - 3.58 (1 H, m), 3.64 - 3.75 (1 H, m), 3.78 - 3.88 (2 H, m), 4.84 (2 H, td, $J=16.08, 2.87$ Hz), 4.96 (1 H, d, $J=5.48$ Hz), 6.55 (1 H, tt, $J=54.60, 3.00$ Hz), 6.76 (1 H, d, $J=7.94$ Hz), 7.23 (1 H, d, $J=2.74$ Hz), 7.65 (1 H, d, $J=2.74$ Hz), 7.73 (1 H, d, $J=8.49$ Hz), 7.95 (1 H, d, $J=8.21$ Hz), 9.71 (1 H, s); ESIMS found for $C_{20}H_{21}F_2N_7O_2$ m/z 430.2 (M+1).

**1867**


[0747] 5-(3-(2,2-Difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-((3S,4R)-3-methoxytetrahydro-2H-pyran-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1867**.

[0748] Off-white solid (69 mg, 0.156 mmol, 75.0% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.47 - 1.61 (1 H, m), 1.96 - 2.06 (1 H, m), 2.61 (3 H, s), 3.11 (1 H, dd, *J*=11.23, 9.03 Hz), 3.28 (1 H, td, *J*=8.90, 4.38 Hz), 3.34 (3 H, s), 3.38 (1 H, td, *J*=11.29, 2.33 Hz), 3.78 - 3.91 (2 H, m), 4.03 (1 H, dd, *J*=11.23, 4.38 Hz), 4.84 (2 H, td, *J*=16.02, 3.01 Hz), 6.55 (1 H, tt, *J*=54.60, 3.00 Hz), 6.99 (1 H, d, *J*=8.21 Hz), 7.24 (1 H, d, *J*=2.74 Hz), 7.65 (1 H, d, *J*=2.74 Hz), 7.73 (1 H, d, *J*=8.21 Hz), 7.95 (1 H, d, *J*=8.21 Hz), 9.71 (1 H, s); ESIMS found for C₂₁H₂₃F₂N₇O₂ *m/z* 444.2 (M+1).

**1868**

[0749] *cis*-1-Methyl-4-((5-(2-methyl-3-(2,2,2-trifluoroethyl)-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclohexan-1-ol **1868**.


[0750] Yellow solid (12.1 mg, 0.026 mmol, 13.7% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.13 (3 H, s), 1.32 - 1.42 (2 H, m), 1.59 (2 H, br d, *J*=12.59 Hz), 1.63 - 1.77 (4 H, m), 2.63 (3 H, s), 3.48 - 3.61 (1 H, m), 4.02 (1 H, s), 5.30 - 5.39 (2 H, m), 6.75 (1 H, br d, *J*=7.67 Hz), 7.23 (1 H, br s), 7.63 (1 H, br s), 7.76 (1 H, br d, *J*=8.21 Hz), 7.97 (1 H, br d, *J*=8.21 Hz), 9.71 (1 H, s); ESIMS found for C₂₂H₂₄F₃N₇O *m/z* 460.2 (M+1).



1869

[0751] 3-(5-(2-((*cis*-4-Hydroxy-4-methylcyclohexyl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)-2-methyl-3H-imidazo[4,5-b]pyridin-3-yl)-2,2-dimethylpropanenitrile **1869**.


[0752] Yellow solid (17.2 mg, 0.038 mmol, 15.8% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.13 (3 H, s), 1.37 (2 H, td, *J*=13.07, 4.24 Hz), 1.50 (6 H, s), 1.58 (2 H, br d, *J*=12.05 Hz), 1.61 - 1.69 (2 H, m), 1.69 - 1.75 (2 H, m), 2.69 (3 H, s), 3.46 - 3.59 (1 H, m), 4.02 (1 H, br s), 4.57 (2 H, s), 6.78 (1 H, d, *J*=7.94 Hz), 7.22 (1 H, d, *J*=2.74 Hz), 7.63 (1 H, d, *J*=2.74 Hz), 7.74 (1 H, d, *J*=8.21 Hz), 7.94 (1 H, d, *J*=8.21 Hz), 9.79 (1 H, s); ESIMS found for C₂₅H₃₀N₈O *m/z* 459.3 (M+1).



1870

[0753] 1-(5-(2-((4,4-Difluorocyclohexyl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)-2-methyl-3H-imidazo[4,5-b]pyridin-3-yl)-2-methylpropan-2-ol **1870**.

[0754] Yellow solid (12.2 mg, 0.027 mmol, 13.7% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.19 (6 H, s), 1.57 - 1.71 (2 H, m), 1.87 - 2.03 (4 H, m), 2.04 - 2.16 (2 H, m), 2.64 (3 H, s), 3.74 - 3.88 (1 H, m), 4.23 (2 H, s), 4.86 (1 H, br s), 7.00 (1 H, d, *J*=7.67 Hz), 7.23 (1 H, d, *J*=2.19 Hz), 7.65 (1 H, d, *J*=2.74 Hz), 7.69 (1 H, d, *J*=8.76 Hz), 7.90 (1 H, d, *J*=8.21 Hz), 9.77 (1 H, s); ESIMS found for C₂₃H₂₇F₂N₇O *m/z* 456.3 (M+1).




1871

[0755] 2-Methyl-1-(2-methyl-5-(2-((tetrahydro-2H-pyran-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)-3H-imidazo[4,5-b]pyridin-3-yl)propan-2-ol **1871**.

[0756] Yellow solid (15.9 mg, 0.038 mmol, 17.3% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.19 (6 H, s), 1.46 - 1.60 (2 H, m), 1.91 (2 H, br dd, *J*=12.59, 2.19 Hz), 2.64 (3 H, s), 3.41 (2 H, td, *J*=11.50, 2.19 Hz), 3.72 - 3.85 (1 H, m), 3.85 - 3.94 (2 H, m), 4.23 (2 H, s), 4.86 (1 H, s), 6.95 (1 H, d, *J*=8.21 Hz), 7.22 (1 H, d, *J*=2.74 Hz), 7.65 (1 H, d, *J*=2.19 Hz), 7.68 (1


H, d, $J=8.21$ Hz), 7.89 (1 H, d, $J=8.21$ Hz), 9.76 (1 H, s); ESIMS found for $C_{22}H_{27}N_7O_2$ m/z 422.2 (M+1).



1872

[0757] 2-(5-(2-((*cis*-4-Hydroxy-4-methylcyclohexyl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)-2-methyl-3H-imidazo[4,5-b]pyridin-3-yl)-N,N-dimethylacetamide **1872**.


[0758] Yellow solid (23.9 mg, 0.052 mmol, 25.5% yield). 1H NMR (499 MHz, DMSO- d_6) δ ppm 1.13 (3 H, s), 1.37 (2 H, td, $J=13.07$, 4.24 Hz), 1.58 (2 H, br d, $J=12.32$ Hz), 1.62 - 1.69 (2 H, m), 1.69 - 1.75 (2 H, m), 2.47 (3 H, s), 2.89 (3 H, s), 3.23 (3 H, s), 3.46 - 3.58 (1 H, m), 4.01 (1 H, s), 5.27 (2 H, s), 6.77 (1 H, d, $J=7.94$ Hz), 7.18 (1 H, d, $J=2.74$ Hz), 7.61 (1 H, d, $J=2.46$ Hz), 7.67 (1 H, d, $J=8.49$ Hz), 7.91 (1 H, d, $J=8.21$ Hz), 9.59 (1 H, s); ESIMS found for $C_{24}H_{30}N_8O_2$ m/z 463.3 (M+1).



1873


[0759] 5-(3-(Azetidin-3-ylmethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(4,4-difluorocyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1873**.

[0760] Yellow solid (18.0 mg, 0.040 mmol, 34.3% yield). 1H NMR (499 MHz, DMSO- d_6) δ ppm 1.57 - 1.71 (2 H, m), 1.86 - 2.03 (4 H, m), 2.05 - 2.16 (2 H, m), 2.59 (3 H, s), 3.07 - 3.19 (2 H, m), 3.36 - 3.46 (1 H, m), 3.49 (2 H, br t, $J=7.39$ Hz), 3.78 - 3.90 (1 H, m), 4.54 (2 H, br d, $J=7.39$ Hz), 7.01 (1 H, d, $J=7.67$ Hz), 7.24 (1 H, d, $J=2.46$ Hz), 7.66 (1 H, d, $J=2.74$ Hz), 7.70 (1 H, d, $J=8.21$ Hz), 7.90 (1 H, d, $J=8.49$ Hz), 9.79 (1 H, s); ESIMS found for $C_{23}H_{26}F_2N_8$ m/z 453.2 (M+1).

**1875**


[0761] *cis*-1-Methyl-4-((5-(2-methyl-3-(oxetan-3-ylmethyl)-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclohexan-1-ol **1875**.

[0762] Off-white solid (19.9 mg, 0.045 mmol, 19.8% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.13 (3 H, s), 1.37 (2 H, td, *J*=13.00, 4.38 Hz), 1.59 (2 H, br d, *J*=12.05 Hz), 1.62 - 1.69 (2 H, m), 1.70 - 1.75 (2 H, m), 2.59 (3 H, s), 3.47 - 3.60 (2 H, m), 4.02 (1 H, br s), 4.53 (2 H, t, *J*=5.89 Hz), 4.62 - 4.67 (4 H, m), 6.78 (1 H, d, *J*=7.94 Hz), 7.21 (1 H, d, *J*=2.74 Hz), 7.63 (1 H, d, *J*=2.46 Hz), 7.69 (1 H, d, *J*=8.49 Hz), 7.90 (1 H, d, *J*=8.21 Hz), 9.74 (1 H, s); ESIMS found for C₂₄H₂₉N₇O₂ *m/z* 448.3 (M+1).

**1876**

[0763] 5-(1-(2,2-Difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*cis*-4-(methoxy-*d*₃)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1876**.


[0764] Light brown solid (62 mg, 0.140 mmol, 41.6% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.44 - 1.55 (2 H, m), 1.55 - 1.66 (2 H, m), 1.66 - 1.75 (2 H, m), 1.80 - 1.90 (2 H, m), 2.62 (3 H, s), 3.33 - 3.37 (1 H, m), 3.59 - 3.70 (1 H, m), 4.90 (2 H, td, *J*=15.95, 2.87 Hz), 6.52 (1 H, tt, *J*=54.60, 3.00 Hz), 6.80 (1 H, d, *J*=7.94 Hz), 6.97 (1 H, d, *J*=2.46 Hz), 7.71 (1 H, d, *J*=2.46 Hz), 8.23 (1 H, d, *J*=1.92 Hz), 8.66 (1 H, d, *J*=2.19 Hz), 9.10 (1 H, s); ESIMS found for C₂₂H₂₂[2H₃]F₂N₇O *m/z* 445.1 (M+1).



1877

[0765] N-(*cis*-4-(2,2-Difluoroethoxy)cyclohexyl)-5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1877**.


[0766] Yellow solid (27 mg, 0.055 mmol, 20.6% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.50 - 1.60 (2 H, m), 1.60 - 1.68 (2 H, m), 1.69 - 1.75 (2 H, m), 1.82 - 1.92 (2 H, m), 2.62 (3 H, s), 3.59 (1 H, br s), 3.62 - 3.69 (1 H, m), 3.67 (2 H, td, *J*=15.06, 3.83 Hz), 4.90 (2 H, td, *J*=15.88, 2.74 Hz), 6.13 (1 H, tt, *J*=55.12, 3.85 Hz), 6.52 (1 H, tt, *J*=54.60, 3.00 Hz), 6.83 (1 H, d, *J*=7.67 Hz), 6.97 (1 H, d, *J*=2.74 Hz), 7.71 (1 H, d, *J*=2.19 Hz), 8.23 (1 H, d, *J*=1.64 Hz), 8.66 (1 H, d, *J*=1.64 Hz), 9.10 (1 H, s); ESIMS found for C₂₃H₂₅F₄N₇O *m/z* 492.2 (M+1).



1878

[0767] 2-((*cis*-4-((5-(1-(2,2-Difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclohexyl)oxy)ethan-1-ol **1878**.

[0768] Olive green solid (19 mg, 0.040 mmol, 20.5% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.45 - 1.57 (2 H, m), 1.60 - 1.75 (4 H, m), 1.79 - 1.89 (2 H, m), 2.62 (3 H, s), 3.39 - 3.42 (2 H, m), 3.46 - 3.52 (1 H, m), 3.50 - 3.53 (2 H, m), 3.59 - 3.71 (1 H, m), 4.51 (1 H, t, *J*=5.48 Hz), 4.90 (2 H, td, *J*=15.88, 2.74 Hz), 6.52 (1 H, tt, *J*=54.60, 3.00 Hz), 6.78 (1 H, d, *J*=7.67 Hz), 6.97 (1 H, d, *J*=2.74 Hz), 7.71 (1 H, d, *J*=2.74 Hz), 8.23 (1 H, d, *J*=2.19 Hz), 8.66 (1 H, d, *J*=2.19 Hz), 9.10 (1 H, s); ESIMS found for C₂₃H₂₇F₂N₇O₂ *m/z* 472.2 (M+1).




1879

[0769] *trans*-4-((5-(1-(2,2-Difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclohexan-1-ol **1879**.


[0770] Olive green solid (38 mg, 0.086 mmol, 28.0% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.15 (3 H, s), 1.39 - 1.52 (4 H, m), 1.58 - 1.66 (2 H, m), 1.84 - 1.94 (2 H, m), 2.62 (3 H, s), 3.61 - 3.71 (1 H, m), 4.23 (1 H, s), 4.83 - 4.96 (2 H, m), 6.52 (1 H, tt, *J*=54.60, 3.00

Hz), 6.72 (1 H, d, $J=7.67$ Hz), 6.97 (1 H, d, $J=2.19$ Hz), 7.72 (1 H, d, $J=2.19$ Hz), 8.23 (1 H, d, $J=1.64$ Hz), 8.66 (1 H, d, $J=2.19$ Hz), 9.10 (1 H, s); ESIMS found for $C_{22}H_{25}F_2N_7O$ m/z 442.2 (M+1).

**1880**


[0771] 5-(1-(2,2-Difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(1,4-dioxaspiro[4.5]decan-8-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1880**.

[0772] Light yellow solid (36 mg, 0.077 mmol, 26.6% yield). 1H NMR (499 MHz, DMSO- d_6) δ ppm 1.51 - 1.67 (4 H, m), 1.70 - 1.78 (2 H, m), 1.88 - 1.97 (2 H, m), 2.62 (3 H, s), 3.61 - 3.75 (1 H, m), 3.81 - 3.92 (4 H, m), 4.90 (2 H, td, $J=15.81, 2.87$ Hz), 6.52 (1 H, tt, $J=54.60, 3.00$ Hz), 6.86 (1 H, d, $J=7.94$ Hz), 6.97 (1 H, d, $J=2.46$ Hz), 7.72 (1 H, d, $J=2.19$ Hz), 8.23 (1 H, d, $J=1.92$ Hz), 8.66 (1 H, d, $J=2.19$ Hz), 9.10 (1 H, s); ESIMS found for $C_{23}H_{25}F_2N_7O_2$ m/z 470.2 (M+1).

**1881**


[0773] 5-(1-(2,2-Difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(1-(2-fluoroethyl)piperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1881**.

[0774] Yellow solid (7 mg, 0.015 mmol, 13.1% yield). 1H NMR (499 MHz, DMSO- d_6) δ ppm 1.48 - 1.60 (2 H, m), 1.91 (2 H, br d, $J=13.42$ Hz), 2.12 (2 H, br t, $J=10.95$ Hz), 2.62 (2 H, dt, $J=28.52, 4.93$ Hz), 2.62 (3 H, s), 2.89 (2 H, br d, $J=11.77$ Hz), 3.53 - 3.65 (1 H, m), 4.53 (2 H, dt, $J=47.65, 4.95$ Hz), 4.90 (2 H, td, $J=15.81, 2.33$ Hz), 6.53 (1 H, tt, $J=54.40, 3.00$ Hz), 6.84 (1 H, d, $J=7.94$ Hz), 6.98 (1 H, d, $J=2.46$ Hz), 7.72 (1 H, d, $J=2.46$ Hz), 8.23 (1 H, d, $J=1.64$ Hz), 8.66 (1 H, d, $J=1.92$ Hz), 9.12 (1 H, s); ESIMS found for $C_{22}H_{25}F_3N_8$ m/z 459.2 (M+1).

**1882**


[0775] 5-(1-(2,2-Difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(1-(2,2-difluoroethyl)piperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1882**.

[0776] Yellow solid (18 mg, 0.038 mmol, 34.0% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.48 - 1.62 (2 H, m), 1.90 (2 H, br d, *J*=13.14 Hz), 2.22 - 2.32 (2 H, m), 2.62 (3 H, s), 2.73 (2 H, td, *J*=15.61, 4.38 Hz), 2.91 (2 H, br d, *J*=11.77 Hz), 3.53 - 3.65 (1 H, m), 4.85 - 4.97 (2 H, m), 6.14 (1 H, tt, *J*=55.95, 4.10 Hz), 6.53 (1 H, tt, *J*=54.60, 3.00 Hz), 6.85 (1 H, d, *J*=7.94 Hz), 6.98 (1 H, d, *J*=2.46 Hz), 7.72 (1 H, d, *J*=2.46 Hz), 8.23 (1 H, d, *J*=1.64 Hz), 8.66 (1 H, d, *J*=1.92 Hz), 9.12 (1 H, s); ESIMS found for C₂₂H₂₄F₄N₈ *m/z* 477.2 (M+1).

**1883**

[0777] 5-(1-(2,2-Difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(1-(3,3,3-trifluoropropyl)piperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1883**.


[0778] Dark yellow solid (13 mg, 0.026 mmol, 16.7% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.45 - 1.59 (2 H, m), 1.87 - 1.96 (2 H, m), 2.01 - 2.10 (2 H, m), 2.41 - 2.48 (2 H, m), 2.52 - 2.56 (2 H, m), 2.62 (3 H, s), 2.88 (2 H, br d, *J*=11.50 Hz), 3.52 - 3.65 (1 H, m), 4.84 - 4.97 (2 H, m), 6.53 (1 H, tt, *J*=54.60, 3.00 Hz), 6.84 (1 H, d, *J*=7.94 Hz), 6.98 (1 H, d, *J*=2.74 Hz), 7.72 (1 H, d, *J*=2.46 Hz), 8.23 (1 H, d, *J*=1.64 Hz), 8.66 (1 H, d, *J*=1.92 Hz), 9.11 (1 H, s); ESIMS found for C₂₃H₂₅F₅N₈ *m/z* 509.2 (M+1).



1884

[0779] 5-(1-(2,2-Difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1884**.


[0780] Dark yellow solid (16 mg, 0.036 mmol, 29.5% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.74 (1 H, br d, *J*=11.77 Hz), 1.91 - 2.03 (1 H, m), 2.07 - 2.35 (2 H, m), 2.25 (3 H, br s), 2.63 (3 H, s), 2.87 (1 H, br d, *J*=2.74 Hz), 3.09 - 3.23 (1 H, m), 3.73 - 3.92 (1 H, m), 4.86 - 5.02 (2 H, m), 4.91 (1 H, br d, *J*=2.74 Hz), 6.53 (1 H, tt, *J*=54.60, 3.00 Hz), 6.93 (1 H, br d, *J*=5.20 Hz), 7.02 (1 H, d, *J*=2.46 Hz), 7.73 (1 H, d, *J*=2.46 Hz), 8.24 (1 H, d, *J*=1.92 Hz), 8.67 (1 H, d, *J*=1.92 Hz), 9.15 (1 H, s); ESIMS found for C₂₁H₂₃F₃N₈ *m/z* 445.2 (M+1).



1885

[0781] 5-(1-(2,2-Difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-((3R,4R)-3-fluoro-1-methylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1885**.

[0782] Dark yellow solid (16 mg, 0.036 mmol, 29.5% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.46 - 1.66 (1 H, m), 1.94 - 2.16 (3 H, m), 2.26 (3 H, br s), 2.63 (3 H, s), 2.69 - 2.83 (1 H, m), 3.08 - 3.19 (1 H, m), 3.78 - 3.93 (1 H, m), 4.50 - 4.74 (1 H, m), 4.85 - 4.95 (2 H, m), 6.53 (1 H, tt, *J*=54.60, 3.00 Hz), 7.01 (1 H, d, *J*=2.46 Hz), 7.08 (1 H, br d, *J*=7.94 Hz), 7.75 (1 H, d, *J*=2.46 Hz), 8.24 (1 H, d, *J*=1.64 Hz), 8.67 (1 H, d, *J*=1.92 Hz), 9.14 (1 H, s); ESIMS found for C₂₁H₂₃F₃N₈ *m/z* 445.2 (M+1).




1886

[0783] 5-(1-(2,2-Difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-((3S,4S)-3-fluoro-1-methylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1886**.


[0784] Dark yellow solid (19 mg, 0.043 mmol, 35.1% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.47 - 1.66 (1 H, m), 1.93 - 2.16 (3 H, m), 2.26 (3 H, br s), 2.63 (3 H, s), 2.67 -

2.81 (1 H, m), 3.08 - 3.17 (1 H, m), 3.76 - 3.90 (1 H, m), 4.50 - 4.73 (1 H, m), 4.91 (2 H, td, $J=15.88$, 2.74 Hz), 6.53 (1 H, tt, $J=54.60$, 3.00 Hz), 7.01 (1 H, d, $J=2.46$ Hz), 7.08 (1 H, br d, $J=7.67$ Hz), 7.75 (1 H, d, $J=2.46$ Hz), 8.24 (1 H, d, $J=1.92$ Hz), 8.67 (1 H, d, $J=1.92$ Hz), 9.14 (1 H, s); ESIMS found for $C_{21}H_{23}F_3N_8$ m/z 445.2 (M+1).

**1887**

[0785] 5-(1-(2,2-Difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-((3R,4S)-3-fluoro-1-methylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1887**.


[0786] Dark yellow solid (16 mg, 0.036 mmol, 33.8% yield). 1H NMR (499 MHz, DMSO- d_6) δ ppm 1.71 (1 H, br dd, $J=8.49$, 3.83 Hz), 1.93 (1 H, qd, $J=12.14$, 3.56 Hz), 2.02 - 2.11 (1 H, m), 2.12 - 2.26 (1 H, m), 2.20 (3 H, s), 2.63 (3 H, s), 2.81 (1 H, br d, $J=11.22$ Hz), 3.00 - 3.12 (1 H, m), 3.70 - 3.86 (1 H, m), 4.87 (1 H, br d, $J=3.29$ Hz), 4.89 - 4.98 (2 H, m), 6.53 (1 H, tt, $J=54.60$, 3.00 Hz), 6.89 (1 H, d, $J=7.94$ Hz), 7.01 (1 H, d, $J=2.74$ Hz), 7.73 (1 H, d, $J=2.46$ Hz), 8.24 (1 H, d, $J=1.92$ Hz), 8.67 (1 H, d, $J=2.19$ Hz), 9.15 (1 H, s); ESIMS found for $C_{21}H_{23}F_3N_8$ m/z 445.2 (M+1).

**1888**

[0787] 1-(4-((5-(1-(2,2-Difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)piperidin-1-yl)-2-methylpropan-1-one **1888**.

[0788] Light brown solid (5 mg, 0.010 mmol, 5.1% yield). 1H NMR (499 MHz, DMSO- d_6) δ ppm 0.94 - 1.06 (6 H, m), 1.34 (1 H, q, $J=10.22$ Hz), 1.44 (1 H, q, $J=10.31$ Hz), 1.94 (1 H, br d, $J=12.32$ Hz), 2.01 (1 H, br d, $J=11.77$ Hz), 2.63 (3 H, s), 2.71 - 2.81 (1 H, m), 2.90 (1 H, spt, $J=6.71$ Hz), 3.17 (1 H, br t, $J=12.05$ Hz), 3.79 - 3.91 (1 H, m), 3.95 (1 H, br d, $J=12.87$ Hz), 4.32 (1 H, br d, $J=12.59$ Hz), 4.91 (2 H, td, $J=15.74$, 2.46 Hz), 6.53 (1 H, tt, $J=54.60$, 3.00 Hz),


6.92 (1 H, d, $J=7.94$ Hz), 7.00 (1 H, d, $J=2.46$ Hz), 7.74 (1 H, d, $J=2.46$ Hz), 8.24 (1 H, d, $J=1.92$ Hz), 8.66 (1 H, d, $J=2.19$ Hz), 9.13 (1 H, s); ESIMS found for $C_{24}H_{28}F_2N_8O$ m/z 483.2 (M+1).



1889

[0789] 5-(1-(2,2-Difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(1-(oxetan-3-yl)piperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1889**.


[0790] Dark yellow solid (29 mg, 0.062 mmol, 54.5% yield). 1H NMR (499 MHz, DMSO- d_6) δ ppm 1.47 - 1.61 (2 H, m), 1.87 (2 H, br t, $J=11.36$ Hz), 1.93 (2 H, br d, $J=10.95$ Hz), 2.62 (3 H, s), 2.69 (2 H, br d, $J=10.13$ Hz), 3.35 - 3.43 (1 H, m), 3.54 - 3.67 (1 H, m), 4.43 (2 H, br t, $J=5.89$ Hz), 4.53 (2 H, t, $J=6.43$ Hz), 4.84 - 4.97 (2 H, m), 6.53 (1 H, tt, $J=54.60, 3.00$ Hz), 6.88 (1 H, br d, $J=7.67$ Hz), 6.98 (1 H, d, $J=2.46$ Hz), 7.72 (1 H, d, $J=2.46$ Hz), 8.23 (1 H, d, $J=1.64$ Hz), 8.66 (1 H, d, $J=2.19$ Hz), 9.12 (1 H, s); ESIMS found for $C_{23}H_{26}F_2N_8O$ m/z 469.3 (M+1).



1890

[0791] *trans*-4-((5-(1-(2,2-Difluoroethyl)-1H-benzo[d][1,2,3]triazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclohexan-1-ol **1890**.


[0792] Yellow solid (5 mg, 0.012 mmol, 8.9% yield). 1H NMR (499 MHz, DMSO- d_6) δ ppm 1.15 (3 H, s), 1.39 - 1.53 (4 H, m), 1.57 - 1.66 (2 H, m), 1.84 - 1.93 (2 H, m), 3.65 (1 H, br dd, $J=8.35, 3.97$ Hz), 4.24 (1 H, s), 5.38 (2 H, td, $J=15.54, 3.15$ Hz), 6.62 (1 H, tt, $J=54.30, 3.15$ Hz), 6.79 (1 H, d, $J=7.94$ Hz), 7.03 (1 H, d, $J=2.74$ Hz), 7.73 - 7.78 (2 H, m), 8.10 (1 H, d, $J=8.49$ Hz), 8.14 (1 H, s), 9.19 (1 H, s); ESIMS found for $C_{21}H_{23}F_2N_7O$ m/z 428.2 (M+1).



1891

[0793] *trans*-1-Methyl-4-((5-(pyrazolo[1,5-a]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclohexan-1-ol **1891**.


[0794] Yellow solid (80 mg, 0.221 mmol, 71.8% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.14 (3 H, s), 1.36 - 1.52 (4 H, m), 1.57 - 1.66 (2 H, m), 1.82 - 1.94 (2 H, m), 3.64 (1 H, br dd, *J*=7.67, 3.56 Hz), 4.24 (1 H, s), 6.59 (1 H, d, *J*=1.92 Hz), 6.83 (1 H, d, *J*=7.94 Hz), 7.05 (1 H, d, *J*=2.46 Hz), 7.21 (1 H, dd, *J*=7.26, 1.78 Hz), 7.72 (1 H, d, *J*=2.46 Hz), 7.98 (1 H, s), 7.98 (1 H, s), 8.67 (1 H, d, *J*=7.12 Hz), 9.16 (1 H, s); ESIMS found for C₂₀H₂₂N₆O *m/z* 363.2 (M+1).



1892

[0795] 5-(3-(2,2-Difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*cis*-3-morpholinocyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1893**.


[0796] Yellow solid (37 mg, 0.079 mmol, 11.4% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 2.02 - 2.13 (2 H, m), 2.18 - 2.35 (6 H, m), 2.61 (3 H, s), 2.79 - 2.87 (1 H, m), 3.60 (4 H, br s), 4.12 - 4.21 (1 H, m), 4.84 (2 H, td, *J*=15.95, 2.87 Hz), 6.55 (1 H, tt, *J*=54.60, 3.00 Hz), 7.23 (1 H, d, *J*=2.74 Hz), 7.29 (1 H, br d, *J*=6.57 Hz), 7.66 (1 H, d, *J*=2.74 Hz), 7.73 (1 H, d, *J*=8.49 Hz), 7.95 (1 H, d, *J*=8.21 Hz), 9.70 (1 H, s); ESIMS found for C₂₃H₂₆F₂N₈O *m/z* 469.2 (M+1).



1893


[0797] 5-(3-(2,2-Difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*trans*-3-morpholinocyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1893**.

[0798] Yellow solid (32 mg, 0.068 mmol, 9.9% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.75 - 1.86 (2 H, m), 2.26 (4 H, br s), 2.40 - 2.48 (3 H, m), 2.60 (3 H, s), 3.54 - 3.63 (4 H, m), 3.89 - 4.00 (1 H, m), 4.84 (2 H, td, *J*=16.08, 2.87 Hz), 6.55 (1 H, tt, *J*=54.60, 3.00 Hz), 7.18 (1 H, s), 7.24 (1 H, d, *J*=2.74 Hz), 7.63 (1 H, d, *J*=2.46 Hz), 7.73 (1 H, d, *J*=8.21 Hz), 7.95 (1 H, d, *J*=8.21 Hz), 9.70 (1 H, s); ESIMS found for C₂₃H₂₆F₂N₈O *m/z* 469.2 (M+1).

**1894**


[0799] 5-(3-(2,2-Difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*cis*-4-((3-fluoroazetidin-1-yl)methyl)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1894**.

[0800] Yellow solid (5.7 mg, 0.011 mmol, 22.1% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.48 (5 H, br s), 1.53 - 1.63 (2 H, m), 1.68 (2 H, br s), 2.37 - 2.44 (1 H, m), 2.51 - 2.53 (1 H, m), 2.61 (3 H, s), 2.93 - 3.12 (2 H, m), 3.47 - 3.63 (2 H, m), 3.79 (1 H, br d, *J*=3.29 Hz), 4.82 (2 H, td, *J*=15.95, 2.87 Hz), 5.05 - 5.28 (1 H, m), 6.55 (1 H, tt, *J*=54.60, 3.00 Hz), 6.69 (1 H, br d, *J*=7.12 Hz), 7.22 (1 H, d, *J*=2.74 Hz), 7.64 (1 H, d, *J*=2.74 Hz), 7.72 (1 H, d, *J*=8.21 Hz), 7.95 (1 H, d, *J*=8.21 Hz), 9.70 (1 H, s); ESIMS found for C₂₅H₂₉F₃N₈ *m/z* 250.2 (*M*+1).

**1895**

[0801] *trans*-4-((5-(3-(2,2-Difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-N,N-dimethylcyclohexane-1-carboxamide **1895**.


[0802] Yellow solid (8 mg, 0.017 mmol, 6.1% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.29 - 1.40 (2 H, m), 1.34 - 1.34 (2 H, m), 1.40 - 1.51 (2 H, m), 1.74 (2 H, br d, *J*=12.05 Hz), 2.05 (2 H, br dd, *J*=12.18, 2.60 Hz), 2.56 (1 H, tt, *J*=11.64, 3.42 Hz), 2.61 (3 H, s), 2.81 (3 H, s), 3.02 (3 H, s), 3.51 - 3.65 (1 H, m), 4.83 (2 H, td, *J*=15.95, 2.87 Hz), 6.55 (1 H, tt, *J*=54.60, 3.00 Hz), 6.81 (1 H, d, *J*=7.94 Hz), 7.22 (1 H, d, *J*=2.74 Hz), 7.66 (1 H, d, *J*=2.46 Hz), 7.72 (1 H, d, *J*=8.21 Hz), 7.95 (1 H, d, *J*=8.21 Hz), 9.69 (1 H, s); ESIMS found for C₂₄H₂₈F₂N₈O *m/z* 483.2 (*M*+1).

**276**

1896

[0803] Azetidin-1-yl(*cis*-4-((5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclohexyl)methanone **1896**.


[0804] Yellow solid (7 mg, 0.014 mmol, 14.3% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.42 - 1.50 (2 H, m), 1.57 - 1.66 (2 H, m), 1.73 - 1.83 (2 H, m), 1.92 (2 H, dt, *J*=6.64, 3.39 Hz), 2.13 - 2.22 (2 H, m), 2.31 (1 H, tt, *J*=8.62, 4.11 Hz), 2.61 (3 H, s), 3.75 - 3.80 (1 H, m), 3.82 (2 H, t, *J*=7.67 Hz), 4.15 (2 H, t, *J*=7.53 Hz), 4.83 (2 H, td, *J*=15.95, 2.60 Hz), 6.55 (1 H, tt, *J*=54.60, 3.00 Hz), 6.77 (1 H, d, *J*=6.30 Hz), 7.22 (1 H, d, *J*=2.74 Hz), 7.64 (1 H, d, *J*=2.46 Hz), 7.72 (1 H, d, *J*=8.21 Hz), 7.95 (1 H, d, *J*=8.21 Hz), 9.70 (1 H, s); ESIMS found for C₂₃H₂₆F₂N₈O *m/z* 495.3 (M+1).



1898

[0805] N-(*cis*-4-((5-(3-(2,2-Difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclohexyl)acetamide **1898**.

[0806] Yellow solid (60 mg, 0.128 mmol, 72.8% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.52 - 1.59 (2 H, m), 1.61 - 1.73 (4 H, m), 1.74 - 1.80 (2 H, m), 1.82 (3 H, s), 2.61 (3 H, s), 3.68 (2 H, br d, *J*=3.29 Hz), 4.83 (2 H, td, *J*=15.95, 2.87 Hz), 6.55 (1 H, tt, *J*=54.60, 3.00 Hz), 6.72 (1 H, d, *J*=6.57 Hz), 7.23 (1 H, d, *J*=2.74 Hz), 7.65 (1 H, d, *J*=2.46 Hz), 7.71 - 7.75 (1 H, m), 7.73 (1 H, d, *J*=8.21 Hz), 7.95 (1 H, d, *J*=8.21 Hz), 9.71 (1 H, s); ESIMS found for C₂₅H₂₈F₂N₈O *m/z* 469.2 (M+1).




1899

[0807] 1-(7-((5-(3-(2,2-Difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-2-azaspiro[3.5]nonan-2-yl)ethan-1-one **1899**.


[0808] Yellow solid (33 mg, 0.067 mmol, 54.9% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.27 - 1.41 (2 H, m), 1.50 - 1.62 (2 H, m), 1.73 - 1.79 (3 H, m), 1.88 (4 H, br d, *J*=10.13

Hz), 2.60 (3 H, s), 3.45 - 3.55 (2 H, m), 3.55 - 3.66 (1 H, m), 3.70 - 3.85 (2 H, m), 4.77 - 4.90 (2 H, m), 6.55 (1 H, tt, $J=54.60$, 3.00 Hz), 6.74 (1 H, dd, $J=12.05$, 7.94 Hz), 7.23 (1 H, d, $J=2.74$ Hz), 7.65 (1 H, t, $J=3.01$ Hz), 7.72 (1 H, d, $J=8.21$ Hz), 7.95 (1 H, d, $J=8.21$ Hz), 9.69 (1 H, s); ESIMS found for $C_{25}H_{28}F_2N_8O$ m/z 495.25 (M+1).

**1900**


[0809] 5-(3-(2,2-Difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-((3R,4S)-4-fluoro-1-methylpyrrolidin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1900**.

[0810] Yellow solid (36 mg, 0.084 mmol, 26.3% yield). 1H NMR (499 MHz, DMSO- d_6) δ ppm 2.33 (3 H, s), 2.61 (3 H, s), 2.62 - 2.72 (2 H, m), 2.95 (1 H, br t, $J=8.21$ Hz), 3.15 (1 H, ddd, $J=30.20$, 11.77, 4.65 Hz), 4.23 - 4.37 (1 H, m), 4.84 (2 H, td, $J=16.02$, 2.74 Hz), 5.22 (1 H, dtd, $J=55.70$, 4.86, 4.86, 2.05 Hz), 6.56 (1 H, tt, $J=54.60$, 3.00 Hz), 7.01 (1 H, d, $J=7.94$ Hz), 7.28 (1 H, d, $J=2.74$ Hz), 7.68 (1 H, d, $J=2.46$ Hz), 7.75 (1 H, d, $J=8.49$ Hz), 7.96 (1 H, d, $J=8.21$ Hz), 9.74 (1 H, s); ESIMS found for $C_{20}H_{21}F_3N_8$ m/z 431.2 (M+1).

**1901**


[0811] 5-(3-(2,2-Difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-((3S,4S)-4-fluoro-1-methylpyrrolidin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1901**.

[0812] Yellow solid (34 mg, 0.079 mmol, 24.8% yield). 1H NMR (499 MHz, DMSO- d_6) δ ppm 2.24 - 2.30 (1 H, m), 2.32 (3 H, s), 2.61 (3 H, s), 2.62 - 2.75 (1 H, m), 2.88 - 3.01 (1 H, m), 3.24 - 3.30 (1 H, m), 4.24 - 4.35 (1 H, m), 4.84 (2 H, td, $J=16.02$, 3.01 Hz), 5.09 (1 H, dd, $J=53.20$, 4.70 Hz), 6.55 (1 H, tt, $J=54.60$, 3.00 Hz), 7.22 (1 H, d, $J=7.12$ Hz), 7.28 (1 H, d, $J=2.74$ Hz), 7.70 (1 H, d, $J=2.46$ Hz), 7.75 (1 H, d, $J=8.21$ Hz), 7.96 (1 H, d, $J=8.21$ Hz), 9.73 (1 H, s); ESIMS found for $C_{20}H_{21}F_3N_8$ m/z 431.2 (M+1).

**1902**


[0813] 5-(3-(2,2-Difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-((3R,4R)-4-fluoro-1-methylpyrrolidin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1902**.

[0814] Yellow solid (28 mg, 0.065 mmol, 20.4% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 2.34 (4 H, br s), 2.61 (3 H, s), 2.66 - 2.80 (1 H, m), 2.91 - 3.05 (1 H, m), 3.28 - 3.31 (1 H, m), 4.24 - 4.38 (1 H, m), 4.84 (2 H, td, *J*=16.08, 2.87 Hz), 5.10 (1 H, dd, *J*=53.20, 4.25 Hz), 6.55 (1 H, tt, *J*=54.60, 3.00 Hz), 7.22 (1 H, d, *J*=7.12 Hz), 7.28 (1 H, d, *J*=2.74 Hz), 7.71 (1 H, d, *J*=2.74 Hz), 7.75 (1 H, d, *J*=8.49 Hz), 7.96 (1 H, d, *J*=8.21 Hz), 9.74 (1 H, s); ESIMS found for C₂₀H₂₁F₃N₈ *m/z* 431.2 (M+1).

**1903**

[0815] 5-(3-(2,2-Difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-((3S,4R)-4-fluoro-1-methylpyrrolidin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1903**.


[0816] Yellow solid (35 mg, 0.081 mmol, 25.5% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 2.33 (3 H, s), 2.61 (3 H, s), 2.63 - 2.73 (2 H, m), 2.95 (1 H, t, *J*=8.21 Hz), 3.16 (1 H, ddd, *J*=30.20, 11.77, 4.65 Hz), 4.23 - 4.37 (1 H, m), 4.84 (2 H, td, *J*=15.95, 2.87 Hz), 5.22 (1 H, dtd, *J*=55.65, 4.77, 4.77, 1.64 Hz), 6.56 (1 H, tt, *J*=54.60, 3.00 Hz), 7.01 (1 H, d, *J*=7.67 Hz), 7.28 (1 H, d, *J*=2.74 Hz), 7.68 (1 H, d, *J*=2.46 Hz), 7.75 (1 H, d, *J*=8.21 Hz), 7.96 (1 H, d, *J*=8.21 Hz), 9.74 (1 H, s); ESIMS found for C₂₀H₂₁F₃N₈ *m/z* 431.2 (M+1).



1906

[0817] (3S,4R)-4-((5-(3-(2,2-Difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)tetrahydrofuran-3-ol **1906**.


[0818] yellow solid (80 mg, 0.193 mmol, 57.6% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 2.61 (3 H, s), 3.55 (1 H, dd, *J*=9.31, 2.19 Hz), 3.64 - 3.73 (1 H, m), 3.92 (1 H, dd, *J*=9.31, 4.38 Hz), 4.00 - 4.07 (2 H, m), 4.26 (1 H, td, *J*=4.04, 2.05 Hz), 4.84 (2 H, td, *J*=16.08, 2.87 Hz), 5.21 (1 H, d, *J*=4.11 Hz), 6.55 (1 H, tt, *J*=54.50, 3.00 Hz), 7.13 (1 H, d, *J*=6.02 Hz), 7.26 (1 H, d, *J*=2.74 Hz), 7.68 (1 H, d, *J*=2.46 Hz), 7.74 (1 H, d, *J*=8.49 Hz), 7.95 (1 H, d, *J*=8.21 Hz), 9.72 (1 H, s); ESIMS found for C₁₉H₁₉F₂N₇O₂ *m/z* 416.2 (M+1).



1908

[0819] 5-(3-(2,2-Difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-((3S,4R)-3-fluoro-1-isobutylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1908**.

[0820] Yellow solid (22 mg, 0.045 mmol, 55.8% yield). ¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 0.86 (6 H, br d, *J*=6.31 Hz), 1.65 - 1.83 (2 H, m), 1.86 - 1.99 (1 H, m), 2.02 - 2.11 (3 H, m), 2.12 - 2.26 (1 H, m), 2.61 (3 H, s), 2.85 (1 H, br d, *J*=10.70 Hz), 3.05 - 3.17 (1 H, m), 3.74 - 3.94 (1 H, m), 4.84 (2 H, td, *J*=16.05, 2.47 Hz), 4.83 - 4.96 (1 H, m), 6.55 (1 H, tt, *J*=54.60, 3.00 Hz), 6.85 (1 H, br d, *J*=7.96 Hz), 7.26 (1 H, br s), 7.66 (1 H, d, *J*=2.47 Hz), 7.74 (1 H, d, *J*=8.23 Hz), 7.96 (1 H, d, *J*=8.23 Hz), 9.73 (1 H, s); ESIMS found for C₂₄H₂₉F₃N₈ *m/z* 487.3 (M+1).




1909

[0821] 5-(3-(2,2-Difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-((3R,4S)-3-fluoro-1-isobutylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1909**.


[0822] Yellow solid (15 mg, 0.031 mmol, 35.7% yield). ¹H NMR (500 MHz, DMSO-*d*₆) δ ppm 0.86 (6 H, br d, *J*=6.31 Hz), 1.66 - 1.82 (2 H, m), 1.88 - 1.99 (1 H, m), 2.00 - 2.11 (3 H, m), 2.12 - 2.26 (1 H, m), 2.61 (3 H, s), 2.85 (1 H, br d, *J*=10.70 Hz), 3.05 - 3.17 (1 H, m), 3.74 - 3.94 (1 H, m), 4.84 (2 H, td, *J*=16.05, 2.47 Hz), 4.83 - 4.96 (1 H, m), 6.55 (1 H, tt, *J*=54.60, 3.00 Hz), 6.85 (1 H, br d, *J*=7.96 Hz), 7.26 (1 H, br s), 7.66 (1 H, d, *J*=2.47 Hz), 7.74 (1 H, d, *J*=8.23 Hz), 7.96 (1 H, d, *J*=8.23 Hz), 9.73 (1 H, s); ESIMS found for C₂₄H₂₉F₃N₈ *m/z* 487.3 (M+1).

m), 2.12 - 2.27 (1 H, m), 2.61 (3 H, s), 2.80 - 2.91 (1 H, m), 3.05 - 3.17 (1 H, m), 3.73 - 3.92 (1 H, m), 4.84 (2 H, td, $J=15.85$, 2.61 Hz), 4.94 (1 H, br s), 6.55 (1 H, tt, $J=54.60$, 3.00 Hz), 6.86 (1 H, br d, $J=7.68$ Hz), 7.26 (1 H, d, $J=2.47$ Hz), 7.66 (1 H, d, $J=2.47$ Hz), 7.74 (1 H, d, $J=8.51$ Hz), 7.96 (1 H, d, $J=8.51$ Hz), 9.73 (1 H, s); ESIMS found for $C_{24}H_{29}F_3N_8$ m/z 487.3 (M+1).

**1910**


[0823] 1-(4-((5-(1-(2,2-Difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)piperidin-1-yl)ethan-1-one **1910**.

[0824] Light brown solid (8 mg, 0.0178 mmol, 3.4% yield). 1H NMR (499 MHz, DMSO- d_6) δ ppm 1.29 - 1.39 (1 H, m), 1.40 - 1.53 (1 H, m), 1.90 - 2.00 (2 H, m), 2.01 (3 H, s), 2.63 (3 H, s), 2.71 - 2.81 (1 H, m), 3.13 - 3.23 (1 H, m), 3.78 - 3.89 (2 H, m), 4.28 (1 H, br dd, $J=13.42$, 1.37 Hz), 4.91 (2 H, td, $J=15.88$, 2.74 Hz), 6.53 (1 H, tt, $J=54.60$, 3.00 Hz), 6.95 (1 H, d, $J=7.94$ Hz), 6.99 (1 H, d, $J=2.74$ Hz), 7.74 (1 H, d, $J=2.46$ Hz), 8.24 (1 H, d, $J=1.92$ Hz), 8.66 (1 H, d, $J=1.92$ Hz), 9.13 (1 H, s) ESIMS found for $C_{22}H_{24}F_2N_8O$ m/z 455.2 (M+1).

**1911**


[0825] (S)-4-((5-(3-(2,2-Difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylpiperidin-2-one **1911**.

[0826] Yellow solid (12 mg, 0.027 mmol, 67.9% yield). 1H NMR (499 MHz, DMSO- d_6) δ ppm 1.90 - 1.97 (1 H, m), 1.98 - 2.06 (1 H, m), 2.28 - 2.44 (2 H, m), 2.61 (3 H, s), 2.81 (3 H, s), 3.26 (1 H, dd, $J=12.05$, 7.94 Hz), 3.58 (1 H, dd, $J=11.77$, 4.93 Hz), 4.05 - 4.16 (1 H, m), 4.84 (2 H, td, $J=15.95$, 2.60 Hz), 6.55 (1 H, tt, $J=54.60$, 3.00 Hz), 7.13 (1 H, d, $J=7.12$ Hz), 7.27 (1 H, d, $J=2.46$ Hz), 7.70 (1 H, d, $J=2.74$ Hz), 7.74 (1 H, d, $J=8.49$ Hz), 7.96 (1 H, d, $J=8.21$ Hz), 9.73 (1 H, s); ESIMS found for $C_{21}H_{22}F_2N_8O$ m/z 441.2 (M+1).

**1912**


[0827] 5-(3-(2,2-Difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-((3S,4R)-3-fluorotetrahydro-2H-pyran-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1912**.

[0828] Yellow solid (17 mg, 0.039 mmol, 62.0% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.57 - 1.67 (1 H, m), 2.05 - 2.12 (1 H, m), 2.61 (3 H, s), 3.43 (1 H, ddd, *J*=11.43, 8.15, 6.16 Hz), 3.46 - 3.52 (1 H, m), 3.79 - 3.87 (1 H, m), 3.97 - 4.05 (1 H, m), 4.06 - 4.16 (1 H, m), 4.49 - 4.66 (1 H, m), 4.84 (2 H, td, *J*=15.95, 2.87 Hz), 6.55 (1 H, tt, *J*=54.60, 3.00 Hz), 7.17 (1 H, d, *J*=8.21 Hz), 7.27 (1 H, d, *J*=2.46 Hz), 7.69 (1 H, d, *J*=2.74 Hz), 7.74 (1 H, d, *J*=8.49 Hz), 7.96 (1 H, d, *J*=8.21 Hz), 9.73 (1 H, s); ESIMS found for C₂₀H₂₀F₃N₇O *m/z* 432.2 (M+1).

**1914**

[0829] N-((1R,5S,6s)-3-Oxabicyclo[3.1.0]hexan-6-yl)-5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1914**.


[0830] Yellow solid (58 mg, 0.141 mmol, 80.0% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 2.03 (2 H, d, *J*=6.84 Hz), 2.61 (3 H, s), 2.89 (1 H, td, *J*=6.78, 3.42 Hz), 3.84 (4 H, s), 4.83 (2 H, td, *J*=15.95, 2.87 Hz), 6.55 (1 H, tt, *J*=54.60, 3.00 Hz), 6.57 (1 H, d, *J*=3.29 Hz), 7.26 (1 H, d, *J*=2.74 Hz), 7.69 (1 H, d, *J*=2.46 Hz), 7.74 (1 H, d, *J*=8.21 Hz), 7.96 (1 H, d, *J*=8.21 Hz), 9.71 (1 H, s); ESIMS found for C₂₀H₁₉F₂N₇O *m/z* 412.2 (M+1).



1915

[0831] (R)-N-(4,4-Difluorocyclohexyl)-5-((5-(1-fluoroethyl)-1,3,4-oxadiazol-2-yl)methyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1915**.


[0832] Beige solid (15 mg, 0.029 mmol, 16.6% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.59 - 1.68 (2 H, m), 1.70 (3 H, dd, *J*=24.10, 6.55 Hz), 1.86 - 2.03 (4 H, m), 2.03 - 2.15 (2 H, m), 2.65 (3 H, s), 3.80 (1 H, br d, *J*=8.21 Hz), 5.97 (1 H, dq, *J*=47.15, 6.60 Hz), 6.04 (2 H, s), 6.96 - 7.01 (2 H, m), 7.72 (1 H, d, *J*=2.19 Hz), 8.28 (1 H, d, *J*=2.19 Hz), 8.69 (1 H, d, *J*=2.19 Hz), 9.13 (1 H, s); ESIMS found for C₂₄H₂₄F₃N₉O *m/z* 512.2 (M+1).



1916

[0833] 5-(3-(2,2-Difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(piperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1916**.

[0834] Yellow solid (220 mg, 0.533 mmol, 58.2% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.36 (2 H, qd, *J*=11.59, 3.83 Hz), 1.88 (2 H, br d, *J*=9.86 Hz), 2.51 - 2.55 (2 H, m), 2.60 (3 H, s), 2.96 (2 H, br d, *J*=12.32 Hz), 3.59 - 3.72 (1 H, m), 4.83 (2 H, td, *J*=15.95, 2.60 Hz), 6.55 (1 H, tt, *J*=54.60, 3.00 Hz), 6.80 (1 H, d, *J*=7.94 Hz), 7.22 (1 H, d, *J*=2.74 Hz), 7.64 (1 H, d, *J*=2.46 Hz), 7.72 (1 H, d, *J*=8.49 Hz), 7.95 (1 H, d, *J*=8.21 Hz), 9.69 (1 H, s); ESIMS found for C₂₀H₂₂F₂N₈ *m/z* 413.2 (M+1).




1917

[0835] (S)-(2,2-Difluorocyclopropyl)(4-((5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)piperidin-1-yl)methanone **1917**.


[0836] Yellow solid (9 mg, 0.017 mmol, 14.4% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.30 - 1.62 (2 H, m), 1.78 - 1.87 (1 H, m), 1.87 - 1.94 (1 H, m), 1.97 (1 H, br d, *J*=13.42 Hz), 1.99 - 2.12 (1 H, m), 2.61 (3 H, s), 2.86 - 2.98 (1 H, m), 3.10 - 3.30 (2 H, m), 3.85 - 3.97 (1 H,

m), 3.99 - 4.14 (1 H, m), 4.22 - 4.34 (1 H, m), 4.77 - 4.91 (2 H, m), 6.55 (1 H, tt, $J=54.60$, 3.00 Hz), 6.97 (1 H, dd, $J=7.80$, 4.24 Hz), 7.25 (1 H, d, $J=2.46$ Hz), 7.67 (1 H, dd, $J=5.34$, 2.60 Hz), 7.73 (1 H, d, $J=8.49$ Hz), 7.95 (1 H, d, $J=8.49$ Hz), 9.72 (1 H, d, $J=1.37$ Hz); ESIMS found for $C_{24}H_{24}F_4N_8O$ m/z 517.2 (M+1).

**1918**


[0837] (R)-((2,2-Difluorocyclopropyl)(4-((5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)piperidin-1-yl)methanone **1918**.

[0838] Yellow solid (14 mg, 0.027 mmol, 22.4% yield). 1H NMR (499 MHz, DMSO- d_6) δ ppm 1.29 - 1.62 (2 H, m), 1.78 - 1.86 (1 H, m), 1.87 - 1.94 (1 H, m), 1.97 (1 H, br d, $J=13.42$ Hz), 1.99 - 2.12 (1 H, m), 2.61 (3 H, s), 2.85 - 2.98 (1 H, m), 3.10 - 3.31 (2 H, m), 3.86 - 3.97 (1 H, m), 3.99 - 4.13 (1 H, m), 4.28 (1 H, br t, $J=12.32$ Hz), 4.77 - 4.91 (2 H, m), 6.55 (1 H, tt, $J=54.60$, 3.00 Hz), 6.97 (1 H, dd, $J=7.94$, 4.11 Hz), 7.25 (1 H, d, $J=2.46$ Hz), 7.67 (1 H, dd, $J=5.48$, 2.74 Hz), 7.73 (1 H, d, $J=8.21$ Hz), 7.95 (1 H, d, $J=8.49$ Hz), 9.72 (1 H, d, $J=1.37$ Hz); ESIMS found for $C_{24}H_{24}F_4N_8O$ m/z 517.2 (M+1).

**1920**


[0839] N-((1r,3r)-3-((5-(1-(2,2-Difluoroethyl)-2-methyl-1H-benzo[d]imidazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclobutyl)acetamide **1920**.

[0840] Yellow solid (23 mg, 0.051 mmol, 24.5% yield). 1H NMR (499 MHz, DMSO- d_6) δ ppm 1.37 (3 H, s), 1.82 (3 H, s), 1.90 - 2.01 (2 H, m), 2.56 (3 H, s), 2.65 (2 H, ddd, $J=10.20$, 7.87, 2.74 Hz), 4.19 (1 H, sxt, $J=7.83$ Hz), 4.85 (2 H, td, $J=15.88$, 2.46 Hz), 6.49 (1 H, tt, $J=54.50$, 3.00 Hz), 6.89 (1 H, d, $J=2.46$ Hz), 7.16 (1 H, d, $J=7.12$ Hz), 7.45 (1 H, dd, $J=8.35$, 1.51 Hz), 7.57 (1 H, d, $J=8.21$ Hz), 7.66 (1 H, d, $J=2.46$ Hz), 7.80 (1 H, s), 7.95 (1 H, s), 9.06 (1 H, s); ESIMS found for $C_{23}H_{25}F_2N_7O$ m/z 454.2 (M+1).

**1940**


[0841] 1-((3S,4R)-3-((5-(3-(2,2-Difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-4-fluoropyrrolidin-1-yl)ethan-1-one **1940**.

[0842] Yellow solid (9 mg, 0.020 mmol, 45.4% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.93 - 2.03 (3 H, m), 2.61 (3 H, s), 3.47 - 3.78 (2 H, m), 3.81 (0.5 H, s), 3.84 - 3.92 (1 H, m), 3.97 (0.5 H, t, *J*=9.03 Hz), 4.31 - 4.62 (1 H, m), 4.77 - 4.92 (2 H, m), 5.23 - 5.51 (1 H, m), 6.56 (1 H, tt, *J*=54.50, 3.00 Hz), 7.26 - 7.32 (2 H, m), 7.70 (1 H, dd, *J*=4.65, 2.74 Hz), 7.76 (1 H, dd, *J*=8.35, 0.96 Hz), 7.96 (1 H, d, *J*=8.21 Hz), 9.76 (1 H, d, *J*=3.83 Hz); ESIMS found for C₂₁H₂₁F₃N₈O *m/z* 459.2 (M+1).

**1941**

[0843] 1-((3R,4S)-3-((5-(3-(2,2-Difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-4-fluoropyrrolidin-1-yl)ethan-1-one **1941**.


[0844] Yellow solid (8 mg, 0.018 mmol, 22.7% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.94 - 2.01 (3 H, m), 2.61 (3 H, s), 3.48 - 3.76 (2 H, m), 3.81 (0.5 H, s), 3.84 - 3.91 (1 H, m), 3.97 (0.5 H, t, *J*=9.03 Hz), 4.33 - 4.60 (1 H, m), 4.79 - 4.90 (2 H, m), 5.27 - 5.48 (1 H, m), 6.56 (1 H, tt, *J*=54.50, 3.00 Hz), 7.27 - 7.32 (2 H, m), 7.70 (1 H, dd, *J*=4.65, 2.46 Hz), 7.76 (1 H, dd, *J*=8.35, 0.96 Hz), 7.97 (1 H, d, *J*=8.49 Hz), 9.76 (1 H, d, *J*=4.11 Hz); ESIMS found for C₂₁H₂₁F₃N₈O *m/z* 459.2 (M+1).

**285**

1944

[0845] 5-(3-(2,2-Difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-((3S,4R)-4-fluoro-1-(oxetan-3-yl)pyrrolidin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1944**.


[0846] Yellow solid (80 mg, 0.169 mmol, 51.1% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 2.61 (3 H, s), 2.71 (1 H, t, *J*=9.17 Hz), 2.80 (1 H, dd, *J*=28.50, 11.20 Hz), 3.04 (1 H, t, *J*=8.21 Hz), 3.17 (1 H, ddd, *J*=33.45, 12.05, 4.40 Hz), 3.80 (1 H, quin, *J*=6.16 Hz), 4.23 - 4.40 (1 H, m), 4.48 (2 H, t, *J*=5.89 Hz), 4.60 (2 H, t, *J*=6.57 Hz), 4.84 (2 H, td, *J*=16.02, 2.74 Hz), 5.26 (1 H, dt, *J*=56.25, 3.55 Hz), 6.56 (1 H, tt, *J*=54.50, 3.00 Hz), 7.06 (1 H, d, *J*=7.94 Hz), 7.28 (1 H, d, *J*=2.74 Hz), 7.69 (1 H, d, *J*=2.46 Hz), 7.75 (1 H, d, *J*=8.49 Hz), 7.96 (1 H, d, *J*=8.21 Hz), 9.74 (1 H, s); ESIMS found for C₂₂H₂₃F₃N₈O *m/z* 473.3 (M+1).



1945

[0847] 5-(3-(2,2-Difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-((3R,4S)-4-fluoro-1-(oxetan-3-yl)pyrrolidin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1945**.


[0848] Yellow solid (59 mg, 0.125 mmol, 38.5% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 2.61 (3 H, s), 2.71 (1 H, br t, *J*=9.17 Hz), 2.80 (1 H, dd, *J*=29.65, 11.80 Hz), 3.04 (1 H, br t, *J*=8.21 Hz), 3.17 (1 H, ddd, *J*=33.45, 12.05, 4.10 Hz), 3.81 (1 H, quin, *J*=5.95 Hz), 4.26 - 4.40 (1 H, m), 4.48 (2 H, t, *J*=5.89 Hz), 4.60 (2 H, t, *J*=6.57 Hz), 4.84 (2 H, td, *J*=15.95, 2.87 Hz), 5.26 (1 H, dt, *J*=56.40, 3.55 Hz), 6.56 (1 H, tt, *J*=54.50, 3.00 Hz), 7.06 (1 H, br d, *J*=7.67 Hz), 7.28 (1 H, d, *J*=2.74 Hz), 7.69 (1 H, d, *J*=2.46 Hz), 7.75 (1 H, d, *J*=8.49 Hz), 7.96 (1 H, d, *J*=8.21 Hz), 9.74 (1 H, s); ESIMS found for C₂₂H₂₃F₃N₈O *m/z* 473.2 (M+1).



1950

[0849] (3,3-Difluoroazetidin-1-yl)(*cis*-4-((5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclohexyl)methanone **1950**.


[0850] Yellow solid (10 mg, 0.019 mmol, 19.1% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.49 - 1.57 (2 H, m), 1.60 - 1.68 (2 H, m), 1.77 - 1.85 (2 H, m), 1.86 - 1.94 (2 H, m), 2.44 (1 H, tt, *J*=8.38, 4.07 Hz), 2.61 (3 H, s), 3.79 (1 H, br d, *J*=5.48 Hz), 4.46 (4 H, dt, *J*=195.00, 12.35 Hz), 4.83 (2 H, td, *J*=15.95, 2.87 Hz), 6.55 (1 H, tt, *J*=54.60, 3.00 Hz), 6.81 (1 H, d, *J*=6.57 Hz), 7.22 (1 H, d, *J*=2.46 Hz), 7.64 (1 H, d, *J*=2.46 Hz), 7.72 (1 H, d, *J*=8.21 Hz), 7.95 (1 H, d, *J*=8.49 Hz), 9.70 (1 H, s); ESIMS found for C₂₅H₂₆F₄N₈O *m/z* 531.2 (M+1).



1951

[0851] 1-((3S,4R)-4-((5-(3-(2,2-Difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-3-fluoropiperidin-1-yl)ethan-1-one **1951**.

[0852] Yellow solid (31 mg, 0.066 mmol, 58.8% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.67 - 1.90 (2 H, m), 1.98 - 2.07 (3 H, m), 2.61 (3 H, s), 2.67 - 2.77 (0.5 H, m), 2.84 - 2.99 (0.5 H, m), 3.18 - 3.27 (0.5 H, m), 3.38 - 3.52 (0.5 H, m), 3.91 (0.5 H, br d, *J*=13.14 Hz), 3.98 - 4.06 (0.5 H, m), 4.07 - 4.18 (1 H, m), 4.41 - 4.49 (0.5 H, m), 4.66 - 4.76 (0.5 H, m), 4.84 (2 H, td, *J*=15.95, 2.33 Hz), 4.90 - 5.06 (1 H, m), 6.55 (1 H, tt, *J*=54.50, 3.00 Hz), 7.00 (1 H, br d, *J*=7.94 Hz), 7.27 (1 H, d, *J*=2.74 Hz), 7.66 (1 H, d, *J*=2.74 Hz), 7.74 (1 H, d, *J*=8.21 Hz), 7.96 (1 H, d, *J*=8.21 Hz), 9.74 (1 H, s); ESIMS found for C₂₂H₂₃F₃N₈O *m/z* 473.25 (M+1).




1952

[0853] 1-((3R,4S)-4-((5-(3-(2,2-Difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-3-fluoropiperidin-1-yl)ethan-1-one **1952**.

[0854] Yellow solid (30 mg, 0.064 mmol, 51.6% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.65 - 1.75 (1 H, m), 1.80 (0.5 H, ddd, *J*=13.21, 9.51, 4.11 Hz), 1.86 (0.5 H, dd, *J*=12.46, 3.97 Hz), 1.98 - 2.07 (3 H, m), 2.61 (3 H, s), 2.68 - 2.76 (0.5 H, m), 2.84 - 2.98 (0.5 H, m), 3.18 - 3.26 (0.5 H, m), 3.38 - 3.51 (0.5 H, m), 3.91 (0.5 H, br d, *J*=14.78 Hz), 3.98 - 4.06 (0.5 H, m), 4.06


- 4.17 (1 H, m), 4.40 - 4.50 (0.5 H, m), 4.64 - 4.75 (0.5 H, m), 4.84 (2 H, td, $J=16.02$, 2.74 Hz), 4.91 - 5.07 (1 H, m), 6.55 (1 H, tt, $J=54.50$, 3.00 Hz), 7.00 (1 H, d, $J=7.94$ Hz), 7.27 (1 H, d, $J=2.74$ Hz), 7.66 (1 H, d, $J=2.74$ Hz), 7.74 (1 H, d, $J=8.49$ Hz), 7.96 (1 H, d, $J=8.49$ Hz), 9.74 (1 H, s); ESIMS found for $C_{22}H_{23}F_3N_8O$ m/z 473.2 (M+1).



1953

[0855] (4,4-Difluorocyclohexyl)(4-((5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)piperidin-1-yl)methanone **1953**.

[0856] Yellow solid (18 mg, 0.032 mmol, 44.3% yield). 1H NMR (499 MHz, DMSO- d_6) δ ppm 1.30 - 1.39 (1 H, m), 1.41 - 1.51 (1 H, m), 1.53 - 1.67 (2 H, m), 1.73 (2 H, br d, $J=13.14$ Hz), 1.81 - 1.92 (1 H, m), 1.92 - 1.98 (2 H, m), 1.98 - 2.12 (3 H, m), 2.61 (3 H, s), 2.74 - 2.81 (1 H, m), 2.84 (1 H, br t, $J=11.23$ Hz), 3.20 (1 H, br t, $J=11.91$ Hz), 3.82 - 3.94 (1 H, m), 3.99 (1 H, br d, $J=13.42$ Hz), 4.31 (1 H, br d, $J=12.59$ Hz), 4.83 (2 H, td, $J=16.02$, 2.74 Hz), 6.55 (1 H, tt, $J=54.50$, 3.00 Hz), 6.91 (1 H, d, $J=7.94$ Hz), 7.24 (1 H, d, $J=2.74$ Hz), 7.66 (1 H, d, $J=2.74$ Hz), 7.73 (1 H, d, $J=8.49$ Hz), 7.95 (1 H, d, $J=8.49$ Hz), 9.71 (1 H, s); ESIMS found for $C_{27}H_{30}F_4N_8O$ m/z 559.3 (M+1).




1954

[0857] 5-(3-(2,2-Difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-((3S,4R)-3-fluoro-1-(oxetan-3-yl)piperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1954**.

[0858] Yellow solid (67 mg, 0.138 mmol, 38.0% yield). 1H NMR (499 MHz, DMSO- d_6) δ ppm 1.75 (1 H, br d, $J=9.86$ Hz), 1.92 (1 H, qd, $J=12.09$, 3.42 Hz), 1.99 - 2.08 (1 H, m), 2.17 (1 H, dd, $J=37.05$, 12.90 Hz), 2.61 (3 H, s), 2.76 (1 H, br d, $J=9.31$ Hz), 2.99 (1 H, br t, $J=10.13$ Hz), 3.50 (1 H, quin, $J=6.37$ Hz), 3.77 - 3.94 (1 H, m), 4.41 (1 H, t, $J=6.16$ Hz), 4.46 (1 H, t, $J=6.16$ Hz).


Hz), 4.54 (2 H, td, $J=6.57, 3.01$ Hz), 4.79 - 4.87 (2 H, m), 4.92 (1 H, d, $J=52.65$ Hz), 6.55 (1 H, tt, $J=54.50, 3.00$ Hz), 6.92 (1 H, d, $J=7.94$ Hz), 7.26 (1 H, d, $J=2.74$ Hz), 7.66 (1 H, d, $J=2.46$ Hz), 7.74 (1 H, d, $J=8.49$ Hz), 7.95 (1 H, d, $J=8.21$ Hz), 9.73 (1 H, s); ESIMS found for $C_{23}H_{25}F_3N_8O$ m/z 487.3 (M+1).



1955

[0859] 5-(3-(2,2-Difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-((3R,4S)-3-fluoro-1-(oxetan-3-yl)piperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1955**.

[0860] Yellow solid (69 mg, 0.142 mmol, 40.7% yield). 1H NMR (499 MHz, DMSO- d_6) δ ppm 1.71 - 1.79 (1 H, m), 1.92 (1 H, qd, $J=12.00, 3.70$ Hz), 1.99 - 2.07 (1 H, m), 2.17 (1 H, dd, $J=37.00, 12.90$ Hz), 2.61 (3 H, s), 2.76 (1 H, br d, $J=10.68$ Hz), 2.95 - 3.04 (1 H, m), 3.50 (1 H, quin, $J=6.37$ Hz), 3.79 - 3.93 (1 H, m), 4.41 (1 H, t, $J=6.16$ Hz), 4.46 (1 H, t, $J=6.02$ Hz), 4.54 (2 H, td, $J=6.43, 3.01$ Hz), 4.79 - 4.87 (2 H, m), 4.93 (1 H, d, $J=52.65$ Hz), 6.55 (1 H, tt, $J=54.50, 3.00$ Hz), 6.92 (1 H, d, $J=7.94$ Hz), 7.26 (1 H, d, $J=2.74$ Hz), 7.66 (1 H, d, $J=2.74$ Hz), 7.74 (1 H, d, $J=8.49$ Hz), 7.96 (1 H, d, $J=8.21$ Hz), 9.73 (1 H, s); ESIMS found for $C_{23}H_{25}F_3N_8O$ m/z 487.3 (M+1).




1961

[0861] 5-(3-(2,2-Difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(2-oxaspiro[3.5]nonan-7-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1961**.

[0862] Yellow solid (60 mg, 0.132 mmol, 38.5% yield). 1H NMR (499 MHz, DMSO- d_6) δ ppm 1.21 - 1.33 (2 H, m), 1.53 (2 H, td, $J=12.87, 3.29$ Hz), 1.88 (2 H, br dd, $J=13.14, 3.29$ Hz), 2.07 (2 H, br d, $J=12.87$ Hz), 2.60 (3 H, s), 3.50 - 3.63 (1 H, m), 4.24 (2 H, s), 4.33 (2 H, s), 4.83 (2 H, td, $J=15.95, 2.87$ Hz), 6.55 (1 H, tt, $J=54.50, 3.00$ Hz), 6.71 (1 H, d, $J=7.94$ Hz), 7.22 (1


H, d, $J=2.74$ Hz), 7.64 (1 H, d, $J=2.46$ Hz), 7.72 (1 H, d, $J=8.21$ Hz), 7.95 (1 H, d, $J=8.21$ Hz), 9.69 (1 H, s); ESIMS found for $C_{23}H_{25}F_2N_7O$ m/z 454.25 (M+1).



1970

[0863] 5-(1-(2,2-Difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyrazin-6-yl)-N-(*cis*-4-(trifluoromethoxy)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1970**.


[0864] White solid (6.52 mg, 0.013 mmol, 10.0% yield). 1H NMR (400 MHz, DMSO- d_6) δ ppm 1.60 - 1.80 (4 H, m), 1.81 - 1.89 (2 H, m), 1.95 (2 H, br dd, $J=9.05$, 3.91 Hz), 2.68 (3 H, s), 3.67 - 3.80 (1 H, m), 4.62 (1 H, br d, $J=2.69$ Hz), 4.84 - 4.99 (2 H, m), 6.56 (1 H, tt, $J=54.60$, 3.00 Hz), 6.98 (1 H, d, $J=7.95$ Hz), 7.39 (1 H, d, $J=2.69$ Hz), 7.70 (1 H, d, $J=2.32$ Hz), 8.97 (1 H, s), 9.65 (1 H, s); ESIMS found for $C_{21}H_{21}F_5N_8O$ m/z 497.1 (M+1).



1971

[0865] 5-(1-(2,2-Difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyrazin-5-yl)-N-(*cis*-4-(trifluoromethoxy)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine **1971**.

[0866] White solid (6.75 mg, 0.014 mmol, 10.3% yield). 1H NMR (400 MHz, DMSO- d_6) δ ppm 1.62 - 1.80 (4 H, m), 1.81 - 1.89 (2 H, m), 1.91 - 2.02 (2 H, m), 2.69 (3 H, s), 3.66 - 3.78 (1 H, m), 4.60 (1 H, br s), 4.74 - 4.91 (2 H, m), 6.51 (1 H, tt, $J=54.08$, 3.00 Hz), 7.09 (1 H, d, $J=7.58$ Hz), 7.36 (1 H, d, $J=2.81$ Hz), 7.70 (1 H, d, $J=2.69$ Hz), 8.87 (1 H, s), 9.57 (1 H, s); ESIMS found for $C_{21}H_{21}F_5N_8O$ m/z 497.1 (M+1).




290

1974

[0867] *cis*-4-((5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyrazin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclohexan-1-ol **1974**.


[0868] Yellow fluffy solid (27 mg, 0.06 mmol, 24.8% yield). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.13 (3 H, s), 1.31 - 1.44 (2 H, m), 1.54 - 1.62 (2 H, m), 1.64 - 1.75 (4 H, m), 2.68 (3 H, s), 3.47 - 3.62 (1 H, m), 4.03 (1 H, s), 4.83 - 4.97 (2 H, m), 6.56 (1 H, tt, *J*=54.30, 3.00 Hz), 6.81 (1 H, d, *J*=8.07 Hz), 7.37 (1 H, d, *J*=2.69 Hz), 7.68 (1 H, d, *J*=2.57 Hz), 8.97 (1 H, s), 9.63 (1 H, s); ESIMS found for C₂₁H₂₄F₂N₈O *m/z* 443.2 (M+1).



1980

[0869] N-((1r,3r)-1-Methyl-3-((5-(quinolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclobutyl)acetamide **1980**.

[0870] Yellow solid (4 mg, 0.010 mmol, 11.7% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.37 (3 H, s), 1.82 (3 H, s), 1.91 - 2.02 (2 H, m), 2.60 - 2.71 (2 H, m), 4.20 (1 H, sxt, *J*=7.72 Hz), 7.09 (1 H, d, *J*=2.74 Hz), 7.30 (1 H, d, *J*=7.12 Hz), 7.54 (1 H, dd, *J*=8.35, 4.24 Hz), 7.73 (1 H, d, *J*=2.46 Hz), 7.95 (1 H, s), 8.03 - 8.07 (1 H, m), 8.08 - 8.12 (1 H, m), 8.29 (1 H, d, *J*=1.92 Hz), 8.43 (1 H, dd, *J*=8.35, 1.23 Hz), 8.86 (1 H, dd, *J*=4.24, 1.78 Hz), 9.23 (1 H, s); ESIMS found for C₂₂H₂₂N₆O *m/z* 387.2 (M+1).




1981

[0871] N-((1r,3r)-1-Methyl-3-((5-(quinoxalin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclobutyl)acetamide **1981**.

[0872] Yellow solid (14 mg, 0.036 mmol, 40.7% yield). ¹H NMR (499 MHz, DMSO-*d*₆) δ ppm 1.37 (3 H, s), 1.82 (3 H, s), 1.90 - 2.01 (2 H, m), 2.66 (2 H, ddd, *J*=10.27, 7.94, 2.60 Hz), 4.20 (1 H, sxt, *J*=7.72 Hz), 7.19 (1 H, d, *J*=2.74 Hz), 7.36 (1 H, d, *J*=7.12 Hz), 7.75 (1 H, d, *J*=2.46 Hz), 7.96 (1 H, s), 8.13 (1 H, d, *J*=8.76 Hz), 8.23 (1 H, dd, *J*=8.76, 1.92 Hz), 8.31 (1 H, d, *J*=2.19 Hz).


Hz), 8.90 (1 H, d, $J=1.92$ Hz), 8.95 (1 H, d, $J=1.92$ Hz), 9.19 (1 H, s); ESIMS found for $C_{21}H_{21}N_7O$ m/z 388.2 (M+1).



1983

[0873] N-(*trans*-1-Methyl-3-((5-(pyrazolo[1,5-a]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclobutyl)acetamide **1983**.

[0874] Yellow solid (10 mg, 0.027 mmol, 22.5% yield). 1H NMR (499 MHz, DMSO- d_6) δ ppm 1.36 (3 H, s), 1.82 (3 H, s), 1.91 - 2.02 (2 H, m), 2.60 - 2.71 (2 H, m), 4.12 - 4.26 (1 H, m), 6.59 (1 H, d, $J=1.64$ Hz), 7.06 (1 H, d, $J=2.46$ Hz), 7.21 (1 H, dd, $J=7.26$, 2.05 Hz), 7.32 (1 H, d, $J=7.39$ Hz), 7.70 (1 H, d, $J=2.19$ Hz), 7.95 (1 H, s), 7.98 - 8.00 (2 H, m), 8.67 (1 H, d, $J=7.12$ Hz), 9.17 (1 H, s); ESIMS found for $C_{20}H_{21}N_7O$ m/z 376.2 (M+1).



1985

[0875] 2-Methoxy-N-(*trans*-1-methyl-3-((5-(quinoxalin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclobutyl)acetamide **1985**.

[0876] Yellow solid (8 mg, 0.019 mmol, 14.7% yield). 1H NMR (499 MHz, DMSO- d_6) δ ppm 1.40 (3 H, s), 1.94 - 2.06 (2 H, m), 2.69 - 2.81 (2 H, m), 3.33 (3 H, s), 3.79 (2 H, s), 4.19 (1 H, sxt, $J=7.67$ Hz), 7.19 (1 H, d, $J=2.46$ Hz), 7.37 (1 H, d, $J=7.12$ Hz), 7.74 (1 H, s), 7.76 (1 H, d, $J=2.46$ Hz), 8.13 (1 H, d, $J=8.76$ Hz), 8.23 (1 H, dd, $J=8.76$, 1.92 Hz), 8.31 (1 H, d, $J=1.92$ Hz), 8.90 (1 H, d, $J=1.92$ Hz), 8.95 (1 H, d, $J=1.64$ Hz), 9.19 (1 H, s); ESIMS found for $C_{22}H_{23}N_7O_2$ m/z 418.2 (M+1).

Example 13.

[0877] Representative compounds were screened using the assay procedure for DYRK1A kinase activity as described below.

[0878] Each compound was dissolved in DMSO as a 10 mM stock and used to prepare compound source plates. Serial dilution (1:3, 11-point dose-response curves from 10 μ M to 0.00016

μM) and compound transfer was performed using the ECHO 550 (Labcyte, Sunnyvale, CA) into 1536-well black-walled round bottom plates (Corning).

[0879] The DYRK1A kinase assay was run using the Ser/Thr 18 peptide Z-lyte assay kit according to manufacturer's instructions (Life Technologies- a Division of Thermo-Fisher). This is a non-radioactive assay using fluorescence resonance energy transfer (FRET) between coumarin and fluorescein to detect kinase activity which is represented as a ratio of coumarin emission/fluorescein emission.

[0880] Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μM, and 4 μM respectively. The mixture was allowed to incubate with the representative compounds for one hour at room temperature. All reactions were performed in duplicate. Unphosphorylated ("0% Control") and phosphorylated ("100% control") forms of Ser/Thr 18 served as control reactions. Additionally, an 11-point dose-response curve of Staurosporine (1 μM top) was run to serve as a positive compound control.

[0881] After incubation, Development Reagent A was diluted in Development Buffer then added to the reaction and allowed to further incubate for one hour at room temperature. The plate was read at Ex 400 Em 455 to detect the coumarin signal and Ex 400 Em 520 to measure the signal (EnVision Multilabel Plate Reader, PerkinElmer).

[0882] The Emission ratio (Em) was calculated as a ratio of the coumarin (C) emission signal (at 445 nm)/Fluorescein (F) emission signal (at 520 nm). The percent phosphorylation was then calculated using the following formula: $[1 - ((\text{Em ratio} \times F_{100\%}) - C_{100\%}) / ((C_{0\%} - C_{100\%}) + (\text{Em ratio} \times (F_{100\%} - F_{0\%})))]$. Dose-response curves were generated, and inhibitory concentration (IC₅₀) values were calculated using non-linear regression curve fit in the Dotmatics' Studies Software (Bishops Stortford, UK).

[0883] Table 2 shows the measured activity for representative compounds of Formula I as described herein.

Table 2.

Compound	EC ₅₀ (μM)	Compound	EC ₅₀ (μM)	Compound	EC ₅₀ (μM)	Compound	EC ₅₀ (μM)
2	0.041	683	0.006	1747	0.003	1876	0.002
3	0.023	684	0.004	1756	0.018	1877	0.002
4	0.073	685	0.003	1771	0.005	1878	0.002
9	0.081	686	0.005	1780	0.007	1879	0.002
11	0.116	687	0.002	1786	0.005	1880	0.003
12	0.045	691	0.003	1792	0.026	1881	0.002
16	0.048	692	0.028	1798	0.004	1882	0.004
20	0.067	706	0.005	1801	0.005	1883	0.009
21	0.061	713	0.011	1802	0.005	1884	0.007
23	0.028	784	0.011	1803	0.003	1885	0.006

26	0.011	855	0.043	1813	0.004	1886	0.003
43	0.019	926	0.027	1819	0.003	1887	0.031
64	0.192	1037	0.020	1825	0.005	1888	0.003
65	0.025	1068	0.004	1828	0.010	1889	0.007
66	0.264	1088	0.004	1829	0.033	1890	0.014
67	0.040	1091	3.335	1830	0.016	1891	0.011
74	5.100	1108	0.008	1831	0.007	1892	0.002
145	0.045	1109	0.006	1832	0.006	1893	0.005
214	0.033	1110	0.003	1833	0.008	1894	0.011
215	0.006	1111	0.003	1834	0.003	1895	0.003
216	0.012	1113	0.007	1835	0.003	1896	0.003
218	0.013	1115	0.003	1836	0.003	1898	0.003
219	0.014	1117	0.004	1837	0.006	1899	0.001
220	0.014	1118	0.005	1838	0.006	1900	0.005
221	0.029	1125	0.018	1839	0.004	1901	0.004
223	0.101	1131	0.016	1840	0.003	1902	0.006
225	0.011	1132	0.005	1841	0.006	1903	0.012
226	0.011	1179	0.026	1842	0.005	1906	0.004
227	0.004	1210	0.066	1843	0.033	1908	0.007
228	0.013	1281	0.015	1844	0.003	1909	0.005
229	0.009	1309	0.003	1845	0.004	1910	0.004
230	0.058	1322	0.393	1846	0.004	1911	0.004
231	0.028	1323	0.007	1847	0.005	1912	0.007
232	0.009	1332	0.020	1848	0.005	1914	0.005
235	0.377	1336	0.025	1849	0.007	1915	0.009
236	0.009	1348	0.005	1850	0.008	1916	0.005
237	0.003	1352	0.027	1851	0.011	1917	0.009
239	0.006	1375	0.006	1852	0.009	1918	0.007
240	0.014	1376	0.014	1853	0.005	1920	0.001
242	0.005	1377	0.008	1854	0.008	1940	0.007
244	0.005	1392	0.529	1855	0.006	1941	0.004
256	0.005	1393	0.023	1856	0.006	1944	0.013
258	0.010	1394	0.014	1857	0.003	1945	0.001
259	0.007	1395	0.011	1858	0.007	1950	0.003
260	0.009	1418	0.011	1859	0.008	1951	0.005
263	0.006	1423	0.149	1860	0.005	1952	0.004
265	0.006	1520	0.963	1861	0.007	1953	0.007
279	0.049	1522	0.003	1862	0.006	1954	0.006
280	0.015	1535	0.007	1863	0.008	1955	0.004
281	0.003	1536	0.005	1864	0.003	1961	0.003
282	0.007	1537	0.003	1865	0.020	1970	0.007
283	0.020	1541	0.003	1866	0.033	1971	0.379
287	0.170	1543	0.002	1867	0.032	1974	0.002
358	0.025	1544	0.005	1868	0.009	1980	0.001
398	0.012	1551	0.038	1869	0.016	1981	0.002
429	0.654	1557	0.018	1870	0.078	1983	0.001
500	0.044	1720	0.005	1871	0.072	1985	0.003
571	0.011	1723	0.004	1872	0.498		
642	0.004	1724	0.011	1873	0.131		
682	0.004	1732	0.013	1875	0.014		

Example 14.

[0884] Representative compounds were screened using the assay procedure for tau phosphorylation activity described below.

[0885] HEK293T cells (ATCC, CRL3216) cultured in DMEM (Thermo Fisher Scientific, 10566024) supplemented with 10% FBS (Corning, 35-011-CV) and Penicillin/Streptomycin (Thermo Fisher Scientific, 15140163) were seeded in a 75 cm² flask at 8.1×10^6 cells/flask. The HEK293T cells were then transiently transfected with 5 µg DYRK1A (NM_001396) human untagged clone (OriGene, SC314641) and 2.5 µg MAPT (441 a.a. Tau gene) (NM_005910) human untagged clone (OriGene, TP313312) using Lipofectamine 3000 (Thermo Fisher Scientific, L30000015) and incubated for 20-30 hours in a humidified incubator at 37°C and 5% CO₂. Post-incubation, HEK293T cells transfected with the DYRK1A and MAPT expression vectors were harvested and seeded in BioCoat poly-D lysine coated 96-well plates (Corning, 354461) at 3×10^4 cells/well.

[0886] The above synthesized compounds were screened using the cell assay procedure to assess decreased Tau phosphorylation at Thr212 (pThr212) described below.

[0887] Each compound was dissolved in DMSO (Sigma-Aldrich, D8418-100 mL) as a 10 mM stock. 10 mM stocks were serially diluted 1:3, 10-point dose-response curve and added to the cells with a final concentration ranging from 20 µM to 1.1 nM. Cells were treated with compounds in duplicate and incubated for 18-24 hours in a humidified incubator at 37°C and 5% CO₂.

[0888] Following the overnight compound treatment, cells were lysed with 1X Alpha Surefire Ultra Lysis Buffer (Perkin Elmer, ALSU-LB-100ML) complemented with 1X Halt Phosphatase Inhibitor Cocktail (Thermo Fisher Scientific, 78427) and 1X Halt Protease Inhibitor Cocktail (Thermo Fisher Scientific, 78438). Lysates were spun down at 12,000g for 10 min to remove any cellular debris and 5 µL of lysates were dispensed into a 384-well Opti-Plate (Perkin Elmer, 6007290) for the measurement of Tau phosphorylation in the phosphoTau (Thr212) AlphaLISA assay. Donor antibody, biotinylated HT7Tau (Thermo Fisher Scientific, MN1000B), and acceptor antibody, pThr212Tau (Thermo Fisher Scientific, 44740G) were both added to the cell lysates at a final concentration of 3 nM and incubated for 1 hour at room temperature. Following incubation of the lysates with the donor and acceptor antibodies, anti-rabbit IgG(Fc specific) AlphaLISA acceptor beads (Perkin Elmer, AL104C) were added at a 10 µg/mL final concentration and incubated for 1 hour at room temperature protected from light. Lastly, AlphaScreen streptavidin donor beads (PerkinElmer, 6760002) were added at 40 µg/mL final

concentration and incubated for 1 hour at room temperature protected from light. Plates were read at Ex= 665 nm, and Em=615 nm on the EnVision Multilabel Plate Reader (Perkin Elmer)

[0889] phospho-Tau (Thr212) AlphaLISA signal was used to plot, draw the curve fitting, and determine each compound's EC₅₀ in Prism (GraphPad).


[0890] Table 3 shows the activity of representative compounds as provided herein.

Table 3.

Compound	pTau (Thr212) EC ₅₀ (μM)	Compound	pTau (Thr212) EC ₅₀ (μM)	Compound	pTau (Thr212) EC ₅₀ (μM)	Compound	pTau (Thr212) EC ₅₀ (μM)
3	1.841	256	0.220	1068	0.159	1395	0.380
23	0.794	259	0.150	1108	0.126	1418	0.212
26	0.238	281	0.070	1111	0.071	1724	0.305
43	0.504	282	0.172	1179	0.470	1801	0.152
65	0.828	571	0.725	1332	0.524		
216	0.455	784	0.516	1393	0.718		
228	0.292	1037	0.403	1394	0.709		

WHAT IS CLAIMED IS:

1. A compound, or a pharmaceutically acceptable salt thereof, of Formula I:



I

wherein:

R¹ is heteroaryl optionally substituted with 1-10 R³;

R² is selected from the group consisting of unsubstituted -(C₁₋₉ alkyl), unsubstituted -(C₂₋₉ alkenyl), unsubstituted -(C₂₋₉ alkynyl), unsubstituted -(C₁₋₉ haloalkyl), -(C₁₋₅ alkylene)_pOR⁴, -(C₁₋₅ alkylene)_pheterocyclyl optionally substituted with 1-10 R⁵, -heteroaryl optionally substituted with 1-10 R⁶, and -(C₁₋₅ alkylene)_pcarbocyclyl optionally substituted with 1-12 R⁷, wherein each -(C₁₋₅ alkylene) is, independently, optionally substituted with 1-5 halide and/or 1-3 unsubstituted -(C₁₋₃ alkyl);

each R³ is independently selected from the group consisting of halide, unsubstituted -(C₁₋₉ alkyl), unsubstituted -(C₂₋₉ alkenyl), unsubstituted -(C₂₋₉ alkynyl), unsubstituted -(C₁₋₉ haloalkyl), -(C₁₋₅ alkylene)_pOR⁸, -(C₁₋₅ alkylene)CN, -(C₁₋₅ alkylene)_pheterocyclyl optionally substituted with 1-10 R⁹, -carbocyclyl optionally substituted with 1-12 R¹⁰, -(C₁₋₅ alkylene)_pheteroaryl optionally substituted with 1-10 R¹⁹, -(C₁₋₅ alkylene)_pC(=O)N(R¹¹)₂, and -C(=O)R¹², wherein each -(C₁₋₅ alkylene) is, independently, optionally substituted with 1-5 halide and/or 1-3 unsubstituted -(C₁₋₃ alkyl);

each R⁴ is independently selected from the group consisting of H, unsubstituted -(C₁₋₉ alkyl), unsubstituted -(C₂₋₉ alkenyl), unsubstituted -(C₂₋₉ alkynyl), and unsubstituted -(C₁₋₉ haloalkyl);

each R⁵ is independently selected from the group consisting of halide, unsubstituted -(C₁₋₉ alkyl), unsubstituted -(C₂₋₉ alkenyl), unsubstituted -(C₂₋₉ alkynyl), unsubstituted -(C₁₋₉ haloalkyl), -heterocyclyl optionally substituted with 1-10 R¹⁵, -(C₁₋₅ alkylene)_pOR²⁰, -SO₂R²², and -C(=O)R²³, wherein the -(C₁₋₅ alkylene) is optionally substituted with 1-5 halide and/or 1-3 unsubstituted -(C₁₋₃ alkyl);

alternatively, two R⁵ attached to the same carbon atom are taken together to form a carbonyl group;

each R^6 is independently selected from the group consisting of halide, unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, unsubstituted $-(C_{1-9} \text{ haloalkyl})$, and $-\text{OMe}$;

each R^7 is independently selected from the group consisting of halide, unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, unsubstituted $-(C_{1-9} \text{ haloalkyl})$, $-\text{N}(R^{13})_2$, $-(C_{1-5} \text{ alkylene})_p\text{OR}^{14}$, $-(C_{1-5} \text{ alkylene})_p\text{heterocyclyl}$ optionally substituted with 1-10 R^{15} , $-\text{C}(=\text{O})R^{21}$, and $-\text{NH}(=\text{O})R^{22}$, wherein each $-(C_{1-5} \text{ alkylene})$ is, independently, optionally substituted with 1-5 halide and/or 1-3 unsubstituted $-(C_{1-3} \text{ alkyl})$;

each R^8 is independently selected from the group consisting of H, unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, and unsubstituted $-(C_{1-9} \text{ haloalkyl})$;

each R^9 is independently selected from the group consisting of halide, unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, and unsubstituted $-(C_{1-9} \text{ haloalkyl})$;

each R^{10} is independently selected from the group consisting of halide, unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, and unsubstituted $-(C_{1-9} \text{ haloalkyl})$;

each R^{11} is independently selected from the group consisting of H, unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, unsubstituted $-(C_{1-9} \text{ haloalkyl})$, $-(C_{1-5} \text{ alkylene})_p\text{carbocyclyl}$ optionally substituted with 1-12 R^{16} , $-\text{heterocyclyl}$ optionally substituted with 1-10 R^{17} , and $-\text{heteroaryl}$ optionally substituted with 1-10 R^{18} , wherein the $-(C_{1-5} \text{ alkylene})$ is optionally substituted with 1-5 halide and/or 1-3 unsubstituted $-(C_{1-3} \text{ alkyl})$;

each R^{12} is $-\text{heterocyclyl}$ optionally substituted with 1-10 R^{17} ;

each R^{13} is independently selected from the group consisting of H, unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, and unsubstituted $-(C_{1-9} \text{ haloalkyl})$;

each R^{14} is independently selected from the group consisting of H, unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, unsubstituted $-(C_{1-9} \text{ haloalkyl})$, and $-(C_{1-5} \text{ alkylene})_p\text{OR}^{20}$;

each R^{15} is independently selected from the group consisting of halide, unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, and unsubstituted $-(C_{1-9} \text{ haloalkyl})$;

alternatively, two R^{15} attached to the same carbon atom are taken together to form a carbonyl group;

each R^{16} is independently selected from the group consisting of halide, $-OMe$, unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, and unsubstituted $-(C_{1-9} \text{ haloalkyl})$;

each R^{17} is independently selected from the group consisting of halide, unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, and unsubstituted $-(C_{1-9} \text{ haloalkyl})$;

each R^{18} is independently selected from the group consisting of halide, unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, and unsubstituted $-(C_{1-9} \text{ haloalkyl})$;

each R^{19} is independently selected from the group consisting of halide, unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, and unsubstituted $-(C_{1-9} \text{ haloalkyl})$;

each R^{20} is independently selected from the group consisting of H, unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, and unsubstituted $-(C_{1-9} \text{ haloalkyl})$;

each R^{21} is independently selected from the group consisting of $-\text{heterocyclyl}$ optionally substituted with 1-10 R^{17} , $-N(R^{11})_2$ and $-OR^{20}$;

each R^{22} is independently selected from the group consisting of unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, unsubstituted $-(C_{1-9} \text{ haloalkyl})$, and $-(C_{1-5} \text{ alkylene})_p OR^{20}$;


each R^{23} is independently selected from the group consisting of unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, unsubstituted $-(C_{1-9} \text{ haloalkyl})$, and $-\text{carbocyclyl}$ optionally substituted with 1-12 R^{24} ;

each R^{24} is independently selected from the group consisting of halide, unsubstituted $-(C_{1-9} \text{ alkyl})$, unsubstituted $-(C_{2-9} \text{ alkenyl})$, unsubstituted $-(C_{2-9} \text{ alkynyl})$, and unsubstituted $-(C_{1-9} \text{ haloalkyl})$;


each p is independently 0 or 1; and

wherein each H atom is optionally, independently replaced by 2H (D) (deuterium).


2. The compound of claim 1, wherein R^1 is selected from the group consisting of:




3. The compound according to any one of claims 1-2, wherein R^1 is selected from the group consisting of:



4. The compound according to any one of claims 1-3, wherein R^1 is selected from the group consisting of:



5. The compound according to any one of claims 1-4, wherein R^1 is selected from the group consisting of:



6. The compound according to any one of claims 1-4, wherein R^3 is selected from the group consisting of halide, unsubstituted $-(C_{1-4} \text{ alkyl})$, unsubstituted $-(C_{1-4} \text{ haloalkyl})$, – heterocyclyl optionally substituted with 1-3 R^9 , and –carbocyclyl optionally substituted with 1-3 R^{10} .

7. The compound according to any one of claims 1-6, wherein R^2 is selected from the group consisting of unsubstituted $-(C_{1-5} \text{ alkyl})$, unsubstituted $-(C_{1-5} \text{ haloalkyl})$, $-(C_{1-2} \text{ alkylene})_p$ heterocyclyl optionally substituted with 1-3 R^5 , and $-(C_{1-2} \text{ alkylene})_p$ carbocyclyl optionally substituted with 1-3 R^7 , wherein each $-(C_{1-5} \text{ alkylene})$ is, independently, optionally substituted with 1-2 halide.

8. The compound according to any one of claims 1-7, wherein the compound of Formula I is selected from the group consisting of:

5-(imidazo[1,2-a]pyridin-6-yl)-N-isopropylpyrrolo[2,1-f][1,2,4]triazin-2-amine [1];

5-(imidazo[1,2-a]pyridin-6-yl)-N-isobutylpyrrolo[2,1-f][1,2,4]triazin-2-amine [2];

N-(2-fluoro-2-methylpropyl)-5-(imidazo[1,2-a]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [3];

N-(2,2-difluoropropyl)-5-(imidazo[1,2-a]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [4];

5-(imidazo[1,2-a]pyridin-6-yl)-N-(2,2,2-trifluoroethyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [5];

(R)-5-(imidazo[1,2-a]pyridin-6-yl)-N-(1,1,1-trifluoropropan-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [6];

5-(imidazo[1,2-a]pyridin-6-yl)-N-(3,3,3-trifluoropropyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [7];

5-(imidazo[1,2-a]pyridin-6-yl)-N-(3,3,3-trifluoro-2,2-dimethylpropyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [8];

5-(imidazo[1,2-a]pyridin-6-yl)-N-(2-methoxyethyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [9];

(R)-5-(imidazo[1,2-a]pyridin-6-yl)-N-(1-methoxypropan-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [10];

5-(imidazo[1,2-a]pyridin-6-yl)-N-(2-isopropoxyethyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [11];

5-(imidazo[1,2-a]pyridin-6-yl)-N-((1-methylcyclopropyl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [12];

5-(imidazo[1,2-a]pyridin-6-yl)-N-((1-(trifluoromethyl)cyclopropyl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [13];

N-((1-fluorocyclobutyl)methyl)-5-(imidazo[1,2-a]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [14];

N-((3-fluoro-oxetan-3-yl)methyl)-5-(imidazo[1,2-a]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [15];

N-(cyclopropylmethyl)-5-(imidazo[1,2-a]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [16];

(S)-N-(1-cyclopropylethyl)-5-(imidazo[1,2-a]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [17];

(R)-N-(1-cyclopropylethyl)-5-(imidazo[1,2-a]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [18];

N-(2-cyclopropyl-2,2-difluoroethyl)-5-(imidazo[1,2-a]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [19];

5-(imidazo[1,2-a]pyridin-6-yl)-N-(oxetan-3-ylmethyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [20];

5-(imidazo[1,2-a]pyridin-6-yl)-N-((tetrahydrofuran-2-yl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [21];

N-cyclobutyl-5-(imidazo[1,2-a]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [22];

N-(3,3-difluorocyclobutyl)-5-(imidazo[1,2-a]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [23];

N-(3,3-dimethylcyclobutyl)-5-(imidazo[1,2-a]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [24];

3-((5-(imidazo[1,2-a]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclobutan-1-ol [25];

5-(imidazo[1,2-a]pyridin-6-yl)-N-(*cis*-3-methoxycyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [26];

5-(imidazo[1,2-a]pyridin-6-yl)-N-(*trans*-3-methoxycyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [27];

5-(imidazo[1,2-a]pyridin-6-yl)-N-(*trans*-3-(methoxymethyl)cyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [28];

N-(*cis*-3-ethoxycyclobutyl)-5-(imidazo[1,2-a]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [29];

N-(*trans*-3-ethoxycyclobutyl)-5-(imidazo[1,2-a]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [30];

5-(imidazo[1,2-a]pyridin-6-yl)-N-(*cis*-3-(2-methoxyethoxy)cyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [31];

5-(imidazo[1,2-a]pyridin-6-yl)-N-(*trans*-3-(2-methoxyethoxy)cyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [32];

cis-N¹-(5-(imidazo[1,2-a]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclobutane-1,3-diamine [33];

trans-N¹-(5-(imidazo[1,2-a]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclobutane-1,3-diamine [34];

cis-N¹-(5-(imidazo[1,2-a]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N³-methylcyclobutane-1,3-diamine [35];

trans-N¹-(5-(imidazo[1,2-a]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N³-methylcyclobutane-1,3-diamine [36];

cis-N¹-(5-(imidazo[1,2-a]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N³,N³-dimethylcyclobutane-1,3-diamine [37];

trans-N¹-(5-(imidazo[1,2-a]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N³,N³-dimethylcyclobutane-1,3-diamine [38];

5-(imidazo[1,2-a]pyridin-6-yl)-N-(*cis*-3-morpholinocyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [39];

5-(imidazo[1,2-a]pyridin-6-yl)-N-(*trans*-3-morpholinocyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [40];

5-(imidazo[1,2-a]pyridin-6-yl)-N-(*cis*-3-(4-methylpiperazin-1-yl)cyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [41];

5-(imidazo[1,2-a]pyridin-6-yl)-N-(*trans*-3-(4-methylpiperazin-1-yl)cyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [42];

N-(4,4-difluorocyclohexyl)-5-(imidazo[1,2-a]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [43];

cis-4-((5-(imidazo[1,2-a]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclohexan-1-ol [44];

(1*s*,4*s*)-4-((5-(imidazo[1,2-a]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclohexan-1-ol [45];

5-(imidazo[1,2-a]pyridin-6-yl)-N-(*cis*-4-methoxycyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [46];

5-(imidazo[1,2-a]pyridin-6-yl)-N-(*trans*-4-methoxycyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [47];

N-(*cis*-4-(difluoromethoxy)cyclohexyl)-5-(imidazo[1,2-a]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [48];

N-(*trans*-4-(difluoromethoxy)cyclohexyl)-5-(imidazo[1,2-a]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [49];

N-(*cis*-4-ethoxycyclohexyl)-5-(imidazo[1,2-a]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [50];

N-(*trans*-4-ethoxycyclohexyl)-5-(imidazo[1,2-a]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [51];

5-(imidazo[1,2-a]pyridin-6-yl)-N-(*cis*-4-(2-methoxyethoxy)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [52];

5-(imidazo[1,2-a]pyridin-6-yl)-N-(*trans*-4-(2-methoxyethoxy)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [53];

cis-N¹-(5-(imidazo[1,2-a]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclohexane-1,4-diamine [54];

trans-N¹-(5-(imidazo[1,2-a]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclohexane-1,4-diamine [55];

cis-N¹-(5-(imidazo[1,2-a]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N⁴-methylcyclohexane-1,4-diamine [56];

trans-N¹-(5-(imidazo[1,2-a]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N⁴-methylcyclohexane-1,4-diamine [57];

cis-N¹-(5-(imidazo[1,2-a]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N⁴,N⁴-dimethylcyclohexane-1,4-diamine [58];

trans-N¹-(5-(imidazo[1,2-a]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N⁴,N⁴-dimethylcyclohexane-1,4-diamine [59];

5-(imidazo[1,2-a]pyridin-6-yl)-N-(*cis*-4-morpholinocyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [60];

5-(imidazo[1,2-a]pyridin-6-yl)-N-(*trans*-4-morpholinocyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [61];

5-(imidazo[1,2-a]pyridin-6-yl)-N-(*cis*-4-(4-methylpiperazin-1-yl)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [62];

5-(imidazo[1,2-a]pyridin-6-yl)-N-(*trans*-4-(4-methylpiperazin-1-yl)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [63];

5-(imidazo[1,2-a]pyridin-6-yl)-N-(1-methylazetidin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [64];

5-(imidazo[1,2-a]pyridin-6-yl)-N-(oxetan-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [65];

5-(imidazo[1,2-a]pyridin-6-yl)-N-(1-methylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [66];

5-(imidazo[1,2-a]pyridin-6-yl)-N-(tetrahydro-2H-pyran-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [67];

N-(6,6-difluorospiro[3.3]heptan-2-yl)-5-(imidazo[1,2-a]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [68];

5-(imidazo[1,2-a]pyridin-6-yl)-N-(2-oxaspiro[3.3]heptan-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [69];

5-(imidazo[1,2-a]pyridin-6-yl)-N-(2-methyl-2-azaspiro[3.3]heptan-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [70];

5-(imidazo[1,2-a]pyridin-6-yl)-N-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [71];

(6-(2-(isopropylamino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)imidazo[1,2-a]pyridin-3-yl)(pyrrolidin-1-yl)methanone [72];

(6-(2-(isobutylamino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)imidazo[1,2-a]pyridin-3-yl)(pyrrolidin-1-yl)methanone [73];

(6-(2-((2-fluoro-2-methylpropyl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)imidazo[1,2-a]pyridin-3-yl)(pyrrolidin-1-yl)methanone [74];

(6-(2-((2,2-difluoropropyl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)imidazo[1,2-a]pyridin-3-yl)(pyrrolidin-1-yl)methanone [75];

pyrrolidin-1-yl(6-(2-((2,2,2-trifluoroethyl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)imidazo[1,2-a]pyridin-3-yl)methanone [76];

(R)-pyrrolidin-1-yl(6-(2-((1,1,1-trifluoropropan-2-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)imidazo[1,2-a]pyridin-3-yl)methanone [77];

pyrrolidin-1-yl(6-(2-((3,3,3-trifluoropropyl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)imidazo[1,2-a]pyridin-3-yl)methanone [78];

pyrrolidin-1-yl(6-(2-((3,3,3-trifluoro-2,2-dimethylpropyl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)imidazo[1,2-a]pyridin-3-yl)methanone [79];

(6-(2-((2-methoxyethyl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)imidazo[1,2-a]pyridin-3-yl)(pyrrolidin-1-yl)methanone [80];

(R)-(6-(2-((1-methoxypropan-2-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)imidazo[1,2-a]pyridin-3-yl)(pyrrolidin-1-yl)methanone [81];

(6-(2-((2-isopropoxyethyl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)imidazo[1,2-a]pyridin-3-yl)(pyrrolidin-1-yl)methanone [82];

(6-(2-(((1-methylcyclopropyl)methyl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)imidazo[1,2-a]pyridin-3-yl)(pyrrolidin-1-yl)methanone [83];

pyrrolidin-1-yl(6-(2-(((1-(trifluoromethyl)cyclopropyl)methyl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)imidazo[1,2-a]pyridin-3-yl)methanone [84];

(6-(2-(((1-fluorocyclobutyl)methyl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)imidazo[1,2-a]pyridin-3-yl)(pyrrolidin-1-yl)methanone [85];

(6-(2-(((3-fluorooxetan-3-yl)methyl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)imidazo[1,2-a]pyridin-3-yl)(pyrrolidin-1-yl)methanone [86];

(6-(2-((cyclopropylmethyl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)imidazo[1,2-a]pyridin-3-yl)(pyrrolidin-1-yl)methanone [87];

(S)-(6-(2-((1-cyclopropylethyl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)imidazo[1,2-a]pyridin-3-yl)(pyrrolidin-1-yl)methanone [88];

(R)-(6-(2-((1-cyclopropylethyl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)imidazo[1,2-a]pyridin-3-yl)(pyrrolidin-1-yl)methanone [89];

(6-(2-((2-cyclopropyl-2,2-difluoroethyl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)imidazo[1,2-a]pyridin-3-yl)(pyrrolidin-1-yl)methanone [90];

(6-(2-((oxetan-3-ylmethyl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)imidazo[1,2-a]pyridin-3-yl)(pyrrolidin-1-yl)methanone [91];

pyrrolidin-1-yl(6-(2-(((tetrahydrofuran-2-yl)methyl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)imidazo[1,2-a]pyridin-3-yl)methanone [92];
 (6-(2-(cyclobutylamino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)imidazo[1,2-a]pyridin-3-yl)(pyrrolidin-1-yl)methanone [93];
 (6-(2-((3,3-difluorocyclobutyl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)imidazo[1,2-a]pyridin-3-yl)(pyrrolidin-1-yl)methanone [94];
 (6-(2-((3,3-dimethylcyclobutyl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)imidazo[1,2-a]pyridin-3-yl)(pyrrolidin-1-yl)methanone [95];
 (6-(2-((3-hydroxy-3-methylcyclobutyl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)imidazo[1,2-a]pyridin-3-yl)(pyrrolidin-1-yl)methanone [96];
 (6-(2-((*cis*-3-methoxycyclobutyl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)imidazo[1,2-a]pyridin-3-yl)(pyrrolidin-1-yl)methanone [97];
 (6-(2-((*trans*-3-methoxycyclobutyl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)imidazo[1,2-a]pyridin-3-yl)(pyrrolidin-1-yl)methanone [98];
 (6-(2-((*trans*-3-(methoxymethyl)cyclobutyl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)imidazo[1,2-a]pyridin-3-yl)(pyrrolidin-1-yl)methanone [99]; and
 (6-(2-((*cis*-3-ethoxycyclobutyl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)imidazo[1,2-a]pyridin-3-yl)(pyrrolidin-1-yl)methanone [100]; or a pharmaceutically acceptable salt thereof.

9. The compound according to any one of claims 1-7, wherein the compound of Formula I is selected from the group consisting of:

(6-(2-((*trans*-3-ethoxycyclobutyl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)imidazo[1,2-a]pyridin-3-yl)(pyrrolidin-1-yl)methanone [101];
 (6-(2-((*cis*-3-(2-methoxyethoxy)cyclobutyl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)imidazo[1,2-a]pyridin-3-yl)(pyrrolidin-1-yl)methanone [102];
 (6-(2-((*trans*-3-(2-methoxyethoxy)cyclobutyl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)imidazo[1,2-a]pyridin-3-yl)(pyrrolidin-1-yl)methanone [103];
 (6-(2-((*cis*-3-aminocyclobutyl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)imidazo[1,2-a]pyridin-3-yl)(pyrrolidin-1-yl)methanone [104];
 (6-(2-((*trans*-3-aminocyclobutyl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)imidazo[1,2-a]pyridin-3-yl)(pyrrolidin-1-yl)methanone [105];
 (6-(2-((*cis*-3-(methylamino)cyclobutyl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)imidazo[1,2-a]pyridin-3-yl)(pyrrolidin-1-yl)methanone [106];
 (6-(2-((*trans*-3-(methylamino)cyclobutyl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)imidazo[1,2-a]pyridin-3-yl)(pyrrolidin-1-yl)methanone [107];

- (6-(2-((*cis*-3-(dimethylamino)cyclobutyl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)imidazo[1,2-a]pyridin-3-yl)(pyrrolidin-1-yl)methanone [108];
- (6-(2-((*trans*-3-(dimethylamino)cyclobutyl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)imidazo[1,2-a]pyridin-3-yl)(pyrrolidin-1-yl)methanone [109];
- (6-(2-((*cis*-3-morpholinocyclobutyl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)imidazo[1,2-a]pyridin-3-yl)(pyrrolidin-1-yl)methanone [110];
- (6-(2-((*trans*-3-morpholinocyclobutyl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)imidazo[1,2-a]pyridin-3-yl)(pyrrolidin-1-yl)methanone [111];
- (6-(2-((*cis*-3-(4-methylpiperazin-1-yl)cyclobutyl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)imidazo[1,2-a]pyridin-3-yl)(pyrrolidin-1-yl)methanone [112];
- (6-(2-((*trans*-3-(4-methylpiperazin-1-yl)cyclobutyl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)imidazo[1,2-a]pyridin-3-yl)(pyrrolidin-1-yl)methanone [113];
- (6-(2-((4,4-difluorocyclohexyl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)imidazo[1,2-a]pyridin-3-yl)(pyrrolidin-1-yl)methanone [114];
- (6-(2-((*cis*-4-hydroxycyclohexyl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)imidazo[1,2-a]pyridin-3-yl)(pyrrolidin-1-yl)methanone [115];
- (6-(2-(((1*s*,4*s*)-4-hydroxy-4-methylcyclohexyl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)imidazo[1,2-a]pyridin-3-yl)(pyrrolidin-1-yl)methanone [116];
- (6-(2-((*cis*-4-methoxycyclohexyl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)imidazo[1,2-a]pyridin-3-yl)(pyrrolidin-1-yl)methanone [117];
- (6-(2-((*trans*-4-methoxycyclohexyl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)imidazo[1,2-a]pyridin-3-yl)(pyrrolidin-1-yl)methanone [118];
- (6-(2-((*cis*-4-(difluoromethoxy)cyclohexyl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)imidazo[1,2-a]pyridin-3-yl)(pyrrolidin-1-yl)methanone [119];
- (6-(2-((*trans*-4-(difluoromethoxy)cyclohexyl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)imidazo[1,2-a]pyridin-3-yl)(pyrrolidin-1-yl)methanone [120];
- (6-(2-((*cis*-4-ethoxycyclohexyl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)imidazo[1,2-a]pyridin-3-yl)(pyrrolidin-1-yl)methanone [121];
- (6-(2-((*trans*-4-ethoxycyclohexyl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)imidazo[1,2-a]pyridin-3-yl)(pyrrolidin-1-yl)methanone [122];
- (6-(2-((*cis*-4-(2-methoxyethoxy)cyclohexyl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)imidazo[1,2-a]pyridin-3-yl)(pyrrolidin-1-yl)methanone [123];
- (6-(2-((*trans*-4-(2-methoxyethoxy)cyclohexyl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)imidazo[1,2-a]pyridin-3-yl)(pyrrolidin-1-yl)methanone [124];

(6-(2-((*cis*-4-aminocyclohexyl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)imidazo[1,2-a]pyridin-3-yl)(pyrrolidin-1-yl)methanone [125];

(6-(2-((*trans*-4-aminocyclohexyl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)imidazo[1,2-a]pyridin-3-yl)(pyrrolidin-1-yl)methanone [126];

(6-(2-((*cis*-4-(methylamino)cyclohexyl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)imidazo[1,2-a]pyridin-3-yl)(pyrrolidin-1-yl)methanone [127];

(6-(2-((*trans*-4-(methylamino)cyclohexyl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)imidazo[1,2-a]pyridin-3-yl)(pyrrolidin-1-yl)methanone [128];

(6-(2-((*cis*-4-(dimethylamino)cyclohexyl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)imidazo[1,2-a]pyridin-3-yl)(pyrrolidin-1-yl)methanone [129];

(6-(2-((*trans*-4-(dimethylamino)cyclohexyl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)imidazo[1,2-a]pyridin-3-yl)(pyrrolidin-1-yl)methanone [130];

(6-(2-((*cis*-4-morpholinocyclohexyl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)imidazo[1,2-a]pyridin-3-yl)(pyrrolidin-1-yl)methanone [131];

(6-(2-((*trans*-4-morpholinocyclohexyl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)imidazo[1,2-a]pyridin-3-yl)(pyrrolidin-1-yl)methanone [132];

(6-(2-((*cis*-4-(4-methylpiperazin-1-yl)cyclohexyl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)imidazo[1,2-a]pyridin-3-yl)(pyrrolidin-1-yl)methanone [133];

(6-(2-((*trans*-4-(4-methylpiperazin-1-yl)cyclohexyl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)imidazo[1,2-a]pyridin-3-yl)(pyrrolidin-1-yl)methanone [134];

(6-(2-((1-methylazetidin-3-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)imidazo[1,2-a]pyridin-3-yl)(pyrrolidin-1-yl)methanone [135];

(6-(2-(oxetan-3-ylamino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)imidazo[1,2-a]pyridin-3-yl)(pyrrolidin-1-yl)methanone [136];

(6-(2-((1-methylpiperidin-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)imidazo[1,2-a]pyridin-3-yl)(pyrrolidin-1-yl)methanone [137];

pyrrolidin-1-yl(6-(2-((tetrahydro-2H-pyran-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)imidazo[1,2-a]pyridin-3-yl)methanone [138];

(6-(2-((6,6-difluorospiro[3.3]heptan-2-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)imidazo[1,2-a]pyridin-3-yl)(pyrrolidin-1-yl)methanone [139];

(6-(2-((2-oxaspiro[3.3]heptan-6-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)imidazo[1,2-a]pyridin-3-yl)(pyrrolidin-1-yl)methanone [140];

(6-(2-((2-methyl-2-azaspiro[3.3]heptan-6-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)imidazo[1,2-a]pyridin-3-yl)(pyrrolidin-1-yl)methanone [141];

(6-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)imidazo[1,2-a]pyridin-3-yl)(pyrrolidin-1-yl)methanone [142];

5-(imidazo[1,2-b]pyridazin-6-yl)-N-isopropylpyrrolo[2,1-f][1,2,4]triazin-2-amine [143];

5-(imidazo[1,2-b]pyridazin-6-yl)-N-isobutylpyrrolo[2,1-f][1,2,4]triazin-2-amine [144];

N-(2-fluoro-2-methylpropyl)-5-(imidazo[1,2-b]pyridazin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [145];

N-(2,2-difluoropropyl)-5-(imidazo[1,2-b]pyridazin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [146];

5-(imidazo[1,2-b]pyridazin-6-yl)-N-(2,2,2-trifluoroethyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [147];

(R)-5-(imidazo[1,2-b]pyridazin-6-yl)-N-(1,1,1-trifluoropropan-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [148];

5-(imidazo[1,2-b]pyridazin-6-yl)-N-(3,3,3-trifluoropropyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [149];

5-(imidazo[1,2-b]pyridazin-6-yl)-N-(3,3,3-trifluoro-2,2-dimethylpropyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [150];

5-(imidazo[1,2-b]pyridazin-6-yl)-N-(2-methoxyethyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [151];

(R)-5-(imidazo[1,2-b]pyridazin-6-yl)-N-(1-methoxypropan-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [152];

5-(imidazo[1,2-b]pyridazin-6-yl)-N-(2-isopropoxyethyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [153];

5-(imidazo[1,2-b]pyridazin-6-yl)-N-((1-methylcyclopropyl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [154];

5-(imidazo[1,2-b]pyridazin-6-yl)-N-((1-(trifluoromethyl)cyclopropyl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [155];

N-((1-fluorocyclobutyl)methyl)-5-(imidazo[1,2-b]pyridazin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [156];

N-((3-fluorooxetan-3-yl)methyl)-5-(imidazo[1,2-b]pyridazin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [157];

N-(cyclopropylmethyl)-5-(imidazo[1,2-b]pyridazin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [158];

(S)-N-(1-cyclopropylethyl)-5-(imidazo[1,2-b]pyridazin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [159];

(R)-N-(1-cyclopropylethyl)-5-(imidazo[1,2-b]pyridazin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [160];

N-(2-cyclopropyl-2,2-difluoroethyl)-5-(imidazo[1,2-b]pyridazin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [161];

5-(imidazo[1,2-b]pyridazin-6-yl)-N-(oxetan-3-ylmethyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [162];

5-(imidazo[1,2-b]pyridazin-6-yl)-N-((tetrahydrofuran-2-yl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [163];

N-cyclobutyl-5-(imidazo[1,2-b]pyridazin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [164];

N-(3,3-difluorocyclobutyl)-5-(imidazo[1,2-b]pyridazin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [165];

N-(3,3-dimethylcyclobutyl)-5-(imidazo[1,2-b]pyridazin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [166];

3-((5-(imidazo[1,2-b]pyridazin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclobutanol [167];

5-(imidazo[1,2-b]pyridazin-6-yl)-N-(*cis*-3-methoxycyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [168];

5-(imidazo[1,2-b]pyridazin-6-yl)-N-(*trans*-3-methoxycyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [169];

5-(imidazo[1,2-b]pyridazin-6-yl)-N-(*trans*-3-(methoxymethyl)cyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [170];

N-(*cis*-3-ethoxycyclobutyl)-5-(imidazo[1,2-b]pyridazin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [171];

N-(*trans*-3-ethoxycyclobutyl)-5-(imidazo[1,2-b]pyridazin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [172];

5-(imidazo[1,2-b]pyridazin-6-yl)-N-(*cis*-3-(2-methoxyethoxy)cyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [173];

5-(imidazo[1,2-b]pyridazin-6-yl)-N-(*trans*-3-(2-methoxyethoxy)cyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [174];

cis-N¹-(5-(imidazo[1,2-b]pyridazin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclobutane-1,3-diamine [175];

trans-N¹-(5-(imidazo[1,2-b]pyridazin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclobutane-1,3-diamine [176];

cis-N¹-(5-(imidazo[1,2-b]pyridazin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N³-methylcyclobutane-1,3-diamine [177];

trans-N¹-(5-(imidazo[1,2-b]pyridazin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N³-methylcyclobutane-1,3-diamine [178];

cis-N¹-(5-(imidazo[1,2-b]pyridazin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N³,N³-dimethylcyclobutane-1,3-diamine [179];

trans-N¹-(5-(imidazo[1,2-b]pyridazin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N³,N³-dimethylcyclobutane-1,3-diamine [180];

5-(imidazo[1,2-b]pyridazin-6-yl)-N-(*cis*-3-morpholinocyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [181];

5-(imidazo[1,2-b]pyridazin-6-yl)-N-(*trans*-3-morpholinocyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [182];

5-(imidazo[1,2-b]pyridazin-6-yl)-N-(*cis*-3-(4-methylpiperazin-1-yl)cyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [183];

5-(imidazo[1,2-b]pyridazin-6-yl)-N-(*trans*-3-(4-methylpiperazin-1-yl)cyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [184];

N-(4,4-difluorocyclohexyl)-5-(imidazo[1,2-b]pyridazin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [185];

cis-4-((5-(imidazo[1,2-b]pyridazin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclohexan-1-ol [186];

(1*s*,4*s*)-4-((5-(imidazo[1,2-b]pyridazin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclohexan-1-ol [187];

5-(imidazo[1,2-b]pyridazin-6-yl)-N-(*cis*-4-methoxycyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [188];

5-(imidazo[1,2-b]pyridazin-6-yl)-N-(*trans*-4-methoxycyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [189];

N-(*cis*-4-(difluoromethoxy)cyclohexyl)-5-(imidazo[1,2-b]pyridazin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [190];

N-(*trans*-4-(difluoromethoxy)cyclohexyl)-5-(imidazo[1,2-b]pyridazin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [191];

N-(*cis*-4-ethoxycyclohexyl)-5-(imidazo[1,2-b]pyridazin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [192];

N-(*trans*-4-ethoxycyclohexyl)-5-(imidazo[1,2-b]pyridazin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [193];

5-(imidazo[1,2-b]pyridazin-6-yl)-N-(*cis*-4-(2-methoxyethoxy)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [194];

5-(imidazo[1,2-b]pyridazin-6-yl)-N-(*trans*-4-(2-methoxyethoxy)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [195];

cis-N¹-(5-(imidazo[1,2-b]pyridazin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclohexane-1,4-diamine [196];

trans-N¹-(5-(imidazo[1,2-b]pyridazin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclohexane-1,4-diamine [197];

cis-N¹-(5-(imidazo[1,2-b]pyridazin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N⁴-methylcyclohexane-1,4-diamine [198];

trans-N¹-(5-(imidazo[1,2-b]pyridazin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N⁴-methylcyclohexane-1,4-diamine [199]; and

cis-N¹-(5-(imidazo[1,2-b]pyridazin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N⁴,N⁴-dimethylcyclohexane-1,4-diamine [200]; or a pharmaceutically acceptable salt thereof.

10. The compound according to any one of claims 1-7, wherein the compound of Formula I is selected from the group consisting of:

trans-N¹-(5-(imidazo[1,2-b]pyridazin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N⁴,N⁴-dimethylcyclohexane-1,4-diamine [201];

5-(imidazo[1,2-b]pyridazin-6-yl)-N-(*cis*-4-morpholinocyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [202];

5-(imidazo[1,2-b]pyridazin-6-yl)-N-(*trans*-4-morpholinocyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [203];

5-(imidazo[1,2-b]pyridazin-6-yl)-N-(*cis*-4-(4-methylpiperazin-1-yl)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [204];

5-(imidazo[1,2-b]pyridazin-6-yl)-N-(*trans*-4-(4-methylpiperazin-1-yl)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [205];

5-(imidazo[1,2-b]pyridazin-6-yl)-N-(1-methylazetidin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [206];

5-(imidazo[1,2-b]pyridazin-6-yl)-N-(oxetan-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [207];

5-(imidazo[1,2-b]pyridazin-6-yl)-N-(1-methylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [208];

5-(imidazo[1,2-b]pyridazin-6-yl)-N-(tetrahydro-2H-pyran-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [209];

N-(6,6-difluorospiro[3.3]heptan-2-yl)-5-(imidazo[1,2-b]pyridazin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [210];

5-(imidazo[1,2-b]pyridazin-6-yl)-N-(2-oxaspiro[3.3]heptan-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [211];

5-(imidazo[1,2-b]pyridazin-6-yl)-N-(2-methyl-2-azaspiro[3.3]heptan-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [212];

5-(imidazo[1,2-b]pyridazin-6-yl)-N-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [213];

5-(imidazo[1,2-a]pyrimidin-6-yl)-N-isopropylpyrrolo[2,1-f][1,2,4]triazin-2-amine [214];

5-(imidazo[1,2-a]pyrimidin-6-yl)-N-isobutylpyrrolo[2,1-f][1,2,4]triazin-2-amine [215];

N-(2-fluoro-2-methylpropyl)-5-(imidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [216];

N-(2,2-difluoropropyl)-5-(imidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [217];

5-(imidazo[1,2-a]pyrimidin-6-yl)-N-(2,2,2-trifluoroethyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [218];

(R)-5-(imidazo[1,2-a]pyrimidin-6-yl)-N-(1,1,1-trifluoropropan-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [219];

5-(imidazo[1,2-a]pyrimidin-6-yl)-N-(3,3,3-trifluoropropyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [220];

5-(imidazo[1,2-a]pyrimidin-6-yl)-N-(3,3,3-trifluoro-2,2-dimethylpropyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [221];

5-(imidazo[1,2-a]pyrimidin-6-yl)-N-(2-methoxyethyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [222];

(R)-5-(imidazo[1,2-a]pyrimidin-6-yl)-N-(1-methoxypropan-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [223];

5-(imidazo[1,2-a]pyrimidin-6-yl)-N-(2-isopropoxyethyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [224];

5-(imidazo[1,2-a]pyrimidin-6-yl)-N-((1-methylcyclopropyl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [225];

5-(imidazo[1,2-a]pyrimidin-6-yl)-N-((1-(trifluoromethyl)cyclopropyl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [226];

N-((1-fluorocyclobutyl)methyl)-5-(imidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [227];

N-((3-fluorooxetan-3-yl)methyl)-5-(imidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [228];

N-(cyclopropylmethyl)-5-(imidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [229];

(S)-N-(1-cyclopropylethyl)-5-(imidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [230];

(R)-N-(1-cyclopropylethyl)-5-(imidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [231];

N-(2-cyclopropyl-2,2-difluoroethyl)-5-(imidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [232];

5-(imidazo[1,2-a]pyrimidin-6-yl)-N-(oxetan-3-ylmethyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [233];

5-(imidazo[1,2-a]pyrimidin-6-yl)-N-((tetrahydrofuran-2-yl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [234];

N-cyclobutyl-5-(imidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [235];

N-(3,3-difluorocyclobutyl)-5-(imidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [236];

N-(3,3-dimethylcyclobutyl)-5-(imidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [237];

3-((5-(imidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclobutan-1-ol [238];

5-(imidazo[1,2-a]pyrimidin-6-yl)-N-(*cis*-3-methoxycyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [239];

5-(imidazo[1,2-a]pyrimidin-6-yl)-N-(*trans*-3-methoxycyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [240];

5-(imidazo[1,2-a]pyrimidin-6-yl)-N-(*trans*-3-(methoxymethyl)cyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [241];

N-(*cis*-3-ethoxycyclobutyl)-5-(imidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [242];

N-(*trans*-3-ethoxycyclobutyl)-5-(imidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [243];

5-(imidazo[1,2-a]pyrimidin-6-yl)-N-(*cis*-3-(2-methoxyethoxy)cyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [244];

5-(imidazo[1,2-a]pyrimidin-6-yl)-N-(*trans*-3-(2-methoxyethoxy)cyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [245];

cis-N¹-(5-(imidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclobutane-1,3-diamine [246];

trans-N¹-(5-(imidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclobutane-1,3-diamine [247];

cis-N¹-(5-(imidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N³-methylcyclobutane-1,3-diamine [248];

trans-N¹-(5-(imidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N³-methylcyclobutane-1,3-diamine [249];

cis-N¹-(5-(imidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N³,N³-dimethylcyclobutane-1,3-diamine [250];

trans-N¹-(5-(imidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N³,N³-dimethylcyclobutane-1,3-diamine [251];

5-(imidazo[1,2-a]pyrimidin-6-yl)-N-(*cis*-3-morpholinocyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [252];

5-(imidazo[1,2-a]pyrimidin-6-yl)-N-(*trans*-3-morpholinocyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [253];

5-(imidazo[1,2-a]pyrimidin-6-yl)-N-(*cis*-3-(4-methylpiperazin-1-yl)cyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [254];

5-(imidazo[1,2-a]pyrimidin-6-yl)-N-(*trans*-3-(4-methylpiperazin-1-yl)cyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [255];

N-(4,4-difluorocyclohexyl)-5-(imidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [256];

cis-4-((5-(imidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclohexan-1-ol [257];

(1*s*,4*s*)-4-((5-(imidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclohexan-1-ol [258];

5-(imidazo[1,2-a]pyrimidin-6-yl)-N-(*cis*-4-methoxycyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [259];

5-(imidazo[1,2-a]pyrimidin-6-yl)-N-(*trans*-4-methoxycyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [260];

N-(*cis*-4-(difluoromethoxy)cyclohexyl)-5-(imidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [261];

N-(*trans*-4-(difluoromethoxy)cyclohexyl)-5-(imidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [262];

N-(*cis*-4-ethoxycyclohexyl)-5-(imidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [263];

N-(*trans*-4-ethoxycyclohexyl)-5-(imidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [264];

5-(imidazo[1,2-a]pyrimidin-6-yl)-N-(*cis*-4-(2-methoxyethoxy)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [265];

5-(imidazo[1,2-a]pyrimidin-6-yl)-N-(*trans*-4-(2-methoxyethoxy)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [266];

cis-N¹-(5-(imidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclohexane-1,4-diamine [267];

trans-N¹-(5-(imidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclohexane-1,4-diamine [268];

cis-N¹-(5-(imidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N⁴-methylcyclohexane-1,4-diamine [269];

trans-N¹-(5-(imidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N⁴-methylcyclohexane-1,4-diamine [270];

cis-N¹-(5-(imidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N⁴,N⁴-dimethylcyclohexane-1,4-diamine [271];

trans-N¹-(5-(imidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N⁴,N⁴-dimethylcyclohexane-1,4-diamine [272];

5-(imidazo[1,2-a]pyrimidin-6-yl)-N-(*cis*-4-morpholinocyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [273];

5-(imidazo[1,2-a]pyrimidin-6-yl)-N-(*trans*-4-morpholinocyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [274];

5-(imidazo[1,2-a]pyrimidin-6-yl)-N-(*cis*-4-(4-methylpiperazin-1-yl)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [275];

5-(imidazo[1,2-a]pyrimidin-6-yl)-N-(*trans*-4-(4-methylpiperazin-1-yl)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [276];

5-(imidazo[1,2-a]pyrimidin-6-yl)-N-(1-methylazetidin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [277];

5-(imidazo[1,2-a]pyrimidin-6-yl)-N-(oxetan-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [278];

5-(imidazo[1,2-a]pyrimidin-6-yl)-N-(1-methylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [279];

5-(imidazo[1,2-a]pyrimidin-6-yl)-N-(tetrahydro-2H-pyran-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [280];

N-(6,6-difluorospiro[3.3]heptan-2-yl)-5-(imidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [281];

5-(imidazo[1,2-a]pyrimidin-6-yl)-N-(2-oxaspiro[3.3]heptan-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [282];

5-(imidazo[1,2-a]pyrimidin-6-yl)-N-(2-methyl-2-azaspiro[3.3]heptan-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [283];

5-(imidazo[1,2-a]pyrimidin-6-yl)-N-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [284];

5-(3-chloroimidazo[1,2-a]pyrimidin-6-yl)-N-isopropylpyrrolo[2,1-f][1,2,4]triazin-2-amine [285];

5-(3-chloroimidazo[1,2-a]pyrimidin-6-yl)-N-isobutylpyrrolo[2,1-f][1,2,4]triazin-2-amine [286];

5-(3-chloroimidazo[1,2-a]pyrimidin-6-yl)-N-(2-fluoro-2-methylpropyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [287];

5-(3-chloroimidazo[1,2-a]pyrimidin-6-yl)-N-(2,2-difluoropropyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [288];

5-(3-chloroimidazo[1,2-a]pyrimidin-6-yl)-N-(2,2,2-trifluoroethyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [289];

(R)-5-(3-chloroimidazo[1,2-a]pyrimidin-6-yl)-N-(1,1,1-trifluoropropan-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [290];

5-(3-chloroimidazo[1,2-a]pyrimidin-6-yl)-N-(3,3,3-trifluoropropyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [291];

5-(3-chloroimidazo[1,2-a]pyrimidin-6-yl)-N-(3,3,3-trifluoro-2,2-dimethylpropyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [292];

5-(3-chloroimidazo[1,2-a]pyrimidin-6-yl)-N-(2-methoxyethyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [293];

(R)-5-(3-chloroimidazo[1,2-a]pyrimidin-6-yl)-N-(1-methoxypropan-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [294];

5-(3-chloroimidazo[1,2-a]pyrimidin-6-yl)-N-(2-isopropoxyethyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [295];

5-(3-chloroimidazo[1,2-a]pyrimidin-6-yl)-N-((1-methylcyclopropyl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [296];

5-(3-chloroimidazo[1,2-a]pyrimidin-6-yl)-N-((1-(trifluoromethyl)cyclopropyl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [297];
5-(3-chloroimidazo[1,2-a]pyrimidin-6-yl)-N-((1-fluorocyclobutyl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [298];
5-(3-chloroimidazo[1,2-a]pyrimidin-6-yl)-N-((3-fluorooxetan-3-yl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [299]; and
5-(3-chloroimidazo[1,2-a]pyrimidin-6-yl)-N-(cyclopropylmethyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [300]; or a pharmaceutically acceptable salt thereof.

11. The compound according to any one of claims 1-7, wherein the compound of Formula I is selected from the group consisting of:

(S)-5-(3-chloroimidazo[1,2-a]pyrimidin-6-yl)-N-(1-cyclopropylethyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [301];
(R)-5-(3-chloroimidazo[1,2-a]pyrimidin-6-yl)-N-(1-cyclopropylethyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [302];
5-(3-chloroimidazo[1,2-a]pyrimidin-6-yl)-N-(2-cyclopropyl-2,2-difluoroethyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [303];
5-(3-chloroimidazo[1,2-a]pyrimidin-6-yl)-N-(oxetan-3-ylmethyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [304];
5-(3-chloroimidazo[1,2-a]pyrimidin-6-yl)-N-((tetrahydrofuran-2-yl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [305];
5-(3-chloroimidazo[1,2-a]pyrimidin-6-yl)-N-cyclobutylpyrrolo[2,1-f][1,2,4]triazin-2-amine [306];
5-(3-chloroimidazo[1,2-a]pyrimidin-6-yl)-N-(3,3-difluorocyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [307];
5-(3-chloroimidazo[1,2-a]pyrimidin-6-yl)-N-(3,3-dimethylcyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [308];
3-(((5-(3-chloroimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclobutan-1-ol [309];
5-(3-chloroimidazo[1,2-a]pyrimidin-6-yl)-N-(*cis*-3-methoxycyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [310];
5-(3-chloroimidazo[1,2-a]pyrimidin-6-yl)-N-(*trans*-3-methoxycyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [311];
5-(3-chloroimidazo[1,2-a]pyrimidin-6-yl)-N-(*trans*-3-(methoxymethyl)cyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [312];

5-(3-chloroimidazo[1,2-a]pyrimidin-6-yl)-N-(*cis*-3-ethoxycyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [313];

5-(3-chloroimidazo[1,2-a]pyrimidin-6-yl)-N-(*trans*-3-ethoxycyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [314];

5-(3-chloroimidazo[1,2-a]pyrimidin-6-yl)-N-(*cis*-3-(2-methoxyethoxy)cyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [315];

5-(3-chloroimidazo[1,2-a]pyrimidin-6-yl)-N-(*trans*-3-(2-methoxyethoxy)cyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [316];

cis-N¹-(5-(3-chloroimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclobutane-1,3-diamine [317];

trans-N¹-(5-(3-chloroimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclobutane-1,3-diamine [318];

cis-N¹-(5-(3-chloroimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N³-methylcyclobutane-1,3-diamine [319];

trans-N¹-(5-(3-chloroimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N³-methylcyclobutane-1,3-diamine [320];

cis-N¹-(5-(3-chloroimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N³,N³-dimethylcyclobutane-1,3-diamine [321];

trans-N¹-(5-(3-chloroimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N³,N³-dimethylcyclobutane-1,3-diamine [322];

5-(3-chloroimidazo[1,2-a]pyrimidin-6-yl)-N-(*cis*-3-morpholinocyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [323];

5-(3-chloroimidazo[1,2-a]pyrimidin-6-yl)-N-(*trans*-3-morpholinocyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [324];

5-(3-chloroimidazo[1,2-a]pyrimidin-6-yl)-N-(*cis*-3-(4-methylpiperazin-1-yl)cyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [325];

5-(3-chloroimidazo[1,2-a]pyrimidin-6-yl)-N-(*trans*-3-(4-methylpiperazin-1-yl)cyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [326];

5-(3-chloroimidazo[1,2-a]pyrimidin-6-yl)-N-(4,4-difluorocyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [327];

cis-4-((5-(3-chloroimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclohexan-1-ol [328];

(1*s*,4*s*)-4-((5-(3-chloroimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclohexan-1-ol [329];

- 5-(3-chloroimidazo[1,2-a]pyrimidin-6-yl)-N-(*cis*-4-methoxycyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [330];
- 5-(3-chloroimidazo[1,2-a]pyrimidin-6-yl)-N-(*trans*-4-methoxycyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [331];
- 5-(3-chloroimidazo[1,2-a]pyrimidin-6-yl)-N-(*cis*-4-(difluoromethoxy)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [332];
- 5-(3-chloroimidazo[1,2-a]pyrimidin-6-yl)-N-(*trans*-4-(difluoromethoxy)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [333];
- 5-(3-chloroimidazo[1,2-a]pyrimidin-6-yl)-N-(*cis*-4-ethoxycyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [334];
- 5-(3-chloroimidazo[1,2-a]pyrimidin-6-yl)-N-(*trans*-4-ethoxycyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [335];
- 5-(3-chloroimidazo[1,2-a]pyrimidin-6-yl)-N-(*cis*-4-(2-methoxyethoxy)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [336];
- 5-(3-chloroimidazo[1,2-a]pyrimidin-6-yl)-N-(*trans*-4-(2-methoxyethoxy)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [337];
- cis*-N¹-(5-(3-chloroimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclohexane-1,4-diamine [338];
- trans*-N¹-(5-(3-chloroimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclohexane-1,4-diamine [339];
- cis*-N¹-(5-(3-chloroimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N⁴-methylcyclohexane-1,4-diamine [340];
- trans*-N¹-(5-(3-chloroimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N⁴-methylcyclohexane-1,4-diamine [341];
- cis*-N¹-(5-(3-chloroimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N⁴,N⁴-dimethylcyclohexane-1,4-diamine [342];
- trans*-N¹-(5-(3-chloroimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N⁴,N⁴-dimethylcyclohexane-1,4-diamine [343];
- 5-(3-chloroimidazo[1,2-a]pyrimidin-6-yl)-N-(*cis*-4-morpholinocyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [344];
- 5-(3-chloroimidazo[1,2-a]pyrimidin-6-yl)-N-(*trans*-4-(4-methylpiperazin-1-yl)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [345];
- 5-(3-chloroimidazo[1,2-a]pyrimidin-6-yl)-N-(*cis*-4-(4-methylpiperazin-1-yl)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [346];

5-(3-chloroimidazo[1,2-a]pyrimidin-6-yl)-N-(*trans*-4-(4-methylpiperazin-1-yl)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [347];

5-(3-chloroimidazo[1,2-a]pyrimidin-6-yl)-N-(1-methylazetidin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [348];

5-(3-chloroimidazo[1,2-a]pyrimidin-6-yl)-N-(oxetan-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [349];

5-(3-chloroimidazo[1,2-a]pyrimidin-6-yl)-N-(1-methylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [350];

5-(3-chloroimidazo[1,2-a]pyrimidin-6-yl)-N-(tetrahydro-2H-pyran-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [351];

5-(3-chloroimidazo[1,2-a]pyrimidin-6-yl)-N-(6,6-difluorospiro[3.3]heptan-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [352];

5-(3-chloroimidazo[1,2-a]pyrimidin-6-yl)-N-(2-oxaspiro[3.3]heptan-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [353];

5-(3-chloroimidazo[1,2-a]pyrimidin-6-yl)-N-(2-methyl-2-azaspiro[3.3]heptan-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [354];

5-(3-chloroimidazo[1,2-a]pyrimidin-6-yl)-N-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [355];

N-isopropyl-5-(3-methylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [356];

N-isobutyl-5-(3-methylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [357];

N-(2-fluoro-2-methylpropyl)-5-(3-methylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [358];

N-(2,2-difluoropropyl)-5-(3-methylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [359];

5-(3-methylimidazo[1,2-a]pyrimidin-6-yl)-N-(2,2,2-trifluoroethyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [360];

(R)-5-(3-methylimidazo[1,2-a]pyrimidin-6-yl)-N-(1,1,1-trifluoropropan-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [361];

5-(3-methylimidazo[1,2-a]pyrimidin-6-yl)-N-(3,3,3-trifluoropropyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [362];

5-(3-methylimidazo[1,2-a]pyrimidin-6-yl)-N-(3,3,3-trifluoro-2,2-dimethylpropyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [363];

N-(2-methoxyethyl)-5-(3-methylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [364];

(R)-N-(1-methoxypropan-2-yl)-5-(3-methylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [365];

N-(2-isopropoxyethyl)-5-(3-methylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [366];

N-((1-methylcyclopropyl)methyl)-5-(3-methylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [367];

5-(3-methylimidazo[1,2-a]pyrimidin-6-yl)-N-((1-(trifluoromethyl)cyclopropyl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [368];

N-((1-fluorocyclobutyl)methyl)-5-(3-methylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [369];

N-((3-fluorooxetan-3-yl)methyl)-5-(3-methylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [370];

N-(cyclopropylmethyl)-5-(3-methylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [371];

(S)-N-(1-cyclopropylethyl)-5-(3-methylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [372];

(R)-N-(1-cyclopropylethyl)-5-(3-methylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [373];

N-(2-cyclopropyl-2,2-difluoroethyl)-5-(3-methylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [374];

5-(3-methylimidazo[1,2-a]pyrimidin-6-yl)-N-(oxetan-3-ylmethyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [375];

5-(3-methylimidazo[1,2-a]pyrimidin-6-yl)-N-((tetrahydrofuran-2-yl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [376];

N-cyclobutyl-5-(3-methylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [377];

N-(3,3-difluorocyclobutyl)-5-(3-methylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [378];

N-(3,3-dimethylcyclobutyl)-5-(3-methylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [379];

1-methyl-3-((5-(3-methylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclobutan-1-ol [380];

N-(*cis*-3-methoxycyclobutyl)-5-(3-methylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [381];

N-(*trans*-3-methoxycyclobutyl)-5-(3-methylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [382];

N-(*trans*-3-(methoxymethyl)cyclobutyl)-5-(3-methylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [383];

N-(*cis*-3-ethoxycyclobutyl)-5-(3-methylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [384];

N-(*trans*-3-ethoxycyclobutyl)-5-(3-methylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [385];

N-(*cis*-3-(2-methoxyethoxy)cyclobutyl)-5-(3-methylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [386];

N-(*trans*-3-(2-methoxyethoxy)cyclobutyl)-5-(3-methylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [387];

cis-N¹-(5-(3-methylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclobutane-1,3-diamine [388];

trans-N¹-(5-(3-methylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclobutane-1,3-diamine [389];

cis-N¹-methyl-N³-(5-(3-methylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclobutane-1,3-diamine [390];

trans-N¹-methyl-N³-(5-(3-methylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclobutane-1,3-diamine [391];

cis-N¹,N¹-dimethyl-N³-(5-(3-methylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclobutane-1,3-diamine [392];

trans-N¹,N¹-dimethyl-N³-(5-(3-methylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclobutane-1,3-diamine [393];

5-(3-methylimidazo[1,2-a]pyrimidin-6-yl)-N-(*cis*-3-morpholinocyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [394];

5-(3-methylimidazo[1,2-a]pyrimidin-6-yl)-N-(*trans*-3-morpholinocyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [395];

5-(3-methylimidazo[1,2-a]pyrimidin-6-yl)-N-(*cis*-3-(4-methylpiperazin-1-yl)cyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [396];

5-(3-methylimidazo[1,2-a]pyrimidin-6-yl)-N-(*trans*-3-(4-methylpiperazin-1-yl)cyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [397];

N-(4,4-difluorocyclohexyl)-5-(3-methylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [398];

cis-4-((5-(3-methylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclohexan-1-ol [399]; and
 (1*s*,4*s*)-1-methyl-4-((5-(3-methylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclohexan-1-ol [400]; or a pharmaceutically acceptable salt thereof.

12. The compound according to any one of claims 1-7, wherein the compound of Formula I is selected from the group consisting of:

N-(*cis*-4-methoxycyclohexyl)-5-(3-methylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [401];
 N-(*trans*-4-methoxycyclohexyl)-5-(3-methylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [402];
 N-(*cis*-4-(difluoromethoxy)cyclohexyl)-5-(3-methylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [403];
 N-(*trans*-4-(difluoromethoxy)cyclohexyl)-5-(3-methylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [404];
 N-(*cis*-4-ethoxycyclohexyl)-5-(3-methylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [405];
 N-(*trans*-4-ethoxycyclohexyl)-5-(3-methylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [406];
 N-(*cis*-4-(2-methoxyethoxy)cyclohexyl)-5-(3-methylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [407];
 N-(*trans*-4-(2-methoxyethoxy)cyclohexyl)-5-(3-methylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [408];
cis-N¹-(5-(3-methylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclohexane-1,4-diamine [409];
trans-N¹-(5-(3-methylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclohexane-1,4-diamine [410];
cis-N¹-methyl-N⁴-(5-(3-methylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclohexane-1,4-diamine [411];
trans-N¹-methyl-N⁴-(5-(3-methylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclohexane-1,4-diamine [412];
cis-N¹,N¹-dimethyl-N⁴-(5-(3-methylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclohexane-1,4-diamine [413];
trans-N¹,N¹-dimethyl-N⁴-(5-(3-methylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclohexane-1,4-diamine [414];

- 5-(3-methylimidazo[1,2-a]pyrimidin-6-yl)-N-(*cis*-4-morpholinocyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [415];
- 5-(3-methylimidazo[1,2-a]pyrimidin-6-yl)-N-(*trans*-4-morpholinocyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [416];
- 5-(3-methylimidazo[1,2-a]pyrimidin-6-yl)-N-(*cis*-4-(4-methylpiperazin-1-yl)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [417];
- 5-(3-methylimidazo[1,2-a]pyrimidin-6-yl)-N-(*trans*-4-(4-methylpiperazin-1-yl)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [418];
- N-(1-methylazetidin-3-yl)-5-(3-methylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [419];
- 5-(3-methylimidazo[1,2-a]pyrimidin-6-yl)-N-(oxetan-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [420];
- 5-(3-methylimidazo[1,2-a]pyrimidin-6-yl)-N-(1-methylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [421];
- 5-(3-methylimidazo[1,2-a]pyrimidin-6-yl)-N-(tetrahydro-2H-pyran-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [422];
- N-(6,6-difluorospiro[3.3]heptan-2-yl)-5-(3-methylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [423];
- 5-(3-methylimidazo[1,2-a]pyrimidin-6-yl)-N-(2-oxaspiro[3.3]heptan-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [424];
- N-(2-methyl-2-azaspiro[3.3]heptan-6-yl)-5-(3-methylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [425];
- N-(1-methyl-1H-pyrazol-4-yl)-5-(3-methylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [426];
- 5-(3-ethylimidazo[1,2-a]pyrimidin-6-yl)-N-isopropylpyrrolo[2,1-f][1,2,4]triazin-2-amine [427];
- 5-(3-ethylimidazo[1,2-a]pyrimidin-6-yl)-N-isobutylpyrrolo[2,1-f][1,2,4]triazin-2-amine [428];
- 5-(3-ethylimidazo[1,2-a]pyrimidin-6-yl)-N-(2-fluoro-2-methylpropyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [429];
- N-(2,2-difluoropropyl)-5-(3-ethylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [430];
- 5-(3-ethylimidazo[1,2-a]pyrimidin-6-yl)-N-(2,2,2-trifluoroethyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [431];
- (R)-5-(3-ethylimidazo[1,2-a]pyrimidin-6-yl)-N-(1,1,1-trifluoropropan-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [432];

- 5-(3-ethylimidazo[1,2-a]pyrimidin-6-yl)-N-(3,3,3-trifluoropropyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [433];
- 5-(3-ethylimidazo[1,2-a]pyrimidin-6-yl)-N-(3,3,3-trifluoro-2,2-dimethylpropyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [434];
- 5-(3-ethylimidazo[1,2-a]pyrimidin-6-yl)-N-(2-methoxyethyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [435];
- (R)-5-(3-ethylimidazo[1,2-a]pyrimidin-6-yl)-N-(1-methoxypropan-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [436];
- 5-(3-ethylimidazo[1,2-a]pyrimidin-6-yl)-N-(2-isopropoxyethyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [437];
- 5-(3-ethylimidazo[1,2-a]pyrimidin-6-yl)-N-((1-methylcyclopropyl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [438];
- 5-(3-ethylimidazo[1,2-a]pyrimidin-6-yl)-N-((1-(trifluoromethyl)cyclopropyl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [439];
- 5-(3-ethylimidazo[1,2-a]pyrimidin-6-yl)-N-((1-fluorocyclobutyl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [440];
- 5-(3-ethylimidazo[1,2-a]pyrimidin-6-yl)-N-((3-fluorooxetan-3-yl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [441];
- N-(cyclopropylmethyl)-5-(3-ethylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [442];
- (S)-N-(1-cyclopropylethyl)-5-(3-ethylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [443];
- (R)-N-(1-cyclopropylethyl)-5-(3-ethylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [444];
- N-(2-cyclopropyl-2,2-difluoroethyl)-5-(3-ethylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [445];
- 5-(3-ethylimidazo[1,2-a]pyrimidin-6-yl)-N-(oxetan-3-ylmethyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [446];
- 5-(3-ethylimidazo[1,2-a]pyrimidin-6-yl)-N-((tetrahydrofuran-2-yl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [447];
- N-cyclobutyl-5-(3-ethylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [448];
- N-(3,3-difluorocyclobutyl)-5-(3-ethylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [449];

N-(3,3-dimethylcyclobutyl)-5-(3-ethylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [450];

3-((5-(3-ethylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclobutan-1-ol [451];

5-(3-ethylimidazo[1,2-a]pyrimidin-6-yl)-N-(*cis*-3-methoxycyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [452];

5-(3-ethylimidazo[1,2-a]pyrimidin-6-yl)-N-(*trans*-3-methoxycyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [453];

5-(3-ethylimidazo[1,2-a]pyrimidin-6-yl)-N-(*trans*-3-(methoxymethyl)cyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [454];

N-(*cis*-3-ethoxycyclobutyl)-5-(3-ethylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [455];

N-(*trans*-3-ethoxycyclobutyl)-5-(3-ethylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [456];

5-(3-ethylimidazo[1,2-a]pyrimidin-6-yl)-N-(*cis*-3-(2-methoxyethoxy)cyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [457];

5-(3-ethylimidazo[1,2-a]pyrimidin-6-yl)-N-(*trans*-3-(2-methoxyethoxy)cyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [458];

cis-N¹-(5-(3-ethylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclobutane-1,3-diamine [459];

trans-N¹-(5-(3-ethylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclobutane-1,3-diamine [460];

cis-N¹-(5-(3-ethylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N³-methylcyclobutane-1,3-diamine [461];

trans-N¹-(5-(3-ethylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N³-methylcyclobutane-1,3-diamine [462];

cis-N¹-(5-(3-ethylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N³,N³-dimethylcyclobutane-1,3-diamine [463];

trans-N¹-(5-(3-ethylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N³,N³-dimethylcyclobutane-1,3-diamine [464];

5-(3-ethylimidazo[1,2-a]pyrimidin-6-yl)-N-(*cis*-3-morpholinocyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [465];

5-(3-ethylimidazo[1,2-a]pyrimidin-6-yl)-N-(*trans*-3-morpholinocyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [466];

5-(3-ethylimidazo[1,2-a]pyrimidin-6-yl)-N-(*cis*-3-(4-methylpiperazin-1-yl)cyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [467];

5-(3-ethylimidazo[1,2-a]pyrimidin-6-yl)-N-(*trans*-3-(4-methylpiperazin-1-yl)cyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [468];

N-(4,4-difluorocyclohexyl)-5-(3-ethylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [469];

cis-4-((5-(3-ethylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclohexan-1-ol [470];

(1*s*,4*s*)-4-((5-(3-ethylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclohexan-1-ol [471];

5-(3-ethylimidazo[1,2-a]pyrimidin-6-yl)-N-(*cis*-4-methoxycyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [472];

5-(3-ethylimidazo[1,2-a]pyrimidin-6-yl)-N-(*trans*-4-methoxycyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [473];

N-(*cis*-4-(difluoromethoxy)cyclohexyl)-5-(3-ethylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [474];

N-(*trans*-4-(difluoromethoxy)cyclohexyl)-5-(3-ethylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [475];

N-(*cis*-4-ethoxycyclohexyl)-5-(3-ethylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [476];

N-(*trans*-4-ethoxycyclohexyl)-5-(3-ethylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [477];

5-(3-ethylimidazo[1,2-a]pyrimidin-6-yl)-N-(*cis*-4-(2-methoxyethoxy)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [478];

5-(3-ethylimidazo[1,2-a]pyrimidin-6-yl)-N-(*trans*-4-(2-methoxyethoxy)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [479];

cis-N¹-(5-(3-ethylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclohexane-1,4-diamine [480];

trans-N¹-(5-(3-ethylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclohexane-1,4-diamine [481];

cis-N¹-(5-(3-ethylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N⁴-methylcyclohexane-1,4-diamine [482];

trans-N¹-(5-(3-ethylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N⁴-methylcyclohexane-1,4-diamine [483];

cis-N¹-(5-(3-ethylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N⁴,N⁴-dimethylcyclohexane-1,4-diamine [484];

trans-N¹-(5-(3-ethylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N⁴,N⁴-dimethylcyclohexane-1,4-diamine [485];

5-(3-ethylimidazo[1,2-a]pyrimidin-6-yl)-N-(*cis*-4-morpholinocyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [486];

5-(3-ethylimidazo[1,2-a]pyrimidin-6-yl)-N-(*trans*-4-morpholinocyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [487];

5-(3-ethylimidazo[1,2-a]pyrimidin-6-yl)-N-(*cis*-4-(4-methylpiperazin-1-yl)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [488];

5-(3-ethylimidazo[1,2-a]pyrimidin-6-yl)-N-(*trans*-4-(4-methylpiperazin-1-yl)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [489];

5-(3-ethylimidazo[1,2-a]pyrimidin-6-yl)-N-(1-methylazetidin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [490];

5-(3-ethylimidazo[1,2-a]pyrimidin-6-yl)-N-(oxetan-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [491];

5-(3-ethylimidazo[1,2-a]pyrimidin-6-yl)-N-(1-methylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [492];

5-(3-ethylimidazo[1,2-a]pyrimidin-6-yl)-N-(tetrahydro-2H-pyran-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [493];

N-(6,6-difluorospiro[3.3]heptan-2-yl)-5-(3-ethylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [494];

5-(3-ethylimidazo[1,2-a]pyrimidin-6-yl)-N-(2-oxaspiro[3.3]heptan-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [495];

5-(3-ethylimidazo[1,2-a]pyrimidin-6-yl)-N-(2-methyl-2-azaspiro[3.3]heptan-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [496];

5-(3-ethylimidazo[1,2-a]pyrimidin-6-yl)-N-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [497];

5-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)-N-isopropylpyrrolo[2,1-f][1,2,4]triazin-2-amine [498];

5-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)-N-isobutylpyrrolo[2,1-f][1,2,4]triazin-2-amine [499]; and

5-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)-N-(2-fluoro-2-methylpropyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [500]; or a pharmaceutically acceptable salt thereof.

13. The compound according to any one of claims 1-7, wherein the compound of Formula I is selected from the group consisting of:

N-(2,2-difluoropropyl)-5-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [501];

5-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)-N-(2,2,2-trifluoroethyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [502];

(R)-5-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)-N-(1,1,1-trifluoropropan-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [503];

5-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)-N-(3,3,3-trifluoropropyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [504];

5-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)-N-(3,3,3-trifluoro-2,2-dimethylpropyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [505];

5-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)-N-(2-methoxyethyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [506];

(R)-5-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)-N-(1-methoxypropan-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [507];

5-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)-N-(2-isopropoxyethyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [508];

5-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)-N-((1-methylcyclopropyl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [509];

5-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)-N-((1-(trifluoromethyl)cyclopropyl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [510];

5-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)-N-((1-fluorocyclobutyl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [511];

5-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)-N-((3-fluorooxetan-3-yl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [512];

N-(cyclopropylmethyl)-5-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [513];

(S)-N-(1-cyclopropylethyl)-5-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [514];

(R)-N-(1-cyclopropylethyl)-5-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [515];

N-(2-cyclopropyl-2,2-difluoroethyl)-5-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [516];

5-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)-N-(oxetan-3-ylmethyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [517];

5-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)-N-((tetrahydrofuran-2-yl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [518];

N-cyclobutyl-5-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [519];

N-(3,3-difluorocyclobutyl)-5-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [520];

N-(3,3-dimethylcyclobutyl)-5-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [521];

3-((5-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclobutan-1-ol [522];

5-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)-N-(*cis*-3-methoxycyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [523];

5-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)-N-(*trans*-3-methoxycyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [524];

5-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)-N-(*trans*-3-(methoxymethyl)cyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [525];

N-(*cis*-3-ethoxycyclobutyl)-5-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [526];

N-(*trans*-3-ethoxycyclobutyl)-5-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [527];

5-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)-N-(*cis*-3-(2-methoxyethoxy)cyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [528];

5-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)-N-(*trans*-3-(2-methoxyethoxy)cyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [529];

cis-N¹-(5-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclobutane-1,3-diamine [530];

trans-N¹-(5-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclobutane-1,3-diamine [531];

cis-N¹-(5-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N³-methylcyclobutane-1,3-diamine [532];

trans-N¹-(5-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N³-methylcyclobutane-1,3-diamine [533];

cis-N¹-(5-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N³,N³-dimethylcyclobutane-1,3-diamine [534];

trans-N¹-(5-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N³,N³-dimethylcyclobutane-1,3-diamine [535];

5-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)-N-(*cis*-3-morpholinocyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [536];

5-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)-N-(*trans*-3-morpholinocyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [537];

5-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)-N-(*cis*-3-(4-methylpiperazin-1-yl)cyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [538];

5-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)-N-(*trans*-3-(4-methylpiperazin-1-yl)cyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [539];

N-(4,4-difluorocyclohexyl)-5-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [540];

cis-4-((5-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclohexan-1-ol [541];

(1*s*,4*s*)-4-((5-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclohexan-1-ol [542];

5-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)-N-(*cis*-4-methoxycyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [543];

5-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)-N-(*trans*-4-methoxycyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [544];

N-(*cis*-4-(difluoromethoxy)cyclohexyl)-5-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [545];

N-(*trans*-4-(difluoromethoxy)cyclohexyl)-5-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [546];

N-(*cis*-4-ethoxycyclohexyl)-5-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [547];

N-(*trans*-4-ethoxycyclohexyl)-5-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [548];

5-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)-N-(*cis*-4-(2-methoxyethoxy)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [549];

5-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)-N-(*trans*-4-(2-methoxyethoxy)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [550];

cis-N¹-(5-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclohexane-1,4-diamine [551];

trans-N¹-(5-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclohexane-1,4-diamine [552];

cis-N¹-(5-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N⁴-methylcyclohexane-1,4-diamine [553];

trans-N¹-(5-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N⁴-methylcyclohexane-1,4-diamine [554];

cis-N¹-(5-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N⁴,N⁴-dimethylcyclohexane-1,4-diamine [555];

trans-N¹-(5-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N⁴,N⁴-dimethylcyclohexane-1,4-diamine [556];

5-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)-N-(*cis*-4-morpholinocyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [557];

5-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)-N-(*trans*-4-morpholinocyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [558];

5-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)-N-(*cis*-4-(4-methylpiperazin-1-yl)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [559];

5-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)-N-(*trans*-4-(4-methylpiperazin-1-yl)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [560];

5-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)-N-(1-methylazetidin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [561];

5-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)-N-(oxetan-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [562];

5-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)-N-(1-methylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [563];

5-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)-N-(tetrahydro-2H-pyran-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [564];

N-(6,6-difluorospiro[3.3]heptan-2-yl)-5-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [565];

5-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)-N-(2-oxaspiro[3.3]heptan-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [566];

5-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)-N-(2-methyl-2-azaspiro[3.3]heptan-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [567];

5-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)-N-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [568];

N-isopropyl-5-(1-isopropyl-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [569];

N-isobutyl-5-(1-isopropyl-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [570];

N-(2-fluoro-2-methylpropyl)-5-(1-isopropyl-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [571];

N-(2,2-difluoropropyl)-5-(1-isopropyl-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [572];

5-(1-isopropyl-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(2,2,2-trifluoroethyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [573];

(R)-5-(1-isopropyl-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(1,1,1-trifluoropropan-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [574];

5-(1-isopropyl-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(3,3,3-trifluoropropyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [575];

5-(1-isopropyl-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(3,3,3-trifluoro-2,2-dimethylpropyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [576];

5-(1-isopropyl-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(2-methoxyethyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [577];

(R)-5-(1-isopropyl-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(1-methoxypropan-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [578];

N-(2-isopropoxyethyl)-5-(1-isopropyl-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [579];

5-(1-isopropyl-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-((1-methylcyclopropyl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [580];

5-(1-isopropyl-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-((1-(trifluoromethyl)cyclopropyl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [581];

N-((1-fluorocyclobutyl)methyl)-5-(1-isopropyl-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [582];

N-((3-fluorooxetan-3-yl)methyl)-5-(1-isopropyl-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [583];

N-(cyclopropylmethyl)-5-(1-isopropyl-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [584];

(S)-N-(1-cyclopropylethyl)-5-(1-isopropyl-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [585];

(R)-N-(1-cyclopropylethyl)-5-(1-isopropyl-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [586];

N-(2-cyclopropyl-2,2-difluoroethyl)-5-(1-isopropyl-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [587];

5-(1-isopropyl-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(oxetan-3-ylmethyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [588];

5-(1-isopropyl-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-((tetrahydrofuran-2-yl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [589];

N-cyclobutyl-5-(1-isopropyl-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [590];

N-(3,3-difluorocyclobutyl)-5-(1-isopropyl-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [591];

N-(3,3-dimethylcyclobutyl)-5-(1-isopropyl-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [592];

3-((5-(1-isopropyl-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclobutan-1-ol [593];

5-(1-isopropyl-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*cis*-3-methoxycyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [594];

5-(1-isopropyl-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*trans*-3-methoxycyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [595];

5-(1-isopropyl-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*trans*-3-(methoxymethyl)cyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [596];

N-(*cis*-3-ethoxycyclobutyl)-5-(1-isopropyl-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [597];

N-(*trans*-3-ethoxycyclobutyl)-5-(1-isopropyl-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [598];

5-(1-isopropyl-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*cis*-3-(2-methoxyethoxy)cyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [599]; and

5-(1-isopropyl-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*trans*-3-(2-methoxyethoxy)cyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [600]; or a pharmaceutically acceptable salt thereof.

14. The compound according to any one of claims 1-7, wherein the compound of Formula I is selected from the group consisting of:

cis-N¹-(5-(1-isopropyl-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclobutane-1,3-diamine [601];

trans-N¹-(5-(1-isopropyl-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclobutane-1,3-diamine [602];

cis-N¹-(5-(1-isopropyl-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N³-methylcyclobutane-1,3-diamine [603];

trans-N¹-(5-(1-isopropyl-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N³-methylcyclobutane-1,3-diamine [604];

cis-N¹-(5-(1-isopropyl-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N³,N³-dimethylcyclobutane-1,3-diamine [605];

trans-N¹-(5-(1-isopropyl-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N³,N³-dimethylcyclobutane-1,3-diamine [606];

5-(1-isopropyl-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*cis*-3-morpholinocyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [607];

5-(1-isopropyl-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*trans*-3-morpholinocyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [608];

5-(1-isopropyl-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*cis*-3-(4-methylpiperazin-1-yl)cyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [609];

5-(1-isopropyl-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*trans*-3-(4-methylpiperazin-1-yl)cyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [610];

N-(4,4-difluorocyclohexyl)-5-(1-isopropyl-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [611];

cis-4-((5-(1-isopropyl-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclohexan-1-ol [612];

(1*s*,4*s*)-4-((5-(1-isopropyl-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclohexan-1-ol [613];

5-(1-isopropyl-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*cis*-4-methoxycyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [614];

5-(1-isopropyl-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*trans*-4-methoxycyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [615];

N-(*cis*-4-(difluoromethoxy)cyclohexyl)-5-(1-isopropyl-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [616];

N-(*trans*-4-(difluoromethoxy)cyclohexyl)-5-(1-isopropyl-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [617];

N-(*cis*-4-ethoxycyclohexyl)-5-(1-isopropyl-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [618];

N-(*trans*-4-ethoxycyclohexyl)-5-(1-isopropyl-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [619];

5-(1-isopropyl-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*cis*-4-(2-methoxyethoxy)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [620];

5-(1-isopropyl-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*trans*-4-(2-methoxyethoxy)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [621];

cis-N¹-(5-(1-isopropyl-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclohexane-1,4-diamine [622];

trans-N¹-(5-(1-isopropyl-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclohexane-1,4-diamine [623];

cis-N¹-(5-(1-isopropyl-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N⁴-methylcyclohexane-1,4-diamine [624];

trans-N¹-(5-(1-isopropyl-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N⁴-methylcyclohexane-1,4-diamine [625];

cis-N¹-(5-(1-isopropyl-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N⁴,N⁴-dimethylcyclohexane-1,4-diamine [626];

trans-N¹-(5-(1-isopropyl-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N⁴,N⁴-dimethylcyclohexane-1,4-diamine [627];

5-(1-isopropyl-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*cis*-4-morpholinocyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [628];

5-(1-isopropyl-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*trans*-4-morpholinocyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [629];

5-(1-isopropyl-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*cis*-4-(4-methylpiperazin-1-yl)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [630];

5-(1-isopropyl-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*trans*-4-(4-methylpiperazin-1-yl)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [631];

5-(1-isopropyl-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(1-methylazetidin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [632];

5-(1-isopropyl-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(oxetan-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [633];

5-(1-isopropyl-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(1-methylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [634];

5-(1-isopropyl-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(tetrahydro-2H-pyran-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [635];

N-(6,6-difluorospiro[3.3]heptan-2-yl)-5-(1-isopropyl-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [636];

5-(1-isopropyl-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(2-oxaspiro[3.3]heptan-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [637];

5-(1-isopropyl-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(2-methyl-2-azaspiro[3.3]heptan-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [638];

5-(1-isopropyl-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [639];

5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-isopropylpyrrolo[2,1-f][1,2,4]triazin-2-amine [640];

5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-isobutylpyrrolo[2,1-f][1,2,4]triazin-2-amine [641];

5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(2-fluoro-2-methylpropyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [642];

5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(2,2-difluoropropyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [643];

5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(2,2,2-trifluoroethyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [644];

(R)-5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(1,1,1-trifluoropropan-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [645];

5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(3,3,3-trifluoropropyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [646];

5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(3,3,3-trifluoro-2,2-dimethylpropyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [647];

5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(2-methoxyethyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [648];

(R)-5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(1-methoxypropan-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [649];

5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(2-isopropoxyethyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [650];

5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-((1-methylcyclopropyl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [651];

5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-((1-(trifluoromethyl)cyclopropyl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [652];

5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-((1-fluorocyclobutyl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [653];

5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-((3-fluorooxetan-3-yl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [654];

N-(cyclopropylmethyl)-5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [655];

(S)-N-(1-cyclopropylethyl)-5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [656];

(R)-N-(1-cyclopropylethyl)-5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [657];

N-(2-cyclopropyl-2,2-difluoroethyl)-5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [658];

5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(oxetan-3-ylmethyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [659];

5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-((tetrahydrofuran-2-yl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [660];

N-cyclobutyl-5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [661];

N-(3,3-difluorocyclobutyl)-5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [662];

5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(3,3-dimethylcyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [663];

3-((5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclobutan-1-ol [664];

5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*cis*-3-methoxycyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [665];

5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*trans*-3-methoxycyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [666];

5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*trans*-3-(methoxymethyl)cyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [667];

5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*cis*-3-ethoxycyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [668];

5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*trans*-3-ethoxycyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [669];

5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*cis*-3-(2-methoxyethoxy)cyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [670];

5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*trans*-3-(2-methoxyethoxy)cyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [671];

cis-N¹-(5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclobutane-1,3-diamine [672];

trans-N¹-(5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclobutane-1,3-diamine [673];

cis-N¹-(5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N³-methylcyclobutane-1,3-diamine [674];

trans-N¹-(5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N³-methylcyclobutane-1,3-diamine [675];

cis-N¹-(5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N³,N³-dimethylcyclobutane-1,3-diamine [676];

trans-N¹-(5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N³,N³-dimethylcyclobutane-1,3-diamine [677];

5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*cis*-3-morpholinocyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [678];

5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*trans*-3-morpholinocyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [679];

5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*cis*-3-(4-methylpiperazin-1-yl)cyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [680];

5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*trans*-3-(4-methylpiperazin-1-yl)cyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [681];

N-(4,4-difluorocyclohexyl)-5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [682];

cis-4-((5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclohexan-1-ol [683];

(1*s*,4*s*)-4-((5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclohexan-1-ol [684];

5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*cis*-4-methoxycyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [685];

5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*trans*-4-methoxycyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [686];

5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*cis*-4-(difluoromethoxy)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [687];

5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*trans*-4-(difluoromethoxy)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [688];

5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*cis*-4-ethoxycyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [689];

5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*trans*-4-ethoxycyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [690];

5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*cis*-4-(2-methoxyethoxy)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [691];

5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*trans*-4-(2-methoxyethoxy)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [692];

cis-N¹-(5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclohexane-1,4-diamine [693];

trans-N¹-(5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclohexane-1,4-diamine [694];

cis-N¹-(5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N⁴-methylcyclohexane-1,4-diamine [695];

trans-N¹-(5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N⁴-methylcyclohexane-1,4-diamine [696];

cis-N¹-(5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N⁴,N⁴-dimethylcyclohexane-1,4-diamine [697];

trans-N¹-(5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N⁴,N⁴-dimethylcyclohexane-1,4-diamine [698];

5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*cis*-4-morpholinocyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [699]; and

5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*trans*-4-morpholinocyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [700]; or a pharmaceutically acceptable salt thereof.

15. The compound according to any one of claims 1-7, wherein the compound of Formula I is selected from the group consisting of:

5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*cis*-4-(4-methylpiperazin-1-yl)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [701];

5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*trans*-4-(4-methylpiperazin-1-yl)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [702];

5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(1-methylazetidin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [703];

5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(oxetan-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [704];

5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(1-methylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [705];

5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(tetrahydro-2H-pyran-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [706];

5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(6,6-difluorospiro[3.3]heptan-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [707];

5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(2-oxaspiro[3.3]heptan-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [708];

5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(2-methyl-2-azaspiro[3.3]heptan-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [709];

5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [710];

5-(1-(3,3-difluorocyclobutyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-isopropylpyrrolo[2,1-f][1,2,4]triazin-2-amine [711];

5-(1-(3,3-difluorocyclobutyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-isobutylpyrrolo[2,1-f][1,2,4]triazin-2-amine [712];

5-(1-(3,3-difluorocyclobutyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(2-fluoro-2-methylpropyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [713];

5-(1-(3,3-difluorocyclobutyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(2,2-difluoropropyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [714];

5-(1-(3,3-difluorocyclobutyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(2,2,2-trifluoroethyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [715];

(R)-5-(1-(3,3-difluorocyclobutyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(1,1,1-trifluoropropan-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [716];

5-(1-(3,3-difluorocyclobutyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(3,3,3-trifluoropropyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [717];

5-(1-(3,3-difluorocyclobutyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(3,3,3-trifluoro-2,2-dimethylpropyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [718];

5-(1-(3,3-difluorocyclobutyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(2-methoxyethyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [719];

(R)-5-(1-(3,3-difluorocyclobutyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(1-methoxypropan-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [720];

5-(1-(3,3-difluorocyclobutyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(2-isopropoxyethyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [721];

5-(1-(3,3-difluorocyclobutyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-((1-methylcyclopropyl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [722];

5-(1-(3,3-difluorocyclobutyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-((1-(trifluoromethyl)cyclopropyl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [723];

5-(1-(3,3-difluorocyclobutyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-((1-fluorocyclobutyl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [724];

5-(1-(3,3-difluorocyclobutyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-((3-fluoro-oxetan-3-yl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [725];

N-(cyclopropylmethyl)-5-(1-(3,3-difluorocyclobutyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [726];

(S)-N-(1-cyclopropylethyl)-5-(1-(3,3-difluorocyclobutyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [727];

(R)-N-(1-cyclopropylethyl)-5-(1-(3,3-difluorocyclobutyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [728];

N-(2-cyclopropyl-2,2-difluoroethyl)-5-(1-(3,3-difluorocyclobutyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [729];

5-(1-(3,3-difluorocyclobutyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(oxetan-3-ylmethyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [730];

5-(1-(3,3-difluorocyclobutyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-((tetrahydrofuran-2-yl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [731];

N-cyclobutyl-5-(1-(3,3-difluorocyclobutyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [732];

N-(3,3-difluorocyclobutyl)-5-(1-(3,3-difluorocyclobutyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [733];

5-(1-(3,3-difluorocyclobutyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(3,3-dimethylcyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [734];

3-((5-(1-(3,3-difluorocyclobutyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclobutan-1-ol [735];

5-(1-(3,3-difluorocyclobutyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*cis*-3-methoxycyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [736];

5-(1-(3,3-difluorocyclobutyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*trans*-3-methoxycyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [737];

5-(1-(3,3-difluorocyclobutyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*trans*-3-(methoxymethyl)cyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [738];

5-(1-(3,3-difluorocyclobutyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*cis*-3-ethoxycyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [739];

5-(1-(3,3-difluorocyclobutyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*trans*-3-ethoxycyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [740];

5-(1-(3,3-difluorocyclobutyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*cis*-3-(2-methoxyethoxy)cyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [741];

5-(1-(3,3-difluorocyclobutyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*trans*-3-(2-methoxyethoxy)cyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [742];

cis-N¹-(5-(1-(3,3-difluorocyclobutyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclobutane-1,3-diamine [743];

trans-N¹-(5-(1-(3,3-difluorocyclobutyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclobutane-1,3-diamine [744];

cis-N¹-(5-(1-(3,3-difluorocyclobutyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N³-methylcyclobutane-1,3-diamine [745];

trans-N¹-(5-(1-(3,3-difluorocyclobutyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N³-methylcyclobutane-1,3-diamine [746];

cis-N¹-(5-(1-(3,3-difluorocyclobutyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N³,N³-dimethylcyclobutane-1,3-diamine [747];

trans-N¹-(5-(1-(3,3-difluorocyclobutyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N³,N³-dimethylcyclobutane-1,3-diamine [748];

5-(1-(3,3-difluorocyclobutyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*cis*-3-morpholinocyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [749];

5-(1-(3,3-difluorocyclobutyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*trans*-3-morpholinocyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [750];

5-(1-(3,3-difluorocyclobutyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*cis*-3-(4-methylpiperazin-1-yl)cyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [751];

5-(1-(3,3-difluorocyclobutyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*trans*-3-(4-methylpiperazin-1-yl)cyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [752];

5-(1-(3,3-difluorocyclobutyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(4,4-difluorocyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [753];

cis-4-((5-(1-(3,3-difluorocyclobutyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclohexan-1-ol [754];

(1*s*,4*s*)-4-((5-(1-(3,3-difluorocyclobutyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclohexan-1-ol [755];

5-(1-(3,3-difluorocyclobutyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*cis*-4-methoxycyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [756];

5-(1-(3,3-difluorocyclobutyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*trans*-4-methoxycyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [757];

5-(1-(3,3-difluorocyclobutyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*cis*-4-(difluoromethoxy)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [758];

5-(1-(3,3-difluorocyclobutyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*trans*-4-(difluoromethoxy)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [759];

5-(1-(3,3-difluorocyclobutyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*cis*-4-ethoxycyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [760];

5-(1-(3,3-difluorocyclobutyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*trans*-4-ethoxycyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [761];

5-(1-(3,3-difluorocyclobutyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*cis*-4-(2-methoxyethoxy)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [762];

5-(1-(3,3-difluorocyclobutyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*trans*-4-(2-methoxyethoxy)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [763];

cis-N¹-(5-(1-(3,3-difluorocyclobutyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclohexane-1,4-diamine [764];

trans-N¹-(5-(1-(3,3-difluorocyclobutyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclohexane-1,4-diamine [765];

cis-N¹-(5-(1-(3,3-difluorocyclobutyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N⁴-methylcyclohexane-1,4-diamine [766];

trans-N¹-(5-(1-(3,3-difluorocyclobutyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N⁴-methylcyclohexane-1,4-diamine [767];

cis-N¹-(5-(1-(3,3-difluorocyclobutyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N⁴,N⁴-dimethylcyclohexane-1,4-diamine [768];

trans-N¹-(5-(1-(3,3-difluorocyclobutyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N⁴,N⁴-dimethylcyclohexane-1,4-diamine [769];

5-(1-(3,3-difluorocyclobutyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*cis*-4-morpholinocyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [770];

5-(1-(3,3-difluorocyclobutyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*trans*-4-morpholinocyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [771];

5-(1-(3,3-difluorocyclobutyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*cis*-4-(4-methylpiperazin-1-yl)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [772];

5-(1-(3,3-difluorocyclobutyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*trans*-4-(4-methylpiperazin-1-yl)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [773];

5-(1-(3,3-difluorocyclobutyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(1-methylazetidin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [774];

5-(1-(3,3-difluorocyclobutyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(oxetan-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [775];

5-(1-(3,3-difluorocyclobutyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(1-methylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [776];

5-(1-(3,3-difluorocyclobutyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(tetrahydro-2H-pyran-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [777];

5-(1-(3,3-difluorocyclobutyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(6,6-difluorospiro[3.3]heptan-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [778];

5-(1-(3,3-difluorocyclobutyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(2-oxaspiro[3.3]heptan-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [779];

5-(1-(3,3-difluorocyclobutyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(2-methyl-2-azaspiro[3.3]heptan-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [780];

5-(1-(3,3-difluorocyclobutyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [781];

N-isopropyl-5-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [782];

N-isobutyl-5-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [783];

N-(2-fluoro-2-methylpropyl)-5-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [784];

N-(2,2-difluoropropyl)-5-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [785];

5-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-b]pyridin-6-yl)-N-(2,2,2-trifluoroethyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [786];

(R)-5-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-b]pyridin-6-yl)-N-(1,1,1-trifluoropropan-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [787];

5-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-b]pyridin-6-yl)-N-(3,3,3-trifluoropropyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [788];

5-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-b]pyridin-6-yl)-N-(3,3,3-trifluoro-2,2-dimethylpropyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [789];

N-(2-methoxyethyl)-5-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [790];

(R)-N-(1-methoxypropan-2-yl)-5-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [791];

N-(2-isopropoxyethyl)-5-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [792];

5-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-b]pyridin-6-yl)-N-((1-methylcyclopropyl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [793];

5-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-b]pyridin-6-yl)-N-((1-(trifluoromethyl)cyclopropyl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [794];

N-((1-fluorocyclobutyl)methyl)-5-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [795];

N-((3-fluorooxetan-3-yl)methyl)-5-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [796];

N-(cyclopropylmethyl)-5-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [797];

(S)-N-(1-cyclopropylethyl)-5-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [798];

(R)-N-(1-cyclopropylethyl)-5-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [799]; and

N-(2-cyclopropyl-2,2-difluoroethyl)-5-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [800]; or a pharmaceutically acceptable salt thereof.

16. The compound according to any one of claims 1-7, wherein the compound of Formula I is selected from the group consisting of:

- 5-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-b]pyridin-6-yl)-N-(oxetan-3-ylmethyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [801];
- 5-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-b]pyridin-6-yl)-N-((tetrahydrofuran-2-yl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [802];
- N-cyclobutyl-5-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [803];
- N-(3,3-difluorocyclobutyl)-5-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [804];
- N-(3,3-dimethylcyclobutyl)-5-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [805];
- 1-methyl-3-((5-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclobutan-1-ol [806];
- N-(*cis*-3-methoxycyclobutyl)-5-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [807];
- N-(*trans*-3-methoxycyclobutyl)-5-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [808];
- N-(*trans*-3-(methoxymethyl)cyclobutyl)-5-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [809];
- N-(*cis*-3-ethoxycyclobutyl)-5-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [810];
- N-(*trans*-3-ethoxycyclobutyl)-5-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [811];
- N-(*cis*-3-(2-methoxyethoxy)cyclobutyl)-5-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [812];
- N-(*trans*-3-(2-methoxyethoxy)cyclobutyl)-5-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [813];
- cis*-N¹-(5-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclobutane-1,3-diamine [814];

trans-N¹-(5-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclobutane-1,3-diamine [815];

cis-N¹-methyl-N³-(5-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclobutane-1,3-diamine [816];

trans-N¹-methyl-N³-(5-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclobutane-1,3-diamine [817];

cis-N¹,N¹-dimethyl-N³-(5-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclobutane-1,3-diamine [818];

trans-N¹,N¹-dimethyl-N³-(5-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclobutane-1,3-diamine [819];

5-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*cis*-3-morpholinocyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [820];

5-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*trans*-3-morpholinocyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [821];

5-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*cis*-3-(4-methylpiperazin-1-yl)cyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [822];

5-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*trans*-3-(4-methylpiperazin-1-yl)cyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [823];

N-(4,4-difluorocyclohexyl)-5-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [824];

cis-4-((5-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclohexan-1-ol [825];

(1*s*,4*s*)-1-methyl-4-((5-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclohexan-1-ol [826];

N-(*cis*-4-methoxycyclohexyl)-5-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [827];

N-(*trans*-4-methoxycyclohexyl)-5-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [828];

N-(*cis*-4-(difluoromethoxy)cyclohexyl)-5-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [829];

N-(*trans*-4-(difluoromethoxy)cyclohexyl)-5-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [830];

N-(*cis*-4-ethoxycyclohexyl)-5-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [831];

N-(*trans*-4-ethoxycyclohexyl)-5-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [832];

N-(*cis*-4-(2-methoxyethoxy)cyclohexyl)-5-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [833];

N-(*trans*-4-(2-methoxyethoxy)cyclohexyl)-5-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [834];

cis-N¹-(5-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclohexane-1,4-diamine [835];

trans-N¹-(5-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclohexane-1,4-diamine [836];

cis-N¹-methyl-N⁴-(5-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclohexane-1,4-diamine [837];

trans-N¹-methyl-N⁴-(5-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclohexane-1,4-diamine [838];

cis-N¹,N¹-dimethyl-N⁴-(5-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclohexane-1,4-diamine [839];

trans-N¹,N¹-dimethyl-N⁴-(5-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclohexane-1,4-diamine [840];

5-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*cis*-4-morpholinocyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [841];

5-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*trans*-4-morpholinocyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [842];

5-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*cis*-4-(4-methylpiperazin-1-yl)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [843];

5-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*trans*-4-(4-methylpiperazin-1-yl)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [844];

5-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-b]pyridin-6-yl)-N-(1-methylazetidin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [845];

5-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-b]pyridin-6-yl)-N-(oxetan-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [846];

5-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-b]pyridin-6-yl)-N-(1-methylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [847];

5-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-b]pyridin-6-yl)-N-(tetrahydro-2H-pyran-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [848];

N-(6,6-difluorospiro[3.3]heptan-2-yl)-5-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [849];

5-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-b]pyridin-6-yl)-N-(2-oxaspiro[3.3]heptan-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [850];

5-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-b]pyridin-6-yl)-N-(2-methyl-2-azaspiro[3.3]heptan-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [851];

5-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-b]pyridin-6-yl)-N-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [852];

5-(2,3-dimethyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-isopropylpyrrolo[2,1-f][1,2,4]triazin-2-amine [853];

5-(2,3-dimethyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-isobutylpyrrolo[2,1-f][1,2,4]triazin-2-amine [854];

5-(2,3-dimethyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(2-fluoro-2-methylpropyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [855];

N-(2,2-difluoropropyl)-5-(2,3-dimethyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [856];

5-(2,3-dimethyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(2,2,2-trifluoroethyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [857];

(R)-5-(2,3-dimethyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(1,1,1-trifluoropropan-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [858];

5-(2,3-dimethyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(3,3,3-trifluoropropyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [859];

5-(2,3-dimethyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(3,3,3-trifluoro-2,2-dimethylpropyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [860];

5-(2,3-dimethyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(2-methoxyethyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [861];

(R)-5-(2,3-dimethyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(1-methoxypropan-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [862];

5-(2,3-dimethyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(2-isopropoxyethyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [863];

5-(2,3-dimethyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-((1-methylcyclopropyl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [864];

5-(2,3-dimethyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-((1-(trifluoromethyl)cyclopropyl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [865];

5-(2,3-dimethyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-((1-fluorocyclobutyl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [866];

5-(2,3-dimethyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-((3-fluorooxetan-3-yl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [867];

N-(cyclopropylmethyl)-5-(2,3-dimethyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [868];

(S)-N-(1-cyclopropylethyl)-5-(2,3-dimethyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [869];

(R)-N-(1-cyclopropylethyl)-5-(2,3-dimethyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [870];

N-(2-cyclopropyl-2,2-difluoroethyl)-5-(2,3-dimethyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [871];

5-(2,3-dimethyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(oxetan-3-ylmethyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [872];

5-(2,3-dimethyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-((tetrahydrofuran-2-yl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [873];

N-cyclobutyl-5-(2,3-dimethyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [874];

N-(3,3-difluorocyclobutyl)-5-(2,3-dimethyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [875];

5-(2,3-dimethyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(3,3-dimethylcyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [876];

3-((5-(2,3-dimethyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclobutan-1-ol [877];

5-(2,3-dimethyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*cis*-3-methoxycyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [878];

5-(2,3-dimethyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*trans*-3-methoxycyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [879];

5-(2,3-dimethyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*trans*-3-(methoxymethyl)cyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [880];

5-(2,3-dimethyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*cis*-3-ethoxycyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [881];

5-(2,3-dimethyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*trans*-3-ethoxycyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [882];

5-(2,3-dimethyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*cis*-3-(2-methoxyethoxy)cyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [883];

5-(2,3-dimethyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*trans*-3-(2-methoxyethoxy)cyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [884];

cis-N¹-(5-(2,3-dimethyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclobutane-1,3-diamine [885];

trans-N¹-(5-(2,3-dimethyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclobutane-1,3-diamine [886];

cis-N¹-(5-(2,3-dimethyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N³-methylcyclobutane-1,3-diamine [887];

trans-N¹-(5-(2,3-dimethyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N³-methylcyclobutane-1,3-diamine [888];

cis-N¹-(5-(2,3-dimethyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N³,N³-dimethylcyclobutane-1,3-diamine [889];

trans-N¹-(5-(2,3-dimethyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N³,N³-dimethylcyclobutane-1,3-diamine [890];

5-(2,3-dimethyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*cis*-3-morpholinocyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [891];

5-(2,3-dimethyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*trans*-3-morpholinocyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [892];

5-(2,3-dimethyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*cis*-3-(4-methylpiperazin-1-yl)cyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [893];

5-(2,3-dimethyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*trans*-3-(4-methylpiperazin-1-yl)cyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [894];

N-(4,4-difluorocyclohexyl)-5-(2,3-dimethyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [895];

cis-4-((5-(2,3-dimethyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclohexan-1-ol [896];

(1*s*,4*s*)-4-((5-(2,3-dimethyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclohexan-1-ol [897];

5-(2,3-dimethyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*cis*-4-methoxycyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [898];

5-(2,3-dimethyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*trans*-4-methoxycyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [899]; and

N-(*cis*-4-(difluoromethoxy)cyclohexyl)-5-(2,3-dimethyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [900]; or a pharmaceutically acceptable salt thereof.

17. The compound according to any one of claims 1-7, wherein the compound of Formula I is selected from the group consisting of:

N-(*trans*-4-(difluoromethoxy)cyclohexyl)-5-(2,3-dimethyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [901];

5-(2,3-dimethyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*cis*-4-ethoxycyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [902];

5-(2,3-dimethyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*trans*-4-ethoxycyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [903];

5-(2,3-dimethyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*cis*-4-(2-methoxyethoxy)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [904];

5-(2,3-dimethyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*trans*-4-(2-methoxyethoxy)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [905];

cis-N¹-(5-(2,3-dimethyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclohexane-1,4-diamine [906];

trans-N¹-(5-(2,3-dimethyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclohexane-1,4-diamine [907];

cis-N¹-(5-(2,3-dimethyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N⁴-methylcyclohexane-1,4-diamine [908];

trans-N¹-(5-(2,3-dimethyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N⁴-methylcyclohexane-1,4-diamine [909];

cis-N¹-(5-(2,3-dimethyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N⁴,N⁴-dimethylcyclohexane-1,4-diamine [910];

trans-N¹-(5-(2,3-dimethyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N⁴,N⁴-dimethylcyclohexane-1,4-diamine [911];

5-(2,3-dimethyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*cis*-4-morpholinocyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [912];

5-(2,3-dimethyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*trans*-4-morpholinocyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [913];

5-(2,3-dimethyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*cis*-4-(4-methylpiperazin-1-yl)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [914];

5-(2,3-dimethyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*trans*-4-(4-methylpiperazin-1-yl)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [915];

5-(2,3-dimethyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(1-methylazetidin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [916];

5-(2,3-dimethyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(oxetan-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [917];

5-(2,3-dimethyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(1-methylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [918];

5-(2,3-dimethyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(tetrahydro-2H-pyran-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [919];

N-(6,6-difluorospiro[3.3]heptan-2-yl)-5-(2,3-dimethyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [920];

5-(2,3-dimethyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(2-oxaspiro[3.3]heptan-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [921];

5-(2,3-dimethyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(2-methyl-2-azaspiro[3.3]heptan-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [922];

5-(2,3-dimethyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [923];

5-(3-ethyl-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-isopropylpyrrolo[2,1-f][1,2,4]triazin-2-amine [924];

5-(3-ethyl-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-isobutylpyrrolo[2,1-f][1,2,4]triazin-2-amine [925];

5-(3-ethyl-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(2-fluoro-2-methylpropyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [926];

N-(2,2-difluoropropyl)-5-(3-ethyl-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [927];

5-(3-ethyl-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(2,2,2-trifluoroethyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [928];

(R)-5-(3-ethyl-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(1,1,1-trifluoropropan-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [929];

5-(3-ethyl-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(3,3,3-trifluoropropyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [930];

5-(3-ethyl-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(3,3,3-trifluoro-2,2-dimethylpropyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [931];

5-(3-ethyl-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(2-methoxyethyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [932];

(R)-5-(3-ethyl-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(1-methoxypropan-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [933];

5-(3-ethyl-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(2-isopropoxyethyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [934];

5-(3-ethyl-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-((1-methylcyclopropyl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [935];

5-(3-ethyl-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-((1-(trifluoromethyl)cyclopropyl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [936];

5-(3-ethyl-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-((1-fluorocyclobutyl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [937];

5-(3-ethyl-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-((3-fluorooxetan-3-yl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [938];

N-(cyclopropylmethyl)-5-(3-ethyl-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [939];

(S)-N-(1-cyclopropylethyl)-5-(3-ethyl-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [940];

(R)-N-(1-cyclopropylethyl)-5-(3-ethyl-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [941];

N-(2-cyclopropyl-2,2-difluoroethyl)-5-(3-ethyl-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [942];

5-(3-ethyl-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(oxetan-3-ylmethyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [943];

5-(3-ethyl-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-((tetrahydrofuran-2-yl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [944];

N-cyclobutyl-5-(3-ethyl-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [945];

N-(3,3-difluorocyclobutyl)-5-(3-ethyl-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [946];

N-(3,3-dimethylcyclobutyl)-5-(3-ethyl-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [947];

3-((5-(3-ethyl-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclobutan-1-ol [948];

5-(3-ethyl-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*cis*-3-methoxycyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [949];

5-(3-ethyl-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*trans*-3-methoxycyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [950];

5-(3-ethyl-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*trans*-3-(methoxymethyl)cyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [951];

N-(*cis*-3-ethoxycyclobutyl)-5-(3-ethyl-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [952];

N-(*trans*-3-ethoxycyclobutyl)-5-(3-ethyl-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [953];

5-(3-ethyl-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*cis*-3-(2-methoxyethoxy)cyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [954];

5-(3-ethyl-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*trans*-3-(2-methoxyethoxy)cyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [955];

cis-N¹-(5-(3-ethyl-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclobutane-1,3-diamine [956];

trans-N¹-(5-(3-ethyl-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclobutane-1,3-diamine [957];

cis-N¹-(5-(3-ethyl-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N³-methylcyclobutane-1,3-diamine [958];

trans-N¹-(5-(3-ethyl-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N³-methylcyclobutane-1,3-diamine [959];

cis-N¹-(5-(3-ethyl-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N³,N³-dimethylcyclobutane-1,3-diamine [960];

trans-N¹-(5-(3-ethyl-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N³,N³-dimethylcyclobutane-1,3-diamine [961];

5-(3-ethyl-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*cis*-3-morpholinocyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [962];

5-(3-ethyl-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*trans*-3-morpholinocyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [963];

5-(3-ethyl-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*cis*-3-(4-methylpiperazin-1-yl)cyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [964];

5-(3-ethyl-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*trans*-3-(4-methylpiperazin-1-yl)cyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [965];

N-(4,4-difluorocyclohexyl)-5-(3-ethyl-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [966];

cis-4-((5-(3-ethyl-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclohexan-1-ol [967];

(1*s*,4*s*)-4-((5-(3-ethyl-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclohexan-1-ol [968];

5-(3-ethyl-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*cis*-4-methoxycyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [969];

5-(3-ethyl-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*trans*-4-methoxycyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [970];

N-(*cis*-4-(difluoromethoxy)cyclohexyl)-5-(3-ethyl-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [971];

N-(*trans*-4-(difluoromethoxy)cyclohexyl)-5-(3-ethyl-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [972];

N-(*cis*-4-ethoxycyclohexyl)-5-(3-ethyl-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [973];

N-(*trans*-4-ethoxycyclohexyl)-5-(3-ethyl-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [974];

5-(3-ethyl-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*cis*-4-(2-methoxyethoxy)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [975];

5-(3-ethyl-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*trans*-4-(2-methoxyethoxy)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [976];

cis-N¹-(5-(3-ethyl-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclohexane-1,4-diamine [977];

trans-N¹-(5-(3-ethyl-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclohexane-1,4-diamine [978];

cis-N¹-(5-(3-ethyl-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N⁴-methylcyclohexane-1,4-diamine [979];

trans-N¹-(5-(3-ethyl-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N⁴-methylcyclohexane-1,4-diamine [980];

cis-N¹-(5-(3-ethyl-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N⁴,N⁴-dimethylcyclohexane-1,4-diamine [981];

trans-N¹-(5-(3-ethyl-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N⁴,N⁴-dimethylcyclohexane-1,4-diamine [982];

5-(3-ethyl-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*cis*-4-morpholinocyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [983];

5-(3-ethyl-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*trans*-4-morpholinocyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [984];

5-(3-ethyl-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*cis*-4-(4-methylpiperazin-1-yl)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [985];

5-(3-ethyl-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*trans*-4-(4-methylpiperazin-1-yl)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [986];

5-(3-ethyl-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(1-methylazetidin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [987];

5-(3-ethyl-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(oxetan-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [988];

5-(3-ethyl-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(1-methylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [989];

5-(3-ethyl-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(tetrahydro-2H-pyran-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [990];

N-(6,6-difluorospiro[3.3]heptan-2-yl)-5-(3-ethyl-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [991];

5-(3-ethyl-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(2-oxaspiro[3.3]heptan-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [992];

5-(3-ethyl-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(2-methyl-2-azaspiro[3.3]heptan-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [993];

5-(3-ethyl-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [994];

5-(3-(2-fluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-isopropylpyrrolo[2,1-f][1,2,4]triazin-2-amine [995];

5-(3-(2-fluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-isobutylpyrrolo[2,1-f][1,2,4]triazin-2-amine [996];

N-(2-fluoro-2-methylpropyl)-5-(3-(2-fluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [997];

N-(2,2-difluoropropyl)-5-(3-(2-fluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [998];

5-(3-(2-fluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(2,2,2-trifluoroethyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [999]; and

(R)-5-(3-(2-fluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(1,1,1-trifluoropropan-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1000]; or a pharmaceutically acceptable salt thereof.

18. The compound according to any one of claims 1-7, wherein the compound of Formula I is selected from the group consisting of:

- 5-(3-(2-fluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(3,3,3-trifluoropropyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1001];
- 5-(3-(2-fluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(3,3,3-trifluoro-2,2-dimethylpropyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1002];
- 5-(3-(2-fluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(2-methoxyethyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1003];
- (R)-5-(3-(2-fluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(1-methoxypropan-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1004];
- 5-(3-(2-fluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(2-isopropoxyethyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1005];
- 5-(3-(2-fluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-((1-methylcyclopropyl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1006];
- 5-(3-(2-fluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-((1-(trifluoromethyl)cyclopropyl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1007];
- N-((1-fluorocyclobutyl)methyl)-5-(3-(2-fluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1008];
- 5-(3-(2-fluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-((3-fluorooxetan-3-yl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1009];
- N-(cyclopropylmethyl)-5-(3-(2-fluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1010];
- (S)-N-(1-cyclopropylethyl)-5-(3-(2-fluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1011];
- (R)-N-(1-cyclopropylethyl)-5-(3-(2-fluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1012];
- N-(2-cyclopropyl-2,2-difluoroethyl)-5-(3-(2-fluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1013];
- 5-(3-(2-fluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(oxetan-3-ylmethyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1014];
- 5-(3-(2-fluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-((tetrahydrofuran-2-yl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1015];
- N-cyclobutyl-5-(3-(2-fluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1016];

N-(3,3-difluorocyclobutyl)-5-(3-(2-fluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1017];

N-(3,3-dimethylcyclobutyl)-5-(3-(2-fluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1018];

3-((5-(3-(2-fluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclobutan-1-ol [1019];

5-(3-(2-fluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*cis*-3-methoxycyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1020];

5-(3-(2-fluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*trans*-3-methoxycyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1021];

5-(3-(2-fluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*trans*-3-(methoxymethyl)cyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1022];

N-(*cis*-3-ethoxycyclobutyl)-5-(3-(2-fluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1023];

N-(*trans*-3-ethoxycyclobutyl)-5-(3-(2-fluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1024];

5-(3-(2-fluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*cis*-3-(2-methoxyethoxy)cyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1025];

5-(3-(2-fluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*trans*-3-(2-methoxyethoxy)cyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1026];

cis-N¹-(5-(3-(2-fluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclobutane-1,3-diamine [1027];

trans-N¹-(5-(3-(2-fluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclobutane-1,3-diamine [1028];

cis-N¹-(5-(3-(2-fluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N³-methylcyclobutane-1,3-diamine [1029];

trans-N¹-(5-(3-(2-fluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N³-methylcyclobutane-1,3-diamine [1030];

cis-N¹-(5-(3-(2-fluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N³,N³-dimethylcyclobutane-1,3-diamine [1031];

trans-N¹-(5-(3-(2-fluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N³,N³-dimethylcyclobutane-1,3-diamine [1032];

5-(3-(2-fluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*cis*-3-morpholinocyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1033];

5-(3-(2-fluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*trans*-3-morpholinocyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1034];

5-(3-(2-fluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*cis*-3-(4-methylpiperazin-1-yl)cyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1035];

5-(3-(2-fluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*trans*-3-(4-methylpiperazin-1-yl)cyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1036];

N-(4,4-difluorocyclohexyl)-5-(3-(2-fluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1037];

cis-4-((5-(3-(2-fluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclohexan-1-ol [1038];

(1*s*,4*s*)-4-((5-(3-(2-fluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclohexan-1-ol [1039];

5-(3-(2-fluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*cis*-4-methoxycyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1040];

5-(3-(2-fluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*trans*-4-methoxycyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1041];

N-(*cis*-4-(difluoromethoxy)cyclohexyl)-5-(3-(2-fluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1042];

N-(*trans*-4-(difluoromethoxy)cyclohexyl)-5-(3-(2-fluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1043];

N-(*cis*-4-ethoxycyclohexyl)-5-(3-(2-fluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1044];

N-(*trans*-4-ethoxycyclohexyl)-5-(3-(2-fluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1045];

5-(3-(2-fluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*cis*-4-(2-methoxyethoxy)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1046];

5-(3-(2-fluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*trans*-4-(2-methoxyethoxy)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1047];

cis-N¹-(5-(3-(2-fluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclohexane-1,4-diamine [1048];

trans-N¹-(5-(3-(2-fluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclohexane-1,4-diamine [1049];

cis-N¹-(5-(3-(2-fluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N⁴-methylcyclohexane-1,4-diamine [1050];

trans-N¹-(5-(3-(2-fluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N⁴-methylcyclohexane-1,4-diamine [1051];

cis-N¹-(5-(3-(2-fluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N⁴,N⁴-dimethylcyclohexane-1,4-diamine [1052];

trans-N¹-(5-(3-(2-fluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N⁴,N⁴-dimethylcyclohexane-1,4-diamine [1053];

5-(3-(2-fluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*cis*-4-morpholinocyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1054];

5-(3-(2-fluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*trans*-4-morpholinocyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1055];

5-(3-(2-fluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*cis*-4-(4-methylpiperazin-1-yl)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1056];

5-(3-(2-fluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*trans*-4-(4-methylpiperazin-1-yl)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1057];

5-(3-(2-fluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(1-methylazetidin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1058];

5-(3-(2-fluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(oxetan-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1059];

5-(3-(2-fluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(1-methylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1060];

5-(3-(2-fluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(tetrahydro-2H-pyran-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1061];

N-(6,6-difluorospiro[3.3]heptan-2-yl)-5-(3-(2-fluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1062];

5-(3-(2-fluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(2-oxaspiro[3.3]heptan-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1063];

5-(3-(2-fluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(2-methyl-2-azaspiro[3.3]heptan-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1064];

5-(3-(2-fluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1065];

5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-isopropylpyrrolo[2,1-f][1,2,4]triazin-2-amine [1066];

5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-isobutylpyrrolo[2,1-f][1,2,4]triazin-2-amine [1067];

N-(2-fluoro-2-methylpropyl)-5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1068];

N-(2,2-difluoropropyl)-5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1069];

5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(2,2,2-trifluoroethyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1070];

(R)-5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(1,1,1-trifluoropropan-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1071];

5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(3,3,3-trifluoropropyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1072];

5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(3,3,3-trifluoro-2,2-dimethylpropyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1073];

5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(2-methoxyethyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1074];

(R)-5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(1-methoxypropan-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1075];

5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(2-isopropoxyethyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1076];

5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-((1-methylcyclopropyl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1077];

5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-((1-(trifluoromethyl)cyclopropyl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1078];

N-((1-fluorocyclobutyl)methyl)-5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1079];

5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-((3-fluorooxetan-3-yl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1080];

N-(cyclopropylmethyl)-5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1081];

(S)-N-(1-cyclopropylethyl)-5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1082];

(R)-N-(1-cyclopropylethyl)-5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1083];

N-(2-cyclopropyl-2,2-difluoroethyl)-5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1084];

5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(oxetan-3-ylmethyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1085];

5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-((tetrahydrofuran-2-yl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1086];

N-cyclobutyl-5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1087];

N-(3,3-difluorocyclobutyl)-5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1088];

N-(3,3-dimethylcyclobutyl)-5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1089];

3-((5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclobutan-1-ol [1090];

5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*cis*-3-methoxycyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1091];

5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*trans*-3-methoxycyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1092];

5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*trans*-3-(methoxymethyl)cyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1093];

N-(*cis*-3-ethoxycyclobutyl)-5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1094];

N-(*trans*-3-ethoxycyclobutyl)-5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1095];

5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*cis*-3-(2-methoxyethoxy)cyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1096];

5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*trans*-3-(2-methoxyethoxy)cyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1097];

cis-N¹-(5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclobutane-1,3-diamine [1098];

trans-N¹-(5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclobutane-1,3-diamine [1099]; and

cis-N¹-(5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N³-methylcyclobutane-1,3-diamine [1100]; or a pharmaceutically acceptable salt thereof.

19. The compound according to any one of claims 1-7, wherein the compound of Formula I is selected from the group consisting of:

trans-N¹-(5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N³-methylcyclobutane-1,3-diamine [1101];

cis-N¹-(5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N³,N³-dimethylcyclobutane-1,3-diamine [1102];

trans-N¹-(5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N³,N³-dimethylcyclobutane-1,3-diamine [1103];

5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*cis*-3-morpholinocyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1104];

5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*trans*-3-morpholinocyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1105];

5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*cis*-3-(4-methylpiperazin-1-yl)cyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1106];

5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*trans*-3-(4-methylpiperazin-1-yl)cyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1107];

N-(4,4-difluorocyclohexyl)-5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1108];

cis-4-((5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclohexan-1-ol [1109];

(1*s*,4*s*)-4-((5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclohexan-1-ol [1110];

5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*cis*-4-methoxycyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1111];

5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*trans*-4-methoxycyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1112];

N-(*cis*-4-(difluoromethoxy)cyclohexyl)-5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1113];

N-(*trans*-4-(difluoromethoxy)cyclohexyl)-5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1114];

N-(*cis*-4-ethoxycyclohexyl)-5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1115];

N-(*trans*-4-ethoxycyclohexyl)-5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1116];

5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*cis*-4-(2-methoxyethoxy)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1117];

5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*trans*-4-(2-methoxyethoxy)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1118];

cis-N¹-(5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclohexane-1,4-diamine [1119];

trans-N¹-(5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclohexane-1,4-diamine [1120];

cis-N¹-(5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N⁴-methylcyclohexane-1,4-diamine [1121];

trans-N¹-(5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N⁴-methylcyclohexane-1,4-diamine [1122];

cis-N¹-(5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N⁴,N⁴-dimethylcyclohexane-1,4-diamine [1123];

trans-N¹-(5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N⁴,N⁴-dimethylcyclohexane-1,4-diamine [1124];

5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*cis*-4-morpholinocyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1125];

5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*trans*-4-morpholinocyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1126];

5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*cis*-4-(4-methylpiperazin-1-yl)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1127];

5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*trans*-4-(4-methylpiperazin-1-yl)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1128];

5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(1-methylazetidin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1129];

5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(oxetan-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1130];

5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(1-methylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1131];

5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(tetrahydro-2H-pyran-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1132];

N-(6,6-difluorospiro[3.3]heptan-2-yl)-5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1133];

5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(2-oxaspiro[3.3]heptan-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1134];

5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(2-methyl-2-azaspiro[3.3]heptan-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1135];

5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1136];

N-isopropyl-5-(3-(2-methoxyethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1137];

N-isobutyl-5-(3-(2-methoxyethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1138];

N-(2-fluoro-2-methylpropyl)-5-(3-(2-methoxyethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1139];

N-(2,2-difluoropropyl)-5-(3-(2-methoxyethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1140];

5-(3-(2-methoxyethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(2,2,2-trifluoroethyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1141];

(R)-5-(3-(2-methoxyethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(1,1,1-trifluoropropan-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1142];

5-(3-(2-methoxyethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(3,3,3-trifluoropropyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1143];

5-(3-(2-methoxyethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(3,3,3-trifluoro-2,2-dimethylpropyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1144];

N-(2-methoxyethyl)-5-(3-(2-methoxyethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1145];

(R)-5-(3-(2-methoxyethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(1-methoxypropan-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1146];

N-(2-isopropoxyethyl)-5-(3-(2-methoxyethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1147];

5-(3-(2-methoxyethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-((1-methylcyclopropyl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1148];

5-(3-(2-methoxyethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-((1-(trifluoromethyl)cyclopropyl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1149];

N-((1-fluorocyclobutyl)methyl)-5-(3-(2-methoxyethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1150];

N-((3-fluorooxetan-3-yl)methyl)-5-(3-(2-methoxyethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1151];

N-(cyclopropylmethyl)-5-(3-(2-methoxyethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1152];

(S)-N-(1-cyclopropylethyl)-5-(3-(2-methoxyethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1153];

(R)-N-(1-cyclopropylethyl)-5-(3-(2-methoxyethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1154];

N-(2-cyclopropyl-2,2-difluoroethyl)-5-(3-(2-methoxyethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1155];

5-(3-(2-methoxyethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(oxetan-3-ylmethyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1156];

5-(3-(2-methoxyethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-((tetrahydrofuran-2-yl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1157];

N-cyclobutyl-5-(3-(2-methoxyethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1158];

N-(3,3-difluorocyclobutyl)-5-(3-(2-methoxyethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1159];

N-(3,3-dimethylcyclobutyl)-5-(3-(2-methoxyethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1160];

3-((5-(3-(2-methoxyethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclobutan-1-ol [1161];

N-(*cis*-3-methoxycyclobutyl)-5-(3-(2-methoxyethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1162];

N-(*trans*-3-methoxycyclobutyl)-5-(3-(2-methoxyethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1163];

5-(3-(2-methoxyethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*trans*-3-(methoxymethyl)cyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1164];

N-(*cis*-3-ethoxycyclobutyl)-5-(3-(2-methoxyethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1165];

N-(*trans*-3-ethoxycyclobutyl)-5-(3-(2-methoxyethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1166];

N-(*cis*-3-(2-methoxyethoxy)cyclobutyl)-5-(3-(2-methoxyethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1167];

N-(*trans*-3-(2-methoxyethoxy)cyclobutyl)-5-(3-(2-methoxyethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1168];

cis-N¹-(5-(3-(2-methoxyethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclobutane-1,3-diamine [1169];

trans-N¹-(5-(3-(2-methoxyethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclobutane-1,3-diamine [1170];

cis-N¹-(5-(3-(2-methoxyethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N³-methylcyclobutane-1,3-diamine [1171];

trans-N¹-(5-(3-(2-methoxyethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N³-methylcyclobutane-1,3-diamine [1172];

cis-N¹-(5-(3-(2-methoxyethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N³,N³-dimethylcyclobutane-1,3-diamine [1173];

trans-N¹-(5-(3-(2-methoxyethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N³,N³-dimethylcyclobutane-1,3-diamine [1174];

5-(3-(2-methoxyethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*cis*-3-morpholinocyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1175];

5-(3-(2-methoxyethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*trans*-3-morpholinocyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1176];

5-(3-(2-methoxyethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*cis*-3-(4-methylpiperazin-1-yl)cyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1177];

5-(3-(2-methoxyethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*trans*-3-(4-methylpiperazin-1-yl)cyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1178];

N-(4,4-difluorocyclohexyl)-5-(3-(2-methoxyethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1179];

cis-4-((5-(3-(2-methoxyethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclohexan-1-ol [1180];

(1*s*,4*s*)-4-((5-(3-(2-methoxyethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclohexan-1-ol [1181];

N-(*cis*-4-methoxycyclohexyl)-5-(3-(2-methoxyethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1182];

N-(*trans*-4-methoxycyclohexyl)-5-(3-(2-methoxyethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1183];

N-(*cis*-4-(difluoromethoxy)cyclohexyl)-5-(3-(2-methoxyethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1184];

N-(*trans*-4-(difluoromethoxy)cyclohexyl)-5-(3-(2-methoxyethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1185];

N-(*cis*-4-ethoxycyclohexyl)-5-(3-(2-methoxyethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1186];

N-(*trans*-4-ethoxycyclohexyl)-5-(3-(2-methoxyethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1187];

N-(*cis*-4-(2-methoxyethoxy)cyclohexyl)-5-(3-(2-methoxyethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1188];

N-(*trans*-4-(2-methoxyethoxy)cyclohexyl)-5-(3-(2-methoxyethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1189];

cis-N¹-(5-(3-(2-methoxyethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclohexane-1,4-diamine [1190];

trans-N¹-(5-(3-(2-methoxyethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclohexane-1,4-diamine [1191];

cis-N¹-(5-(3-(2-methoxyethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N⁴-methylcyclohexane-1,4-diamine [1192];

trans-N¹-(5-(3-(2-methoxyethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N⁴-methylcyclohexane-1,4-diamine [1193];

cis-N¹-(5-(3-(2-methoxyethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N⁴,N⁴-dimethylcyclohexane-1,4-diamine [1194];

trans-N¹-(5-(3-(2-methoxyethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N⁴,N⁴-dimethylcyclohexane-1,4-diamine [1195];

5-(3-(2-methoxyethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*cis*-4-morpholinocyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1196];

5-(3-(2-methoxyethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*trans*-4-morpholinocyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1197];

5-(3-(2-methoxyethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*cis*-4-(4-methylpiperazin-1-yl)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1198];

5-(3-(2-methoxyethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*trans*-4-(4-methylpiperazin-1-yl)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1199]; and

5-(3-(2-methoxyethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(1-methylazetidin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1200]; or a pharmaceutically acceptable salt thereof.

20. The compound according to any one of claims 1-7, wherein the compound of Formula I is selected from the group consisting of:

- 5-(3-(2-methoxyethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(oxetan-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1201];
- 5-(3-(2-methoxyethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(1-methylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1202];
- 5-(3-(2-methoxyethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(tetrahydro-2H-pyran-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1203];
- N-(6,6-difluorospiro[3.3]heptan-2-yl)-5-(3-(2-methoxyethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1204];
- 5-(3-(2-methoxyethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(2-oxaspiro[3.3]heptan-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1205];
- 5-(3-(2-methoxyethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(2-methyl-2-azaspiro[3.3]heptan-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1206];
- 5-(3-(2-methoxyethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1207];
- N-isopropyl-5-(1-methyl-1H-benzo[d][1,2,3]triazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1208];
- N-isobutyl-5-(1-methyl-1H-benzo[d][1,2,3]triazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1209];
- N-(2-fluoro-2-methylpropyl)-5-(1-methyl-1H-benzo[d][1,2,3]triazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1210];
- N-(2,2-difluoropropyl)-5-(1-methyl-1H-benzo[d][1,2,3]triazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1211];
- 5-(1-methyl-1H-benzo[d][1,2,3]triazol-6-yl)-N-(2,2,2-trifluoroethyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1212];
- (R)-5-(1-methyl-1H-benzo[d][1,2,3]triazol-6-yl)-N-(1,1,1-trifluoropropan-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1213];
- 5-(1-methyl-1H-benzo[d][1,2,3]triazol-6-yl)-N-(3,3,3-trifluoropropyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1214];
- 5-(1-methyl-1H-benzo[d][1,2,3]triazol-6-yl)-N-(3,3,3-trifluoro-2,2-dimethylpropyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1215];
- N-(2-methoxyethyl)-5-(1-methyl-1H-benzo[d][1,2,3]triazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1216];
- (R)-N-(1-methoxypropan-2-yl)-5-(1-methyl-1H-benzo[d][1,2,3]triazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1217];

N-(2-isopropoxyethyl)-5-(1-methyl-1H-benzo[d][1,2,3]triazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1218];

5-(1-methyl-1H-benzo[d][1,2,3]triazol-6-yl)-N-((1-methylcyclopropyl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1219];

5-(1-methyl-1H-benzo[d][1,2,3]triazol-6-yl)-N-((1-(trifluoromethyl)cyclopropyl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1220];

N-((1-fluorocyclobutyl)methyl)-5-(1-methyl-1H-benzo[d][1,2,3]triazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1221];

N-((3-fluorooxetan-3-yl)methyl)-5-(1-methyl-1H-benzo[d][1,2,3]triazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1222];

N-(cyclopropylmethyl)-5-(1-methyl-1H-benzo[d][1,2,3]triazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1223];

(S)-N-(1-cyclopropylethyl)-5-(1-methyl-1H-benzo[d][1,2,3]triazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1224];

(R)-N-(1-cyclopropylethyl)-5-(1-methyl-1H-benzo[d][1,2,3]triazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1225];

N-(2-cyclopropyl-2,2-difluoroethyl)-5-(1-methyl-1H-benzo[d][1,2,3]triazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1226];

5-(1-methyl-1H-benzo[d][1,2,3]triazol-6-yl)-N-(oxetan-3-ylmethyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1227];

5-(1-methyl-1H-benzo[d][1,2,3]triazol-6-yl)-N-((tetrahydrofuran-2-yl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1228];

N-cyclobutyl-5-(1-methyl-1H-benzo[d][1,2,3]triazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1229];

N-(3,3-difluorocyclobutyl)-5-(1-methyl-1H-benzo[d][1,2,3]triazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1230];

N-(3,3-dimethylcyclobutyl)-5-(1-methyl-1H-benzo[d][1,2,3]triazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1231];

1-methyl-3-((5-(1-methyl-1H-benzo[d][1,2,3]triazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclobutan-1-ol [1232];

N-(*cis*-3-methoxycyclobutyl)-5-(1-methyl-1H-benzo[d][1,2,3]triazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1233];

N-(*trans*-3-methoxycyclobutyl)-5-(1-methyl-1H-benzo[d][1,2,3]triazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1234];

N-(*trans*-3-(methoxymethyl)cyclobutyl)-5-(1-methyl-1H-benzo[d][1,2,3]triazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1235];

N-(*cis*-3-ethoxycyclobutyl)-5-(1-methyl-1H-benzo[d][1,2,3]triazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1236];

N-(*trans*-3-ethoxycyclobutyl)-5-(1-methyl-1H-benzo[d][1,2,3]triazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1237];

N-(*cis*-3-(2-methoxyethoxy)cyclobutyl)-5-(1-methyl-1H-benzo[d][1,2,3]triazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1238];

N-(*trans*-3-(2-methoxyethoxy)cyclobutyl)-5-(1-methyl-1H-benzo[d][1,2,3]triazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1239];

cis-N¹-(5-(1-methyl-1H-benzo[d][1,2,3]triazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclobutane-1,3-diamine [1240];

trans-N¹-(5-(1-methyl-1H-benzo[d][1,2,3]triazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclobutane-1,3-diamine [1241];

cis-N¹-methyl-N³-(5-(1-methyl-1H-benzo[d][1,2,3]triazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclobutane-1,3-diamine [1242];

trans-N¹-methyl-N³-(5-(1-methyl-1H-benzo[d][1,2,3]triazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclobutane-1,3-diamine [1243];

cis-N¹,N¹-dimethyl-N³-(5-(1-methyl-1H-benzo[d][1,2,3]triazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclobutane-1,3-diamine [1244];

trans-N¹,N¹-dimethyl-N³-(5-(1-methyl-1H-benzo[d][1,2,3]triazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclobutane-1,3-diamine [1245];

5-(1-methyl-1H-benzo[d][1,2,3]triazol-6-yl)-N-(*cis*-3-morpholinocyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1246];

5-(1-methyl-1H-benzo[d][1,2,3]triazol-6-yl)-N-(*trans*-3-morpholinocyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1247];

5-(1-methyl-1H-benzo[d][1,2,3]triazol-6-yl)-N-(*cis*-3-(4-methylpiperazin-1-yl)cyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1248];

5-(1-methyl-1H-benzo[d][1,2,3]triazol-6-yl)-N-(*trans*-3-(4-methylpiperazin-1-yl)cyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1249];

N-(4,4-difluorocyclohexyl)-5-(1-methyl-1H-benzo[d][1,2,3]triazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1250];

cis-4-((5-(1-methyl-1H-benzo[d][1,2,3]triazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclohexan-1-ol [1251];

(1s,4s)-1-methyl-4-((5-(1-methyl-1H-benzo[d][1,2,3]triazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclohexan-1-ol [1252];

N-(*cis*-4-methoxycyclohexyl)-5-(1-methyl-1H-benzo[d][1,2,3]triazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1253];

N-(*trans*-4-methoxycyclohexyl)-5-(1-methyl-1H-benzo[d][1,2,3]triazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1254];

N-(*cis*-4-(difluoromethoxy)cyclohexyl)-5-(1-methyl-1H-benzo[d][1,2,3]triazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1255];

N-(*trans*-4-(difluoromethoxy)cyclohexyl)-5-(1-methyl-1H-benzo[d][1,2,3]triazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1256];

N-(*cis*-4-ethoxycyclohexyl)-5-(1-methyl-1H-benzo[d][1,2,3]triazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1257];

N-(*trans*-4-ethoxycyclohexyl)-5-(1-methyl-1H-benzo[d][1,2,3]triazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1258];

N-(*cis*-4-(2-methoxyethoxy)cyclohexyl)-5-(1-methyl-1H-benzo[d][1,2,3]triazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1259];

N-(*trans*-4-(2-methoxyethoxy)cyclohexyl)-5-(1-methyl-1H-benzo[d][1,2,3]triazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1260];

cis-N¹-(5-(1-methyl-1H-benzo[d][1,2,3]triazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclohexane-1,4-diamine [1261];

trans-N¹-(5-(1-methyl-1H-benzo[d][1,2,3]triazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclohexane-1,4-diamine [1262];

cis-N¹-methyl-N⁴-(5-(1-methyl-1H-benzo[d][1,2,3]triazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclohexane-1,4-diamine [1263];

trans-N¹-methyl-N⁴-(5-(1-methyl-1H-benzo[d][1,2,3]triazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclohexane-1,4-diamine [1264];

cis-N¹,N¹-dimethyl-N⁴-(5-(1-methyl-1H-benzo[d][1,2,3]triazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclohexane-1,4-diamine [1265];

trans-N¹,N¹-dimethyl-N⁴-(5-(1-methyl-1H-benzo[d][1,2,3]triazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclohexane-1,4-diamine [1266];

5-(1-methyl-1H-benzo[d][1,2,3]triazol-6-yl)-N-(*cis*-4-morpholinocyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1267];

5-(1-methyl-1H-benzo[d][1,2,3]triazol-6-yl)-N-(*trans*-4-morpholinocyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1268];

5-(1-methyl-1H-benzo[d][1,2,3]triazol-6-yl)-N-(*cis*-4-(4-methylpiperazin-1-yl)cyclohexyl)pyrrolo [2,1-f][1,2,4]triazin-2-amine [1269];

5-(1-methyl-1H-benzo[d][1,2,3]triazol-6-yl)-N-(*trans*-4-(4-methylpiperazin-1-yl)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1270];

5-(1-methyl-1H-benzo[d][1,2,3]triazol-6-yl)-N-(1-methylazetidin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1271];

5-(1-methyl-1H-benzo[d][1,2,3]triazol-6-yl)-N-(oxetan-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1272];

5-(1-methyl-1H-benzo[d][1,2,3]triazol-6-yl)-N-(1-methylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1273];

5-(1-methyl-1H-benzo[d][1,2,3]triazol-6-yl)-N-(tetrahydro-2H-pyran-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1274];

N-(6,6-difluorospiro[3.3]heptan-2-yl)-5-(1-methyl-1H-benzo[d][1,2,3]triazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1275];

5-(1-methyl-1H-benzo[d][1,2,3]triazol-6-yl)-N-(2-oxaspiro[3.3]heptan-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1276];

5-(1-methyl-1H-benzo[d][1,2,3]triazol-6-yl)-N-(2-methyl-2-azaspiro[3.3]heptan-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1277];

5-(1-methyl-1H-benzo[d][1,2,3]triazol-6-yl)-N-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1278];

N-isopropyl-5-(quinolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1279];

N-isobutyl-5-(quinolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1280];

N-(2-fluoro-2-methylpropyl)-5-(quinolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1281];

N-(2,2-difluoropropyl)-5-(quinolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1282];

5-(quinolin-6-yl)-N-(2,2,2-trifluoroethyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1283];

(R)-5-(quinolin-6-yl)-N-(1,1,1-trifluoropropan-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1284];

5-(quinolin-6-yl)-N-(3,3,3-trifluoropropyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1285];

5-(quinolin-6-yl)-N-(3,3,3-trifluoro-2,2-dimethylpropyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1286];

N-(2-methoxyethyl)-5-(quinolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1287];

(R)-N-(1-methoxypropan-2-yl)-5-(quinolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1288];

N-(2-isopropoxyethyl)-5-(quinolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1289];

N-((1-methylcyclopropyl)methyl)-5-(quinolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1290];

5-(quinolin-6-yl)-N-((1-(trifluoromethyl)cyclopropyl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1291];

N-((1-fluorocyclobutyl)methyl)-5-(quinolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1292];

N-((3-fluorooxetan-3-yl)methyl)-5-(quinolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1293];

N-(cyclopropylmethyl)-5-(quinolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1294];

(S)-N-(1-cyclopropylethyl)-5-(quinolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1295];

(R)-N-(1-cyclopropylethyl)-5-(quinolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1296];

N-(2-cyclopropyl-2,2-difluoroethyl)-5-(quinolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1297];

N-(oxetan-3-ylmethyl)-5-(quinolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1298];

5-(quinolin-6-yl)-N-((tetrahydrofuran-2-yl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1299];
and

N-cyclobutyl-5-(quinolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1300]; or a pharmaceutically acceptable salt thereof.

21. The compound according to any one of claims 1-7, wherein the compound of Formula I is selected from the group consisting of:

N-(3,3-difluorocyclobutyl)-5-(quinolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1301];

N-(3,3-dimethylcyclobutyl)-5-(quinolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1302];

1-methyl-3-((5-(quinolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclobutan-1-ol [1303];

N-(*cis*-3-methoxycyclobutyl)-5-(quinolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1304];

N-(*trans*-3-methoxycyclobutyl)-5-(quinolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1305];

N-(*trans*-3-(methoxymethyl)cyclobutyl)-5-(quinolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1306];

N-(*cis*-3-ethoxycyclobutyl)-5-(quinolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1307];

N-(*trans*-3-ethoxycyclobutyl)-5-(quinolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1308];

N-(*cis*-3-(2-methoxyethoxy)cyclobutyl)-5-(quinolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1309];

N-(*trans*-3-(2-methoxyethoxy)cyclobutyl)-5-(quinolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1310];

cis-N¹-(5-(quinolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclobutane-1,3-diamine [1311];

trans-N¹-(5-(quinolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclobutane-1,3-diamine [1312];

cis-N¹-methyl-N³-(5-(quinolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclobutane-1,3-diamine [1313];

trans-N¹-methyl-N³-(5-(quinolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclobutane-1,3-diamine [1314];

cis-N¹,N¹-dimethyl-N³-(5-(quinolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclobutane-1,3-diamine [1315];

trans-N¹,N¹-dimethyl-N³-(5-(quinolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclobutane-1,3-diamine [1316];

N-(*cis*-3-morpholinocyclobutyl)-5-(quinolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1317];

N-(*trans*-3-morpholinocyclobutyl)-5-(quinolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1318];

N-(*cis*-3-(4-methylpiperazin-1-yl)cyclobutyl)-5-(quinolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1319];

N-(*trans*-3-(4-methylpiperazin-1-yl)cyclobutyl)-5-(quinolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1320];

N-(4,4-difluorocyclohexyl)-5-(quinolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1321];

cis-4-((5-(quinolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclohexan-1-ol [1322];

(1s,4s)-1-methyl-4-((5-(quinolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclohexan-1-ol [1323];

N-(*cis*-4-methoxycyclohexyl)-5-(quinolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1324];

N-(*trans*-4-methoxycyclohexyl)-5-(quinolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1325];

N-(*cis*-4-(difluoromethoxy)cyclohexyl)-5-(quinolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1326];

N-(*trans*-4-(difluoromethoxy)cyclohexyl)-5-(quinolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1327];

N-(*cis*-4-ethoxycyclohexyl)-5-(quinolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1328];

N-(*trans*-4-ethoxycyclohexyl)-5-(quinolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1329];

N-(*cis*-4-(2-methoxyethoxy)cyclohexyl)-5-(quinolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1330];

N-(*trans*-4-(2-methoxyethoxy)cyclohexyl)-5-(quinolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1331];

cis-N¹-(5-(quinolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclohexane-1,4-diamine [1332];

trans-N¹-(5-(quinolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclohexane-1,4-diamine [1333];

cis-N¹-methyl-N⁴-(5-(quinolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclohexane-1,4-diamine [1334];

trans-N¹-methyl-N⁴-(5-(quinolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclohexane-1,4-diamine [1335];

cis-N¹,N¹-dimethyl-N⁴-(5-(quinolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclohexane-1,4-diamine [1336];

trans-N¹,N¹-dimethyl-N⁴-(5-(quinolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclohexane-1,4-diamine [1337];

N-(*cis*-4-morpholinocyclohexyl)-5-(quinolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1338];

N-(*trans*-4-morpholinocyclohexyl)-5-(quinolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1339];

N-(*cis*-4-(4-methylpiperazin-1-yl)cyclohexyl)-5-(quinolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1340];

N-(*trans*-4-(4-methylpiperazin-1-yl)cyclohexyl)-5-(quinolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1341];

N-(1-methylazetidin-3-yl)-5-(quinolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1342];

N-(oxetan-3-yl)-5-(quinolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1343];

N-(1-methylpiperidin-4-yl)-5-(quinolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1344];

5-(quinolin-6-yl)-N-(tetrahydro-2H-pyran-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1345];

N-(6,6-difluorospiro[3.3]heptan-2-yl)-5-(quinolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1346];

5-(quinolin-6-yl)-N-(2-oxaspiro[3.3]heptan-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1347];

N-(2-methyl-2-azaspiro[3.3]heptan-6-yl)-5-(quinolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1348];

N-(1-methyl-1H-pyrazol-4-yl)-5-(quinolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1349];

N-isopropyl-5-(quinoxalin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1350];

N-isobutyl-5-(quinoxalin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1351];

N-(2-fluoro-2-methylpropyl)-5-(quinoxalin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1352];

N-(2,2-difluoropropyl)-5-(quinoxalin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1353];

5-(quinoxalin-6-yl)-N-(2,2,2-trifluoroethyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1354];

(R)-5-(quinoxalin-6-yl)-N-(1,1,1-trifluoropropan-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1355];

5-(quinoxalin-6-yl)-N-(3,3,3-trifluoropropyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1356];

5-(quinoxalin-6-yl)-N-(3,3,3-trifluoro-2,2-dimethylpropyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1357];

N-(2-methoxyethyl)-5-(quinoxalin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1358];

(R)-N-(1-methoxypropan-2-yl)-5-(quinoxalin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1359];

N-(2-isopropoxyethyl)-5-(quinoxalin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1360];

N-((1-methylcyclopropyl)methyl)-5-(quinoxalin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1361];

5-(quinoxalin-6-yl)-N-((1-(trifluoromethyl)cyclopropyl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1362];

N-((1-fluorocyclobutyl)methyl)-5-(quinoxalin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1363];
N-((3-fluorooxetan-3-yl)methyl)-5-(quinoxalin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1364];
N-(cyclopropylmethyl)-5-(quinoxalin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1365];
(S)-N-(1-cyclopropylethyl)-5-(quinoxalin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1366];
(R)-N-(1-cyclopropylethyl)-5-(quinoxalin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1367];
N-(2-cyclopropyl-2,2-difluoroethyl)-5-(quinoxalin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1368];
N-(oxetan-3-ylmethyl)-5-(quinoxalin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1369];
5-(quinoxalin-6-yl)-N-((tetrahydrofuran-2-yl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1370];
N-cyclobutyl-5-(quinoxalin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1371];
N-(3,3-difluorocyclobutyl)-5-(quinoxalin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1372];
N-(3,3-dimethylcyclobutyl)-5-(quinoxalin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1373];
1-methyl-3-((5-(quinoxalin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclobutan-1-ol [1374];
N-(*cis*-3-methoxycyclobutyl)-5-(quinoxalin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1375];
N-(*trans*-3-methoxycyclobutyl)-5-(quinoxalin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1376];
N-(*trans*-3-(methoxymethyl)cyclobutyl)-5-(quinoxalin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1377];
N-(*cis*-3-ethoxycyclobutyl)-5-(quinoxalin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1378];
N-(*trans*-3-ethoxycyclobutyl)-5-(quinoxalin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1379];
N-(*cis*-3-(2-methoxyethoxy)cyclobutyl)-5-(quinoxalin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1380];
N-(*trans*-3-(2-methoxyethoxy)cyclobutyl)-5-(quinoxalin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1381];
cis-N¹-(5-(quinoxalin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclobutane-1,3-diamine [1382];
trans-N¹-(5-(quinoxalin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclobutane-1,3-diamine [1383];
cis-N¹-methyl-N³-(5-(quinoxalin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclobutane-1,3-diamine [1384];
trans-N¹-methyl-N³-(5-(quinoxalin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclobutane-1,3-diamine [1385];
cis-N¹,N¹-dimethyl-N³-(5-(quinoxalin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclobutane-1,3-diamine [1386];
trans-N¹,N¹-dimethyl-N³-(5-(quinoxalin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclobutane-1,3-diamine [1387];
N-(*cis*-3-morpholinocyclobutyl)-5-(quinoxalin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1388];

N-(*trans*-3-morpholinocyclobutyl)-5-(quinoxalin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1389];

N-(*cis*-3-(4-methylpiperazin-1-yl)cyclobutyl)-5-(quinoxalin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1390];

N-(*trans*-3-(4-methylpiperazin-1-yl)cyclobutyl)-5-(quinoxalin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1391];

N-(4,4-difluorocyclohexyl)-5-(quinoxalin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1392];

cis-4-((5-(quinoxalin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclohexan-1-ol [1393];

(1*s*,4*s*)-1-methyl-4-((5-(quinoxalin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclohexan-1-ol [1394];

N-(*cis*-4-methoxycyclohexyl)-5-(quinoxalin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1395];

N-(*trans*-4-methoxycyclohexyl)-5-(quinoxalin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1396];

N-(*cis*-4-(difluoromethoxy)cyclohexyl)-5-(quinoxalin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1397];

N-(*trans*-4-(difluoromethoxy)cyclohexyl)-5-(quinoxalin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1398];

N-(*cis*-4-ethoxycyclohexyl)-5-(quinoxalin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1399]; and

N-(*trans*-4-ethoxycyclohexyl)-5-(quinoxalin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1400]; or a pharmaceutically acceptable salt thereof.

22. The compound according to any one of claims 1-7, wherein the compound of Formula I is selected from the group consisting of:

N-(*cis*-4-(2-methoxyethoxy)cyclohexyl)-5-(quinoxalin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1401];

N-(*trans*-4-(2-methoxyethoxy)cyclohexyl)-5-(quinoxalin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1402];

cis-N¹-(5-(quinoxalin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclohexane-1,4-diamine [1403];

trans-N¹-(5-(quinoxalin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclohexane-1,4-diamine [1404];

cis-N¹-methyl-N⁴-(5-(quinoxalin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclohexane-1,4-diamine [1405];

trans-N¹-methyl-N⁴-(5-(quinoxalin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclohexane-1,4-diamine [1406];

cis-N¹,N¹-dimethyl-N⁴-(5-(quinoxalin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclohexane-1,4-diamine [1407];

trans-N¹,N¹-dimethyl-N⁴-(5-(quinoxalin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclohexane-1,4-diamine [1408];

N-(*cis*-4-morpholinocyclohexyl)-5-(quinoxalin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1409];

N-(*trans*-4-morpholinocyclohexyl)-5-(quinoxalin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1410];

N-(*cis*-4-(4-methylpiperazin-1-yl)cyclohexyl)-5-(quinoxalin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1411];

N-(*trans*-4-(4-methylpiperazin-1-yl)cyclohexyl)-5-(quinoxalin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1412];

N-(1-methylazetidin-3-yl)-5-(quinoxalin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1413];

N-(oxetan-3-yl)-5-(quinoxalin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1414];

N-(1-methylpiperidin-4-yl)-5-(quinoxalin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1415];

5-(quinoxalin-6-yl)-N-(tetrahydro-2H-pyran-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1416];

N-(6,6-difluorospiro[3.3]heptan-2-yl)-5-(quinoxalin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1417];

5-(quinoxalin-6-yl)-N-(2-oxaspiro[3.3]heptan-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1418];

N-(2-methyl-2-azaspiro[3.3]heptan-6-yl)-5-(quinoxalin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1419];

N-(1-methyl-1H-pyrazol-4-yl)-5-(quinoxalin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1420];

N-isopropyl-5-(4-methoxyquinazolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1421];

N-isobutyl-5-(4-methoxyquinazolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1422];

N-(2-fluoro-2-methylpropyl)-5-(4-methoxyquinazolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1423];

N-(2,2-difluoropropyl)-5-(4-methoxyquinazolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1424];

5-(4-methoxyquinazolin-6-yl)-N-(2,2,2-trifluoroethyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1425];

(R)-5-(4-methoxyquinazolin-6-yl)-N-(1,1,1-trifluoropropan-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1426];

5-(4-methoxyquinazolin-6-yl)-N-(3,3,3-trifluoropropyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1427];

5-(4-methoxyquinazolin-6-yl)-N-(3,3,3-trifluoro-2,2-dimethylpropyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1428];

N-(2-methoxyethyl)-5-(4-methoxyquinazolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1429];

(R)-N-(1-methoxypropan-2-yl)-5-(4-methoxyquinazolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1430];

N-(2-isopropoxyethyl)-5-(4-methoxyquinazolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1431];
5-(4-methoxyquinazolin-6-yl)-N-((1-methylcyclopropyl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1432];
5-(4-methoxyquinazolin-6-yl)-N-((1-(trifluoromethyl)cyclopropyl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1433];
N-((1-fluorocyclobutyl)methyl)-5-(4-methoxyquinazolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1434];
N-((3-fluorooxetan-3-yl)methyl)-5-(4-methoxyquinazolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1435];
N-(cyclopropylmethyl)-5-(4-methoxyquinazolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1436];
(S)-N-(1-cyclopropylethyl)-5-(4-methoxyquinazolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1437];
(R)-N-(1-cyclopropylethyl)-5-(4-methoxyquinazolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1438];
N-(2-cyclopropyl-2,2-difluoroethyl)-5-(4-methoxyquinazolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1439];
5-(4-methoxyquinazolin-6-yl)-N-(oxetan-3-ylmethyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1440];
5-(4-methoxyquinazolin-6-yl)-N-((tetrahydrofuran-2-yl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1441];
N-cyclobutyl-5-(4-methoxyquinazolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1442];
N-(3,3-difluorocyclobutyl)-5-(4-methoxyquinazolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1443];
N-(3,3-dimethylcyclobutyl)-5-(4-methoxyquinazolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1444];
3-((5-(4-methoxyquinazolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclobutan-1-ol [1445];
N-(*cis*-3-methoxycyclobutyl)-5-(4-methoxyquinazolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1446];
N-(*trans*-3-methoxycyclobutyl)-5-(4-methoxyquinazolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1447];
N-(*trans*-3-(methoxymethyl)cyclobutyl)-5-(4-methoxyquinazolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1448];
N-(*cis*-3-ethoxycyclobutyl)-5-(4-methoxyquinazolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1449];

N-(*trans*-3-ethoxycyclobutyl)-5-(4-methoxyquinazolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1450];

N-(*cis*-3-(2-methoxyethoxy)cyclobutyl)-5-(4-methoxyquinazolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1451];

N-(*trans*-3-(2-methoxyethoxy)cyclobutyl)-5-(4-methoxyquinazolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1452];

cis-N¹-(5-(4-methoxyquinazolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclobutane-1,3-diamine [1453];

trans-N¹-(5-(4-methoxyquinazolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclobutane-1,3-diamine [1454];

cis-N¹-(5-(4-methoxyquinazolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N³-methylcyclobutane-1,3-diamine [1455];

trans-N¹-(5-(4-methoxyquinazolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N³-methylcyclobutane-1,3-diamine [1456];

cis-N¹-(5-(4-methoxyquinazolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N³,N³-dimethylcyclobutane-1,3-diamine [1457];

trans-N¹-(5-(4-methoxyquinazolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N³,N³-dimethylcyclobutane-1,3-diamine [1458];

5-(4-methoxyquinazolin-6-yl)-N-(*cis*-3-morpholinocyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1459];

5-(4-methoxyquinazolin-6-yl)-N-(*trans*-3-morpholinocyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1460];

5-(4-methoxyquinazolin-6-yl)-N-(*cis*-3-(4-methylpiperazin-1-yl)cyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1461];

5-(4-methoxyquinazolin-6-yl)-N-(*trans*-3-(4-methylpiperazin-1-yl)cyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1462];

N-(4,4-difluorocyclohexyl)-5-(4-methoxyquinazolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1463];

cis-4-((5-(4-methoxyquinazolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclohexan-1-ol [1464];

(1*s*,4*s*)-4-((5-(4-methoxyquinazolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclohexan-1-ol [1465];

N-(*cis*-4-methoxycyclohexyl)-5-(4-methoxyquinazolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1466];

N-(*trans*-4-methoxycyclohexyl)-5-(4-methoxyquinazolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1467];

N-(*cis*-4-(difluoromethoxy)cyclohexyl)-5-(4-methoxyquinazolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1468];

N-(*trans*-4-(difluoromethoxy)cyclohexyl)-5-(4-methoxyquinazolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1469];

N-(*cis*-4-ethoxycyclohexyl)-5-(4-methoxyquinazolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1470];

N-(*trans*-4-ethoxycyclohexyl)-5-(4-methoxyquinazolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1471];

N-(*cis*-4-(2-methoxyethoxy)cyclohexyl)-5-(4-methoxyquinazolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1472];

N-(*trans*-4-(2-methoxyethoxy)cyclohexyl)-5-(4-methoxyquinazolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1473];

cis-N¹-(5-(4-methoxyquinazolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclohexane-1,4-diamine [1474];

trans-N¹-(5-(4-methoxyquinazolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclohexane-1,4-diamine [1475];

cis-N¹-(5-(4-methoxyquinazolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N⁴-methylcyclohexane-1,4-diamine [1476];

trans-N¹-(5-(4-methoxyquinazolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N⁴-methylcyclohexane-1,4-diamine [1477];

cis-N¹-(5-(4-methoxyquinazolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N⁴,N⁴-dimethylcyclohexane-1,4-diamine [1478];

trans-N¹-(5-(4-methoxyquinazolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N⁴,N⁴-dimethylcyclohexane-1,4-diamine [1479];

5-(4-methoxyquinazolin-6-yl)-N-(*cis*-4-morpholinocyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1480];

5-(4-methoxyquinazolin-6-yl)-N-(*trans*-4-morpholinocyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1481];

5-(4-methoxyquinazolin-6-yl)-N-(*cis*-4-(4-methylpiperazin-1-yl)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1482];

5-(4-methoxyquinazolin-6-yl)-N-(*trans*-4-(4-methylpiperazin-1-yl)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1483];

5-(4-methoxyquinazolin-6-yl)-N-(1-methylazetidin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1484];

5-(4-methoxyquinazolin-6-yl)-N-(oxetan-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1485];

5-(4-methoxyquinazolin-6-yl)-N-(1-methylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1486];

5-(4-methoxyquinazolin-6-yl)-N-(tetrahydro-2H-pyran-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1487];

N-(6,6-difluorospiro[3.3]heptan-2-yl)-5-(4-methoxyquinazolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1488];

5-(4-methoxyquinazolin-6-yl)-N-(2-oxaspiro[3.3]heptan-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1489];

5-(4-methoxyquinazolin-6-yl)-N-(2-methyl-2-azaspiro[3.3]heptan-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1490];

5-(4-methoxyquinazolin-6-yl)-N-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1491];

N-isopropyl-5-(1,8-naphthyridin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1492];

N-isobutyl-5-(1,8-naphthyridin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1493];

N-(2-fluoro-2-methylpropyl)-5-(1,8-naphthyridin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1494];

N-(2,2-difluoropropyl)-5-(1,8-naphthyridin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1495];

5-(1,8-naphthyridin-3-yl)-N-(2,2,2-trifluoroethyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1496];

(R)-5-(1,8-naphthyridin-3-yl)-N-(1,1,1-trifluoropropan-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1497];

5-(1,8-naphthyridin-3-yl)-N-(3,3,3-trifluoropropyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1498];

5-(1,8-naphthyridin-3-yl)-N-(3,3,3-trifluoro-2,2-dimethylpropyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1499]; and

N-(2-methoxyethyl)-5-(1,8-naphthyridin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1500]; or a pharmaceutically acceptable salt thereof.

23. The compound according to any one of claims 1-7, wherein the compound of Formula I is selected from the group consisting of:

(R)-N-(1-methoxypropan-2-yl)-5-(1,8-naphthyridin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1501];

N-(2-isopropoxyethyl)-5-(1,8-naphthyridin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1502];

N-((1-methylcyclopropyl)methyl)-5-(1,8-naphthyridin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1503];

5-(1,8-naphthyridin-3-yl)-N-((1-(trifluoromethyl)cyclopropyl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1504];

N-((1-fluorocyclobutyl)methyl)-5-(1,8-naphthyridin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1505];

N-((3-fluorooxetan-3-yl)methyl)-5-(1,8-naphthyridin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1506];

N-(cyclopropylmethyl)-5-(1,8-naphthyridin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1507];

(S)-N-(1-cyclopropylethyl)-5-(1,8-naphthyridin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1508];

(R)-N-(1-cyclopropylethyl)-5-(1,8-naphthyridin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1509];

N-(2-cyclopropyl-2,2-difluoroethyl)-5-(1,8-naphthyridin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1510];

5-(1,8-naphthyridin-3-yl)-N-(oxetan-3-ylmethyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1511];

5-(1,8-naphthyridin-3-yl)-N-((tetrahydrofuran-2-yl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1512];

N-cyclobutyl-5-(1,8-naphthyridin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1513];

N-(3,3-difluorocyclobutyl)-5-(1,8-naphthyridin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1514];

N-(3,3-dimethylcyclobutyl)-5-(1,8-naphthyridin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1515];

3-((5-(1,8-naphthyridin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclobutan-1-ol [1516];

N-(*cis*-3-methoxycyclobutyl)-5-(1,8-naphthyridin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1517];

N-(*trans*-3-methoxycyclobutyl)-5-(1,8-naphthyridin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1518];

N-(*trans*-3-(methoxymethyl)cyclobutyl)-5-(1,8-naphthyridin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1519];

N-(*cis*-3-ethoxycyclobutyl)-5-(1,8-naphthyridin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1520];

N-(*trans*-3-ethoxycyclobutyl)-5-(1,8-naphthyridin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1521];

N-(*cis*-3-(2-methoxyethoxy)cyclobutyl)-5-(1,8-naphthyridin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1522];

N-(*trans*-3-(2-methoxyethoxy)cyclobutyl)-5-(1,8-naphthyridin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1523];

cis-N¹-(5-(1,8-naphthyridin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclobutane-1,3-diamine [1524];

trans-N¹-(5-(1,8-naphthyridin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclobutane-1,3-diamine [1525];

cis-N¹-(5-(1,8-naphthyridin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N³-methylcyclobutane-1,3-diamine [1526];

trans-N¹-(5-(1,8-naphthyridin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N³-methylcyclobutane-1,3-diamine [1527];

cis-N¹-(5-(1,8-naphthyridin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N³,N³-dimethylcyclobutane-1,3-diamine [1528];

trans-N¹-(5-(1,8-naphthyridin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N³,N³-dimethylcyclobutane-1,3-diamine [1529];

N-(*cis*-3-morpholinocyclobutyl)-5-(1,8-naphthyridin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1530];

N-(*trans*-3-morpholinocyclobutyl)-5-(1,8-naphthyridin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1531];

N-(*cis*-3-(4-methylpiperazin-1-yl)cyclobutyl)-5-(1,8-naphthyridin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1532];

N-(*trans*-3-(4-methylpiperazin-1-yl)cyclobutyl)-5-(1,8-naphthyridin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1533];

N-(4,4-difluorocyclohexyl)-5-(1,8-naphthyridin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1534];

cis-4-((5-(1,8-naphthyridin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclohexan-1-ol [1535];

(1*s*,4*s*)-4-((5-(1,8-naphthyridin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclohexan-1-ol [1536];

N-(*cis*-4-methoxycyclohexyl)-5-(1,8-naphthyridin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1537];

N-(*trans*-4-methoxycyclohexyl)-5-(1,8-naphthyridin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1538];

N-(*cis*-4-(difluoromethoxy)cyclohexyl)-5-(1,8-naphthyridin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1539];

N-(*trans*-4-(difluoromethoxy)cyclohexyl)-5-(1,8-naphthyridin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1540];

N-(*cis*-4-ethoxycyclohexyl)-5-(1,8-naphthyridin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1541];

N-(*trans*-4-ethoxycyclohexyl)-5-(1,8-naphthyridin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1542];

N-(*cis*-4-(2-methoxyethoxy)cyclohexyl)-5-(1,8-naphthyridin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1543];

N-(*trans*-4-(2-methoxyethoxy)cyclohexyl)-5-(1,8-naphthyridin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1544];

cis-N¹-(5-(1,8-naphthyridin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclohexane-1,4-diamine [1545];

trans-N¹-(5-(1,8-naphthyridin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclohexane-1,4-diamine [1546];

cis-N¹-(5-(1,8-naphthyridin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N⁴-methylcyclohexane-1,4-diamine [1547];

trans-N¹-(5-(1,8-naphthyridin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N⁴-methylcyclohexane-1,4-diamine [1548];

cis-N¹-(5-(1,8-naphthyridin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N⁴,N⁴-dimethylcyclohexane-1,4-diamine [1549];

trans-N¹-(5-(1,8-naphthyridin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N⁴,N⁴-dimethylcyclohexane-1,4-diamine [1550];

N-(*cis*-4-morpholinocyclohexyl)-5-(1,8-naphthyridin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1551];

N-(*trans*-4-morpholinocyclohexyl)-5-(1,8-naphthyridin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1552];

N-(*cis*-4-(4-methylpiperazin-1-yl)cyclohexyl)-5-(1,8-naphthyridin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1553];

N-(*trans*-4-(4-methylpiperazin-1-yl)cyclohexyl)-5-(1,8-naphthyridin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1554];

N-(1-methylazetidin-3-yl)-5-(1,8-naphthyridin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1555];

5-(1,8-naphthyridin-3-yl)-N-(oxetan-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1556];

N-(1-methylpiperidin-4-yl)-5-(1,8-naphthyridin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1557];

5-(1,8-naphthyridin-3-yl)-N-(tetrahydro-2H-pyran-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1558];

N-(6,6-difluorospiro[3.3]heptan-2-yl)-5-(1,8-naphthyridin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1559];

5-(1,8-naphthyridin-3-yl)-N-(2-oxaspiro[3.3]heptan-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1560];

N-(2-methyl-2-azaspiro[3.3]heptan-6-yl)-5-(1,8-naphthyridin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1561];

N-(1-methyl-1H-pyrazol-4-yl)-5-(1,8-naphthyridin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1562];

N-isopropyl-5-(pyrido[2,3-b]pyrazin-7-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1563];

N-isobutyl-5-(pyrido[2,3-b]pyrazin-7-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1564];

N-(2-fluoro-2-methylpropyl)-5-(pyrido[2,3-b]pyrazin-7-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1565];

N-(2,2-difluoropropyl)-5-(pyrido[2,3-b]pyrazin-7-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1566];

5-(pyrido[2,3-b]pyrazin-7-yl)-N-(2,2,2-trifluoroethyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1567];

(R)-5-(pyrido[2,3-b]pyrazin-7-yl)-N-(1,1,1-trifluoropropan-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1568];

5-(pyrido[2,3-b]pyrazin-7-yl)-N-(3,3,3-trifluoropropyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1569];

5-(pyrido[2,3-b]pyrazin-7-yl)-N-(3,3,3-trifluoro-2,2-dimethylpropyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1570];

N-(2-methoxyethyl)-5-(pyrido[2,3-b]pyrazin-7-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1571];

(R)-N-(1-methoxypropan-2-yl)-5-(pyrido[2,3-b]pyrazin-7-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1572];

N-(2-isopropoxyethyl)-5-(pyrido[2,3-b]pyrazin-7-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1573];

N-((1-methylcyclopropyl)methyl)-5-(pyrido[2,3-b]pyrazin-7-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1574];

5-(pyrido[2,3-b]pyrazin-7-yl)-N-((1-(trifluoromethyl)cyclopropyl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine compound with methane (1:1) [1575];

N-((1-fluorocyclobutyl)methyl)-5-(pyrido[2,3-b]pyrazin-7-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1576];

N-((3-fluorooxetan-3-yl)methyl)-5-(pyrido[2,3-b]pyrazin-7-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1577];

N-(cyclopropylmethyl)-5-(pyrido[2,3-b]pyrazin-7-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1578];

(S)-N-(1-cyclopropylethyl)-5-(pyrido[2,3-b]pyrazin-7-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1579];

(R)-N-(1-cyclopropylethyl)-5-(pyrido[2,3-b]pyrazin-7-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1580];

N-(2-cyclopropyl-2,2-difluoroethyl)-5-(pyrido[2,3-b]pyrazin-7-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1581];

N-(oxetan-3-ylmethyl)-5-(pyrido[2,3-b]pyrazin-7-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1582];

5-(pyrido[2,3-b]pyrazin-7-yl)-N-((tetrahydrofuran-2-yl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1583];

N-cyclobutyl-5-(pyrido[2,3-b]pyrazin-7-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1584];

N-(3,3-difluorocyclobutyl)-5-(pyrido[2,3-b]pyrazin-7-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1585];

N-(3,3-dimethylcyclobutyl)-5-(pyrido[2,3-b]pyrazin-7-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1586];

1-methyl-3-((5-(pyrido[2,3-b]pyrazin-7-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclobutan-1-ol [1587];

N-(*cis*-3-methoxycyclobutyl)-5-(pyrido[2,3-b]pyrazin-7-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1588];

N-(*trans*-3-methoxycyclobutyl)-5-(pyrido[2,3-b]pyrazin-7-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1589];

N-(*trans*-3-(methoxymethyl)cyclobutyl)-5-(pyrido[2,3-b]pyrazin-7-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1590];

N-(*cis*-3-ethoxycyclobutyl)-5-(pyrido[2,3-b]pyrazin-7-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1591];

N-(*trans*-3-ethoxycyclobutyl)-5-(pyrido[2,3-b]pyrazin-7-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1592];

N-(*cis*-3-(2-methoxyethoxy)cyclobutyl)-5-(pyrido[2,3-b]pyrazin-7-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1593];

N-(*trans*-3-(2-methoxyethoxy)cyclobutyl)-5-(pyrido[2,3-b]pyrazin-7-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1594];

cis-N¹-(5-(pyrido[2,3-b]pyrazin-7-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclobutane-1,3-diamine [1595];

trans-N¹-(5-(pyrido[2,3-b]pyrazin-7-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclobutane-1,3-diamine [1596];

cis-N¹-methyl-N³-(5-(pyrido[2,3-b]pyrazin-7-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclobutane-1,3-diamine [1597];

trans-N¹-methyl-N³-(5-(pyrido[2,3-*b*]pyrazin-7-yl)pyrrolo[2,1-*f*][1,2,4]triazin-2-yl)cyclobutane-1,3-diamine [1598];

cis-N¹,N¹-dimethyl-N³-(5-(pyrido[2,3-*b*]pyrazin-7-yl)pyrrolo[2,1-*f*][1,2,4]triazin-2-yl)cyclobutane-1,3-diamine [1599]; and

trans-N¹,N¹-dimethyl-N³-(5-(pyrido[2,3-*b*]pyrazin-7-yl)pyrrolo[2,1-*f*][1,2,4]triazin-2-yl)cyclobutane-1,3-diamine [1600]; or a pharmaceutically acceptable salt thereof.

24. The compound according to any one of claims 1-7, wherein the compound of Formula I is selected from the group consisting of:

N-(*cis*-3-morpholinocyclobutyl)-5-(pyrido[2,3-*b*]pyrazin-7-yl)pyrrolo[2,1-*f*][1,2,4]triazin-2-amine [1601];

N-(*trans*-3-morpholinocyclobutyl)-5-(pyrido[2,3-*b*]pyrazin-7-yl)pyrrolo[2,1-*f*][1,2,4]triazin-2-amine [1602];

N-(*cis*-3-(4-methylpiperazin-1-yl)cyclobutyl)-5-(pyrido[2,3-*b*]pyrazin-7-yl)pyrrolo[2,1-*f*][1,2,4]triazin-2-amine [1603];

N-(*trans*-3-(4-methylpiperazin-1-yl)cyclobutyl)-5-(pyrido[2,3-*b*]pyrazin-7-yl)pyrrolo[2,1-*f*][1,2,4] triazin-2-amine [1604];

N-(4,4-difluorocyclohexyl)-5-(pyrido[2,3-*b*]pyrazin-7-yl)pyrrolo[2,1-*f*][1,2,4]triazin-2-amine [1605];

cis-4-((5-(pyrido[2,3-*b*]pyrazin-7-yl)pyrrolo[2,1-*f*][1,2,4]triazin-2-yl)amino)cyclohexan-1-ol [1606];

(1*s*,4*s*)-1-methyl-4-((5-(pyrido[2,3-*b*]pyrazin-7-yl)pyrrolo[2,1-*f*][1,2,4]triazin-2-yl)amino)cyclohexan-1-ol [1607];

N-(*cis*-4-methoxycyclohexyl)-5-(pyrido[2,3-*b*]pyrazin-7-yl)pyrrolo[2,1-*f*][1,2,4]triazin-2-amine [1608];

N-(*trans*-4-methoxycyclohexyl)-5-(pyrido[2,3-*b*]pyrazin-7-yl)pyrrolo[2,1-*f*][1,2,4]triazin-2-amine [1609];

N-(*cis*-4-(difluoromethoxy)cyclohexyl)-5-(pyrido[2,3-*b*]pyrazin-7-yl)pyrrolo[2,1-*f*][1,2,4]triazin-2-amine [1610];

N-(*trans*-4-(difluoromethoxy)cyclohexyl)-5-(pyrido[2,3-*b*]pyrazin-7-yl)pyrrolo[2,1-*f*][1,2,4] triazin-2-amine [1611];

N-(*cis*-4-ethoxycyclohexyl)-5-(pyrido[2,3-*b*]pyrazin-7-yl)pyrrolo[2,1-*f*][1,2,4]triazin-2-amine [1612];

N-(*trans*-4-ethoxycyclohexyl)-5-(pyrido[2,3-*b*]pyrazin-7-yl)pyrrolo[2,1-*f*][1,2,4]triazin-2-amine [1613];

N-(*cis*-4-(2-methoxyethoxy)cyclohexyl)-5-(pyrido[2,3-*b*]pyrazin-7-yl)pyrrolo[2,1-
f][1,2,4]triazin-2-amine [1614];

N-(*trans*-4-(2-methoxyethoxy)cyclohexyl)-5-(pyrido[2,3-*b*]pyrazin-7-yl)pyrrolo[2,1-*f*][1,2,4]
triazin-2-amine [1615];

cis-N¹-(5-(pyrido[2,3-*b*]pyrazin-7-yl)pyrrolo[2,1-*f*][1,2,4]triazin-2-yl)cyclohexane-1,4-diamine
[1616];

trans-N¹-(5-(pyrido[2,3-*b*]pyrazin-7-yl)pyrrolo[2,1-*f*][1,2,4]triazin-2-yl)cyclohexane-1,4-diamine
[1617];

cis-N¹-methyl-N⁴-(5-(pyrido[2,3-*b*]pyrazin-7-yl)pyrrolo[2,1-*f*][1,2,4]triazin-2-yl)cyclohexane-
1,4-diamine [1618];

trans-N¹-methyl-N⁴-(5-(pyrido[2,3-*b*]pyrazin-7-yl)pyrrolo[2,1-*f*][1,2,4]triazin-2-yl)cyclohexane-
1,4-diamine [1619];

cis-N¹,N¹-dimethyl-N⁴-(5-(pyrido[2,3-*b*]pyrazin-7-yl)pyrrolo[2,1-*f*][1,2,4]triazin-2-yl)
cyclohexane-1,4-diamine [1620];

trans-N¹,N¹-dimethyl-N⁴-(5-(pyrido[2,3-*b*]pyrazin-7-yl)pyrrolo[2,1-*f*][1,2,4]triazin-2-yl)
cyclohexane-1,4-diamine [1621];

N-(*cis*-4-morpholinocyclohexyl)-5-(pyrido[2,3-*b*]pyrazin-7-yl)pyrrolo[2,1-*f*][1,2,4]triazin-2-
amine [1622];

N-(*trans*-4-morpholinocyclohexyl)-5-(pyrido[2,3-*b*]pyrazin-7-yl)pyrrolo[2,1-*f*][1,2,4]triazin-2-
amine [1623];

N-(*cis*-4-(4-methylpiperazin-1-yl)cyclohexyl)-5-(pyrido[2,3-*b*]pyrazin-7-yl)pyrrolo[2,1-*f*][1,2,4]
triazin-2-amine [1624];

N-(*trans*-4-(4-methylpiperazin-1-yl)cyclohexyl)-5-(pyrido[2,3-*b*]pyrazin-7-yl)pyrrolo[2,1-*f*]
[1,2,4]triazin-2-amine [1625];

N-(1-methylazetidin-3-yl)-5-(pyrido[2,3-*b*]pyrazin-7-yl)pyrrolo[2,1-*f*][1,2,4]triazin-2-amine
[1626];

N-(oxetan-3-yl)-5-(pyrido[2,3-*b*]pyrazin-7-yl)pyrrolo[2,1-*f*][1,2,4]triazin-2-amine [1627];

N-(1-methylpiperidin-4-yl)-5-(pyrido[2,3-*b*]pyrazin-7-yl)pyrrolo[2,1-*f*][1,2,4]triazin-2-amine
[1628];

5-(pyrido[2,3-*b*]pyrazin-7-yl)-N-(tetrahydro-2H-pyran-4-yl)pyrrolo[2,1-*f*][1,2,4]triazin-2-amine
[1629];

N-(6,6-difluorospiro[3.3]heptan-2-yl)-5-(pyrido[2,3-*b*]pyrazin-7-yl)pyrrolo[2,1-*f*][1,2,4]triazin-2-
amine [1630];

5-(pyrido[2,3-b]pyrazin-7-yl)-N-(2-oxaspiro[3.3]heptan-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1631];

N-(2-methyl-2-azaspiro[3.3]heptan-6-yl)-5-(pyrido[2,3-b]pyrazin-7-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1632];

N-(1-methyl-1H-pyrazol-4-yl)-5-(pyrido[2,3-b]pyrazin-7-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1633];

N-isopropyl-5-(1,5-naphthyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1634];

N-isobutyl-5-(1,5-naphthyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1635];

N-(2-fluoro-2-methylpropyl)-5-(1,5-naphthyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1636];

N-(2,2-difluoropropyl)-5-(1,5-naphthyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1637];

5-(1,5-naphthyridin-2-yl)-N-(2,2,2-trifluoroethyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1638];

(R)-5-(1,5-naphthyridin-2-yl)-N-(1,1,1-trifluoropropan-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1639];

5-(1,5-naphthyridin-2-yl)-N-(3,3,3-trifluoropropyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1640];

5-(1,5-naphthyridin-2-yl)-N-(3,3,3-trifluoro-2,2-dimethylpropyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1641];

N-(2-methoxyethyl)-5-(1,5-naphthyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1642];

(R)-N-(1-methoxypropan-2-yl)-5-(1,5-naphthyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1643];

N-(2-isopropoxyethyl)-5-(1,5-naphthyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1644];

N-((1-methylcyclopropyl)methyl)-5-(1,5-naphthyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1645];

5-(1,5-naphthyridin-2-yl)-N-((1-(trifluoromethyl)cyclopropyl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1646];

N-((1-fluorocyclobutyl)methyl)-5-(1,5-naphthyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1647];

N-((3-fluorooxetan-3-yl)methyl)-5-(1,5-naphthyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1648];

N-(cyclopropylmethyl)-5-(1,5-naphthyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1649];

(S)-N-(1-cyclopropylethyl)-5-(1,5-naphthyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1650];

(R)-N-(1-cyclopropylethyl)-5-(1,5-naphthyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1651];

N-(2-cyclopropyl-2,2-difluoroethyl)-5-(1,5-naphthyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1652];

5-(1,5-naphthyridin-2-yl)-N-(oxetan-3-ylmethyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1653];

5-(1,5-naphthyridin-2-yl)-N-((tetrahydrofuran-2-yl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1654];

N-cyclobutyl-5-(1,5-naphthyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1655];

N-(3,3-difluorocyclobutyl)-5-(1,5-naphthyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1656];

N-(3,3-dimethylcyclobutyl)-5-(1,5-naphthyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1657];

3-((5-(1,5-naphthyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclobutan-1-ol [1658];

N-(*cis*-3-methoxycyclobutyl)-5-(1,5-naphthyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1659];

N-(*trans*-3-methoxycyclobutyl)-5-(1,5-naphthyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1660];

N-(*trans*-3-(methoxymethyl)cyclobutyl)-5-(1,5-naphthyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1661];

N-(*cis*-3-ethoxycyclobutyl)-5-(1,5-naphthyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1662];

N-(*trans*-3-ethoxycyclobutyl)-5-(1,5-naphthyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1663];

N-(*cis*-3-(2-methoxyethoxy)cyclobutyl)-5-(1,5-naphthyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1664];

N-(*trans*-3-(2-methoxyethoxy)cyclobutyl)-5-(1,5-naphthyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1665];

cis-N¹-(5-(1,5-naphthyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclobutane-1,3-diamine [1666];

trans-N¹-(5-(1,5-naphthyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclobutane-1,3-diamine [1667];

cis-N¹-(5-(1,5-naphthyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N³-methylcyclobutane-1,3-diamine [1668];

trans-N¹-(5-(1,5-naphthyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N³-methylcyclobutane-1,3-diamine [1669];

cis-N¹-(5-(1,5-naphthyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N³,N³-dimethylcyclobutane-1,3-diamine [1670];

trans-N¹-(5-(1,5-naphthyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N³,N³-dimethylcyclobutane-1,3-diamine [1671];

N-(*cis*-3-morpholinocyclobutyl)-5-(1,5-naphthyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1672];

N-(*trans*-3-morpholinocyclobutyl)-5-(1,5-naphthyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1673];

N-(*cis*-3-(4-methylpiperazin-1-yl)cyclobutyl)-5-(1,5-naphthyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1674];

N-(*trans*-3-(4-methylpiperazin-1-yl)cyclobutyl)-5-(1,5-naphthyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1675];

N-(4,4-difluorocyclohexyl)-5-(1,5-naphthyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1676];

cis-4-((5-(1,5-naphthyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclohexan-1-ol [1677];

(1*s*,4*s*)-4-((5-(1,5-naphthyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclohexan-1-ol [1678];

N-(*cis*-4-methoxycyclohexyl)-5-(1,5-naphthyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1679];

N-(*trans*-4-methoxycyclohexyl)-5-(1,5-naphthyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1680];

N-(*cis*-4-(difluoromethoxy)cyclohexyl)-5-(1,5-naphthyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1681];

N-(*trans*-4-(difluoromethoxy)cyclohexyl)-5-(1,5-naphthyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1682];

N-(*cis*-4-ethoxycyclohexyl)-5-(1,5-naphthyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1683];

N-(*trans*-4-ethoxycyclohexyl)-5-(1,5-naphthyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1684];

N-(*cis*-4-(2-methoxyethoxy)cyclohexyl)-5-(1,5-naphthyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1685];

N-(*trans*-4-(2-methoxyethoxy)cyclohexyl)-5-(1,5-naphthyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1686];

cis-N¹-(5-(1,5-naphthyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclohexane-1,4-diamine [1687];

trans-N¹-(5-(1,5-naphthyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)cyclohexane-1,4-diamine [1688];

cis-N¹-(5-(1,5-naphthyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N⁴-methylcyclohexane-1,4-diamine [1689];

trans-N¹-(5-(1,5-naphthyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N⁴-methylcyclohexane-1,4-diamine [1690];

cis-N¹-(5-(1,5-naphthyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N⁴,N⁴-dimethylcyclohexane-1,4-diamine [1691];

trans-N¹-(5-(1,5-naphthyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N⁴,N⁴-dimethylcyclohexane-1,4-diamine [1692];

N-(*cis*-4-morpholinocyclohexyl)-5-(1,5-naphthyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1693];

N-(*trans*-4-morpholinocyclohexyl)-5-(1,5-naphthyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1694];

N-(*cis*-4-(4-methylpiperazin-1-yl)cyclohexyl)-5-(1,5-naphthyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1695];

N-(*trans*-4-(4-methylpiperazin-1-yl)cyclohexyl)-5-(1,5-naphthyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1696];

N-(1-methylazetidin-3-yl)-5-(1,5-naphthyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1697];

5-(1,5-naphthyridin-2-yl)-N-(oxetan-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1698];

N-(1-methylpiperidin-4-yl)-5-(1,5-naphthyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1699];

and

5-(1,5-naphthyridin-2-yl)-N-(tetrahydro-2H-pyran-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1700]; or a pharmaceutically acceptable salt thereof.

25. The compound according to any one of claims 1-7, wherein the compound of Formula I is selected from the group consisting of:

N-(6,6-difluorospiro[3.3]heptan-2-yl)-5-(1,5-naphthyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1701];

5-(1,5-naphthyridin-2-yl)-N-(2-oxaspiro[3.3]heptan-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1702];

N-(2-methyl-2-azaspiro[3.3]heptan-6-yl)-5-(1,5-naphthyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1703];

N-(1-methyl-1H-pyrazol-4-yl)-5-(1,5-naphthyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1704];

cis-3-((5-(imidazo[1,2-a]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclobutan-1-ol [1705];

(6-(2-((*cis*-3-hydroxycyclobutyl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)imidazo[1,2-a]pyridin-3-yl)(pyrrolidin-1-yl)methanone [1706];

cis-3-((5-(imidazo[1,2-b]pyridazin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclobutan-1-ol [1707];

cis-3-((5-(imidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclobutan-1-ol [1708];

cis-3-((5-(3-chloroimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclobutan-1-ol [1709];

cis-3-((5-(3-methylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclobutan-1-ol [1710];

cis-3-((5-(3-ethylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclobutan-1-ol [1711];

cis-3-((5-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclobutan-1-ol [1712];

cis-3-((5-(1-isopropyl-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclobutan-1-ol [1713];

cis-3-((5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclobutan-1-ol [1714];

cis-3-((5-(1-(3,3-difluorocyclobutyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclobutan-1-ol [1715];

cis-3-((5-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclobutan-1-ol [1716];

cis-3-((5-(2,3-dimethyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclobutan-1-ol [1717];

cis-3-((5-(3-ethyl-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclobutan-1-ol [1718];

cis-3-((5-(3-(2-fluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclobutan-1-ol [1719];

cis-3-((5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclobutan-1-ol [1720];

cis-3-((5-(3-(2-methoxyethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclobutan-1-ol [1721];

cis-3-((5-(1-methyl-1H-benzo[d][1,2,3]triazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclobutan-1-ol [1722];

cis-3-((5-(quinolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclobutan-1-ol [1723];

cis-3-((5-(quinoxalin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclobutan-1-ol [1724];

cis-3-((5-(4-methoxyquinazolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclobutan-1-ol [1725];

cis-3-((5-(1,8-naphthyridin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclobutan-1-ol [1726];

cis-3-((5-(pyrido[2,3-b]pyrazin-7-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclobutan-1-ol [1727];

cis-3-((5-(1,5-naphthyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclobutan-1-ol [1728];

5-(imidazo[1,2-a]pyridin-6-yl)-N-(2-azaspiro[3.3]heptan-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1729];

(6-(2-((2-azaspiro[3.3]heptan-6-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)imidazo[1,2-a]pyridin-3-yl)(pyrrolidin-1-yl)methanone [1730];

5-(imidazo[1,2-b]pyridazin-6-yl)-N-(2-azaspiro[3.3]heptan-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1731];

5-(imidazo[1,2-a]pyrimidin-6-yl)-N-(2-azaspiro[3.3]heptan-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1732];

5-(3-chloroimidazo[1,2-a]pyrimidin-6-yl)-N-(2-azaspiro[3.3]heptan-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1733];

5-(3-methylimidazo[1,2-a]pyrimidin-6-yl)-N-(2-azaspiro[3.3]heptan-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1734];

5-(3-ethylimidazo[1,2-a]pyrimidin-6-yl)-N-(2-azaspiro[3.3]heptan-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1735];

5-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)-N-(2-azaspiro[3.3]heptan-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1736];

5-(1-isopropyl-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(2-azaspiro[3.3]heptan-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1737];

5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(2-azaspiro[3.3]heptan-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1738];

5-(1-(3,3-difluorocyclobutyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(2-azaspiro[3.3]heptan-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1739];

5-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-b]pyridin-6-yl)-N-(2-azaspiro[3.3]heptan-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1740];

5-(2,3-dimethyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(2-azaspiro[3.3]heptan-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1741];

5-(3-ethyl-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(2-azaspiro[3.3]heptan-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1742];

5-(3-(2-fluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(2-azaspiro[3.3]heptan-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1743];

5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(2-azaspiro[3.3]heptan-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1744];

5-(3-(2-methoxyethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(2-azaspiro[3.3]heptan-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1745];

5-(1-methyl-1H-benzo[d][1,2,3]triazol-6-yl)-N-(2-azaspiro[3.3]heptan-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1746];

5-(quinolin-6-yl)-N-(2-azaspiro[3.3]heptan-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1747];

5-(quinoxalin-6-yl)-N-(2-azaspiro[3.3]heptan-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1748];

5-(4-methoxyquinazolin-6-yl)-N-(2-azaspiro[3.3]heptan-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1749];

5-(1,8-naphthyridin-3-yl)-N-(2-azaspiro[3.3]heptan-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1750];

5-(pyrido[2,3-b]pyrazin-7-yl)-N-(2-azaspiro[3.3]heptan-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1751];

5-(1,5-naphthyridin-2-yl)-N-(2-azaspiro[3.3]heptan-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1752];

5-(imidazo[1,2-a]pyridin-6-yl)-N-(2-isobutyl-2-azaspiro[3.3]heptan-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1753];

(6-(2-((2-isobutyl-2-azaspiro[3.3]heptan-6-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)imidazo[1,2-a]pyridin-3-yl)(pyrrolidin-1-yl)methanone [1754];

5-(imidazo[1,2-b]pyridazin-6-yl)-N-(2-isobutyl-2-azaspiro[3.3]heptan-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1755];

5-(imidazo[1,2-a]pyrimidin-6-yl)-N-(2-isobutyl-2-azaspiro[3.3]heptan-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1756];

5-(3-chloroimidazo[1,2-a]pyrimidin-6-yl)-N-(2-isobutyl-2-azaspiro[3.3]heptan-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1757];

N-(2-isobutyl-2-azaspiro[3.3]heptan-6-yl)-5-(3-methylimidazo[1,2-a]pyrimidin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1758];

5-(3-ethylimidazo[1,2-a]pyrimidin-6-yl)-N-(2-isobutyl-2-azaspiro[3.3]heptan-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1759];

5-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)-N-(2-isobutyl-2-azaspiro[3.3]heptan-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1760];

N-(2-isobutyl-2-azaspiro[3.3]heptan-6-yl)-5-(1-isopropyl-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1761];

5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(2-isobutyl-2-azaspiro[3.3]heptan-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1762];

5-(1-(3,3-difluorocyclobutyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(2-isobutyl-2-azaspiro[3.3]heptan-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1763];

N-(2-isobutyl-2-azaspiro[3.3]heptan-6-yl)-5-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1764];

5-(2,3-dimethyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(2-isobutyl-2-azaspiro[3.3]heptan-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1765];

5-(3-ethyl-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(2-isobutyl-2-azaspiro[3.3]heptan-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1766];

5-(3-(2-fluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(2-isobutyl-2-azaspiro[3.3]heptan-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1767];

5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(2-isobutyl-2-azaspiro[3.3]heptan-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1768];

N-(2-isobutyl-2-azaspiro[3.3]heptan-6-yl)-5-(3-(2-methoxyethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1769];

N-(2-isobutyl-2-azaspiro[3.3]heptan-6-yl)-5-(1-methyl-1H-benzo[d][1,2,3]triazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1770];

N-(2-isobutyl-2-azaspiro[3.3]heptan-6-yl)-5-(quinolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1771];

N-(2-isobutyl-2-azaspiro[3.3]heptan-6-yl)-5-(quinoxalin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1772];

N-(2-isobutyl-2-azaspiro[3.3]heptan-6-yl)-5-(4-methoxyquinazolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1773];

N-(2-isobutyl-2-azaspiro[3.3]heptan-6-yl)-5-(1,8-naphthyridin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1774];

N-(2-isobutyl-2-azaspiro[3.3]heptan-6-yl)-5-(pyrido[2,3-b]pyrazin-7-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1775];

N-(2-isobutyl-2-azaspiro[3.3]heptan-6-yl)-5-(1,5-naphthyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1776];

5-(imidazo[1,2-a]pyridin-6-yl)-N-(cis-4-(trifluoromethoxy)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1777];

pyrrolidin-1-yl(6-(2-((*cis*-4-(trifluoromethoxy)cyclohexyl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)imidazo[1,2-a]pyridin-3-yl)methanone [1778];

5-(imidazo[1,2-b]pyridazin-6-yl)-N-(*cis*-4-(trifluoromethoxy)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1779];

5-(imidazo[1,2-a]pyrimidin-6-yl)-N-(*cis*-4-(trifluoromethoxy)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1780];

5-(3-chloroimidazo[1,2-a]pyrimidin-6-yl)-N-(*cis*-4-(trifluoromethoxy)cyclohexyl)pyrrolo [2,1-f][1,2,4]triazin-2-amine [1781];

5-(3-methylimidazo[1,2-a]pyrimidin-6-yl)-N-(*cis*-4-(trifluoromethoxy)cyclohexyl)pyrrolo [2,1-f][1,2,4]triazin-2-amine [1782];

5-(3-ethylimidazo[1,2-a]pyrimidin-6-yl)-N-(*cis*-4-(trifluoromethoxy)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1783];

5-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)-N-(*cis*-4-(trifluoromethoxy)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1784];

5-(1-isopropyl-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*cis*-4-(trifluoromethoxy)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1785];

5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*cis*-4-(trifluoromethoxy)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1786];

5-(1-(3,3-difluorocyclobutyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*cis*-4-(trifluoromethoxy)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1787];

5-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*cis*-4-(trifluoromethoxy)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1788];

5-(2,3-dimethyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*cis*-4-(trifluoromethoxy)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1789];

5-(3-ethyl-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*cis*-4-(trifluoromethoxy)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1790];

5-(3-(2-fluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*cis*-4-(trifluoromethoxy)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1791];

5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*cis*-4-(trifluoromethoxy)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1792];

5-(3-(2-methoxyethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*cis*-4-(trifluoromethoxy)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1793];

5-(1-methyl-1H-benzo[d][1,2,3]triazol-6-yl)-N-(*cis*-4-(trifluoromethoxy)cyclohexyl)pyrrolo [2,1-f][1,2,4]triazin-2-amine [1794];

5-(quinolin-6-yl)-N-(*cis*-4-(trifluoromethoxy)cyclohexyl)pyrrolo[2,1-*f*][1,2,4]triazin-2-amine [1795];

5-(quinoxalin-6-yl)-N-(*cis*-4-(trifluoromethoxy)cyclohexyl)pyrrolo[2,1-*f*][1,2,4]triazin-2-amine [1796];

5-(4-methoxyquinazolin-6-yl)-N-(*cis*-4-(trifluoromethoxy)cyclohexyl)pyrrolo[2,1-*f*][1,2,4]triazin-2-amine [1797];

5-(1,8-naphthyridin-3-yl)-N-(*cis*-4-(trifluoromethoxy)cyclohexyl)pyrrolo[2,1-*f*][1,2,4]triazin-2-amine [1798];

5-(pyrido[2,3-*b*]pyrazin-7-yl)-N-(*cis*-4-(trifluoromethoxy)cyclohexyl)pyrrolo[2,1-*f*][1,2,4]triazin-2-amine [1799]; and

5-(1,5-naphthyridin-2-yl)-N-(*cis*-4-(trifluoromethoxy)cyclohexyl)pyrrolo[2,1-*f*][1,2,4]triazin-2-amine [1800]; or a pharmaceutically acceptable salt thereof.

26. The compound according to any one of claims 1-7, wherein the compound of Formula I is selected from the group consisting of:

N-(2-fluoro-2-methylpropyl)-5-(3-isopropyl-2-methyl-3H-imidazo[4,5-*b*]pyridin-5-yl)pyrrolo[2,1-*f*][1,2,4]triazin-2-amine [1801];

5-(imidazo[1,2-*a*]pyrimidin-6-yl)-N-(*cis*-4-(methoxy-*d*₃)cyclohexyl)pyrrolo[2,1-*f*][1,2,4] triazin-2-amine [1802];

5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-*b*]pyridin-5-yl)-N-(*cis*-4-(methoxy-*d*₃)cyclohexyl)pyrrolo[2,1-*f*][1,2,4]triazin-2-amine [1803];

cis-3-((5-(imidazo[1,2-*a*]pyridin-6-yl)pyrrolo[2,1-*f*][1,2,4]triazin-2-yl)amino)-1-methylcyclobutan-1-ol [1804];

(6-(2-((*cis*-3-hydroxy-3-methylcyclobutyl)amino)pyrrolo[2,1-*f*][1,2,4]triazin-5-yl)imidazo[1,2-*a*]pyridin-3-yl)(pyrrolidin-1-yl)methanone [1805];

cis-3-((5-(imidazo[1,2-*b*]pyridazin-6-yl)pyrrolo[2,1-*f*][1,2,4]triazin-2-yl)amino)-1-methylcyclobutan-1-ol [1806];

cis-3-((5-(imidazo[1,2-*a*]pyrimidin-6-yl)pyrrolo[2,1-*f*][1,2,4]triazin-2-yl)amino)-1-methylcyclobutan-1-ol [1807];

cis-3-((5-(3-chloroimidazo[1,2-*a*]pyrimidin-6-yl)pyrrolo[2,1-*f*][1,2,4]triazin-2-yl)amino)-1-methylcyclobutan-1-ol [1808];

cis-1-methyl-3-((5-(3-methylimidazo[1,2-*a*]pyrimidin-6-yl)pyrrolo[2,1-*f*][1,2,4]triazin-2-yl)amino)cyclobutan-1-ol [1809];

cis-3-((5-(3-ethylimidazo[1,2-*a*]pyrimidin-6-yl)pyrrolo[2,1-*f*][1,2,4]triazin-2-yl)amino)-1-methylcyclobutan-1-ol [1810];

cis-3-((5-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclobutan-1-ol [1811];

cis-3-((5-(1-isopropyl-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclobutan-1-ol [1812];

cis-3-((5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclobutan-1-ol [1813];

cis-3-((5-(1-(3,3-difluorocyclobutyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclobutan-1-ol [1814];

cis-1-methyl-3-((5-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclobutan-1-ol [1815];

cis-3-((5-(2,3-dimethyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclobutan-1-ol [1816];

cis-3-((5-(3-ethyl-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclobutan-1-ol [1817];

cis-3-((5-(3-(2-fluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclobutan-1-ol [1818];

cis-3-((5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclobutan-1-ol [1819];

cis-3-((5-(3-(2-methoxyethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclobutan-1-ol [1820];

cis-1-methyl-3-((5-(1-methyl-1H-benzo[d][1,2,3]triazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclobutan-1-ol [1821];

cis-1-methyl-3-((5-(quinolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclobutan-1-ol [1822];

cis-1-methyl-3-((5-(quinoxalin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclobutan-1-ol [1823];

cis-3-((5-(4-methoxyquinazolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclobutan-1-ol [1824];

cis-3-((5-(1,8-naphthyridin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclobutan-1-ol [1825];

cis-1-methyl-3-((5-(pyrido[2,3-b]pyrazin-7-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclobutan-1-ol [1826];

cis-3-((5-(1,5-naphthyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclobutan-1-ol [1827];

trans-4-((5-(imidazo[1,2-a]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclohexan-1-ol [1828];

cis-4-((5-(3-isobutyl-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclohexan-1-ol [1829];

(R)-2-((5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)propan-1-ol [1830];

(R)-1-((5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)propan-2-ol [1831];

(S)-1-((5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)propan-2-ol [1832];

1-((5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-2-methylpropan-2-ol [1833];

(*cis*-3-((5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclobutyl)methanol [1834];

trans-3-((5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclobutan-1-ol [1835];

5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(7-methyl-7-azaspiro[3.5]nonan-2-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1836];

(*cis*-4-((5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclohexyl)methanol [1837];

N-(*cis*-4-(2,2-difluoroethoxy)cyclohexyl)-5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1838];

2-((*cis*-4-((5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclohexyl)oxy)ethan-1-ol [1839];

trans-4-((5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclohexan-1-ol [1840];

5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*cis*-4-((4-methylpiperazin-1-yl)methyl)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1841];

5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*cis*-4-(morpholinomethyl)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1842];

ethyl *cis*-4-((5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclohexane-1-carboxylate [1843];

N-(*trans*-4-((5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclohexyl)acetamide [1844];

cis-4-((5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-N,N-dimethylcyclohexane-1-carboxamide [1845];

5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(2-methyl-2-azaspiro[3.5]nonan-7-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1846];

5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(1,4-dioxaspiro[4.5]decan-8-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1847];

5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-((4-methylmorpholin-2-yl)methyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1848];

5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(1-(2-fluoroethyl)piperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1849];

5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(1-(2,2-difluoroethyl)piperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1850];

5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(1-(3,3,3-trifluoropropyl)piperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1851];

2-(4-((5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)piperidin-1-yl)ethan-1-ol [1852];

5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1853];

5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-((3R,4R)-3-fluoro-1-methylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1854];

5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-((3S,4S)-3-fluoro-1-methylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1855];

5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-((3R,4S)-3-fluoro-1-methylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1856];

1-(4-((5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)piperidin-1-yl)ethan-1-one [1857];

1-(4-((5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)piperidin-1-yl)propan-1-one [1858];

1-(4-((5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)piperidin-1-yl)-2-methylpropan-1-one [1859];

cyclopropyl(4-((5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)piperidin-1-yl)methanone [1860];

5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(1-(methylsulfonyl)piperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1861];

5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(1-(oxetan-3-yl)piperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1862];

(R)-5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(tetrahydro-2H-pyran-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1863];

(S)-5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(tetrahydro-2H-pyran-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1864];

(3R,4R)-4-((5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)tetrahydro-2H-pyran-3-ol [1865];

(3S,4R)-4-((5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)tetrahydro-2H-pyran-3-ol [1866];

5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-((3S,4R)-3-methoxytetrahydro-2H-pyran-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1867];

cis-1-methyl-4-((5-(2-methyl-3-(2,2,2-trifluoroethyl)-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclohexan-1-ol [1868];

3-(5-(2-((*cis*-4-hydroxy-4-methylcyclohexyl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)-2-methyl-3H-imidazo[4,5-b]pyridin-3-yl)-2,2-dimethylpropanenitrile [1869];

1-(5-(2-((4,4-difluorocyclohexyl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)-2-methyl-3H-imidazo[4,5-b]pyridin-3-yl)-2-methylpropan-2-ol [1870];

2-methyl-1-(2-methyl-5-(2-((tetrahydro-2H-pyran-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)-3H-imidazo[4,5-b]pyridin-3-yl)propan-2-ol [1871];

2-(5-(2-((*cis*-4-hydroxy-4-methylcyclohexyl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)-2-methyl-3H-imidazo[4,5-b]pyridin-3-yl)-N,N-dimethylacetamide [1872];

5-(3-(azetidin-3-ylmethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(4,4-difluorocyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1873];

N-(4,4-difluorocyclohexyl)-5-(2-methyl-3-((1-methylazetidin-3-yl)methyl)-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1874];

cis-1-methyl-4-((5-(2-methyl-3-(oxetan-3-ylmethyl)-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclohexan-1-ol [1875];

5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(*cis*-4-(methoxy-*d*₃)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1876];

N-(*cis*-4-(2,2-difluoroethoxy)cyclohexyl)-5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1877];

2-((*cis*-4-((5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclohexyl)oxy)ethan-1-ol [1878];

trans-4-((5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclohexan-1-ol [1879];

5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(1,4-dioxaspiro[4.5]decan-8-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1880];

5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(1-(2-fluoroethyl)piperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1881];

5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(1-(2,2-difluoroethyl)piperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1882];

5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(1-(3,3,3-trifluoropropyl)piperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1883];

5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1884];

5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-((3R,4R)-3-fluoro-1-methylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1885];

5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-((3S,4S)-3-fluoro-1-methylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1886];

5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-((3R,4S)-3-fluoro-1-methylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1887];

1-(4-((5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)piperidin-1-yl)-2-methylpropan-1-one [1888];

5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(1-(oxetan-3-yl)piperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1889];

trans-4-((5-(1-(2,2-difluoroethyl)-1H-benzo[d][1,2,3]triazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclohexan-1-ol [1890];

trans-1-methyl-4-((5-(pyrazolo[1,5-a]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclohexan-1-ol [1891];

5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*cis*-3-morpholinocyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1892];

5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*trans*-3-morpholinocyclobutyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1893];

5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(*cis*-4-((3-fluoroazetidin-1-yl)methyl)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1894];

trans-4-((5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-N,N-dimethylcyclohexane-1-carboxamide [1895];

azetidin-1-yl(*cis*-4-((5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclohexyl)methanone [1896];
(*cis*-4-((5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclohexyl)(pyrrolidin-1-yl)methanone [1897];
N-(*cis*-4-((5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclohexyl)acetamide [1898];
1-(7-((5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-2-azaspiro[3.5]nonan-2-yl)ethan-1-one [1899]; and
5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-((3R,4S)-4-fluoro-1-methylpyrrolidin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1900]; or a pharmaceutically acceptable salt thereof.

27. The compound of any of claims 1-7, wherein the compound of Formula I is selected from the group consisting of:

5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-((3S,4S)-4-fluoro-1-methylpyrrolidin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1901];
5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-((3R,4R)-4-fluoro-1-methylpyrrolidin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1902];
5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-((3S,4R)-4-fluoro-1-methylpyrrolidin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1903];
(S)-1-(3-((5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)pyrrolidin-1-yl)ethan-1-one [1904];
(R)-1-(3-((5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)pyrrolidin-1-yl)ethan-1-one [1905];
(3S,4R)-4-((5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)tetrahydrofuran-3-ol [1906];
(3R,4S)-4-((5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)tetrahydrofuran-3-ol [1907];
5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-((3S,4R)-3-fluoro-1-isobutylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1908];
5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-((3R,4S)-3-fluoro-1-isobutylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1909];
1-(4-((5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)piperidin-1-yl)ethan-1-one [1910];

(S)-4-((5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylpiperidin-2-one [1911];

5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-((3S,4R)-3-fluorotetrahydro-2H-pyran-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1912];

N-((1R,5S,6r)-3-Oxabicyclo[3.1.0]hexan-6-yl)-5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1913];

N-((1R,5S,6s)-3-Oxabicyclo[3.1.0]hexan-6-yl)-5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1914];

(R)-N-(4,4-difluorocyclohexyl)-5-(1-((5-(1-fluoroethyl)-1,3,4-oxadiazol-2-yl)methyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1915];

5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(piperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1916];

(S)-(2,2-difluorocyclopropyl)(4-((5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)piperidin-1-yl)methanone [1917];

(R)-(2,2-difluorocyclopropyl)(4-((5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)piperidin-1-yl)methanone [1918];

N-((1s,3s)-3-((5-(1-(2,2-difluoroethyl)-2-methyl-1H-benzo[d]imidazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclobutyl)acetamide [1919];

N-((1r,3r)-3-((5-(1-(2,2-difluoroethyl)-2-methyl-1H-benzo[d]imidazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclobutyl)acetamide [1920];

(1r,3r)-3-((5-(1-(2,2-difluoroethyl)-2-methyl-1H-benzo[d]imidazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-N,N,1-trimethylcyclobutane-1-carboxamide [1921];

(1s,3s)-3-((5-(1-(2,2-difluoroethyl)-2-methyl-1H-benzo[d]imidazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-N,N,1-trimethylcyclobutane-1-carboxamide [1922];

((1s,3s)-3-((5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclobutyl)(pyrrolidin-1-yl)methanone [1923];

((1r,3r)-3-((5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclobutyl)(pyrrolidin-1-yl)methanone [1924];

1-(2-((5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-7-azaspiro[3.5]nonan-7-yl)ethan-1-one [1925];

1-((3aR,5s,6aS)-5-((5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)hexahydrocyclopenta[c]pyrrol-2(1H)-yl)ethan-1-one [1926];

1-((3aR,5r,6aS)-5-((5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)hexahydrocyclopenta[c]pyrrol-2(1H)-yl)ethan-1-one [1927];

1-(7-((5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-2-azaspiro[3.5]nonan-2-yl)ethan-1-one [1928];

5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyridin-6-yl)-N-(2-oxaspiro[3.5]nonan-7-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1929];

N-((1s,3s)-3-((5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclobutyl)acetamide [1930];

N-((1r,3r)-3-((5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclobutyl)acetamide [1931];

N-((1s,3s)-3-((5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclobutyl)propionamide [1932];

N-((1r,3r)-3-((5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclobutyl)propionamide [1933];

(1s,3s)-3-((5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-N,N,1-trimethylcyclobutane-1-carboxamide [1934];

(1r,3r)-3-((5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-N,N,1-trimethylcyclobutane-1-carboxamide [1935];

((1s,3s)-3-((5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclobutyl)(pyrrolidin-1-yl)methanone [1936];

((1r,3r)-3-((5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclobutyl)(pyrrolidin-1-yl)methanone [1937];

1-((1s,3s)-3-((5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclobutyl)pyrrolidin-2-one [1938];

1-((1r,3r)-3-((5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclobutyl)pyrrolidin-2-one [1939];

1-((3S,4R)-3-((5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-4-fluoropyrrolidin-1-yl)ethan-1-one [1940];

1-((3R,4S)-3-((5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-4-fluoropyrrolidin-1-yl)ethan-1-one [1941];

1-((3R,4R)-3-((5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-4-fluoropyrrolidin-1-yl)ethan-1-one [1942];

1-((3S,4S)-3-((5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-4-fluoropyrrolidin-1-yl)ethan-1-one [1943];

5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-((3S,4R)-4-fluoro-1-(oxetan-3-yl)pyrrolidin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1944];

5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-((3R,4S)-4-fluoro-1-(oxetan-3-yl)pyrrolidin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1945];

5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-((3R,4R)-4-fluoro-1-(oxetan-3-yl)pyrrolidin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1946];

5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-((3S,4S)-4-fluoro-1-(oxetan-3-yl)pyrrolidin-3-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1947];

N-((1s,4s)-4-((5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclohexyl)acetamide [1948];

N-((1r,4r)-4-((5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclohexyl)acetamide [1949];

(3,3-difluoroazetidin-1-yl)((1s,4s)-4-((5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclohexyl)methanone [1950];

1-((3S,4R)-4-((5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-3-fluoropiperidin-1-yl)ethan-1-one [1951];

1-((3R,4S)-4-((5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-3-fluoropiperidin-1-yl)ethan-1-one [1952];

(4,4-difluorocyclohexyl)(4-((5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)piperidin-1-yl)methanone [1953];

5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-((3S,4R)-3-fluoro-1-(oxetan-3-yl)piperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1954];

5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-((3R,4S)-3-fluoro-1-(oxetan-3-yl)piperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1955];

5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-((3R,4R)-3-fluoro-1-(oxetan-3-yl)piperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1956];

5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-((3S,4S)-3-fluoro-1-(oxetan-3-yl)piperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1957];

1-(2-((5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-7-azaspiro[3.5]nonan-7-yl)ethan-1-one [1958];

1-((3aR,5s,6aS)-5-((5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)hexahydrocyclopenta[c]pyrrol-2(1H)-yl)ethan-1-one [1959];

1-((3aR,5r,6aS)-5-((5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)hexahydrocyclopenta[c]pyrrol-2(1H)-yl)ethan-1-one [1960];

5-(3-(2,2-difluoroethyl)-2-methyl-3H-imidazo[4,5-b]pyridin-5-yl)-N-(2-oxaspiro[3.5]nonan-7-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1961];

N-((1s,3s)-3-((5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyrazin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclobutyl)acetamide [1962];

N-((1r,3r)-3-((5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyrazin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclobutyl)acetamide [1963];

(1s,3s)-3-((5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyrazin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-N,N,1-trimethylcyclobutane-1-carboxamide [1964];

(1r,3r)-3-((5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyrazin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-N,N,1-trimethylcyclobutane-1-carboxamide [1965];

((1s,3s)-3-((5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyrazin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclobutyl)(pyrrolidin-1-yl)methanone [1966];

((1r,3r)-3-((5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyrazin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclobutyl)(pyrrolidin-1-yl)methanone [1967];

1-((1s,3s)-3-((5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyrazin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclobutyl)pyrrolidin-2-one [1968];

1-((1r,3r)-3-((5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyrazin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclobutyl)pyrrolidin-2-one [1969];

5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyrazin-6-yl)-N-(*cis*-4-(trifluoromethoxy)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1970];

5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyrazin-5-yl)-N-(*cis*-4-(trifluoromethoxy)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1971];

N-((1s,4s)-4-((5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyrazin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclohexyl)acetamide [1972];

N-((1r,4r)-4-((5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyrazin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclohexyl)acetamide [1973];

(1s,4s)-4-((5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyrazin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclohexan-1-ol [1974];

1-(2-((5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyrazin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-7-azaspiro[3.5]nonan-7-yl)ethan-1-one [1975];

1-((3aR,5s,6aS)-5-((5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyrazin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)hexahydrocyclopenta[c]pyrrol-2(1H)-yl)ethan-1-one [1976];

1-((3aR,5r,6aS)-5-((5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyrazin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)hexahydrocyclopenta[c]pyrrol-2(1H)-yl)ethan-1-one [1977];

1-(7-((5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyrazin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-2-azaspiro[3.5]nonan-2-yl)ethan-1-one [1978];

5-(1-(2,2-difluoroethyl)-2-methyl-1H-imidazo[4,5-b]pyrazin-6-yl)-N-(2-oxaspiro[3.5]nonan-7-yl)pyrrolo[2,1-f][1,2,4]triazin-2-amine [1979];

N-((1r,3r)-1-methyl-3-((5-(quinolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclobutyl)acetamide [1980];

N-((1r,3r)-1-methyl-3-((5-(quinoxalin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclobutyl)acetamide [1981];

N-(*cis*-3-((5-(1-(2,2-difluoroethyl)-2-methyl-1H-benzo[d]imidazol-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1-methylcyclobutyl)acetamide [1982];

N-(*trans*-1-methyl-3-((5-(pyrazolo[1,5-a]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclobutyl)acetamide [1983];

N-(*cis*-1-methyl-3-((5-(quinolin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclobutyl)acetamide [1984];

2-methoxy-N-(*trans*-1-methyl-3-((5-(quinoxalin-6-yl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)cyclobutyl)acetamide [1985]; or a pharmaceutically acceptable salt thereof.

28. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any one of claims 1-27, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

29. A method of treating a disorder or disease in a patient, wherein the disorder or disease is selected from the group consisting of: a neurological disorder, diabetes, and cancer, the method comprising administering to the patient a therapeutically effective amount of a compound according to any one of claims 1-27 or a pharmaceutically acceptable salt, or the pharmaceutical composition of claim 28.

30. The method of claim 29, wherein the disorder or disease is cancer.

31. The method of claim 29, wherein the disorder or disease is diabetes.

32. The method of claim 29, wherein the disorder or disease is a neurological disorder.

33. The method according to any one of claims 29-30, wherein the cancer is selected from the group consisting of: brain tumors, glioblastoma, ovarian, breast, head and neck squamous cell carcinoma, hepatocellular carcinoma, pancreatic cancer, acute lymphoblastic leukemia, acute megakaryoblastic leukemia, and chronic myeloid leukemia.

34. The method according to any one of claims 29 and 32, wherein the disorder or disease is a neurological disorder, wherein the neurological disorder is selected from the group consisting of: Alzheimer's Disease, Amyotrophic Lateral Sclerosis, CDKL5 Deficiency Disorder, Down Syndrome, Frontotemporal Dementia with Parkinsonism-17 (FTDP-17), Lewy body dementia, Parkinson's Disease, Pick's Disease, and additional diseases with pronounced

neurodegeneration such as Autism, Dementia, Epilepsy, Huntington's Disease, Multiple Sclerosis; diseases and disorders associated with acquired brain injury such as Chronic Traumatic Encephalopathy, Traumatic Brain Injury, Tumor, Stroke, Pick disease, progressive supranuclear palsy, corticobasal degeneration, argyrophilic grain disease, globular glial tauopathies, primary age-related tauopathy, neurofibrillary tangle dementia, chronic traumatic encephalopathy (CTE), frontotemporal lobar degeneration with tau inclusions (FTLD-tau), and aging-related tau astroglipathy.

35. The method according to any one of claims 29, 32, and 34, wherein the disorder or disease is Alzheimer's disease.

36. The method according to any one of claims 29-35, wherein the patient is a human.

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2022/046416

A. CLASSIFICATION OF SUBJECT MATTER INV. A61P3/00 A61P25/00 A61P35/00 C07D487/04 C07D519/00 A61K31/519 ADD. According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) A61P C07D A61K Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) EPO-Internal, CHEM ABS Data, WPI Data		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 2017/040993 A1 (UNIV ARIZONA [US]) 9 March 2017 (2017-03-09) claims 1-24 -----	1-36
A	US 2020/039989 A1 (HULME CHRISTOPHER [US] ET AL) 6 February 2020 (2020-02-06) claims 1-34 -----	1-36
☐ Further documents are listed in the continuation of Box C. ☒ See patent family annex.		
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search 13 January 2023		Date of mailing of the international search report 24/01/2023
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016		Authorized officer Marzi, Elena

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2022/046416

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2017040993 A1	09-03-2017	AU 2016315881 A1	29-03-2018
		CA 2997556 A1	09-03-2017
		EP 3344039 A1	11-07-2018
		JP 2018526452 A	13-09-2018
		US 2019062284 A1	28-02-2019
		WO 2017040993 A1	09-03-2017

US 2020039989 A1	06-02-2020	NONE	
